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The principal goal of this work was to synthesise and fully characterise a range of 
platinum group metal chelates of bis(pyridine-imine) ligands. These four-nitrogen donor 
Schiff base ligands are underdeveloped relative to their salen (ONNO donor) 
counterparts. The purified metal complexes were to be tested for their cytotoxicity 
against cancer cell lines and their mode of interaction (expected to be intercalation) 
studied. 
 
The syntheses, spectroscopic and structural properties of some novel and some already 
known bis(pyridine-imine) ligands are described. Furthermore, UV-Vis, IR and NMR 
spectroscopy, as well as electrospray ionisation mass spectrometry, have been used to 
characterize the ligands and comparisons were made with relevant literature. Fifteen 
Schiff base ligands were successfully condensed from a 2-formyl or 2-ketopyridine 
starting material and a diamine bridging group, while the attempted syntheses of a 
further three are described. Literature methods or variations thereof were employed in 
the syntheses of these derivatives, which generally resulted in good yields. X-ray quality 
crystals were obtained and X-ray structures were determined for four novel ligands and 
five unexpected cyclised hexahydropyrimidine- and imidazole-containing bidentate 
ligands, of which three were novel structures. 
 
The series of bicationic palladium and platinum complexes synthesised here were 
analysed by NMR, IR and UV-Vis techniques, as well as X-ray crystallography when 
possible. The complexes were prepared by reacting the free ligands with platinum group 
metal salts in refluxing acetonitrile. The complexes exhibit infrared bands for the imine 
C=N stretch between 1604–1670 cm-1; around 15–40 cm-1 lower than the free ligands. 
The 1H NMR spectra in the CH=N chemical shift region also display shifts (0.1 to 0.8 
ppm for the palladium complexes or 0.4 to 0.9 ppm for the platinum complexes) which 
are consistent with metallation.  
 
X-ray crystal structures were obtained for eight novel metal complexes, which all 
crystallised in the monoclinic crystal system. The solid state analysis shows changes in 
the free ligands upon introduction of the metal ions, caused by the coordination process. 
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Metallation of the free ligands led to twisting of the ligands due to size effects and the 
spatial restrictions of the coordination geometry of the central metal ions. The structures 
were generally solved by direct methods and refined to R1 = 0.0729 or less. Single-
crystal X-ray diffraction analysis confirmed that the mononuclear complexes exhibit a 
distorted square planar coordination sphere composed of the four donor nitrogen atoms 
(two imine and two pyridyl nitrogen atoms) from the Schiff base ligands. The complexes 
were generally very stable and differed by the type of metal ion (platinum(II) or 
palladium(II)) and the diamine bridging group (2-carbon or 3-carbon linking chain with 
various substituted groups). A range of unconventional F···H−C contacts is revealed to 
play an important role in the overall bonding and crystal packing of many complexes. 
 
To better understand our measured data and to separate the intrinsic properties of our 
molecules from intermolecular interactions, theoretical calculations at the DFT (B3LYP) 
level were carried out. These calculations predict the structural and spectroscopic 
properties for the free ligands and their metallated counterparts. DFT simulations were 
performed for the fifteen synthesised ligands (B3LYP functional, 6-31G** basis set), as 
well as three projected ligands that could not be synthesised, and for all proposed thirty-
six metal complexes (B3LYP functional, SDD basis set). DFT simulations were used to 
obtain theoretical IR frequency data which was compared to the literature and used to 
prove the location of a local minimum energy structure in the geometry optimisation 
rather than a transition state. Our results collectively showed the B3LYP level of theory to 
be useful in the prediction of IR frequencies for these Schiff base ligands as well as the 
platinum(II) and palladium(II) complexes. 
 
Geometry optimisations performed using density functional theory for the free ligands 
and metal complexes were compared, where possible, with X-ray data. For the free 
ligands the main structural differences were observed for the position of the pyridyl-imine 
"arms" of the ligands with relatively good agreement between the two structures for the 
bridging groups. On the other hand, the metal complexes showed greater discrepancies 
for the bridging groups rather than for the pyridine rings. These differences were also 
affected by the length of the carbon bridge; the longer the carbon bridge, the less 
variation was observed. The trends in the variation of bond distances and angles with the 
metal ion identity and ligand structure delineated by DFT simulations were matched by 
similar trends in the X-ray data. 
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Differences between the gas phase calculated geometries and those determined by X-
ray diffraction were attributed to packing effects in the solid state and intermolecular 
interactions not being accounted for during DFT computations. The impressive similarity 
observed between the structures obtained from X-ray crystallography and computed by 
DFT shows the applicability of these computations at the B3LYP level of theory. They 
were able to accurately predict structural and spectroscopic properties for the ligands 
and complexes presented in this work. 
 
The in vitro cytotoxicities of some of the metal complexes were evaluated against two 
mouse cancer cell lines. The compounds tested had lower than expected cytotoxicity 
towards the cell lines studied with IC50 values > 100 μM. The interaction of the 
complexes with calf thymus DNA has been explored by using absorption studies. From 
the observed changes in absorption possible modes of binding to DNA have been 
proposed for the metal complexes. Significant changes were observed in the absorption 
spectra upon interaction of the complexes with DNA, from which large binding constants 
were determined. The changes were, however, not as intense as expected nor were the 
spectral variations typical of intercalating drugs. There were also no bathochromic shifts 
nor any isobestic points observed for most of the metal complexes, except one. For the 
cationic PGM chelates studied, the lack of shift in the wavelength of the visible range 
MLCT band maximum and small changes in the band intensity were more indicative of 
weak electrostatic interactions. Our spectral data were thus interpreted as being 
consistent with non-intercalative binding; either simple electrostatic adduct formation or 
major/minor groove binding. 
 
The binding constant values (Kb) of the metal complexes estimated from the titration with 
calf thymus DNA monitored by absorption spectroscopy were all in the range of 105 M-1. 
This is within the range of those reported for other platinum(II) and palladium(II) metal 
complexes that have shown intercalation and/or groove binding. With the lack of 
inhibition of growth of the selected cancer cell lines it is possible that the compounds do 
not reach nuclear DNA in living cells or that such compounds are possibly substrates for 
efflux transporters. All the metal complexes in this work were determined to not be pure 
DNA intercalators as had been expected; however, in some cases partial intercalation 
cannot be ruled out from the spectral data.  
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CHAPTER 1 – Introduction 
 
1.1 Introduction  
1.1.1 The Quandary 
South Africa is a developing country with its economy classified as one of the major 
emerging markets in the world. A significant problem is that although this emerging 
market has a high potential for growth, it will eventually reach a limit due to the fact that 
the economy is mainly resource based. Mining is a common and well-recognised 
industry in South Africa.1 South Africa is known throughout the world for its mineral 
resources due to its significant proportion to the world reserves: platinum metals (90%), 
manganese (80%), chrome (73%), vanadium (45%) and gold (41%). Some experts 
believe that although South Africa does not have crude oil and bauxite, there may be 
other world-class deposits waiting to be discovered.1 
 
The raw materials mined in South Africa (minerals and fossil fuels) are exported to other 
countries as crude products. This means that other countries then have the opportunity 
to use those crude products and develop them into something with an improved value 
and application. These products are then bought back by South Africa at an elevated 
price resulting in financial losses for the South African economy. To make sure that the 
economy can continue to grow there needs to be some way of continuing to find potential 
for those resources that are available. 
 
1.1.2 A Solution 
South Africa is fortunate to have an abundance of these natural resources (especially 
precious metals), but they will not be infinitely available. Effort therefore needs to be 
made now to discover and develop new technology and new materials (so that value 
may be added to these primary resources), as well as new industries and market 
opportunities in order to benefit the economy and people.  By doing this (e.g. by 
processing raw materials into secondary or tertiary goods that can be sold at a higher 
price than the primary form) the economy will be secured for a longer period of time, 
allowing further growth. Without this type of change South Africa will continue to sell all 
its resources to developed countries, making the other countries richer and South Africa 
poorer.  
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South Africa is the largest producer of platinum and a major producer and supplier of 
palladium.2 These are therefore a good choice of metals to be used and developed in 
this study. These metals can be used to develop novel metal-based pharmaceutical 
drugs for the treatment of cancer, malaria, and life-threatening viral infections, resulting 
in not only a positive contribution to the South African economy, but also to South Africa 
itself.  
 
1.2 Schiff Bases 
1.2.1 Background 
Schiff base ligands were first recognised when they were prepared and characterised by 
a German chemist, Hugo Schiff, in 1864.3 Hugo Schiff (1834–1915) studied in Germany 
with Friedrich Wohler, but spent most of his more than 60 year career in Italy.4 There are 
earlier reports that Ettling had synthesised similar complexes in 1840;5 however, it was 
Schiff‟s name that came to represent this class of compounds from around 1869. Schiff 
bases are imines that have a hydrocarbon substituent group (alkyl or aryl, but not 
hydrogen) on the nitrogen atom. An azomethine is a Schiff base that has a hydrogen 
atom on the carbon of the imine bond. (Thus most of the ligands in this work are more 
correctly azomethines; however, they are more commonly referred to in the literature as 
Schiff base ligands.) Schiff base ligands are relatively stable; however, owing to the 
imine group in these compounds they are susceptible to hydrolysis and transamination 
by nucleophiles,6 as shown by Holanda et al.7  
 
There has been a great deal of research and many publications devoted to Schiff bases 
due to their inexpensive and simple syntheses, stability, structural differences and wide-
ranging denticities, as well as the variety of their possible applications.8,9,10,11,12,13 Schiff 
base ligand synthesis usually employs the use of a high boiling point volatile organic 
solvent (however, solventless methods have been proposed14). The coordination of 
metals to Schiff base ligands takes place through the imine nitrogen and another group, 
which is connected to the aldehyde used to form the ligand. There are a vast number of 
publications showing the development of coordination chemistry using Schiff bases and 
their metal complexes including pure synthetic work as well as bio- and physiochemical 
studies.15  
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Schiff bases have been widely studied and employed in amongst other things: catalysis, 
molecular electronics, magnetism and photochemistry. Schiff base complexes have, in 
particular, become ubiquitous in the literature of catalysis. Ruthenium complexes have 
been known to act as catalysts16,17 for the activation of small molecules.18 Other Schiff 
base metal complexes that have shown catalytic activity include copper(II)19,20 and 
manganese(III)21 as well as uranium complexes of multidentate N-donor ligands.22 
Manganese, cobalt, chromium and nickel Schiff base complexes have found application 
as catalysts for oxidation reactions.23,24,25 Chiral metal Schiff base complexes have 
shown catalytic activity towards the epoxidation of terminal olefins.26 They have also 
been applied in different asymmetric catalysis reactions, for example: 
cyclopropanation,27 aziridination28 and hetero-Diels–Alder.29 Schiff base ligands are still 
regularly prepared and some of these well-designed schiffs are referred to as “privileged 
ligands”.30 These ligands have the ability to stabilise a range of metals in a range of 
oxidation states; this subsequently allows them to control the performance of the 
complex in catalytic transformations. 
 
An interesting utilisation of Schiff base ligands is for metal ion transport due to their 
innate ability to bind with varying affinities to a wide range of metal ions. One example of 
this is oligosalicylaldehyde and its Schiff base oligomers, which are capable of forming 
polymer-metal complexes with metal salts. This allows the ligand to carry (and remove) 
metal ions from industrial waste waters.31 A range of Schiff bases have also been used 
as new lead(II) extracting agents to remove this toxic metal ion from the water carried by 
popular lead piping used in service pipes and household plumbing, etc.32,33 Elimination of 
toxic heavy metal contaminants from aqueous waste streams has become one of the 
most significant environmental problems being explored. In addition to the free ligands, 
cobalt(II) complexes of Schiff bases have also been studied for transportation, in this 
case, for the reversible process of O2 transfer.
34 Schiff bases have also found application 
in materials chemistry; where they have shown photophysical, conducting and magnetic 
potentials.35,36,37 They have been used for reversible optical data storage38 and have 
found application as non-linear optical (NLO) materials.39,40 Schiff base complexes have 
also found application in producing stereochemical models concerning main group and 
transition metal coordination chemistry.41 
 
The potential for applications of Schiff base ligands and complexes also extends to 
biological behaviour and activities. This is due to the coordination behaviour of 
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polydentate ligands with transition metals sometimes modelling or even being able to 
mimic specific physical and chemical properties of numerous biological molecules.42 
Schiff base compounds may operate as important intermediates in enzymatic reactions30 
or even inhibit enzymatic action.43 In particular, the structural similarity of Schiff base 
compounds to biological systems has resulted in many studies. Some Schiff base 
compounds have shown pharmacological and antitumour activity,44,45 have been found to 
be good biological inhibitors46,47 or modeled or used in biological 
systems.48,49,50,51,52,53,54,55 Other complexes have shown resistance reversal (the ability to 
reverse multidrug resistance (MDR) in cancer patients) and the ability to slow the cell 
growth of leukemia,56,57 as well as in vitro antibacterial, antiviral and antitumoural 
activities.6,58 Some metallated Schiff base complexes were found to have antibacterial 
and antifungal activity,59,60,61,62 and some of these exhibited varying strengths of 
cytotoxicity as well59,61,62 (against various cancer cell lines). A few other complexes of 
Schiff base ligands have also been preliminarily screened as potential anticancer 
drugs.63,64,65,66  
 
In particular, Schiff base complexes with Co(II), Ni(II), Cu(II) and Zn(II) have already 
shown promising biological and antitumour activity.15,67 Certain Schiff base complexes, 
e.g. diorganotin(IV) complexes, have even shown higher anti-tumour activity (in vitro and 
in vivo) and lower toxicity than the well-known cisplatin (see Section 1.4).68,69,70,71 A 
series of Schiff bases derived from gossypol (a disesquiterpene extracted from cotton 
seeds) have shown antimalarial activity;72 while antibacterial activity has been seen for a 
range of novel Mn(II), Co(II), Ni(II), Cu(II), and Zn(II) complexes with vitamin K3-
thiosemicarbazone.73 Schiff base complexes have even been used in conjunction with 
99mTc and 186/188Re to form a new class of potential radiopharmaceuticals.74 
 
There are intensive studies for Schiff bases of o-hydroxy acylaromatics (ON-donors) in 
both the liquid and the solid state using UV techniques, NMR, neutron diffraction and X-
rays.75 However, a more common structure seen in the literature is that of the 
tetradentate derivative synthesised from salicylaldehyde and a diamine, known as a 
Salen derivative. These Salen structures (salicylethylenediamine) can be considered to 
be the prototype for N,N,O,O tetradentate Schiff base ligands. These Salen ligands are 
relatively stable due to their characteristic structural feature of intramolecular hydrogen 
bonding, common in these types of compounds.76,77,78 Another well-documented Schiff 
base compound is “acacen” (acetylacetoneiminate). Like Salen, it is a convenient 
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structural block for the creation of supramolecular structures. Nickel and copper 
complexes of N,N‟-ethylene-bis(acetylacetoneiminates) have been studied.79,80,81,82 
 
Schiff base complexes, particularly those of the salen-type are attractive due to the 
active role of the metal centre, the presence of charge-transfer (CT) transitions at low 
energies and their thermal stability.83 Salens are quadridentate ligands that coordinate 
through two N and two O atoms to the central metal cation. If necessary a base will 
occupy one axial coordination site and dioxygen binds to the other. This particular type of 
chelating ligand has been examined at length in order to expand the understanding of 
the thermodynamics and kinetics of oxygen binding in these model systems.84 
 
One of the first Salen ligands with its copper complex was reported in 1889 by Combes 
et al.85 Therefore these metal complexes subsequently became a fundamental class of 
compounds in coordination chemistry (with more than 2000 being characterised). Interest 
intensified in salen-type complexes after the preparation of salen complexes by the 
Jacobsen86 and Katsuki87 groups (applied in the early 1990s in epoxidation reactions). 
Since then, there have been many 3d transition metal complexes in the literature that 
involve N2O2 tetradentate Schiff base ligands. The specific properties of these 
complexes depend mainly on the nature and conformation of the ligand. For example, 
Salens have found remarkable application as anticorrosive materials; they inhibit the 
corrosion of mild steel.88,89  
 
Schiff bases, particularly those derived from aromatic o-hydroxyaldehydes (Salen), are 
examples of interesting compounds that have attracted a great deal of attention due to 
their interesting thermochromism and/or photochromism properties. The characteristics 
responsible for these properties are thought to be directly connected to the ground state 
and excited state proton transfer.90,91 Photochromism and thermochromism are 
phenomena exhibited in the solid state and in solution, and are caused by reversible 
colour changes induced by irradiation or by a change in temperature, respectively.92,93 
Thermochromism in Salen systems has been explained by the intramolecular proton 
transfer reaction, while photochromism has been attributed to photo-induced proton 
transfer.91 Reports have shown that there seems to be a link between planarity and 
these chromic properties; i.e. molecules showing thermochromism are, in general, planar 
while those exhibiting photochromism are non-planar.94,95,96 It has, however, been 
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suggested that what determines thermochromic or photochromic behaviour is not the 
planarity, but instead the imino nitrogen atom‟s  lone pair electron density.97 
 
In 1994 modifications to copper(II) complexes of Salen-type Schiff base compounds 
gave a series of DNA intercalators and groove-binders98 and in 2004, a chromium-salen 
complex was found to have an inhibitory effect on the growth of Shigella dysenteriae 
(enteropathogens that may cause bacillary dysentery in humans and monkeys)99. There 
is a great deal of literature for iron-salen complexes, both in the solid state and 
solution.100,101,102,103,104,105,106,107,108 They have demonstrated catalytic activity107 as well 
as electron transfer reactions which imitate the catalytic functions of peroxidases.108 
Despite the considerable occurrence of iron in living systems less attention has been 
dedicated to the biological features of iron–Salen complexes. In their quest to find stable 
iron complexes that would interact powerfully with DNA in aqueous solutions, Silvestri 
and co-workers have reported on the interaction between Fe(Salen)Cl and native calf 
thymus DNA.109 Zinc salen complexes have shown application as sensing 
materials110,111, emissive materials (OLEDs)112, and as building blocks for 
supramolecular structures.113,114  
 
Metallated bidentate Schiff base ligands115,116 with nitrogen donors are also present in 
the literature (with cobalt, nickel, iron palladium and platinum). The metallation of 
tridentate nitrogen donor ligands (pyridinaldazine with iron(II) and nickel(II)) were studied 
in a series of three papers by Stratton et al.117,118,119 Less literature exists for Schiff base 
ligands that have four nitrogen atom donors. However, the coordination chemistry of 
compounds with nitrogen donor atoms of varying denticity has been studied for many 
years. Some of the ligands to be presented in this work are not novel. Studies also exist 
for many of the ligands in this particular range as well as similarly structured Schiff base 
ligands that have been metallated. These metallations take place most commonly with 
copper,120,121,122,123,124 nickel,125,126 cobalt,127 manganese128,129, and iron130,131 as well as 
with lanthanide metals132 and ruthenium.133  
 
1.2.2 This Work 
The particular series of neutral tetradentate (4-nitrogen) Schiff base ligand systems first 
chosen for this research have the standard structure of two pyridine fragments 
connected by different diamino bridges. The first type of ligand relating to these was 
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reported in 1915 with the synthesis of 2-pyridinaldazine.134 The 2-Pyridinaldazine (Figure 
1.1) is the simplest form of this type of ligand as it does not contain a particular 
hydrocarbon-bridging group, only the two imines, each with a pyridine ring. Since then 
many variations on these bis(pyridine-imine) ligands have been designed and 
synthesised. Some of the variations synthesised in this work have been previously 
synthesised L1123,124,125,126,129,130,132,133,135,136,137,138,139,140,141,142,143, 
L2127,128,133,134,135,137139,144,145,146, L3126,128,147,148, L4149, L5138,150,151,152,153,154,155,156,157,158, 
L6159,160,161,162,163,164,165,166, L1m138,167,168,169,170,171,172,173,174, L2m146,168,170,175,176,177,178,179, 
L3m180, L4m181, L5m182, L6m, L1b125,146,172,173,174,183,184,185,186,187,188,189, 
L2b127,146,185,189,190,191,192,193, L3b, L4b, L5b and L6b. Some of them have also been used 
as starting materials for the synthesis of a range of other ligands14 or metallated with a 












Figure 1.1: The structure of 2-pyridinaldazine. 
 
After the synthesis of the original six ligands (L1–L6, Figure 1.2) it was decided to extend 
the range of ligands by changing the group on the imine carbon atom. In doing this it 
would also allow us to study the influence of this group, not only on the structure but also 
the effect it may have on the cytotoxicity of the complexes. It was decided to introduce 
bulk first in the form of a methyl subsistent (L1m–L6m) and then a phenyl ring (L1b–
L6b). The resulting range of complexes to be synthesised is shown in Figure 1.2. This 
work therefore aims to prepare a series of tetradentate bis(pyridine-imine) chelates and 
study their reactivity with some transition metals: platinum and palladium (Figure 1.2). 
The final complexes will be of interest for their technical application, molecular structures, 
spectroscopic properties, and their biochemical significance.  
 
These Schiff base ligands form part of the symmetrical Np, Ni, Ni, Np type, where Np and 
Ni are N(pyridine) and N(imine) donor centres, respectively. The N(imine) donor atoms 
are part of the bridge that connects the two pyridyl groups and the nature of this bridge 
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will be altered by using different diamine starting materials. This will produce an 
assortment of different ligands to determine the effect of the different attached groups. 
This range of neutral tetradentate Schiff base ligand systems which possesses two 
pyridine functional groups will be prepared by the one-pot reaction. This involves the 
condensation of 2-pyridinecarboxaldehyde, 2-acetylpyridine or 2-benzoylpyridine with the 
appropriate diamines (e.g. H2N-X-NH2, where X = a hydrocarbon bridging chain in 
Scheme 1.1) in a 2:1 mole ratio in dry ethanolic medium. This condensation is a rather 
simple, high-yielding and well-documented procedure. The reactants are 
structurally/conformationally predisposed in forming a ligand with no steric constraints 
and there is limited freedom for side reactions. Each of the ligands will be synthesised 





















            X    R                                            M 
 
1 : CH2CH2     H                       Pt(II)
 
 2 : CH2CH2CH2    CH3 (m)                     Pd(II) 
 3 : CH2CH(OH)CH2    Ph (b) 
 4 : CH2C(CH3)2CH2      
 5 : C6H8 
 6 : C6H4   
 
Figure 1.2: Structure of the N,N-bis-(2-pyridinecarboxaldimine) ligand systems and their metal 
complexes. 
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The ligands must be capable of presenting the bonding donor atoms, which are 
members of the continuous chain, to a suitable metal atom (either with or without 
preliminary loss of protons). For a four-covalent metal ion (e.g. platinum, palladium) a 
quadridentate ligand must be spatially capable of offering the four donor atoms in order 
to form either a tetrahedron or a square shape so that they may bond readily to the metal 
ion. For a six-covalent metal ion (e.g. vanadium and iron) a quadridentate ligand must be 
capable of presenting its four donor atoms spatially so that two apices either in the trans 
position or in cis positions may be occupied by other atoms. Organic compounds which 
are capable of offering their four donor atoms to a metal atom to form a square („planar 
quadridentates‟) are most often of the linear (open-chain) type, with the four donor atoms 
being members of the chain or on attached rings within the chain. These molecules are 
mostly flat, which is the orientation seen for their metal derivatives as well. 
 
The four available nitrogen atoms in this range of ligands allow for tetrafunctional 
coordination to metals. The Np atoms are easily accessible to metal ions due to the 
flexibility of the ligand and there is suitable separation between the two Ni atoms to allow 
for coordinating. The neutral ligand therefore coordinates via the two pyridine-nitrogen 
and the two imine-nitrogen atoms forming a N4 square-plane around the metal ion. The 
range of ligands synthesised in this work differ by the spacer chain between the two 
picolinylaldimine fragments and the group on the imine carbon atom, we therefore expect 
to see similarities between the free ligands as well as their metal complexes. 
 
Thus far no literature for the metallation or applications of any of these Schiff base 
ligands with platinum or palladium could be found. Indeed, a search of the Cambridge 
Structural Database194 (CSD) reveals that there are numerous crystallographically 
characterised complexes for 4N donor Schiff base complexes containing transition group 
metal ions such as nickel and copper and a few were also found to contain zinc and iron. 
However, only one palladium structure could be found, PAKLOD (Figure 1.3), which had 
a similarly structured 4N donor Schiff base ligand to those of this work. This Schiff base 
complex synthesised by Kettunen et al. in 2005 differed by the structure of the extended 
bridge.  
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Figure 1.3: The structure of a palladium(II) 4N donor Schiff base complex comprising two 
pyridyl-imine chelating units, PAKLOD.195 
 
This proposed range of eighteen ligands in combination with these metals is therefore 
expected to produce novel complexes. These thirty-six complexes will hopefully present 
some interesting biological activity and, most importantly, possible cytotoxicity towards 
cancer cells. Due to the lack of literature for the metallation of this type of ligand with the 
metals chosen in this work, a new procedure was developed specifically for this. This 
method is shown in Scheme 1.2. Due to the slower kinetics of platinum(II) a greater time 
period is needed to obtain the Pt(II) derivatives in comparison to the Pd(II) derivatives. 
An attractive feature of these complexes is that they generate a much greater diversity of 
adjustable properties due to the coordinated metal centre or by the adaptation of the 




Scheme 1.2: A typical metallation reaction for the formation of platinum(II) and palladium(II) 
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1.3 Metal-based pharmaceutical drugs 
1.3.1 Background 
Metals may cause harm to the body, e.g. an over exposure to cadmium results in itai-itai 
disease and a deficiency of iron causes anaemia; however, metals used for medicinal 
purposes date back around 5000 years.196 Many different metals have been used as 
treatments of a variety of ailments. Bismuth has been used to rehydrate infants with 
diarrhoea197 and silver has been used as an antibiotic.198 Copper has found application in 
treating, amongst other things: tuberculosis, burns, chronic wounds and seisures.199 
Although gadolinium has no known biological activity itself, it is used in the research 
techniques that examine biological systems, e.g. as an MRI (Magnetic Resonance 
Imaging) contrast agent.200 Gold compounds have been used clinically in the alleviation 
of various symptoms, particularly those normally associated with rheumatoid arthritis.201 
 
After the elucidation of the structure of the DNA double helix in 1953 by Watson and 
Crick202 important insights into the structure of genes were exposed. This resulted in the 
investigation of how genes could be modified as this could help to develop new 
approaches in the treatment of various diseases. By developing gene therapy techniques 
the growth of malignant genes can be stopped and damaged genes repaired. Metal 
compounds have subsequently found useful application in this particularly important field. 
This has made inorganic chemistry a fast developing area with novel diagnostic and 
therapeutic metal drugs having a significant influence on the field. 
 
The development of metal complexes as new drugs is not an easy undertaking. It is 
important that biodistribution and clearance of the metal complexes are considered, as 
an accumulation of metal ions in the body can have detrimental consequences. It is also 
necessary to investigate the drug‟s pharmacological specificity. Before a drug may be 
entered into clinical trials it is necessary to first show favourable physiological responses 
to in vitro (with targeted biomolecules and tissues) and in vivo (with xenografts and 
animal models) studies.203,204 
 
It is important to understand the mechanism of action that a metal complex uses to 
achieve its activities. This is imperative for the clinical success of the complex in addition 
to the logical planning for new compounds with improved potency.203 This also helps with 
the understanding of undesirable effects and helps to assess the risk the drugs may 
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have for humans. Positively charged metal centres are favoured for the binding to 
negatively charged biomolecules, e.g. proteins and nucleic acids. Consequently, 
numerous prospects exist for the use of metal complexes in the pharmaceutical 
discipline. A broad array of medicinal applications has thus been found for metal 
complexes and the number of complexes gaining wider acceptance is ever increasing.203 
 
In order to investigate and produce new pharmaceutical drugs certain standards and 
criteria must also be taken into account. These drugs need to be designed so that they 
possess the appropriate structure and features. It is important that the drug has 
specificity, which can either be inherent or added onto the structure (e.g. monoclonal 
antibodies, targeting groups). The final drug needs to have a medium to high cytotoxicity 
(LC50 < 10 mM; ideal ca. 10–100 nM) in order to be considered. Another important 
feature is the cost. The expense of making the new drug will need to be cheaper than the 
currently available drugs for it to become market-competitive. For metal drugs it is also 
important to take into account the possible accumulation of metals in the body as this 
may have detrimental effects. 
 
The range of metal complexes to be synthesised for this work are expected to be planar 
structures of aromatic tetradentate (4-nitrogen donor) ligands based on pyridyl ring 
systems (Figure 1.1). The choice of metals for the complexes of these ligands has been 
made with biological activity in mind: platinum(II) and palladium(II). The metals selected 
have previously shown a range of bioactivity in literature, including anti-cancer activity 
(see Sections 1.4.1 and 1.4.2). These ions are capable of introducing a positive net 
charge to the neutral ligand and this coupled with the planar aromatic character of the 
ligand system is expected to afford an efficient DNA intercalator and thus a possible 
topoisomerase I/II inhibitor. The key objective of this research project is, therefore, to 
synthesise, fully characterise, and screen this range of novel metal complexes for their 
cytotoxicity against cancer.  
 
1.3.2 Drug actions against cancer 
There are three main treatments for cancer: 1) Surgery – which can be risky and often 
not possible, 2) Radiation therapy – involves treatment with high-energy X-rays and other 
types of radiation either externally or internally, and 3) Chemotherapy – uses drugs to 
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either inhibit the growth of tumours or to kill the cancer cells.205 The choice and 
particulars of a treatment is dependant on the type and stage of the cancer.  
 
Drugs are classified according to an assortment of criteria: chemical structure, 
pharmalogical action etc. It is necessary to differentiate between a drug‟s action and its 
effects. An action is the biochemical physiological mechanism and the effect is the 
observable consequence of this action. One common problem is the fact that no drug will 
cause a single consequence and therefore more than one effect will be observed. The 
main mode of action therefore needs be selective toxicity; but this is not easy due to 
similarities between normal and abnormal cells. The anti-cancer drugs currently available 
have different mechanisms and hence produce different effects.  It is impossible to find a 
“single cure” for cancer as more than 100 varieties exist.206 
 
Metal ions have a known influence on cellular processes and have shown interesting 
effects on cell division and gene expression. However, they also affect non-natural 
processes, such as antitumour chemistry, carcinogenicity and toxicity. Treatment with 
cisplatin has been successful for a large number of patients and has been determined as 
a DNA cross-linking agent, as has Carboplatin (a successful cisplatin analogue). They 
bind covalently to DNA; favouring the N-7 position of adenine and guanine. Their ability 
to bind to two different sites on DNA causes a “cross-link”, either to two separate DNA 
strands or within the same one. This then hinders the synthesis and transcription of DNA 
and hence impedes the growth of the cancerous cells.206 This has resulted in interest in 
the interaction between other metals and DNA, in particular, the way in which the metals 
binds to DNA.204 
 
The main concern in chemotherapy is to kill the tumour cells without causing too much 
harm to the healthy cells. Drugs used stem from many different sources, some expected: 
from natural products such as plants, microbes and fungi; and some unexpected: from 
dyestuffs and chemical warfare agents.204 There is a possibility with these types of 
treatments that spontaneous (intrinsic) drug resistance may result for certain tumours. 
This may limit certain drug use; however, the resistance may be easily detected which 
allows new drugs to be screened without difficulty.204  A combination of drugs may then 
be used to overcome certain drug resistances. These drugs may operate by different 
approaches as a wide range of mechanisms exist by which cancer drugs may act. 
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Enzyme Inhibitors Some may directly inhibit enzymes and can be reversible or 
irreversible. A competitive inhibition means the drug will compete with the substrate for 
the active site on the enzyme. A noncompetetive inhibition occurs when the drug binds to 
the enzyme at a separate site, but stops the substrate from being able to bind at the 
active site.206 
 
Suppression of Gene Function Supression of gene function may take place in a 
number of the stages involved in protein synthesis or obstructing nucleic acid 
biosynthesis. The drugs inhibiting nucleic acid biosynthesis are not very selective and 
are therefore very toxic.206 
 
Antimetabolites These drugs hold an extraordinary chemical similarity to a standard 
metabolite. This antimetabolite tricks an enzyme and subsequently produces an imitation 
metabolite which is then useless and cell growth is hampered.206 
 
Stop or retard DNA replication The different modes of action involve blocking certain 
steps of the formation of nucleotides or deoxyribonucleotides which are essential for the 
production of DNA. Damage may be caused by disrupting the replication process which 
either completely stops replication or spoils it. Disruption may be caused to the formation 
of spindle cells that are essential for cell splitting.206 
 
Another mechanism used by anti-cancer drugs is that of DNA intercalation.  
 
1.3.3 DNA Intercalation 
The main mode of action expected to be used by the target chelates of the platinum 
group metals in this work is that of DNA intercalation. The mechanism by which these 
compounds work is through insertion between the base pairs. The molecules that bind in 
this manner are therefore known as intercalators due to the way they “intercalate” into 
the compact array of stacked bases. They cause a change in the tertiary structure of the 
DNA helix207 mainly through non-covalent interactions. In the process the double helix is 
deformed and subsequently impedes DNA replication, repair, transcription or 
recombination. Intercalating agents are therefore often known as potent mutagens. 
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DNA has a double helix structure held together by hydrogen bonding between base 
pairs. The DNA helix has two grooves (major and minor) resulting from the way in which 
the two strands defined by the sugar-phosphodiester backbone (which run "antiparallel" 
to one another) are intertwined. There are several enzymes that are responsible for the 
replication of DNA as well as the repair of DNA.208 The ones that are of particular interest 
for this work would be topoisomerase I and II.   
 
Briefly, most DNA is circular or supercoiled until it has to be replicated. It needs to be 
unwound for this process but it is not just a matter of unwinding the DNA as it is usually 
topologically linked or knotted. In order for it to be unwound, the DNA strand/s need to be 
cleaved and reannealed.208 This is where the topoisomerases come into play. 
Topoisomerase I only cleaves one strand and reanneales it, whereas topoisomerase II 
cleaves both strands and reanneals them both.208 This therefore allows supercoiled DNA 
to unwind and replicate.  
 
Some drugs such as topotecan also H-bond to topoisomerase I at the DNA cleavage site 
and irreversibly arrest the enzyme or poison it. When DNA intercalators alter the tertiary 
structure of DNA, topoisomerases no longer recognise their normal substrate 
(undistorted DNA) and therefore are unable to perform their normal function of regulating 
DNA. The mode of action of many DNA intercalators is thus disruption of cell division and 
gene transcription. Inhibition or termination of the unwinding process prevents cell 
replication and initiates programmed cell death (apoptosis).208 This in turn stops the rapid 
rate at which cancer cells usually replicate. 
 
Thus intercalating drugs have to slot in between DNA adjacent bases to impede this 
replication of the strands. When an intercalator binds to the helix the sugar-phosphate 
backbone of the DNA strand is distorted and the DNA is lengthened (as shown in Figure 
1.3).209 This clearly alters the properties of the DNA significantly. This mechanism of 
DNA intercalation (insertion) takes place between the base pairs of the aforementioned 
minor or major grooves. An opening needs to be created by a degree of unwinding of the 
DNA strands, dependant on the intercalator. In turn the drug needs to be of a suitable 
size and chemical nature; the best ligands are usually polycyclic, aromatic and planar. 
The Schiff base ligand systems chosen for this work fit the above criteria. 
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Figure 1.3. A structural view of how a DNA intercalator inserts itself and binds to the DNA helix 
causing deformation and subsequent interference with replication.209 
 
1.4 The metals 
1.4.1 Platinum(II) 
Platinum has been found in the Egyptian tombs dating back as far as 1200 BC and in 
South America from around 100 BC.210 Platinum‟s value today is due to its function in 
many industrial applications. There are two dominant uses for platinum: catalytic 
converters and fine jewellery, which together consume around 70% of the world's 
resources of platinum.211 Platinum is used worldwide in exhaust pipes as catalytic 
converters by converting harmful nitric oxide, hydrocarbons and carbon monoxide into 
harmless emissions. Its use for jewellery is favoured especially in conjunction with 
diamonds due to the clear, non-yellow shine that platinum allows.  Other uses of 
platinum include catalysts, fuel cells, hard disks, electrodes, spark plugs, oxygen 
sensors, turbine engines and anticancer drugs.211, 212,213 
 
The greatest impact on platinum-cancer chemistry was from the discovery of the 
antitumour activity of cis-diaminedichloroplatinum(II),214 commonly known as cisplatin 
(see Section 1.5). It has been a little over 45 years since this discovery and various other 
drugs have since been tested, but those showing promising results are mostly cisplatin 
analogs. However, promising pharmacological character has also been seen for platinum 
complexes with distinctively different DNA binding modes from that of cisplatin.  
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Platinum(II) complexes have shown considerable biological activity as determined in 
cytotoxicity assays.215 DNA binding properties of Pt(II) and Pd(II) complexes have been 
studied in vitro216 and have shown cytotoxicity comparable to that of cisplatin.217 Many of 
the well-known platinum anticancer complexes developed since cisplatin have amine 
ligands. We expect our platinum complexes with imine ligands will have a fundamentally 
different manner of binding to DNA than that of cisplatin. These molecules are most likely 
to be planar with only slight deviations from the plane which should make good examples 
of DNA intercalators.  
 
1.4.2 Palladium(II) 
Palladium was discovered and named by William Hyde Wollaston (6 August 1766 – 22 
December 1828) in 1803.218 As a member of the platinum group metals (PGMs), 
palladium shares many properties with platinum and therefore parallels some of 
platinum‟s uses. Palladium has also been used as an autocatalyst, as well as in 
electronics, jewellery (since 1939), fuel cells, coinage, oil refining, polyester, 
photography, water treatment, hydrogen purification and medicine.219  
 
Due to the results seen for complexes using platinum(II), attention has shifted to other 
platinum group metals. In particular, palladium(II) complexes have found great potential 
as antitumour agents.220,221,222 A strong interaction with DNA has been seen for Pt(II) and 
Pd(II) Schiff bases with pyrimidine rings.223 The DNA helicoidal structure is found to be 
destabilised after in vitro and in vivo studies of the interaction of palladium complexes 
with DNA.224 Ligand exchange has been revealed as a factor for the success with 
platinum drugs, but Pd(II) is known to undergo faster ligand exchange reactions than 
Pt(II). Palladium(II) therefore seems unlikely to follow the same mechanism as some of 
the original platinum(II)-based drugs on the market. Palladium(II) will, however, be a four 
coordinate square planer structure which is expected to have similar properties to that of 
some of the platinum complexes. Therefore appropriately designed palladium complexes 
may find use as DNA intercalators as well. 
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1.5 Drug Discoveries 
1.5.1 Cisplatin 
This compound was first described in 1845225, but its anticancer properties were only 
discovered in 1964. It has been found that cisplatin is able to enter cells by passive 
diffusion226 and also in a different manner, as more recently discovered, by active 
transport mediated by the copper transporter, Ctr1p227,228, in yeast and mammals. The 
cytotoxicity of cisplatin has been shown to be due to its cross-linking binding to DNA that 
interferes with replication and transcription, in turn causing cell death.203 
 
Cisplatin (Figure 1.4), marketed as Platinol®, showed incredible success by providing 
the first cure for small cell lung cancer and improving survival of patients with ovarian 
cancer in the advanced stages. It was also used for bladder, neck and head cancers and 
cured 80% of patients with testicular cancer.229 Unfortunately, side effects and drug 
resistance started to limit cisplatin‟s clinical applications. Biological carriers were then 
added to cisplatin to increase specificity which subsequently reduced side effects and 
drug resistance. Other drugs that are more effective with less toxic side effects, and 
possibly more favourable properties such as solubility in aqueous solution, were 
therefore required. Therefore since the early 1970s more than 3000 platinum complexes 
have been synthesised and tested.230 
 
 
Figure 1.4: The structure of the dimethylformamide solvate of cis-diaminedichloroplatinum(II),231 
known as cisplatin (hydrogen atoms have been excluded for clarity). 
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1.5.2 Platinum-based Drugs 
Even minor modifications to the structure of drugs can have an impact on their biological 
character including their antitumour activity and toxicity. Thus research efforts for 
platinum complexes that might produce more specific anticancer drugs with a broader 
range of antitumour activity have been investigated. Subsequently, a few more platinum-
based drugs have been accepted by the Food and Drug Administration (FDA)232: 
Carboplatin (ovarian cancer)233, Satraplatin (hormone-refractory prostate cancer)234, 
Oxaliplatin (metastatic colorectal cancer)235, and Picoplatin (small-cell lung cancer)236 
(Figure 1.5). Side effects have also been noted for some of these drugs: suppression of 









































Figure 1.5: Some of the platinum-based drugs accepted by the Food and Drug Administration 
(FDA)232 for clinical use in treating cancer. 
 
1.5.3 Examples of Other Cancer Drugs
238,239 
Methotrexate, marketed as Trexall™ (originally approved by FDA on 21 March 2001) is 
an antimetabolite used to treat epidermoid cancers of the head and neck, breast cancer 
and lung cancer (particularly squamous and small cell). It operates by competitive 
inhibition of folic acid reductase to interfere with DNA synthesis, repair and replication. 
 
Carac® (originally approved by FDA on 27 October 2000) contains fluorouracil which is 
an antimetabolite and obstructs the methylation reaction of deoxyuridylic acid to 
thymidylic acid. It has found use on the skin treating pre-cancerous and cancerous skin 
growths. 
 
Hydrea® (originally approved by FDA on 7 December 1967) is an antineoplastic agent, 
of which the mechanism cannot currently be described. It contains hydroxyurea which 
Carboplatin Satraplatin Oxaliplatin Picoplatin 
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affects cancer cells or sickled red blood cells in the body. It has been used to treat 
melanoma, primary squamous cell (epidermoid) carcinomas of the head and neck, 
chronic myelocytic leukemia and recurrent, metastatic, or inoperable carcinoma of the 
ovary.  
Mercaptopurine is in a cancer medication sold as Purinethol™ (originally approved by 
FDA on 11 September 1953) and is also an antimetabolite. It inhibits the biosynthesis of 
adenine nucleotides and has been used to treat acute lymphatic leukemia or acute 
myelogenous leukemia. 
 
Cerubidine® (originally approved by FDA on 3 February 1995) has antimitotic and 
cytotoxic activity owing to a number of proposed mechanisms of action, including 
inhibiting topoisomerase II. Its active ingredient is daunorubicin hydrochloride and it has 
shown an antitumour effect against a range of animal tumours. 
 
Doxorubicin hydrochloride is the active ingredient in Doxil® (originally approved by FDA 
on 17 November 1995). It is an anthracycline topoisomerase inhibitor indicated for 
patients with ovarian cancer, where the disease has advanced or recurred after platinum-
based chemotherapy.  
 
Taxol® (originally approved by FDA on 29 December 1992) contains pacitaxel which is a 
novel antimicrotubule agent that promotes the assembly of microtubules from tubulin 
dimers and stabilises microtubules by preventing depolymerisation. It has been indicated 
as initial and ensuing therapy for the treatment of advanced carcinoma of the ovary, as 
well as breast cancer. In combination with cisplatin it has been used to treat non-small 
cell lung cancer. 
 
Mitomycin® (originally approved by FDA on 19 April 1995) has an active ingredient of the 
same name. It is not recommended as a single-agent, but has shown usefulness in 
conjunction with other chemotherapeutic drugs in treating disseminated 
adenocarcinoma. It is a potent DNA cross-linker and has also been used for breast, 
oesophageal and bladder cancers. 
 
Carmustine is the active ingredient in Gliadel® (originally approved by FDA on 23 
September 1996), which is a nitrosourea oncolytic agent. It has been indicated for brain 
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tumours; producing an antineoplastic effect by alkylating DNA and RNA. It also found 
use in treating newly-diagnosed high grade malignant glioma and recurrent glioblastoma 
multiforme. 
 
Camptosar® (originally approved by FDA on 14 June 1996) contains irintecan which is a 
derivative of cemptothecin. Its cytotoxicity has been shown to be caused by double-
strand DNA damage created during DNA synthesis when replication enzymes interact 
with the ternary complex. This drug has found use for metastatic carcinoma of the colon 
or rectum; either as combination first-line therapy or when the disease has recurred or 
progressed. 
 
Recently, the discovery that a metal compound does not have to be extremely cytotoxic 
to have effective anti-cancer properties was made. Some promising discoveries have 
been made for the metals gallium240 and ruthenium241 (which have mainly anti-metastatic 
effects – prevent the spreading of cancers or are discriminatory for metastases), as well 
as for gold242 (Figure 1.6). 
 
Even though some complexes have successfully been through Phase I and II human 
clinical trials, the mechanisms of their action are still often (but not always) unknown. The 
combination of different drugs that have varying modes of action often synergises their 
effects. Thus there is continued interest in the various metallopharmaceutical 
mechanisms due to the anticipation that together they might provide an even wider range 









































Figure 1.6: Structures of oral gallium complexes240 (left) and gold(III)–porphyrin complexes242 
(right) that have been used for cancer treatment. 
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1.6 Feasibility and Objectives 
The metals chosen for this research have all shown some kind of bioactivity, particularly 
as anticancer drugs. The biological activity of various drugs containing platinum is well 
documented203,204,244 and palladium has also found bioactive applications.220,221,222 
 
The best ligands for DNA intercalators are usually polycyclic, aromatic and planar. The 
ligand systems synthesised as the basis of this work fit the above criteria, and in 
combination with the bioactive metals, result in complexes that are likely to present some 
interesting activity towards cancer cells. Our work is also novel as very little literature 
concerning the metallation of Schiff base ligands (particularly those similar in structure to 
our choice of ligands) could be found with platinum or palladium.  
 
In planning the present study, we anticipated that the complexes of interest would 
function well as DNA intercalators due to several key design criteria. The overall positive 
charge on the complex will effectively target the negatively charged DNA double helix 
electrostatically and bind by π–π stacking with pyrimidine and purine bases. This results 
in their mode of action in most cases being to inhibit topoisomerase II. We have already 
seen positive results for similar ligands (patent pending) and therefore expect that the 
slightly larger aromatic rings and extended π-electron system in pyridine-based ligands 
should enhance the DNA-binding affinity of the compound relative to related N-
heterocycle analogues. With the total charge of the cation being +2 we anticipate 
improved cytotoxicity due to improved electrostatic contributions to the recognition of 
DNA. The literature also shows other agents with similar metals and ligands that have 
already displayed biological activity (as discussed). 
 
The principal objectives for this work were to: 
(1) synthesise a range of free Schiff base ligands (some novel and some currently 
known); 
(2) fully characterise all these free ligands using UV-Vis, IR and liquid 
chromatography mass spectrometry (LC-MS), as well as 1H and 13C NMR 
spectroscopy; 
(3) metallate these free ligands with platinum(II) and palladium(II); 
(4) fully characterise the resulting metal complexes using UV-Vis, IR and 1H, 13C and 
195Pt NMR spectroscopy; 
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(5) obtain X-ray crystal structures for the free ligands and metal complexes, where 
possible; 
(6) perform DFT computational studies for each of these free ligands and their 
respective metallated derivatives; 
(7) observe and investigate the similarities and differences between DFT simulation 
data and X-ray structures; 
(8) screen the metal complexes against a range of cancer cells to determine their 
bioactivity; and 
(9) perform titrations of the metal complexes with DNA using electronic absorption 
spectroscopy in order to determine equilibrium constants. 
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CHAPTER 2 – Experimental 
 
2.1 General Information 
Solvents were obtained from Merck and were used as received, unless otherwise stated. 
Hexane was dried by distillation over pressed sodium wire. Tetrahydrofuran (THF) was 
dried by distillation over Na/K alloy and absolute ethanol was dried using activated 
molecular sieves (3 Å). Acetonitrile was dried using an Innovative Technology PurSolv 
solvent purification system. 
 
The six diamines:    1,2-diaminoethane (≥99.5%),    1,3-diaminopropane (99%),          
1,3-diaminopropan-2-ol (95%), 1,3-diamino-2,2-dimethylpropane (99%),                       
cis-1,2-diaminocyclohexane (97%) and 1,2-diaminophenylene (99.5%); and the metal 
precursors potassium tetrachloroplatinate (K2[PtCl4], 99.99%) and potassium 
tetrachloropalladate (K2[PdCl4], 98%), were all used as received from Aldrich. 
 
2-Pyridinecarboxaldehyde (99%, Aldrich) was stored at 6 ºC until use. 2-Acetylpyridine 
(≥99%, Aldrich) and 2-benzoylpyridine (≥99%, Aldrich) were stored at room temperature. 
Silver hexafluoroantimonate (AgSbF6, 98%), silver tetrafluoroborate (AgBF4, 98%) and 
silver hexafluorophosphate (AgPF6, 98%) were obtained from Aldrich and stored and 
dispensed under inert conditions. 
 
2.2 Instrumentation 
Electronic UV-Vis spectra were recorded using a UV-1800 Shimadzu spectrophotometer. 
FT-IR spectra were obtained on a Bruker Alpha-P spectrometer with a diamond ATR 
crystal (36 scans, spectral resolution ≥ 2.0 cm 1).  
 
1H, 13C and 195Pt NMR spectra of solutions of the ligands and complexes were recorded 
using either a Bruker Avance 500 (11.7 T Oxford magnet) or Bruker Avance 400 (9.4 T 
Bruker magnet) equipped with a 5 mm BBO-Z probe. The proton and carbon NMR 
spectra were assigned with the use of DEPT and 2D COSY and HSQC data. Coupling 
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constants are reported as averages calculated from peak separations measured with 
SpinWorks.245  
 
Molecular weights, for the ligands and metal complexes, were obtained using 
electrospray ionisation in the positive and negative modes (sample specific) on a Waters 
LCT Premier mass spectrometer. 
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Figure 2.1: A basic framework of the Schiff base structure showing the notation used for 
labelling the atoms for each free ligand. 
 
2.3.1 Synthesis of N,N'-bis[(pyridin-2-yl)methylene]diamine 
Where diamine = 1,2-diaminoethane (L1),129,139 1,3-diaminopropane (L2)127, 129, 146 or cis-
1,2-diaminocyclohexane (L5).152,158 
 
To a solution of 2-pyridinecarboxaldehyde (1.50 mL, 15.8 mmol) in absolute ethanol (15 
mL) at 40 ºC, was added dropwise the respective diamine (7.90 mmol). The resulting 
solution was heated at reflux for a period of 6 hours and thereafter the resulting solution 
was cooled to room temperature. The solution was dried by the addition of anhydrous 
MgSO4, which was subsequently removed by filtration. The filtrate was then passed 
through a column of aluminium oxide with dichloromethane (DCM) as the eluting solvent 
to remove any traces of starting material. The yellow/orange liquid was concentrated to 
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afford an oil from which the product either precipitated as a yellow-orange solid (L1 and 
L5) upon standing, or remained as an oil (L2). 
 
L1: Yield: 1.244 g, 66%. UV-Vis (CH3OH; λmax, nm): 235.0, 272.5. 
1H NMR (500 MHz, 
CD3OD) [δ, ppm]: 8.55 (d of q, J = 40.7, 2H, Ha), 8.38 (s, 2H, He), 7.97 (d, J = 7.8, 2H, 
Hd), 7.78 (t of d, J = 7.7, 1.6, 2H, Hc), 7.36 (m, 2H, Hb), 4.04 (s, 4H, Hf) 
13C NMR (125 
MHz, CD3OD) [δ, ppm]: 163.5 (Ci), 153.7 (Cp), 149.0 (Ca), 137.2(Cc), 125.3 (Cb), 121.6 
(Cd), 60.9 (Cf). IR (cm
-1): 3051, 3007, 2903, 2866, 2842, 1648, 1585, 1567, 1465, 1435, 
1348, 1283, 1226, 1197, 1152, 1092, 1044, 1022, 991, 977, 957, 871, 796, 772, 742, 
663, 617, 518, 470, 406. HR-ESI-MS: m/z 261.1119 [M+Na]+ calculated for C14H14N4Na 
261.1116. 
 
L2: Yield: 1.674 g, 84%. UV-Vis (CH3OH; λmax, nm): 235.5, 272.5. 
1H NMR (400 MHz, 
CD3OD) [δ, ppm]: 8.63 (d of d, J = 4.8, 2H, Ha), 8.41 (s, 2H, He), 7.99 (d, J =  8.1, 2H, 
Hd), 7.72 (t of d, J = 7.7, 1.7, 2H, Hc), 7.29 (m, 2H, Hb), 3.79 (s, 4H, Hf), 2.16 (p, J = 6.9, 
2H, Hg). 
13C NMR (125 MHz, CD3OD) [δ, ppm]: 162.2(Ci), 153.9 (Cp), 148.9 (Ca), 137.3 
(Cc), 125.2 (Cb), 121.4 (Cd), 58.5 (Cf), 31.2 (Cg). IR (cm
-1): 3400, 3296, 3279, 3053, 
3009, 2925, 2886, 2841, 1647, 1586, 1567, 1467, 1435, 1333, 1293, 1227, 1147, 1044, 
1022, 991, 974, 860, 770, 742, 654, 616, 501, 405. HR-ESI-MS: m/z 275.1274 [M+Na]+ 
calculated for C15H16N4Na 275.1273. 
 
L5: Yield: 1.789 g, 78%. UV-Vis (CH3OH; λmax, nm): 237.0, 273.0. 
1H NMR (500 MHz, 
CDCl3) [δ, ppm]: 8.60 (d of q, J = 5.0, 2H, Ha), 8.35 (s, 2H, He), 8.03 (d, J = 7.9, 2H, Hd), 
7.68 (t of d, J = 7.7, 1.6, 2H, Hc), 7.27 (m, 2H, Hb), 3.71 (m, 2H, Hf), 2.11 (m, 2H, Hg), 
2.04 (m, 2H, Hh), 1.77 (m, 2H, Hg), 1.60 (m, 2H, Hh). 
13C NMR (125 MHz, CDCl3) [δ, 
ppm]: 166.0 (Ci), 155.1 (Cp), 149.1 (Ca), 136.4 (Cc), 124.4 (Cb), 121.2 (Cd), 70.0 (Cf), 30.9 
(Cg), 22.9 (Ch). IR (cm
-1): 3059, 3012, 2957, 2925, 2898, 2854, 1649, 1638, 1585, 1563, 
1467, 1445, 1435,  1379, 1336, 1327, 1316, 1288, 1226, 1194, 1147, 1138, 1131, 1071, 
1042, 992, 978, 967, 931, 895, 875, 856, 819, 790, 772, 747, 740, 686, 666, 648, 621, 
617, 596, 516, 484, 448, 409. HR-ESI-MS: m/z 315.1587 [M+Na]+ calculated for 
C18H20N4Na 315.1586. 
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To a stirred solution of 2-pyridinecarboxaldehyde (1.00 mL, 10.5 mmol) in acetonitrile (20 
mL), was added dropwise 1,3-diaminopropan-2-ol (0.47 mL, 5.30 mmol). The resulting 
solution was heated to 40 ºC for an hour and then left to stir at room temperature for     
72 hours. The solution was concentrated yielding a dark-yellow oil. Several aliquots of 
ether were used to extract a clean yellow oil, leaving behind a dirty green residue. The 
ether was evaporated and the yellow oil was collected. 
 
Yield: 1.391g, 98%. UV-Vis (CH3OH; λmax, nm): 237.0, 267.0, 280.5 (sh), 272.0. 
1H NMR 
(400 MHz, CDCl3) [δ, ppm]: 8.63 (ddd, 2H, J = 4.8, 1.8, 0.9, Ha), 8.48 (s, 2H, He), 7.99 
(ddd, J = 8.0, 1.3, 0.9, 2H, Hd), 7.72 (m, 2H, Hc), 7.30 (m, 2H, Hb), 5.18 (s, O-H), 4.29 (m, 
1H, Hg), 3.90 (ddd, J = 12.4, 4.7, 1.5, 2H, Hf), 3.85 (ddd, J =12.4, 6.7, 1.5, 2H, Hf). 
13C 
NMR (125 MHz, CDCl3) [δ, ppm]: 163.9 (Ci), 154.3 (Cp), 149.5 (Ca), 136.6 (Cc), 124.9 
(Cb), 121.4 (Cd), 70.8 (Cg), 64.6 (Cf). IR (cm
-1): 3336, 3316, 3308, 3295, 3290, 3282, 
3275, 3014, 2908, 2896, 1711, 1649, 1590, 1568, 1471, 1437, 1366, 1301, 1228, 1150, 
1088, 1028, 999, 860, 772, 743, 662, 624, 501, 405. HR-ESI-MS: m/z 269.1404 [M]+ 
calculated for C15H17N4O 169.1402. 
 
2.3.3 Synthesis of N,N'-bis[(pyridin-2-yl)methylene]1,3-
diamino-2,2-dimethylpropane (L4)
149 
To a stirred solution of 2-pyridinecarboxaldehyde (1.50 mL, 15.8 mmol) in 2-propanol (10 
mL), was added dropwise 1,3-diamino-2,2-dimethylpropane (0.66 mL, 7.90 mmol) 
dissolved in 2-propanol (10 mL). The resulting solution was then stirred at room 
temperature for 24 hours. The solution was concentrated and the resulting dark orange 
oil solidified into a low melting dark orange solid on standing.  
 
Yield: 1.511 g, 68%. UV-Vis (CH3OH; λmax, nm): 236.5, 272.0. 
1H NMR (500 MHz, 
CDCl3)     [δ, ppm]: 8.52 (d of q, J = 5.0, 2H, Ha), 8.31 (s, 2H, He), 7.98 (d of t, J = 8.1, 
2H, Hd), 7.63 (t of d, J = 7.8, 1.6, 2H, Hc), 7.19 (m, 2H, Hb), 3.52 (d, J = 1.4, 4H, Hf), 0.98 
(s, 6H, Hh). 
13C NMR (125 MHz, CDCl3) [δ, ppm]: 162.0 (Ci), 154.6 (Cp), 149.0 (Ca), 
136.3 (Cc), 124.4 (Cb), 120.8 (Cd), 69.8 (Cf), 36.9 (Cg), 24.4 (Ch). IR (cm
-1): 3275, 3046, 
3004,  2957, 2937, 2900, 2879, 2866, 2833,  1645, 1585, 1566, 1466, 1436,  1384, 
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1365, 1331, 1290, 1255, 1227, 1188, 1166, 1144, 1096, 1056, 1041, 1024, 990, 958, 
948, 920, 895, 857, 847,  775, 758, 745, 668, 618,  503, 492, 431, 408. HR-ESI-MS: m/z 
303.1578 [M+Na]+ calculated for C17H20N4Na 303.1586. 
 
2.3.4 Synthesis of N,N'-bis[(pyridin-2-yl)methylene]1,2-
diaminophenylene (L6)
162 
To a solution of 2-pyridinecarboxaldehyde (0.72 mL, 7.61 mmol) in acetonitrile (20 mL), 
was added dropwise a solution of 1,2-diaminophenylene (0.37 g, 3.38 mmol) in 
acetonitrile (10 mL). The resulting solution was heated to 40 ºC for 1 hour and thereafter 
left to stir at room temperature for a period of 72 hours. The solution was filtered to 
remove a fluffy pale orange solid that had formed.* The filtrate evaporated and gave a 
yellow powder found to contain  
 
Yield: ~ 0.2 g, ~ 19%. UV-Vis (CH3OH; λmax, nm): 214.0 (sh), 239.5, 264.0, 309.0, 322.0 
(sh). IR (cm-1): 3294, 3112, 3051, 2166, 2151, 2001, 1714, 1675, 1588, 1569, 1524, 
1438, 1314, 1279, 996, 797, 740, 702, 692, 677, 614, 542, 499, 429, 420, 403. LR-ESI-
MS: m/z 309.11 [M+Na]+ C18H14N4Na and 218.06 [M+Na]
+ C12H9N3Na. 
 
2.3.5 Synthesis of N,N'-bis[(pyridin-2-yl)ethylene]diamine  
Where diamine = 1,2-diaminoethane (L1m),138 1,3-diaminopropane (L2m)146 or cis-1,2-
diaminocyclohexane (L5m). 
 
To a solution of 2-acetylpyridine (3.35 mL, 29.9 mmol (L1m); 2.69 mL, 24.0 mmol (L2m); 
0.76 mL, 6.80 mmol (L5m)) in absolute ethanol (20 mL), was added dropwise a solution 
of the corresponding diamine (1.00 mL, 14.9 mmol (L1m); 10.0 mL, 11.2 mmol (L2m); 
0.40 mL, 3.40 mmol (L5m)) in ethanol (10 mL). The resulting solution was heated at 
reflux for a period of 23 hours.† The solution was then cooled to room temperature and 
passed through a column of aluminium oxide with DCM as the eluting solvent to remove 
any traces of starting material. The low melting solids were collected and weighed. 
 
                                                 
*
 This pale orange solid was found to be the cyclised imidazole-containing bidentate ligand: L6h. See 
2.3.13 b) for characterisation details. 
†
 2-Acetylpyridine (0.50 mL, 4.50 mmol) was added to the reaction mixture of L5m after 15 hours at reflux. 
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L1m: Yield: 2.862 g, 72%. UV-Vis (CH3OH; λmax, nm): 231.0, 262.0, 268.0 (sh). 
1H NMR 
(500 MHz, CDCl3) [δ, ppm]: 8.54 (d, 2H, Ha), 7.97 (d, 2H, Hd), 7.57 (m, 2H, Hc), 7.12 (m, 
2H, Hb), 3.86 (s, 4H, Hf), 2.35 (s, 6H, He). 
13C NMR (125 MHz, CDCl3) [δ, ppm]: 167.4 
(Ci), 157.7 (Cp), 148.5 (Ca), 136.4 (Cc), 122.1 (Cb), 120.9 (Cd), 52.8 (Cf), 14.9 (Ce). IR 
(cm-1): 3356, 3324, 3297, 3051, 3002, 2972, 2929, 2872, 1697, 1638, 1585, 1566, 
1465, 1430, 1357, 1344, 1297, 1282, 1238, 1149, 1135, 1083, 1045, 993, 957, 779, 745, 
700, 620, 588, 550, 403. LR-ESI-MS: m/z 289.12 [M+Na]+ C16H18N4Na. 
 
L2m: Yield: 2.600 g, 83%. UV-Vis (CH3OH; λmax, nm): 231.0, 261.0, 264.5 (sh). 
1H NMR 
(500 MHz, CDCl3) [δ, ppm]: 8.52 (d, 2H, Ha), 7.96 (d, 2H, Hd), 7.58 (m, 2H, Hc), 7.15 (m, 
2H, Hb), 3.69 (t, 4H, Hf), 3.42 (pent, 2H, Hg), 2.34 (m, 6H, He). 
13C NMR (125 MHz, 
CDCl3) [δ, ppm]: 166.9 (Ci), 157.4 (Cp), 148.7 (Ca), 136.3 (Cc), 122.1 (Cb), 121.1 (Cd), 
50.2 (Cf), 37.8 (Cg), 13.7 (Ce). IR (cm
-1): 3372, 3350, 3325, 3308, 3052, 3002, 2930, 
2866, 1698, 1637, 1585, 1565, 1464, 1431, 1355, 1298, 1283, 1239, 1203, 1150, 1117, 
1091, 1044, 993, 975, 900, 782, 744, 719, 589, 576, 542, 499, 461, 405. LR-ESI-MS: 
m/z 303.14 [M+Na]+ C17H20N4Na. 
 
L5m: Yield: 0.975 g, 89%. UV-Vis (CH3OH; λmax, nm): 220.0 (sh), 262.0, 268.0 (sh), 
299.0. 1H NMR (400 MHz, CDCl3) [δ, ppm]: 8.56 (d, 2H, Ha), 7.97 (d, 2H, Hd), 7.56 (t, 2H, 
Hc), 7.16 (m, 2H, Hb), 3.87 (m, 2H, Hf), 2.37 (m, 6H, He), 1.94 and 1.72 (m, 4H and 4H, 
Hg and Hh). IR (cm
-1): 3053, 3005, 2930, 2857, 1698, 1666, 1584, 1567, 1465, 1434, 
1357, 1296, 1282, 1238, 1149, 1100, 1043, 995, 954, 897, 778, 732, 701, 622, 589, 404. 
HR-ESI-MS: m/z 319.1919 [M]+ calculated for C20H23N4 319.1923. 
 
2.3.6 Synthesis of N,N'-bis[(pyridin-2-yl)ethylene] 1,3-
diaminopropan-2-ol (L3m) 
To a solution of 2-acetylpyridine (0.75 mL, 6.66 mmol) in absolute ethanol (10 mL), was 
added dropwise 1,3-diaminopropan-2-ol (0.30 g, 3.33 mmol) in absolute ethanol (10 mL). 
The resulting solution was heated at reflux for a period of 9 hours and thereafter cooled 
to room temperature. The cooled solution was passed through a column of aluminium 
oxide with DCM as the eluting solvent to remove any traces of starting material.The 
solvent was removed and the resulting yellow-brown oil was collected. 
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Yield: 0.611 g, 62%. UV-Vis (CH3OH; λmax, nm): 231.0, 261.0, 266. (sh). 
1H NMR (400 
MHz, CDCl3) [δ, ppm]: 8.58 (d, 2H, Ha), 7.80 (d, 2H, Hd), 7.67 (t, 2H, Hc), 7.16 (m, 2H, 
Hb), 5.46 (s, O-H), 4.37 (m, 1H, Hg), 3.71 (m, 4H, Hf), 2.40 (s, 6H, He). IR (cm
-1): 3291, 
3051, 3003, 2974, 2924, 2870, 1697, 1637, 1586, 1566, 1465, 1430, 1358, 1283, 1239, 
1174, 1152, 1093, 1044, 993, 957, 897, 857, 827, 782, 732, 700, 621, 547, 493, 404. 
LR-ESI-MS: m/z 319.13 [M+Na]+ C17H20N4ONa. 
 




To a solution of 2-acetylpyridine (2.25 mL, 20 mmol) in methanol (20 mL), was added 
dropwise 1,3-diamino-2,2-dimethylpropane (0.84 g, 10 mmol) in methanol (20 mL). The 
resulting solution was heated at reflux for a period of 8 hours and thereafter cooled to 
room temperature. The solution was dried by the addition of anhydrous MgSO4, which 
was subsequently removed by filtration, washing with dichloromethane (~ 10 mL). When 
solvent was removed from the filtrate an orange oil was obtained.  
 
Yield: 2.723 g, 89%. UV-Vis (CH3OH; λmax, nm): 259.0 (sh), 266.0, 280.0 (sh), 299.0. 
1H 
NMR (500 MHz, CDCl3) [δ, ppm]: 8.56 (d, J = 4.5, 2H, Ha), 7.73 (d, J = 7.9, 2H, Hd), 7.65 
(t of d, J = 7.5, 1.8, 2H, Hc), 7.14 (t of d, J = 6.1, 1.3, 2H, Hb), 2.52 (d, J = 13.1, 2H, Hf), 
2.38 (d, J = 13.0, 2H, Hf), 1.38 (s, 6H, He), 1.11 (s, 6H, Hh). 
13C NMR (125 MHz, CDCl3) 
[δ, ppm]: 163.6 (Ci), 155.7 (Cp), 148.9 (Ca), 136.6 (Cc), 127.0 (Cb), 121.6 (Cd), 71.0 (Cg), 
53.2 (Cf), 31.6 (Ce), 23.5 (Ch). IR (cm
-1): 3323, 3315, 3052, 3004, 2950, 2924, 2902, 
2864, 1699, 1641, 1587, 1567, 1465, 1429, 1384, 1365, 1297, 1283, 1239, 1201, 1150, 
1097, 1045, 993, 953, 909, 865, 834, 781, 743, 719, 645, 621, 574, 509, 491, 420, 404. 
HR-ESI-MS: m/z 309.2076 [M]+ calculated for C19H25N4 309.2079. 
 
2.3.8 Synthesis of N,N'-bis[(pyridin-2-yl)methylene]1,2-
diaminophenylene (L6m) 
To a solution of 2-acetylpyridine (1.04 mL, 9.25 mmol) dissolved in absolute ethanol    
(20 mL), was added dropwise a solution of 1,2-diaminophenylene (0.50 g, 4.62 mmol) in 
absolute ethanol (10 mL). The resulting solution was heated at reflux for a period of 7 
hours and thereafter cooled to room temperature. The solution was dried by the addition 
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of anhydrous MgSO4, which was subsequently removed by filtration. The filtrate was 
concentrated to afford an orange-yellow oil which was redissolved in diethyl ether. 2-
Aetylpyridine (0.425 mL, 3.80 mmol) was added to the reaction mixture which was then 
heated to reflux for a further 14 hours. A dark, shiny mass was collected by evaporation.  
 
Yield: 1.297 g, 89%. UV-Vis (CH3OH; λmax, nm): 255.0, 331.0 (sh), 426.0 (sh). 
1H NMR 
(500 MHz, CDCl3) [δ, ppm]: 8.79 (d, J = 4.4, 2H, Ha), 8.60 (d, J = 8.0, 2H, Hd), 8.16 (m, 
2H, Hg), 7.90 (t of d, J = 7.7, 1.8, 2H, Hc), 7.79 (m, 2H, Hh), 7.41 (t of d, J = 4.8, 1.1, 2H, 
Hb), 2.63 (s, 2H, He). 
13C NMR (125 MHz, CDCl3) [δ, ppm]: 163.7 (Ci), 154.6 (Cp), 149.4 
(Ca), 141.8 (Cf), 137.2 (Cc), 130.1 (Ch), 129.7 (Cg), 124.6 (Cb), 122.1 (Cd), 26.4 (Ce). IR     
(cm-1): 3352, 3064, 2973, 2926, 2893, 1696, 1649, 1613, 1587, 1569, 1467, 1452, 
1437, 1359, 1299, 1283, 1239, 1151, 1087, 1045, 995, 956, 879, 804, 780, 743, 623, 
590, 495, 430, 395. HR-ESI-MS: m/z 337.1427 [M+Na]+ calculated for C20H18N4Na 
337.1429. 
 
2.3.9 Synthesis of N,N'-bis[phenyl(pyridin-2-yl)methylene]diamine  
Where diamine = 1,2-diaminoethane (L1b)189 or 1,3-diaminopropane (L2b).189 
 
A solution of 2-benzoylpyridine (1.00 g, 5.46 mmol) was stirred with the respective 
diamine (2.73 mmol) in absolute ethanol (15 mL). The resulting mixture was heated at 
reflux for 7 hours and thereafter cooled to room temperature. On prolonged standing the 
solutions both produced white precipitates which were filtered and washed with diethyl 
ether (L1b and L2b).‡ The white crystals isolated from the reaction mixture of L1b 
contained a mixture of L1b and L1bh.  
 
L1b: Yield: 0.537 g, 50%. UV-Vis (CH3OH; λmax, nm): 248.0. 
1H NMR (500 MHz, DMSO-
d6) [δ, ppm]: 8.47 (d, J = 4.5 2H, Ha), 8.10 (d, J = 7.8, 2H, Hd), 7.89 t, J = 7.8, 2H, Hc), 
7.46 (m, 6H, He3,4,5), 7.41 (q, J = 6.2, 2H, Hb), 7.17 (d, J = 8.0, 4H, He2,6), 3.74 (s, 4H, Hf). 
13C NMR (125 MHz, DMSO-d6) [δ, ppm]: 168.9 (Ci), 157.4 (Cp), 148.8 (Ca), 137.2 (Ce1), 
137.0 (Cc), 128.7 (Ce3,4,5), 128.5 (Cb), 128.4 (Ce2,6), 122.1 (Cd), 54.9 (Cf). IR (cm
-1): 
3079, 3052, 3025, 3007, 2940, 2908, 2831, 1665, 1623, 1583, 1465, 1442, 1434, 1280, 
1247, 1180, 1153, 1075, 1047, 1017, 992, 954, 914, 902, 800, 777, 760, 741, 727, 703, 
                                                 
‡
 The ether filtrates produced the cyclised imidazole- or hexahydropyrimidine-containing bidentate ligands 
on standing. See 2.3.13 c) for characterisation details. 
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685, 664, 622, 568, 496, 461, 409. HR-ESI-MS: m/z 413.1734 [M+Na]+ calculated for 
C26H22N4Na 413.1742. 
 
L2b: Yield: 0.067 g, 6%. UV-Vis (CH3OH; λmax, nm): 250.0. 
1H NMR (500 MHz, CDCl3) 
[δ, ppm]: 8.57 (d, J = 3.8, 2H, Ha), 8.09 (d, J = 7.6, 2H, Hd), 7.92  (t, J = 8.1, 2H, Hc), 7.42 
(m, 6H, He3,4,5), 7.25 (m, 2H, Hb), 7.18 (d, J = 7.0, 4H, He2,6), 3.57 and 3.49 (m, 4H, Hf), 
2.13 (m, 2H, Hg).
 13C NMR (125 MHz, CDCl3) [δ, ppm]: 168.3 (Ci), 157.6 (Cp), 149.0 (Ca), 
136.7 (Cc), 136.4 (Ce1), 128.3 (Ce3,4,5), 123.8 (Cb), 122.0 (Ce2,6), 122.8 (Cd), 52.2 and 
51.5 (Cf), 32.7 (Cg). IR (cm
-1): 3051, 3023, 3005, 2984,  2926, 2896, 2878, 2861, 1662, 
1627, 1582, 1567, 1462, 1446, 1431, 1379, 1353, 1308, 1282, 1245, 1157, 1131, 1105, 
1092, 1074, 1046, 1028, 1009, 981, 939, 909, 859, 818, 772, 744, 698, 650, 626, 599, 
584, 516, 401. HR-ESI-MS: m/z 427.1900 [M+Na]+ calculated for C27H24N4Na 427.1899. 
 
2.3.10 Synthesis of N,N'-bis[phenyl(pyridin-2-yl)methylene] 
diamine 
Where diamine = 1,3-diaminopropan-2-ol (L3b) or 1,3-diamino-2,2-dimethylpropane 
(L4b). 
 
A solution of 2-benzoylpyridine (1.00 g, 5.46 mmol) was stirred with the respective 
diamine (1,3-diaminopropan-2-ol (0.25 g, 2.73 mmol) or 2-dimethyl-1,3-propanediamine 
(0.28 g, 2.73 mmol)) in absolute ethanol (10 mL). The resulting mixture was heated at 
reflux for 7 hours and thereafter cooled to room temperature. The solvent was removed 
from the L3b reaction mixture and the resulting oil was redissolved in DCM and cold 
hexane was added. The resulting mixture was decanted leaving the residue (found to 
contain mostly the cyclised hexahydropyrimidine-containing bidentate ligand) behind. 
The dichloromethane was evaporated and the yellow oil was collected and weighed. On 
standing the solution of L4b produced a white crystalline solid that was filtered off.§ The 
remaining solution was collected and additional 2-benzoylpyridine (0.41 g, 2.24 mmol) 
was added. The mixture was heated at reflux in absolute ethanol (15 mL) for 13 hours. A 
crystalline pale yellow solid was collected by filtration and washed with diethyl ether. 
 
                                                 
§
 The white crystals were the cyclised hexahydropyrimidine-containing bidentate ligand (L4bh). See 2.3.13 
d) for characterisation details. 
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L3b: Yield: ~ 0.8 g, ~ 70%. UV-Vis (CH3OH; λmax, nm): 255.0. 
1H NMR (500 MHz, CDCl3) 
[δ, ppm]: 8.56 (d, J = 4.8 2H, Ha), 8.01 (d, J = 7.8, 2H, Hd), 7.70 (t, J = 7.9, 2H, Hc), 7.39 
(m, 6H, He3,4,5), 7.29 (t, J = 7.2, 2H, Hb), 7.07 (m, J = 8.0, 4H, He2,6), 5.88 (s, 1H, O-H), 
4.48 (m, 1H, Hg), 3.48 and 3.18 (m, 3.4, 4H, Hf). 
13C NMR (125 MHz, CDCl3) [δ, ppm]: 
167.6 (Ci), 157.3 (Cp), 148.9 (Ca), 136.3 (Cc), 136.1 (Ce1), 128.2 (Ce3,4,5), 123.9 (Cb), 
122.6 (Ce2,6), 122.5 (Cd), 77.5 (Cg), 57.8 (Cf). IR (cm
-1): 3308, 3298, 3055, 3005, 2924, 
1662, 1630, 1583, 1567, 1466, 1447, 1432, 1302, 1282, 1245, 1157, 1093, 1047, 1028, 
993, 940, 823, 798, 770, 746, 697, 651, 616, 571, 535, 402. HR-ESI-MS: m/z 443.1853 
[M+Na]+ calculated for C27H24N4ONa 443.1848. 
 
L4b: Yield: 0.425 g, 36%. UV-Vis (CH3OH; λmax, nm): 251.0. 
1H NMR (500 MHz, CDCl3) 
[δ, ppm]: 8.52 (d, J = 4.5 2H, Ha), 8.07 (d, J = 7.7, 2H, Hd), 7.71 (m, 2H, Hc), 7.41 (m, 6H, 
He3,4,5), 7.23 (t, J = 6.8, 2H, Hb), 7.16 (m, 4H, He2,6), 3.41 (d, J = 1.6, 4H, Hf), 1.04 (s, 6H, 
Hh).
 13C NMR (125 MHz, CDCl3) [δ, ppm]: 168.0 (Ci), 158.0 (Cp), 148.7 (Ca), 136.3 (Ce1), 
136.0 (Cc), 128.0 (Ce2,3,4,5,6), 123.7 (Cb), 122.1 (Cd), 62.2 (Cf), 37.8 (Cg), 24.7 (Ch).  IR 
(cm-1): 3080, 3057, 3045, 3021, 3000, 2972, 2949, 2897, 2876, 2831, 1626, 1583, 
1564, 1490, 1465, 1447, 1425, 1381, 1351, 1314, 1296, 1281, 1243, 1211, 1176, 1149, 
1092, 1076, 1047, 1024, 992, 961, 942, 890, 846, 793, 777, 749, 694, 649, 616, 602, 
509, 463, 433, 400. HR-ESI-MS: m/z 455.2214 [M+Na]+ calculated for C29H28N4Na 
455.2212. 
 
2.3.11 Synthesis of N,N'-bis[phenyl(pyridin-2-yl)methylene]- 
1,2-diaminocyclohexane (L5b) 
A solution of 2-benzoylpyridine (1.24 g, 6.8 mmol) and cis-1,2-diaminocyclohexane   
(0.40 mL, 3.40 mmol) were stirred in absolute ethanol (10 mL). The resulting mixture was 
heated at reflux for 29 hours. After being cooled to room temperature fluffy pale brown 
needles were collected and washed with diethyl ether.** The filtrate was analysed and 
found to contain trace amounts of L5b.  
 
LR-ESI-MS: m/z 467.21 [M+Na]+ C30H28N4Na. 
 
                                                 
**
 The pale brown crystals were found to be the cyclised imidazole-containing bidentate ligand, L5bh. See 
2.3.13 e) for characterisation details. 
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2.3.12 Synthesis of N,N'-bis[phenyl(pyridin-2-yl)methylene]- 
1,2-diaminophenylene (L6b) 
A solution of 2-benzoylpyridine (1.69 g, 9.25 mmol) was stirred with 1,2-
diaminophenylene (0.50 g, 4.62 mmol) in absolute ethanol (20 mL). The resulting mixture 
was heated at reflux for 7 hours and thereafter cooled to room temperature. The solution 
was dried by the addition of anhydrous MgSO4, which was subsequently removed by 
filtration. The concentrated orange-red oil was redissolved in diethyl ether and on 
standing it produced a yellow solid which was collected.†† 2-Benzoylpyridine (0.25 g, 
1.36 mmol) was added to the filtrate and then heated at reflux for a further 20 hours. A 
single product has not yet been isolated.  
 
LR-ESI-MS: m/z (majority) 296.11 [M+Na]+ C18H15N3Na (L6bh); (small amount) 461.17 
[M+Na]+ C30H22N4Na (L6b). 
 
2.3.13 Characterisation data for the cyclised hexahydro-
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Figure 2.2: Labeled structures of the cyclised hexahydropyrimidine- and imidazole-containing 
bidentate ligands. 
 
                                                 
††
 The yellow powder was found to be majority phenylenediamine with trace amounts of L6bh. 
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a) 2-pyridin-2-yl-1,4,5,6-tetrahydropyrimidine (L2h) 
Pale yellow crystals formed on standing of the orange oil of L2. Yield: ~ 5%. UV-Vis 
(CH3OH; λmax, nm): 259.0, 346.0. 
1H NMR (500 MHz, CDCl3) [δ, ppm]: 8.57 (d, J = 5.0, 
1H, Ha), 7.75 (d of t, J =  7.9, 1.1, 1H, Hd), 7.69 (t of d, J = 7.7, 1.9, 1H, Hc), 7.15 (t of d, J 
= 6.2, 1.2, 1H, Hb), 2.53 (d, J = 13.0, 2H, Hf), 2.40 (d, J  = 13.0, 2H, Hf), 1.12 (m, 1H, N-
H), 1.41 (m, 2H, Hg). 
13C NMR (125 MHz, CDCl3) [δ, ppm]: 163.6 (Cp), 153.6 (Ci), 149.0 
(Ca), 136.6 (Cc), 121.8 (Cb), 121.5 (Cd), 53.3 (Cf), 31.6 (Cg). IR (cm
-1): 3336, 3265, 
2946, 2867, 1647, 1596, 1572, 1462, 1435, 1359, 1317, 1229, 1192, 1152, 1104, 1012, 
1001, 958, 883, 819, 767, 622, 502, 465, 402. LR-ESI-MS: m/z 186.12 [M+Na]+ 
C9H13N3Na. 
 
 b) 2-pyridin-2-yl-1H-benzimidazole (L6h)  
White crystalline material formed on the sides of the flask from the reaction mixture of 
L6. Yield: 0.349 g, 47%. UV-Vis (CH3OH; λmax, nm): 220.0 (sh), 239.5, 309.5, 322.0 (sh). 
1H NMR (500 MHz, CDCl3) [δ, ppm]: 10.87 (s, 1H, N-H), 8.64 (d, J = 5.0, 1H, Ha), 8.47 
(d, J = 7.9, 1H, Hd), 7.87 (t of d, J = 7.7, 1.6, 1H, Hc), 7.67 (s, 2H, Hf), 7.37 (t of d, J = 6.2, 
1.1, 1H), 7.30 (m, 2H, Hg). 
13C NMR (125 MHz, CDCl3) [δ, ppm]: 150.7 (Ce), 149.1 (Ca), 
148.2 (Cp), 137.3 (Cc), 124.6 (Cb), 123.5 (Cf,g), 121.7 (Cd). IR (cm
-1): 3064, 3047, 2965, 
2891, 2774, 2609, 2511, 2349, 1594, 1568, 1443, 1401, 1315, 1280, 1103, 995, 961, 
745, 702, 666, 426. HR-ESI-MS: m/z 218.0695 [M+Na]+ calculated for C12H9N4Na 
218.0694. 
 
c) 2-phenyl-2-pyridin-2-ylhexahydropyrimidine (L2bh) 
A white crystalline solid precipitated out of the filtrate for L2b on standing. Yield: 0.210 g, 
32%. UV-Vis (CH3OH; λmax, nm): 250. 
1H NMR (500 MHz, CDCl3) [δ, ppm]: 8.55 (d of q, 
J = 4.8, 0.9, 1H, Ha), 7.72 (d of d, J = 8.5, 1.3, 2H, He2,6), 7.56 (t of d, J = 7.8, 1.8, 1H, 
Hc), 7.37 (d, J = 8.1, 1H, Hd), 7.34 (t of d, J = 6.8, 1.6, 2H, He3,5), 7.22 (t, J = 7.3, 1H, 
He4), 7.08 (q of d, J = 6.1, 2.7, 1.1, 1H, Hb), 3.01 (m, 4H, Hf), 2.60 (s, 2H, N-H), 1.58 (m, 
1H, Hg), 1.49 (m, 1H, Hg). 
13C NMR (125 MHz, CDCl3) [δ, ppm]: 163.8 (Cp), 148.9 (Ca), 
143.7 (Ce1), 136.7 (Cc), 128.5 (Ce3,5), 127.6 (Ce2.6), 127.1 (Ce4), 121.9 (Cb), 121.7 (Cd), 
75.3 (Ci), 41.3 (Cf), 27.5 (Cg). IR (cm
-1): 3308, 3086 3044 2995, 2939 2921 2903 2862 
2833 2791, 2690, 1585, 1569, 1456, 1355, 1220, 1187, 1105, 1074, 1015, 994, 963, 
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918, 897, 821, 787, 743, 715, 699, 654, 624, 605, 551, 520, 454, 408. HR-ESI-MS: m/z 
240.1502 [M]+ calculated for C15H19N3 240.1501. 
 
d) 5,5-dimethyl-2-phenyl-2-pyridin-2-ylhexahydropyrimidine (L4bh) 
A white crystalline solid precipitated out of the reaction mixture for L4b on standing. 
Yield: 0.111 g, 15%. UV-Vis (CH3OH; λmax, nm): 203, 254. 
1H NMR (500 MHz, CDCl3) [δ, 
ppm]: 8.56 (d, J = 4.8, 1H, Ha), 7.79 (d, J = 7.2, 2H, He2,6), 7.53 (t, J = 7.8, 1H, Hc), 7.34 
(t, J = 7.6, 2H, He3,5), 7.26 (t, J = 7.3, 1H, He4), 7.19 (d, J = 7.7, 1H, Hd), 7.10 (t of d, J = 
6.1, 1.1, 1H, Hb), 2.71, (d, J = 13.4, 2H, Hf), 2.62, (d, J = 13.5, 2H, Hf), 2.76 (s, 2H, N-H), 
1.04 (s, 3H, Hh), 0.80 (s, 3H, Hh). 
13C NMR (125 MHz, CDCl3) [δ, ppm]: 163.1 (Cp), 148.8 
(Ca), 143.7 (Ce1), 136.6 (Cc), 128.4 (Ce3,5), 128.2 (Ce2.6), 127.2 (Ce4), 121.0 (Cb,d), 75.2 
(Ci), 53.3 (Cf), 27.8 (Cg), 23.9 (Ch). IR (cm
-1): 3320, 3059, 3045, 2996, 2975, 2946, 
2860, 2831, 1583, 1565, 1491, 1454, 1385, 1365, 1317, 1277, 1226, 1195, 1142, 1106, 
1090, 1080, 1029, 994, 947, 913, 900, 843, 788, 753, 712, 702, 668, 622, 598, 575, 516, 
491, 468, 424, 412, 838. HR-ESI-MS: m/z 268.1812 [M]+ calculated for C17H22N3 
268.1814. 
 
e) 2-phenyl-2-pyridin-2-yloctahydro-1-benzimidazole (L5bh) 
Pale brown, fine needles formed on evaporation of the filtrate of the L5b solution. Yield: 
0.490 g, 56%. UV-Vis (CH3OH; λmax, nm): 252.0. 
1H NMR (500 MHz, CDCl3) [δ, ppm]: 
8.53 (d, J = 4.9, 1H, Ha), 8.48 (d, J = 4.8, 1H, Ha’), 7.94 (d, J = 7.8, 1H, Hd), 7.91 (d, J = 
7.7, 1H, Hd’), 7.71 (t, J = 7.7, 4H, He2,6), 7.64 (t, J = 7.7, 1H, Hc), 7.59 (t, J = 6.5, 1H, Hc’), 
7.30 (q, J = 7.7, 7.4, 4H, He3,5), 7.20 (q, J = 6.5, 5.7, 4H, He4),7.12 (d, J = 6.0, 1H, Hb), 
7.08 (d, J = 6.0, 1H, Hb’), 3.23 (m, 2H, Hf), 3.15 (m, 2H, Hf’), 2.54 (s, 4H, N-H), 1.69 (m, 
4H, Hg), 1.62 (m, 4H, Hg’), 1.47 (m, 4H, Hh), 1.32 (m, 4H, Hh’). 
13C NMR (125 MHz, 
CDCl3) [δ, ppm]: 166.6 (Ci),165.3 (Ci’), 156.1 (Cp1),  155.2 (Cp2), 148.4 (Ca’), 147.5 (Ca), 
138.9 (Ce1), 136.9 (Cc) 1.36.3 (Ce1
’), 128.3 (Ce3,5), 127.0 (C4), 126.4 (Ce2,6), 122.0 (Cb), 
121.5 (Cb’), 120.1 (Cd), 57.6 (Cf), 56.8 (Cf’), 28.6 (Cg), 27.6 (Cg’), 21.9 (Ch), 21.7 (Ch’). IR 
(cm-1): 3346, 3311, 3051, 3043, 3029, 3002, 2935, 2925, 2884, 2852, 1583, 1567, 
1488, 1431, 1394, 1351, 1310, 1240, 1213, 1156, 1133, 1100, 1083, 1059, 1026, 993, 
963, 935, 927, 915, 891, 859, 847, 814, 781, 757, 748, 723, 702, 672, 627, 606, 530, 
481, 452, 400. HR-ESI-MS: m/z 280.1808 [M]+ calculated for C18H22N3 280.1814. 
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2.4 Platinum Group Metal complexes 
2.4.1 Metallation with PGMs: 
The ligand (0.3 mmol) was dissolved in 1 mL acetonitrile and a metal salt (either 
K2[PtCl4] or K2[PdCl4]) solution dissolved in 1.5 mL of distilled water (1:1 ratio with the 
ligand) was added dropwise. AgSbF6, AgBF4 or AgPF6 (1.2 mmol)) was added dropwise 
to the solution as a suspension in acetonitrile (5 mL). The mixture was heated at reflux 
for more than 30 hours. After cooling to room temperature overnight the solution was 
removed from the silver chloride solid by cannula transfer. The solution was either left to 
slowly evaporate or was put into test tubes and layered with ethanol. Solid that 
precipitated that was not crystalline was redissolved in 2-methoxy ethanol and put in test 
tubes layering with ether. 
 
2.4.2 Template Metallation: 
The metal salt (0.51 mmol, either K2[PtCl4] or K2[PdCl4]) was dissolved in 1–2 mL 
distilled water and 3 mL acetonitrile. The diamine (0.46 mmol) was dissolved in 4 mL 
acetonitrile and added dropwise to the metal solution. The reaction mixture was then 
heated at reflux for a period of 2 hours. LC-MS was used to confirm synthesis of the 
desired product.  The aldehyde (0.92 mmol) was added and reflux was continued for a 
further 6 hours. It was sometimes necessary for additional aldehyde to be added and 
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Figure 2.3: The basic metal complex structure showing the notation used for labelling the 
atoms, where M = Pt(II) or Pd(II). 
 
PtL1 [Pt{N,N'-bis[(pyridin-2-yl)methylene]1,2-diaminoethane}](PF6)2  
UV–vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 200 (14.6 × 103), 263 (3.8 × 103), 306 (2.3 × 
103), 365 (1.1 × 103), 394 (0.8 × 103), 404 (sh). 1H NMR (500 MHz, DMSO-d6) [δ, ppm]: 
9.46 (s, 2H, He), 8.89 (d, J = 5.5, 2H, Ha), 8.45 (t, J = 7.5, 2H, Hc), 8.25 (d, J = 7.5, 2H, 
Hd), 8.04 (t, J = 6.9, 2H, Hb), 4.23 (t, J = 5.8, 4H, Hf). 
13C NMR (125 MHz, DMSO-d6) [δ, 
ppm]: 166.3 (Ci), 160.8 (Cp), 150.1 (Ca), 142.2 (Cc), 130.1 (Cb), 129.4 (Cd), 59.7 (Cf). IR 
(cm-1): 3277, 3171, 3085, 3002, 2924, 2856, 1722, 1632, 1603, 1519, 1441, 1365, 
1329, 1294, 1239, 1055, 878, 836, 764, 696, 682, 627, 556, 520, 472, 435, 422. 
 
PdL1 [Pd{ N,N'-bis[(pyridin-2-yl)methylene]1,2-diaminoethane}](PF6)2 
UV–Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 200 (4.7 × 103), 270 (sh), 344 (0.8 × 103), 418 
(0.4 × 103). 1H NMR (500 MHz, DMSO-d6) [δ, ppm]: 8.99 (d, J = 5.3, 2H, Ha), 8.70 (s, 2H, 
He), 8.31 (t, J = 7.7, 2H, Hc), 8.11 (d, J = 7.6, 2H, Hd), 7.88 (t, J = 6.8, 2H, Hb), 4.17 (s, 
4H, Hf). 
13C NMR (125 MHz, DMSO-d6) [δ, ppm]: 168.1 (Ci), 156.3 (Cp), 150.5 (Ca), 142.1 
(Cc), 129.4 (Cb), 129.1 (Cd), 58.4 (Cf). IR (cm
-1): 3307, 3116, 2916, 2849, 1718, 1664, 
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PtL2 [Pt{N,N'-bis[(pyridin-2-yl)methylene]1,3-diaminopropane}](PF6)2 
UV–Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 202.0, 224.0 (sh), 273.5 (7.1 × 103), 284.5 (5.6 × 
103), 306.5 (4.4 × 103), 324.0 (3.6 × 103), 346.5 (2.3 × 103), 371.0 (2.2 × 103). 1H NMR 
(500 MHz, CD3CN) [δ, ppm]: 9.04 (t, J = 1.9, 2H, He), 8.92 (d, J = 5.6, 2H, Ha), 8.50 (t of 
d, J = 7.7, 1.3, 2H, Hc), 8.27 (d, J = 7.7, 2H, Hd), 8.07 (t of d, J = 6.7, 1.6, 2H, Hb), 4.11 (t 
of d, J = 5.3, 1.9, 4H, Hf), 2.34 (m, 2H, Hg). 
13C NMR (125 MHz, CD3CN) [δ, ppm]: 173.8 
(Ci), 156.4 (Cp), 153.1 (Ca), 144.8 (Cc), 131.1 (Cb), 130.9 (Cd), 57.3 (Cf), 29.9 (Cg). 
195Pt 
NMR (107 MHz at 11.7 T, DMSO-d6) [δ, ppm]: -2810. IR (cm
-1): 3366, 3269, 3117, 
3090, 2946, 2907, 1632, 1605, 1486, 1447, 1405, 1354, 1316, 1238, 1166, 1128, 1054, 
1032, 967, 950, 899, 878, 823, 773, 740, 688, 666, 652, 554, 513, 468, 442, 423, 414, 
399. 
 
PdL2 [Pd{ N,N'-bis[(pyridin-2-yl)methylene]1,3-diaminopropane}](PF6)2 
UV–Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 200.0, 215.0, 237.0 (3.0 × 103), 286.5 (6.5 × 
103), 305.0 (6.8 × 103). 1H NMR (500 MHz, CD3CN) [δ, ppm]: 8.70 (d of d, J = 5.6, 1.4, 
2H, Ha), 8.61 (t, J = 2.0, 2H, He), 8.45 (t of d, J = 7.8, 1.4, 2H, Hc), 8.19 (d of d, J = 7.7, 
1.4, 2H, Hd), 7.99 (t of d, J = 6.8, 1.5, 2H, Hb), 3.86 (t of d, J = 5.5, 2.1, 4H, Hf), 2.27 (m, 
2H, Hg). 
13C NMR (125 MHz, CD3CN) [δ, ppm]: 173.8 (Ci), 155.7 (Cp), 152.5 (Ca), 144.6 
(Cc), 130.9 (Cb,d), 56.3 (Cf), 29.6 (Cg). IR (cm
-1): 3091, 3074, 3057, 3024, 2981, 2947, 
1642, 1604, 1485, 1446, 1352, 1316, 1287, 1237, 1202, 1166, 1050, 1027, 970, 957, 
903, 878, 826, 775, 740, 650, 555, 511, 485, 469, 451, 428. 
 
PtL4 [Pt{N,N'-bis[(pyridin-2-yl)methylene]1,3-diamino-2,2-dimethylpropane}](PF6)2 
UV-Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]:  207.0 (19.3 × 103), 225.5 (15.5 × 103), 274.0 
(4.0 × 103), 285.0 (4.2 × 103), 307.5 (4.5 × 103), 324.0 (2.9 × 103), 346.5 (2.9 × 103), 
375.5 (3.7 × 103). 1H NMR (400 MHz, D2O) [δ, ppm]: 9.31 (s, 2H, He), 9.14 (d, 2H, J = 
5.7, Ha), 8.58 (t, J = 7.7, 2H, Hc), 8.38 (d, J = 7.5, 2H, Hd), 8.16 (t, J = 6.4, 2H, Hb), 4.03 
(s, 4H, Hf), 1.31 (s, 6H, Hh). 
13C NMR (125 MHz, D2O) [δ, ppm]: 173.5 (Ci), 155.7 (Cp), 
151.6 (Ca), 143.5 (Cc), 129.6 (Cb,d), 65.9 (Cf), 38.1 (Cg), 22.7 (Ch). 
195Pt NMR (107 MHz 
at 11.7 T, DMSO-d6) [δ, ppm]: -2807. IR (cm
-1): 3306, 3271, 3089, 2967, 2880, 1604, 
1592, 1480, 1463, 1442, 1386, 1338, 1297, 1234, 1169, 1117, 1080, 1060, 1035, 1003, 
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PdL4 [Pd{ N,N'-bis[(pyridin-2-yl)methylene]1,3-diamino-2,2-dimethylpropane}](PF6)2 
UV-Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]:  206.0 (23.1 × 103), 281.0 (3.0 × 103), 310.5 (2.7 
× 103). 1H NMR (500 MHz, D2O) [δ, ppm]: 8.89 (d, 2H, J = 5.6, Ha), 8.86 (s, 2H, He), 8.52 
(t, J = 7.8, 2H, Hc), 8.29 (d, J = 7.7, 2H, Hd), 8.07 (t, J = 6.7, 2H, Hb), 3.77 (s, 4H, Hf), 
1.27 (s, 6H, Hh). 
13C NMR (125 MHz, D2O) [δ, ppm]: 173.4 (Ci), 155.0 (Cp), 150.9 (Ca), 
143.2 (Cc), 129.5 (Cb,d), 65.0 (Cf), 37.9 (Cg), 22.7 (Ch). IR (cm
-1): 3296, 3253, 3163, 
3080, 2962, 2933, 2909, 2877, 1629, 1598, 1568, 1476, 1458, 1439, 1424, 1408, 1384, 
1370, 1342, 1330, 1297, 1230, 1194, 1161, 1028, 942, 911, 886, 871, 850, 790, 766, 
738, 710, 677, 666, 659, 617, 580, 562, 518, 466, 446, 424.  
 
PtL5 [Pt{N,N'-bis[pyridin-2-yl)methylene]1,2-diaminocyclohexane}](PF6)2 
UV-Vis (CH3CN; λmax, nm): 263.5. IR (cm
-1): 3367, 3261, 2955, 1721, 1634, 1600, 1573, 
1470, 1378, 1327, 1295, 1223, 1162, 1096, 1064, 1035, 676, 604, 521, 472.  
 
PdL5 [Pd{N,N'-bis[pyridin-2-yl)methylene]1,2-diaminocyclohexane}](PF6)2 
UV-Vis (CH3CN; λmax, nm): 269.5, 277.0, 306.0, 361.5, 404.5, 434.5. IR (cm
-1): 3332, 
3314, 3179, 3098, 3055, 3036, 2984, 2948, 1642, 1604, 1572, 1534, 1509, 1476, 1424, 
1322, 1278, 1266, 1195, 1148, 1092, 1058, 857, 817, 758, 718, 683, 670, 624, 569, 560, 
522, 473, 425, 411. 
 
Pt(L6h)2 [Pt{2-pyridin-2-yl-1H-benzimidazole}2](PF6)2 
UV-Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 206 (2.9 × 103), 239 (4.2 × 103), 307 (3.1 × 103). 
1H NMR (400 MHz, DMSO-d6) [δ, ppm]: 8.80 (d, 2H, J = 4.8, Ha), 8.35 (d, J = 7.9, 2H, 
Hd), 8.07 (t of d, J = 7.7, 1.6, 2H, Hc), 7.69 (q, J = 3.2, 2.7, 4H, Hg), 7.60 (t, J = 6.1, 2H, 
Hb), 7.34 (q, J = 3.1, 4H, Hh). 
13C NMR (125 MHz, DMSO-d6) [δ, ppm]: 171.9 (Cp), 150.3 
(Ca), 138.5 (Cc), 133.3 (Cf), 126.1 (Cb), 122.6 (Cd), 124.2 (Ch), 115.9 (Cg). IR (cm
-1): 
3048, 3011, 3005, 2943, 2907, 2860, 2833, 2778, 2756, 1651, 1614, 1569, 1520, 1489, 
1458, 1423, 1404, 1329, 1312, 1257, 1226, 1153, 1108, 1096, 1053, 1096, 1053, 992, 
966, 832, 788, 737, 689, 617, 556, 532, 481, 455, 398. 
 
PdL6h’ [Pd{ N-(pyridin-2-ylmethylene)benzene-1,2-diamine}](PF6)2 
UV-Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 200 (4.1 × 103), 305 (sh), 331 (1.0 × 103), 341 
(0.9 × 103), 417 (sh). 1H NMR (400 MHz, DMSO-d6) [δ, ppm]: 9.09 (d, 1H, J = 5.7, Ha), 
8.68 (d, J = 8.4, 1H, Hj), 8.54 (d, J = 6.9, 2H, Hd, He), 8.39 (t of d, J = 7.8, 1.5, 1H, Hc), 
7.79 (m, 1H, Hb), 7.73 (d, J = 8.3, 1H, Hg), 7.49 (m, 1H, Hh), 7.38 (m, 1H, Hi). 
13C NMR 
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(125 MHz, DMSO-d6) [δ, ppm]: 152.7 (Cp), 150.6 (Ca), 148.1 (Ci), 141.8 (Cc), 133.5 (Cf), 
128.0 (Ci), 127.6 (Cb), 126.0 (Ch), 123.8 (Cd), 119.2 (Cj), 113.8 (Cg). IR (cm
-1): 3066, 
3054, 3012, 3005, 2974, 2946, 2902, 2840, 2782, 2750, 1611, 1594, 1583, 1487, 1449, 
1440, 1367, 1292, 1270, 1241, 1215, 1189, 1170, 1156, 1111, 1097, 1026, 961, 919, 
8353, 780, 768, 740, 665, 618, 554, 544, 509, 467, 422, 393. 
 
PdL4m [Pd{N,N'-bis[(pyridin-2-yl)ethylene]1,3-diamino-2,2-dimethylpropane}](PF6)2 
UV-Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]:  202.5, 217.0, 266.0 (3.8 × 103), 286.0 (4.1 × 
103), 300.0 (4.1 × 103). 1H NMR (400 MHz, CD3CN) [δ, ppm]: 8.66 (d, 2H, J = 5.6, Ha), 
8.45 (t, J = 7.8, 1.4, 2H, Hc), 8.22 (d pf d, J = 8.1, 1.2, 2H, Hd), 7.98 (t of d, J = 6.6, 1.4, 
2H, Hb), 3.52 (s, 4H, Hf), 2.69 (s, 6H, He) 1.26 (s, 6H, Hh). 
13C NMR (125 MHz, CD3CN) 
[δ, ppm]: 182.7 (Ci), 158.1 (Cp), 152.1 (Ca), 144.2 (Cc), 130.9 (Cb), 129.4 (Cd), 61.4 (Cf), 
39.8 (Cg), 24.5 (Ch), 18.5 (Ce). IR (cm
-1): 3099, 3079, 2981, 2975, 2943, 2934, 1623, 
1600, 1575, 1467, 1381, 1344, 1264, 1170, 1107, 1029, 877, 823, 780, 745, 664, 652, 
585, 555, 466, 422, 389, 383.  
 
PtL1b [Pt{N,N'-bis[phenyl(pyridin-2-yl)methylene]1,2-diaminoethane}](PF6)2 
UV-Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 200 (0.8 × 103), 354 (3.0 × 103), 368 (2.8 × 103), 
388 (3.3 × 103). 1H NMR (400 MHz, DMSO-d6) [δ, ppm]: 9.36 (d, 2H, J = 5.2, Ha), 8.52 (t 
of d, J = 7.9, 1.3, 2H, Hc), 8.26 (t of d, J = 6.8, 1.3, 2H, Hb), 7.99 (m, 6H, He,3,4,5), 7.77 (d, 
J = 7.6, 2H, Hd), 7.55 (m, 4H, He2,6), 4.55 (s, 4H, Hf). 
13C NMR (125 MHz, DMSO-d6) [δ, 
ppm]: 176.5 (Ci), 161.0 (Cp), 153.7 (Ca), 144.1 (Cc), 136.5 (Ce1), 131.1 (Ce3,4,5), 130.8 
(Cb), 129.9 (Cd), 128.7 (Ce2,6), 60.5 (Cf). IR (cm
-1): 3094, 3072, 3002, 2960, 2919, 2841, 
1667, 1630, 1597, 1579, 1473, 1448, 1362, 1338, 1320, 1284, 1244, 1212, 1173, 1162, 
1067, 1028, 1001, 939, 829, 776, 757, 741, 701, 650, 555, 493, 469, 439, 432, 399.  
 
PtL2b [Pt{N,N'-bis[phenyl(pyridin-2-yl)methylene]1,3-diaminopropane}](PF6)2 
UV-Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 212 (6.0 × 103), 235 (sh), 288 (6.0 × 103), 310 
(6.3 × 103), 354 (5.0 × 103), 383 (6.1 × 103).  1H NMR (400 MHz, CD3CN) [δ, ppm]: 9.02 
(d, 2H, J = 5.8, Ha), 8.40 (t of d, 2H, J = 7.8, 1.3, Hc), 8.11 (t of d, J = 6.8, 1.5, 2H, Hb), 
7.77 (m, 6H, He,3,4,5), 7.62 (d, J = 7.2, 2H, Hd), 7.58 (d, J = 8.2, 4H, He2,6), 3.83 (t, J = 5.3, 
4H, Hf), 2.19 (m, 2H, Hg). 
13C NMR (125 MHz, CD3CN) [δ, ppm]: 180.4 (Ci), 157.4 (Cp), 
151.9 (Ca), 143.4 (Cc), 137.6 (Ce), 131.3 (Cd), 129.7 (Cb,e3,4,5), 128.0 (Ce2,6), 54.2 (Cf), 
30.1 (Cg).
 195Pt NMR (107 MHz at 11.7 T, CD3CN) [δ, ppm]: -2825. IR (cm
-1): 3116, 
3101, 3079, 2979, 2918, 1660, 1604, 1575, 1492, 1474, 1441, 1432, 1349, 1318, 1272, 
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1206, 1171, 1128, 1075, 1035, 1000, 972, 907, 878, 827, 755, 743, 702, 680, 663, 621, 
555, 489, 430, 406. 
  
PtL4b [Pt{N,N'-bis[phenyl(pyridin-2-yl)methylene]1,3-diamino-2,2-dimethylpropane}](PF6)2 
UV-Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 238 (2.2 × 103), 243 (sh), 285 (11.0 × 103), 309 
(9.7 × 103), 354 (4.5 × 103), 383 (5.9 × 103). 1H NMR (400 MHz, CD3CN) [δ, ppm]: 8.77 
(d, 2H, J = 4.8, Ha), 8.06 (m, 6H, He,3,4,5), 7.98 (t, 2H, J = 7.6, Hc), 7.62 (d, J = 7.3, 2H, 
Hd), 7.56 (t, J = 5.8, 2H, Hb), 7.50 (m, 4H, He2,6), 2.03 (s, 4H, Hf), 1.27 (s, 6H, Hh). IR 
(cm-1): 3283, 3247, 3118, 3067, 2975, 2917, 2850, 1670, 1609, 1534, 1462, 1451, 
1426, 1377, 1318, 1293, 1239, 1163, 1099, 1043, 999, 953, 814, 767, 741, 722, 692, 
644, 554, 471, 436, 391, 380. 
 
PdL4b [Pd{N,N'-bis[phenyl(pyridin-2-yl)methylene]1,3-diamino-2,2-dimethylpropane}](PF6)2 
UV-Vis (CH3CN) [λmax, nm (ε, M
-1cm-1)]: 212 (3.7 × 103), 270 (sh), 289 (4.2 × 103).  1H 
NMR (400 MHz, CD3CN) [δ, ppm]: 8.81 (d, 2H, J = 5.7, Ha), 8.33 (t of d, J = 7.8, 1.3, 2H, 
Hc), 8.04 (t of d, J = 6.7, 1.5, 2H, Hb), 7.77 (m, 6H, He,3,4,5), 7.53 (d, J = 7.3, 2H, Hd), 7.50 
(m, 4H, He2,6), 3.39 (s, 4H, Hf), 1.04 (s, 6H, Hh). 
13C NMR (125 MHz, CD3CN) [δ, ppm]: 
182.4 (Ci), 158.4 (Cp), 152.4 (Ca), 144.2 (Cc), 133.2 (Ce), 131.1 (Cd), 129.9 (Cb,e3,4,5), 
128.7 (Ce2,6), 63.1 (Cf), 39.8 (Cg), 24.1 (Ch). IR (cm
-1): 3298, 3211, 3110, 2915, 1664, 
1585, 1493, 1475, 1446, 1405, 1377, 1345, 1266, 1218, 1164, 1033, 999, 916, 903, 877, 
827, 793, 774, 752, 739, 702, 680, 659, 647, 626, 620, 555, 518, 479, 425.  
 
2.5 Discussion of the methods and characterisation 
The synthesis of Schiff base ligands is generally a simple procedure, with either only one 
or very few steps necessary. The methods used to synthesise most of the ligands in this 
work were adapted from the literature. The original six ligands were chosen due to the 
availability of their synthons as well as for their similarities and differences in structure. 
The first and second ligands (L1 and L2, respectively) form the basic structures for the 
other four ligands by having direct 2-carbon and 3-carbon bridging groups. This is 
extended by adding a hydroxyl group (L3), two methyl groups (L4) or a cyclic ring system 
(L5 and L6). The effect of the added bulk on these bridges can be observed, as well as 
the consequence of having the 2- or the 3-carbon bridging link. 
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From here the range was extended by adding groups onto the imine carbon, first a 
methyl and then a phenyl. The effect that these groups will have on the structure, 
reactivity and the activity of the ligands was of interest. NMR for the original ligands were 
all assigned except for L6, for which only trace amounts were obtained. Despite 
obtaining relatively clean LC-MS data for the methyl-substituted ligands (with the ligand 
being the prominent peak) the NMR data were not as straightforward. It seems that the 
methyl-ligands generally behaved differently in solution which caused difficulty for the 
assignment of the NMR data. In the case of L3m and L5m 13C NMR spectra were not 
obtained due to poor resolution; however, the assigned 1H NMR data is presented. The 
phenyl-substituted ligands showed clean LC-MS spectra and NMR data was assigned for 
all four of the synthesised phenyl-substituted ligands (L1b–L4b), as well as for the 
cyclised imidazole-containing bidentate ligand L5bh. Only trace amounts of the ‘fully-
reacted’ bis(imine) ligand (L5b) were found in the reaction mixture which could not be 
isolated. The ligand L6b has not been synthesised in this work. 
 
Yields of more than 60% were obtained for all the original six ligands (except for L6 
formed in trace amounts only). The methyl-ligands all had high yields, while the phenyl-
ligands did not. This may be explained by the mere bulk of the phenyl-ligands and the 
presence of unreacted starting material in the methyl-ligand samples. It may also be due 
to the fact that the phenyl-ligand reactions had a greater tendency to form the cyclised 
hexahydropyrimidine- or imidazole-containing bidentate ligands. This was also seen for 
L2 and L6 of the original ligands; L2h and L6h. Crystal structures have been obtained 
for these cyclised bidentate ligands: L2h, L6h, L1bh and L2bh (see Chapter 3), which 
formed during the syntheses of the full ligands. Once one equivalent of aldehyde was 
added to the diamine it cyclised before another equivalent of the aldehyde could be 
added. There seemed little would break the new C–N bond making it a stable (and 
crystalline) product of some of the reactions. The acyclic single condensation 
intermediate was not stable and subsequently the equilibrium shifted towards the cyclic 
structure forming a hexahydropyrimidine or imidazole ring.175 
 
In an endeavour to avoid these 1:1 ratio bidentate ligands and their subsequent 
cyclisation another method was attempted, particularly for PtL6 and PdL6. The first 
involved the formation of [M(br)Cl2] (where M = Pt or Pd and br = bridging diamine) and 
then the subsequent addition of the pyridine rings along with the formation of the imine 
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bonds. Unfortunately this mostly yielded a complex with one addition of the pyridine-2-
carboxaldehyde and was not successful in obtaining any tetradentate metal complexes.   
 
Metallations of the other synthesised ligands were performed using methods altered from 
literature. The first complexes synthesised had a chloride counter ion from the metal salt. 
This produced mainly powder and therefore SbF6
-
 was introduced in order to form high 
quality crystals suitable for X-ray diffraction and spectroscopic characterisation. Limited 
success was observed for SbF6
-




 were introduced as far more 
suitable counter ions. This resulted in a total of eight novel metal complexes producing 
X-ray quality crystals. Despite identical methods with equal conditions being used not all 
of the thirty attempted metal complexes could be synthesised. However, five other metal 
complexes, which produced powder, have been spectroscopically characterised where 
possible. The yields for the metal complexes were not calculated due to the bulk material 
not being pure. 
 
The metal complexes did not give uncontaminated or even identifiable LC-MS spectra 
despite many of the samples being crystalline and clean; as seen in the 1H NMR spectra. 
The samples were even run in different solvents, but similar results were obtained, ruling 
out solvent effects. Thus the use of LC-MS has not been implemented to characterise 
the metal complexes.‡‡ The UV-Vis spectra gave the expected bands for the non planar 
free ligands. For the metal complexes, intraligand π-π* transition bands were observed 
as well as the MLCT bands (in the range of 320–380 nm for Pt(II) complexes and around 
300 nm for Pd(II)). Extinction coefficients were determined for the novel metal complexes 
in acetonitrile, where possible. Despite numerous attempts it was observed that Beer’s 
Law was not obeyed in the region 200–220 nm for PtL2, PdL2 and PdL4m.  
 
There is an obvious change in the shift of the 1H NMR peaks for the metallated 
derivatives from the spectra of the free ligands. These shifts take place downfield from 
the respective free ligands ranging from 0.1 to 0.8 ppm for the palladium complexes or 
0.4 to 0.9 ppm for the platinum complexes. This is due to the electron donating/accepting 
ability of the metal centre causing a redistribution of the electron density in the ligand and 
                                                 
‡‡
 Some samples were submitted for elemental analysis to the University of KwaZulu Natal in Westville, but 
no meaningful data has been presented due to inconsistencies in the results obtained, which were 
attributed to instrument failure. In lieu of this samples have been prepared for submission to Galbraith 
Laboratories  in the USA. 
Chapter 2 – Experimental 
 45 
hence changes the resonance values for its protons. The 195Pt NMR spectra were 
obtained for PtL2 and PtL4, as well as a much weaker signal for PtL2b (Figure 2.4); 
however, no data is presented for the other platinum complexes as the peaks could not 




Figure 2.4: The 107 MHz 195Pt NMR spectra at 11.7 T recorded at room temperature for PtL2, 
PtL4 and PtL2b. 
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CHAPTER 3 – X-ray Crystallography 
 
3.1 Introduction 
The determination of a crystal structure using X-ray diffraction half a century ago was a 
monumental experimental undertaking; however, modern day advances have vastly 
improved the methodology. X-ray structure determinations may be used in the proof of 
synthesis and to show exact stereochemistry. The measurement of three dimensional 
geometries provides important and invaluable information about the properties of 
molecular or network compounds. This information may assist in explaining activity or 
applications of these compounds as well as allowing comparisons to be made to the 
theoretically calculated structural data (see Chapter 4). Studies of Schiff Base ligands 
and their metal complexes have slowly moved towards those of biological importance. 
Interest has therefore grown in this important class of compounds, in particular the 
metallated Schiff bases, so that they may be designed to produce species with particular 
properties. 
 
The Cambridge Structural Database (CSD)246 shows the popularity of Schiff base 
derivatives and their metal complexes as a search for the basic structure of a Schiff base 
gave more than 80 000 results. Searches for Schiff base ligands containing the double 
imine functionality, R-C=N-R-N=C-R, gave more than 30 000 results, of which only 
slightly more than 2 500 had alkyl groups as the bridging agents and only a few hundred 
had four nitrogen donors present. Numerous metallated Schiff base complexes were 
found in the CSD with a range of different metals; including copper, nickel, silver, 
manganese, cobalt, zinc, ruthenium, samarium, gadolinium, ytterbium and lanthanum.246  
 
Although tetradentate Schiff base ligands comprising two pyrrole groups bridged by a 
synthetically variable bridging group have been known for several decades,247 there is 
limited literature available for the ligands in this work (with pyridine rings on either side of 
the bridge). No crystal structures could be found in the CSD for any of the six original 
free ligands synthesised in this work. There are, however, crystal structures for other 
derivatives of ligands L1, L2, L5 and L6. Some examples of these are shown in Figure 
3.1. This includes slight differences to the bridging group (e.g. trans instead of cis 
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orientation for L5), additional ring structures (e.g. quinoline rings instead of a pyridine 
ring for L1 and L5) or extended ligands linked by extra groups. No results were found for 





























Figure 3.1: Some examples of pyridyl-imine Schiff base ligands similar to those described in 
this work found in the Cambridge Structural database and their CSD codes: a) MEQFEU248 or 
SISCEK249, b) ROHBOF250, c) KAGROA251, d) JAXHUM252  e) GIWJAY253 or SISJOA254 
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During the synthesis of these novel free ligands some cyclised “half-ligands” were 
synthesised. These products were formed when the aldehyde and diamine reacted in an 
unexpected 1:1 ratio and the diamine bridge subsequently cyclised at the imine carbon. 
The acyclic single condensation intermediate will not be stable and thus equilibrium will 
be shifted towards the cyclic aminal form. This resulted in a very stable, geometrically 
planar self-condensation product that was an N2 donor rather than the expected 
tetradentate version. Structures of some cyclised 1:1 self-condensation products have 
been previously reported in the literature, e.g. 2-(4,5-dihydro-1H-imidazol-2-yl)pyridine 
(L1h)255 and 2-pyridin-2-yl-1H-benzimidazole (L6h)256,257 (Figure 3.2), but not for any of 
the other four cyclisation products.  
                      
Figure 3.2: Structures of 2-(4,5-dihydro-1H-imidazol-2-yl)pyridine, L1h (LORPUE)255 and 2-
pyridin-2-yl-1H-benzimidazole, L6h (AJOPOE)256. 
 
Metal complexes that coordinate the tetradentate (N4 donor) ligands do exist in the 
literature for four of these ligands, as shown in Table 3.1. No structures were found for 
L4 and only dinuclear complexes for L5 have been described (platinum42 and silver258). 
Most of these metal complexes have been produced and characterised on purely 
synthetic and structural grounds without any definitive applications. Some of these 
complexes have, however, exhibited good conductivities in the solid state on doping with 
iodine.259 Other complexes have also been studied as possible starting materials for the 
synthesis of oxo/hydroxo coordinated polynuclear metal species260 or to assemble novel 
end-to-end thiocyanato-bridged infinite 1D polymeric heptacoordinated metal chains.41  
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Table 3.1: Summary of available CSD246 reference codes for some of the metal complexes of 
ligands L1, L2, L3 and L6. 




















Zinc(II)  MAJDOQ262   
Ruthenium(II)  RUXFOF133   
Cadmium(II) NEDWAV140    
Rhenium(III) QOLQAJ267    
Lanthanides GAJXOF etc.132 GAKBAW268  LUHFEZ269 
 
Not one of these complexes has a square planar geometry; however, the ligands mostly 
coordinate in the equatorial plane in a flat or near-planar orientation around the metal 
centres. This octahedral geometry (tetragonally distorted) was preferred for the copper 
complex of L2, whereas square planar geometry was found for a similar mixed ligand.193 
Karmakar et al. showed that with complexes of L2 the Ni(II) ion constantly formed the 
trans isomer, while the Mn(II) ion gives the cis isomer.129 The tetradentate ligand is more 
planar when the additional non-chelating ligands are at 180º to each other (axial) than in 
the cis isomer. 
 
The structures for the nickel(II) complexes in Table 3.1 are of particular interest as nickel 
is also a group 10 transition metal. Nickel(II) has a d8 configuration and forms octahedral 
complexes with a planar coordination of the tetradentate Schiff base ligands in the 
equatorial positions leaving the two axial trans positions to be coordinated by other 
ligands. Nickel(II) complexes from the literature of L2 and L6 are shown in Figure 3.3. 
The only distortion for L2 from the predominantly flat N4 plane of the ligand (formed by 
the two imine (Ni) and two pyridine (Np) nitrogen atoms) is for the bridging propyl group. 
The central CH2 is pushed up between the other two CH2 groups (which lie in the plane) 
CHAPTER 3 – X-ray Crystallography 
 50 
in an envelope conformation. The phenyl ring in the L6 ligand lies in the N4 plane 
creating an almost perfectly flat ligand structure around the metal centre.  
 
 
Figure 3.3: The nickel(II) complexes of L2 (left) and L6 (right), CSD reference codes: 
UDESOM264 and WIQFIL,161 respectively. 
 
 
Figure 3.4: The cis rhenium(III) 7-coordinate complex of L1 (left)264 and trans ruthenium(II) 
tetragonally distorted octahedral complex of L2 (right).133 
 
Also of interest are the two PGM complexes: QOLQAJ264 and RUXFOF133 (Figure 3.4 
above), which have 7-coordinate and tetragonally distorted octahedral geometry, 
respectively. The tetradentate ligand lies flat in the equatorial plane for the ruthenium 
complex; however, for the rhenium complex the axial ligands form the cis isomer. This 
causes distortions in the symmetry which are reflected by the considerable variation of 
bond lengths and angles about the rhenium atom. This results in a distortion from 
planarity in the ligand conformation and four different metal-nitrogen bond lengths. In the 
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ruthenium complex there is asymmetry with the axial ligand angle being almost 180º and 
each type of metal-nitrogen bond (M-Ni and M-Np) is the same. 
 
In this work, the above range of ligands has been expanded by adding steric bulk to the 
imine bond; this has been accomplished in the form of a methyl group on the imine 
carbon. For this second group of ligands synthesised only one free ligand was found in 
the CSD: L1m174 (Figure 3.5). An interesting and important feature of this structure is the 
trans arrangement of the pyridyl-rings relative to the bridging group. The bridging alkyl 
chain has a staggered conformation between the two imine bonds. The methyl groups 
also display a trans configuration relative to these imine double bonds (and are 
subsequently trans to the pyridine rings). 
 
 














Figure 3.6: The metallated structure of L4m with iron(II) and two NCS
-
 axial ligands 
(HIDFUW).270 
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A range of metal complexes, including the metals nickel(II), copper(II) and cadmium(II) 
have been reported in the literature for L1m and L2m.167,168,172,177,178 Only one metal 
complex has been described by other workers for L4m (Figure 3.6)270 and for L5m271 
only a derivative of the structure is known. The few structures that contained L3m and 
L6m were found to have more than one metal atom present. Structures for the cyclised 
“half-ligands” of two methyl-substituted imine ligands; namely L2mh272 and L3mh,273 are 
available in the literature.  
 
The metal complexes of these ligands have similar coordination geometries (tetragonally 
distorted octahedral) to those described for the original range of ligands. The Schiff base 
ligand is predominantly flat on coordination in the trans isomer, which is again more 
common than the cis isomer. This has been explained by Banerjee and co-workers to be 
due to the better degree of metal-Ni backbonding that takes place when a stronger σ-
donor Np atom is in the trans position resulting in the sharing of the same d-orbital.
274 
Apart from these electronic factors, steric factors will always play a role as the trans 
isomer has far less steric repulsion by having the axial moieties located away from each 
other.178 
 
Deviations from the plane for the bridging group of NiL1m are relatively small (mean 
deviation 0.08 Å), even in comparison to the limited deviation of the individual π-
conjugated chelate rings (mean deviation: 0.01 Å).274 The equatorial plane of NiL2m has 
a higher distortion (mean deviation, 0.021 Å) and the bridging group is puckered into an 
envelope conformation (as seen for NiL2).178 The iron(II) complex of L4m shows a far 
more distorted planarity for the tetradentate Schiff base ligand that encapsulates the 
equatorial plane with a similar envelope conformation for the bridging group of the metal 
complexes of L2 and L2m. The increased length and subsequent increase in bulk for the 
bridging group chains has a distorting effect on the N4 plane of the Schiff base ligand. 
 
In this work, we have also synthesised phenyl-substituted imine derivatives of the 
polydentate bis-(pyridyl-imine) ligands for chelation of Pd(II) and Pt(II).  Such ligand 
derivatives are known to coordinate a range of metal ions. For example, metallated 
derivatives with manganese (L1b173 and L2b275), cadmium (L2b146), copper 
(L2b146,192,276) and nickel (L2b146 and L6b277) (see Figure 3.7 for examples) have been 
reported. X-ray structures of L3b and L4b have not been determined either as metal-free 
ligands or as chelates of metal ions, despite the relatively simple synthetic procedure for 
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their preparation. The same is true for L5b; however, for this ligand the synthesis is far 
more challenging. L1bh is the only cyclised “half-ligand” for which a structure has been 
reported.278 
 
The overall coordination geometry for this range of complexes is also octahedral 
(tetragonally distorted), with the ligated atoms equatorially around the metal centre and 





The four nitrogen atoms of the ligand form an essentially planar arrangement in all 
structures of the more common trans isomers. This has been observed for a nickel 
complex where all four nitrogen donor atoms of the ligand are almost planar with a 
maximum deviation from the equatorial plane being 0.16 Å.259 
 
The prominent difference here is that the imine groups are no longer lying in the plane 
(like the hydrogen and methyl substituents). The pyridine and phenyl rings are 
themselves planar; however, they are twisted out of coplanarity relative to each other. It 
is not possible for these rings to exist in the same plane due to steric hindrance,276 but 
the pyridine rings have limited rotation due to their coordination to the metal. Therefore, 
this steric hindrance can only be relieved by the phenyl rings tilting relative to the main 
N4 plane (see Figure 3.7). This distortion of the phenyl rings‟s orientation takes place to 
varying extents, and subsequently results in reduced planarity of the structures. For a 
copper structure these angles between the phenyl ring and pyridyl ring were found to be 
140.1º, 109.4º and 135.1°, 91.1°, respectively for two independent cations.276 
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Figure 3.7: Metal complexes of the phenyl-substituted ligands L1b, L2b and L6b: a) 
[Mn(L1b)(NO3)2] (KAHHOQ),
173 b) [Ni(L2b)(NCS)2] (UDESUS),
129 c) [Cu(L2b)N3] (TAYMIQ)
146 
and d) [Ni(L6b)Cl2] (XACGAJ).
277 Counterions have been omitted for clarity. 
 
Inspection of the literature for ligands with the same or a similar structure to those 
synthesised in this work, indicates that complexes of copper, nickel, manganese and 
some lanthanides are the most abundant.246 Although platinum and palladium do not 
appear to be popular metals for this class of Schiff bases, some literature relating to 
coordination complexes of PGMs with bis(pyridyl-imine) ligands exists. Structures of 
platinum and palladium complexes with N4 chelating Schiff base ligands (with similar 
bridging groups trans-L5) have been found in the CSD. They are, however, slightly 
different in structure having pyrrole rings rather than pyridine rings.279,280 Platinum and 
palladium complexes have also been observed for one of the ligands in this work (Figure 
3.8), L5,281 and for similarly structured ligands thereof (trans-configuration281,282 of L5 



































     c)            d) 
 
Figure 3.8: Some of the platinum(II/IV) and palladium(II) structures of L5 and similar ligands 
found in the CSD: a) HOZLOX,282 b) XIXGEQ,281 C) UBAQAP
281
 and d) UBAQOD.281 
Counterions have been omitted for clarity. 
 
The most notable difference between these PGM complexes (Figure 3.8) and those in 
Figures 3.3 and 3.7 is the presence of two metal atoms bonded to only one ligand. Each 
of the metals is bonded to one imine-nitrogen (Ni) and one pyridine-nitrogen (Np) with 
various ligands coordinating in the other two (or four, in the case of octahedral platinum) 
available positions on the metal. Despite the fact that most of these reactions took place 
with a 1:1 ligand to metal ratio the final product had a 1:2 ratio.281,282 Some examples of 
these are shown in Figure 3.8 above. 
 
When only one metal atom coordinates all four nitrogen atoms of the tetradentate ligand 
they are all required to be in close proximity. These four nitrogen-donor atoms 
subsequently form a plane around the central metal atom. Distortions from this plane are 
possible, but the general arrangement is constant during this chelation as there is limited 
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obvious that this is not the case. The coordination of only two nitrogen atoms to each of 
the two different metal atoms allows the two pyridyl-imine arms to twist away from each 
other to resist steric hindrance.281 There is nothing forcing the two pyridyl-imine arms 
towards each other (as in the mononuclear complexes) and therefore due to each side of 
the molecule twisting individually there is a lack of planarity for these structures. This will 
not be true for the metal complexes synthesised in this work as they are expected to be 
mononuclear.  
 
There was one mononuclear square planar palladium(II) complex with an N4 donor 
ligand (Figure 3.9).195 This bis(pyridyl-imine) ligand had N,N‟-(6,6‟-dimethylbiphenyl-2,2‟-
diyl)diamine as the bridging group and a hydrogen on the imine carbon. The palladium 
centre of the molecule formed an almost C2-symmetric seven-membered chelate ring 
with this bridge and a five-membered chelating ring on either side with each of the 
pyridyl-imine moieties. The Pd-N bond lengths were within the expected range195 and the 
two planes on either side of the metal spanned an angle of 12.9(5)°. The bridging group 
itself was nonplanar due to the twisting of the phenyl rings to reduce the steric strain 
between the two methyl groups. 
 
A distortion from planarity is also observed for mononuclear complexes of salen ligands 
which have N2O2 donors. When comparing the nickel complexes of L2
263 and L2-
salen283 it is obvious that there is a large discrepancy in their planarity (Figure 3.10). The 
Schiff base ligand is almost completely flat (except for the propyl bridging group) for the 
complex with L2, while it is greatly distorted for L2-salen. These complexes have the 
same metal centre and bridging group, but differ for the axial ligands and coordinated 
rings. Coordination to the metal for the salen-complex still takes place through the two Ni 
atoms, but now it coordinates through two oxygen atoms and not the Np atoms.
283 This 
means that the chelating chains are now extended from 5-membered to 6-membered 
rings, which allows for greater freedom around the metal.283 Coupled with the differences 
in the donor atom to metal bond lengths, this may therefore account for the non-planarity 
of the ligand. In macrocyclic (closed type) N4 tetradentate ligands the deviation from the 
plane is less than for either of these “open-type” ligands (salen or for the ligands in this 
work). These “open-type” ligands have far less opportunity for the ligand to distort as 
there are no free ends that may provide the freedom for the distortion.161 
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Figure 3.9: The structure of the palladium(II) N4 donor Schiff base complex with square planar 














Figure 3.10: The nickel complexes of L2 (N4 donor, left) and L2-salen (ONNO donor, right) 
viewed side on to show the variation in planarity (hydrogen atoms have been omitted for clarity).  
 
When this type of tetradentate ligand coordinates to the metal atom then all four nitrogen 
atoms of the bis(pyridyl-imine) ligand form a plane around that central metal atom. Large 
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high, particularly for the cis isomers, e.g. ten-coordinate lanthanides with L1 or L2,132 in 
order to reduce the steric bulk. The smaller six-coordinate geometries mostly only allow 
minimal distortions from the plane for the trans octahedral structures (these distortions 
are greater in the case of the cis isomer). Manganese has a tendency to form the cis 
isomer of the octahedral structure for L2129 and L3,128 while most other metals favour the 
trans isomer. 
 
The metal complexes of methyl-substituted ligands mostly show tetragonally distorted 
octahedral geometry, which is most often the slightly distorted trans isomer (NiL1m,274 
CuL1m,284 CdL1m,168 MnL1m173 and FeL4m175). There are also some higher 
coordination numbers: 7 and 10; including the lower coordination number of 5 for copper 
with L2m.177 The presence of only one axial ligand causes a fair distortion for the 
tetradentate ligand. Distortion of the N4 plane is also observed for the higher coordination 
numbers. The phenyl-substituted ligands generally coordinate in a tetragonally distorted 
octahedral geometry (trans for CuL2b,190 NiL2b146 and NiL6b;259 cis for MnL2b and 
CdL2b) with some 5-coordinate (CuL2b)146,192 and 7-coordinate structures (MnL2b).173 
Due to the greater steric bulk in these structures there is rotation of the phenyl 
substituents relative to the plane formed by the four coordinating nitrogen atoms. This 
plane may also be distorted by the tilting of the pyridine rings to a much greater extent 
than seen for the original ligands.190  
 
When keeping the metal centre (copper(II)) and axial ligands (ClO4
-
) the same, 
differences in the planarity may then be accounted for by variations in the ligand on the 
equatorial plane for different complexes. The distortions for three copper complexes with 
the propyl bridging group are presented in Figure 3.11. The ligands increase in steric 
bulk on the imine carbon: hydrogen < methyl < phenyl. It is obvious that the smallest 
distortions are observed for the complex with the “smallest” ligand, CuL2,193 with only 
slightly tilted pyridine rings (either side of the N4 plane). The distortions are much larger 
for CuL2m177 and CuL2b190 and are visually rather similar. In both structures the phenyl 
rings are twisted out of the plane, one above the plane and the other below. The same is 
true for the imine groups, but on each side in the opposite direction to the closest 
pyridine ring. Figure 3.11 therefore suggests that alkyl and aryl groups appended to the 









Figure 3.11: The variations in the distortions from planarity for the tetradentate Schiff base 
copper complexes with varying imine-substituent steric bulk. 
 
 
Figure 3.12: The variations in the distortions from planarity for the tetradentate Schiff base 
nickel complexes with varying imine-substituent steric bulk. 
 
For d8 nickel(II) complexes of varying ligand steric bulk the distortions from planarity are 
visually far smaller with NiL2264 and NiL2m178 being almost identical (only a slight 
distortion for NiL2m with tilted pyridine rings). The larger steric bulk of NiL2b264 shows 
greater nonplanarity with the phenyl rings tilted out of the plane and in different directions 
(one up, one down) as well as a greater tilting of the pyridine rings. The methyl group 
therefore doesn‟t have much effect for the nickel complexes, whereas the phenyl ring 
causes fair distortion. There is an obvious distinction between the range of copper 
complexes and the range of complexes with the smaller Ni(II) ion. 
 
The effects of the different types of metals may be clearly observed when keeping the 
ligands constant. The nickel (NiL2263,264) complexes of L2 are almost perfectly planar, 
while the copper (CuL2265) complex of the same ligand is far more distorted. The copper 
member of this series is distorted more strongly than the nickel structures because of the 
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Jahn-Teller effect.285 This distortion is often observed for 3d9 Cu(II) structures due to the 
degeneracy of the d states in an ideal octahedral field. There will be no resistance to 
perturbing fields which lower the degeneracy due to a single d electron or d vacancy 
being unstable.286 The same is true for complexes with the methyl-substituted ligands: 
NiL2m178 and CuL2m,177 and the phenyl-substituted ligands: NiL2b264 and CuL2b.276 
There is slight distortion for the nickel L2b complex, but this may be explained by steric 
bulk and it is still far less than the distortion seen for the copper complex. 
 
The angles around the central metal atom associated with five-membered chelate rings 
are invariably smaller than those associated with six-membered rings.193 For example; 
the corresponding values observed for the angle formed by Ni-Cu-Ni for CuL1m
284 is 
almost 15º smaller than the same angle for the 6-membered ring in CuL2m.177 The 
angles formed by Ni-Cu-Np in five-membered chelate rings are both around 81º for each 
of these two complexes. The same is observed for Ni-Cu-Ni for NiL1m
274 and NiL2m,178 
which differ by slightly less than 13º. The Ni-Ni-Np angles are of similar size to each other 
and to those observed for the copper complexes; however, slightly smaller to 
accommodate the increased Ni-Cu-Ni for angle. The Ni-metal-Ni angles for the 5-
membered chelate rings for copper are slightly larger than for nickel (differ by 0.3º), the 
same is true for the 6-membered chelate rings (differ by 1.7º). This may be attributed to 
the different size in the metal ions. The bond lengths will also be slightly affected by the 
changes in bite angles for each complex; however, the M-Ni bond is always expected to 




The main goals of this chapter were to: 
1) determine and report the crystal structures of each of the four novel „fully-reacted‟ 
bis(imine) and five mono(imine) Schiff Base ligands synthesised in this work; 
2) determine and report the crystal structures of eight metallated tetradentate 
chelates; 
3) report and analyse relevant bond lengths, angles, packing and other interesting 
features to establish correlations between the ligands themselves and the metal 
complexes. This incorporates exploring the similarities and the differences 
between platinum(II) and palladium(II) as metal centres; 
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4) determine whether it is likely that predominantly planar conformations (with only 
slight deviations from the plane) will be observed for the mononuclear structures 
synthesised in this work and thus compare and analyse any distortions from the 
N4 plane; and 
5) imbue the disparity seen in the literature thus far as all the structures have been 
refined to an internal R-factor lower than 10%. 
 
3.3 Methodology 
Single crystals of the free ligands were grown by slow evaporation of the solvent. Single 
crystals of the metal complexes were also obtained by slow evaporation of the solvent or 
by solvent diffusion. Intensity measurements were carried out on the crystals (which 
were all air stable) using two diffractometers and standard procedures. 
 
Oxford Diffraction Xcalibur2 CCD 4-circle diffractometer 
X-ray diffraction data were collected on an Oxford Diffraction Xcalibur2 CCD 4-circle 
diffractometer equipped with an Oxford Instruments Cryojet operating at 100(2) or 298(2) 
K. The data were collected at a crystal-to-detector distance of 50 mm using omega scans 
at θ = 29.389º with 10 to 35 s exposures taken at ~ 2 kW X-ray power with 0.75° frame 
widths. The data were reduced with the program CrysAlis RED288 using outlier rejection, 
scan speed scaling, as well as standard Lorentz and polarisation correction factors. 
Direct methods (SHELXS-97, WinGX32)289,290 were used to solve the structures. All non-
H atoms were located in the E-map and refined anisotropically with SHELXL-97.291 The 
hydrogen atoms in each of the structures were included as idealised contributors in the 
least-squares process with standard SHELXL-97291 parameters. 
 
Bruker Apex II Duo instrument 
Crystal intensity data were collected on a BRUKER SMART APEX or a BRUKER APEX-
II DUO CCD (Charge Coupled Device) Single Crystal X-ray Diffractometer, using 
graphite-monochromated MoKα radiation (λ = 0.71073 Å). The generator was operated 
at 50 kV and 100 mA for the Bruker APEX-II DUO and 50 kV and 30 mA in the case of 
the SMART-APEX.  All data were collected using  and ω scans. Frame widths were 
0.3  on the SMART-APEX and 0.5  on the APEX-II DUO. Unit cell determinations and 
data were measured at 100(2) K. The low temperatures were maintained by cooling the 
crystals with a constant stream of N2 gas at a flow rate of 15 cm
3 min-1 with the aid of a 
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Cryostream cooler (Oxford Cryosystems UK). Data were corrected for Lorentz-
polarisation effects; unit cell refinement and data-reduction were performed using the 
program Bruker Saint.  All data were subjected to absorption correction using the 
program multi-scanSADABS.292 Space group determinations were carried out by 
examining the systematic absences and matching the observed conditions to a known 
space group.293 These assignments were confirmed by running the data through the 
program Xprep.294 SHELXS-97289 input files were generated with Xprep. All structures 
were refined with SHELXL-97291 operating through the interface X-seed.295 
 





























































Figure 3.13: The notation used for labelling the chemically unique atoms in the basic framework 
of the Schiff base ligands and complexes.  
 
Figure 3.13 shows the notation that has been used to label the atom framework of the 
structures throughout this work. Cf, Cg, Ch etc. are used to denote the bridging group 
carbon atoms, while Ca–d denotes the carbon atoms in the pyridine ring. Ci and Cp refer 
to the carbon atoms involved in the imine bond and the quaternary carbon in the pyridine 
ring, respectively. The hydrogen atoms will be named according to the atom to which 
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they are bonded, except for the hydrogen on the imine group which is labelled He. When 
there is a methyl group on Ci the atoms are labelled Ce and He and when it is a phenyl 
ring the carbons are labelled Ce1, Ce2 etc. (and consequently, He1, He2 etc.). The nitrogen 
atoms involved in the imine bond are labelled Ni and those in the pyridine ring, Np. 
 
Mononuclear and dinuclear complexes have been reported for many metal complexes of 
these types of ligands (as discussed earlier). The complexes in this work are expected to 
be mononuclear by design. Platinum(II) and palladium(II) are considered isoelectronic 
and isosymmetric296 and we therefore expect to see similarities in the conformation of the 
ligands around these metal centres, as well as for the bond lengths and angles. The 
main difference in comparison to the literature structures presented here will be that 
platinum and palladium form four-coordinate square planar complexes rather than six-
coordinate octahedral complexes.  
 
The preferred geometry is correlated to the electronic configuration. A square planar 
configuration will be imposed not only by the ligand, but as a result of additional splitting 
of the orbital levels due to lack of z-axis ligands. This additional splitting is most 
advantageous as it allows for the pairing of all electrons (the value of Δo is sufficiently 
high).297 Four ligands that each donate a pair of electrons to the central metal will fill the 
sigma bonding MOs (molecular orbitals) and subsequently the d electrons must be 
divided between the eg, b1g and b1g
* MOs. This reduced symmetry results in no unique 
energy splitting analogous to Δo or Δt. The four approximately nonbonding MOs lie much 
lower in energy than b1g
* and therefore this d8 system will be more stable as four-
coordinate square planar than in an octahedral complex where two electrons will be in 
the eg
* MOs.298  
 
The crystal field stabilisation energy (in terms of Δo) is therefore much greater for square 
planar coordination than for octahedral coordination. The d-orbital splitting generally 
increases per period down a group with around 30–50% going from one transition series 
to the next.299 This subsequently promotes the square planar geometry for complexes of 
the 5th and 6th period (e.g., Pt and Pd, respectively) transition metals. The loss in bond 
energy caused by an octahedral complex being transformed to a square planar complex 
may be made up by this greater energy difference for platinum and palladium; however, 
it is not usually enough to ensure square planar complexes for nickel. Overall, square 
planar complexes are far less common than those of octahedral geometry. The ligand 
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configuration in this work is likely to be square planar (similar to the configuration of the 
ligand seen for the trans isomers of the tetragonally distorted octahedral structures 
reviewed earlier) with the use of platinum(II) and palladium(II) as the coordinating metals. 
An important objective of this work is therefore to describe the structures and properties 
of square planar d8 PGM complexes of this group of ligands. 
 
Despite the predominantly planar tendency of the tetradentate chelating ligands in this 
work some distortions from the N4 plane (formed by the two imine (Ni) and two pyridine 
(Np) nitrogen atoms) are to be expected. The bonded central metal ion will resist undue 
radial expansion or contraction but it can readily distort from a planar geometry; it has 
been known to be quite flexible toward out-of-plane deformation.300 Consequently, the 
central metal ion may be easily displaced in a direction perpendicular to the mean plane; 
however, this is not necessarily the case. The metal may lie in the N4 plane causing the 
distortion elsewhere in the structure. This has been observed for the trans isomer copper 
complexes presented from the literature.193,177,190 
 
Distortions may also be due to packing effects in the crystal lattice or an attempt to 
reduce the strain in the bonding network around the metal. Electrostatic repulsion of the 
inner hydrogen atoms on the pyridine ring, which applies to solution as well as solid state 
species, may cause the pyridine rings to tilt out of the N4 plane created by the ligand and 
metal centre.249 The pyridine ring subunits are themselves always planar but can be tilted 
in order to reduce steric strain. Structures with larger substituents on the imine carbon 
are likely to have a greater tendency towards this type of distortion. This reduction of 
steric crowding may cause substantial nonplanarity for the structures. Thus it is possible 
for either or both of these factors to play a role in the out-of-plane deviations for the 
structures presented in this work. 
 
Lastly, altering the length of the carbon bridge between the imine groups in these 
complexes not only allows change in the molecular conformation, but also facilitates 
different crystal packing architectures for each derivative. Thus the distortion from the 
plane and the nonplanarity of the bridging group are complimentary to each other. The 
chelating ligand makes an arc around the metal centre in order to offer the four nitrogen 
atoms for bonding, resulting in limited space available for the other atoms linking these 
nitrogen atoms. The more atoms in this space, i.e. the larger the bridging group, the 
greater the extent of distortion of the chelate. This will result in the bridging group being 
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pulled out of the N4 plane. The extent to which it is removed from the plane will depend 
on the nonplanarity seen around the metal and the size and bulk of the bridging group.  
 
3.4.2 X-ray data for the free ligands 
N,N'-bis[(pyridin-2-yl)methylene]ethane-1,2-diamine (L1) 
C14H14N4, fw = 238.29 amu, a = 18.9472(19) Å, b = 5.8207(4) Å, c = 13.0548(15) Å, β = 
121.851(15)°, V = 1223.0(2) Å3, monoclinic, C2/c, Z = 4, Dc = 1.294 g cm
-3, μ = 0.081 
mm-1, T = 102(2) K, R1 (wR2) = 0.0461 (0.1188), for 1374 unique data with I > 2σ(I), R1 
(wR2) = 0.0570 (0.1253) for all 2163 data (Rint = 0.0187). 
 
X-Ray diffraction data from a colourless rectangular crystal with the approximate 
dimensions 0.2 x 0.4 x 0.5 mm3 gave a four-molecule monoclinic unit cell. The final R1 
was 0.0461 and wR2 was 0.1188. A semi-empirical absorption correction was applied to 
the data using CrysAlis RED 170.288 The maximum and minimum electron densities on 
the Fourier map were 0.18 e/Å3 (0.73 Å from H7A) and -0.26 e/Å3 (1.37 Å from C3). 
Atomic coordinates, crystal data and structure refinement tables as well as the IUCR301 
CIF check report are available in Appendix A. Full crystallographic data tables can be 
found in Appendix E. 
 
N,N'-bis[(pyridin-2-yl)methylene] 2,2-dimethyl-propane-1,3-diamine (L4) 
C17H20N4, fw = 280.37 amu, a = 5.8140(14) Å, b = 11.526(3) Å, c = 12.033(3) Å, α= 
101.812(2)°, β = 97.454(3)°, γ = 93.603(3)°, V = 779.3(3) Å3, triclinic, P 1 , Z = 2, Dc = 
1.195 g cm-3, μ = 0.073 mm-1, T = 100(2) K, R1 (wR2) = 0.0414 (0.1054), for 3641 unique 
data with I > 2σ(I), R1 (wR2) = 0.0476 (0.1103) for all 8755 data (Rint = 0.0220). 
 
A two-molecule triclinic unit cell was obtained from the colourless shard with the 
approximate dimensions 0.40 x 0.25 x 0.14 mm3. The final R1 was 0.0414 and wR2 was 
0.1054. The maximum electron density on the Fourier map was 0.368 e/Å3 (0.75 Å from 
C8), while the minimum electron density was -0.215 e/Å3 (1.25 Å from C1). Atomic 
coordinates, crystal data and structure refinement tables as well as the IUCR301 CIF 
check report are available in Appendix A. Full crystallographic data tables can be found 
in Appendix E. 
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N,N'-bis[(pyridin-2-yl)methylene]cyclohexane-1,2-diamine (L5) 
C18H20N4, fw = 292.38 amu, a = 10.8006(6) Å, b = 9.7411(5) Å, c = 15.4012(8) Å, β = 
96.412(5)°, V = 1610.22(15) Å3, monoclinic, P21/n, Z = 4, Dc = 1.206 g cm
-3, μ = 0.074 
mm-1, T = 102(2) K, R1 (wR2) = 0.0430 (0.1034), for 3607 unique data with I > 2σ(I), R1 
(wR2) = 0.0593 (0.1086) for all 6230 data (Rint = 0.0299). 
 
A colourless crystal with the approximate dimensions 0.4 x 0.4 x 0.55 mm3 gave a four-
molecule monoclinic unit cell. The final R1 was 0.0430 and wR2 was 0.1034. A semi-
empirical absorption correction was applied to the data using CrysAlis RED 170.288 The 
maximum electron density on the Fourier map was 0.17 e/Å3 (1.43 Å from H15), while 
the minimum electron density was -0.28 e/Å3 (0.85 Å from C14). Atomic coordinates, 
crystal data and structure refinement tables as well as the IUCR301 CIF check report is 
available in Appendix A. Full crystallographic data tables can be found in Appendix E. 
 
2-pyridin-2-yl-1,4,5,6-tetrahydropyrimidinium hydrochloride (L2h) 
C18H26Cl2N6O, fw = 413.35 amu, a = 14.8632(4) Å, b = 7.6289(2) Å, c = 17.8066(5) Å, V 
= 2019.09(9) Å3, orthorhombic, Pbcn, Z = 8, Dc = 1.360 g cm
-3, μ = 3.062 mm-1, T = 
100(2) K, R1 (wR2) = 0.0350 (0.0948), for 1788 unique data with I > 2σ(I), R1 (wR2)= 
0.0380 (0.0970) for all 5131 data (Rint = 0.0271). 
 
X-Ray diffraction data from a rhombic, pale yellow crystal with the approximate 
dimensions 0.30 x 0.20 x 0.10 mm3 gave an eight-molecule monoclinic unit cell. This 
ligand crystallises with a water molecule and a chloride ion as counter ions. The final R1 
was 0.0350 and wR2 was 0.0948. An analytical absorption correction was applied to the 
data using CrysAlis RED 170.288 The maximum electron density on the Fourier map was 
0.221 e/Å3 (1.09 Å from Cl1), while the minimum electron density was -0.318 e/Å3 (0.44 
Å from Cl1). Atomic coordinates, crystal data and structure refinement tables as well as 
the IUCR301 CIF check report are available in Appendix A. Full crystallographic data 
tables can be found in Appendix E. 
 
2-pyridin-2-yl-1H-benzimidazole (L6h) 
C12H9N3, fw = 195.22 amu, a = 18.5652(15) Å, b = 10.7552(11) Å, c = 10.1767(9) Å, V = 
2032.0(3) Å3, orthorhombic, Pbna, Z = 8, Dc = 1.22 g cm
-3, μ = 0.077 mm-1, T = 296(2) K, 
R1 (wR2) = 0.0566 (0.1005), for 1405 unique data with I > 2σ(I), R1 (wR2) = 0.2037 
(0.1341) for all 2374 data (Rint = 0.0972). 
 
CHAPTER 3 – X-ray Crystallography 
 67 
X-Ray diffraction data from a colourless crystal with the approximate dimensions 0.35 x 
0.30 x 0.25 mm3 gave an eight-molecule orthorhombic unit cell. The final R1 was 0.0566 
and wR2 was 0.1005. An analytical absorption correction was applied to the data using 
CrysAlis RED 170.288 The maximum electron density on the Fourier map was 0.155 e/Å3 
(0.03 Å from N2), while the minimum electron density was -0.151 e/Å3 (1.52 Å from C12). 




C29H28N4, fw = 432.55 amu, a = 10.0325(15) Å, b = 24.790(4) Å, c = 10.0691(15) Å, β = 
112.559(2)°, V = 2312.7(6) Å3, monoclinic, P21/c, Z = 4, Dc = 1.242 g cm
-3, μ = 0.074 
mm-1, T = 100(2) K, R1 (wR2) = 0.0539 (0.1419), for 5397 unique data with I > 2σ(I), R1 
(wR2) = 0.0663 (0.1509) for all 13631 data (Rint = 0.0299). 
 
A four-molecule monoclinic unit cell was obtained from the colourless shard with the 
approximate dimensions 0.43 x 0.30 x 0.25 mm3. The final R1 was 0.0539 and wR2 was 
0.1419. The maximum electron density on the Fourier map was 0.573 e/Å3 (1.01 Å from 
N3), while the minimum electron density was -0.430 e/Å3 (0.53 Å from N3). Atomic 
coordinates, crystal data and structure refinement tables as well as the IUCR301 CIF 
check report are available in Appendix A. Full crystallographic data tables can be found 
in Appendix E. 
 
2-(2-phenylimidazolidin-2-yl)pyridine (L1bh) 
C14H15N3, fw = 225.29 amu, a = 16.727(2) Å, b = 5.8039(5) Å, c = 24.4882(17) Å, β = 
95.320(7)°, V = 2367.1(4) Å3, monoclinic, C2/c, Z = 8, Dc = 1.264 g cm
-3, μ = 0.077 mm-1, 
T = 296(2) K, R1 (wR2) = 0.0467 (0.1158), for 2872 unique data with I > 2σ(I), R1 (wR2) = 
0.0555 (0.1192) for all 19111 data (Rint = 0.0426). 
 
The small, white, almost colourless crystal with the approximate dimensions 0.55 x 0.45 
x 0.35 mm3 gave X-ray diffraction data consistent with an eight-molecule monoclinic unit 
cell. The final R1 was 0.0467 and wR2 was 0.1158. A semi-empirical absorption 
correction was applied to the data using CrysAlis RED 170.288 The maximum and 
minimum electron densities on the Fourier map were 0.21 e/Å3 (0.75 Å from C9) and -
0.19 e/Å3 (0.78 Å from C7). Atomic coordinates, crystal data and structure refinement 
tables as well as the IUCR301 CIF check report are available in Appendix A. Full 
crystallographic data tables can be found in Appendix E. 
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2-phenyl-2-pyridin-2-ylhexahydropyrimidine (L2bh) 
C15H17N3, fw = 239.32 amu, a = 8.2380(9) Å, b = 9.0960(8)  Å, c = 9.2759(8) Å, α= 
97.310(7)°, β = 94.450(8)°, γ = 111.855(9)°, V = 633.95(10) Å3, triclinic, P 1 , Z = 2, Dc = 
1.254 g cm-3, μ = 0.076 mm-1, T = 296(2) K, R1 (wR2) = 0.0484 (0.1200), for 2495 unique 
data with I > 2σ(I), R1 (wR2) = 0.0766 (0.1329) for all 7440 data (Rint = 0.0624). 
 
The X-ray diffraction data for a colorless rectangular crystal of L2bh (0.45 x 0.35 x 0.20 
mm3) were consistent with a two-molecule triclinic unit cell. The final R1 was 0.0484 and 
wR2 was 0.1200. A semi-empirical absorption correction was applied to the data using 
CrysAlis RED 170.288 The maximum electron density on the Fourier map was 0.169 e/Å3 
(0.85 Å from H9B), while the minimum electron density was -0.201 e/Å3 (1.12 Å from 
C6). Atomic coordinates, crystal data and structure refinement tables as well as the 
IUCR301 CIF check report is available in Appendix A. Full crystallographic data tables 
can be found in Appendix E. 
 
5,5-dimethyl-2-phenyl-2-pyridin-2-ylhexahydropyrimidine (L4bh) 
C17H21N3, fw = 267.37 amu, a = 14.7533(6) Å, b = 6.0380(2) Å, c = 16.4381(6) Å, β = 
90.923(2)°, V = 1464.12(9) Å3, monoclinic, P21/c, Z = 4, Dc = 1.213 g cm
-3, μ = 0.073 
mm-1, T = 100(2) K, R1 (wR2) = 0.0436 (0.1152), for 4128 unique data with I > 2σ(I), R1 
(wR2) = 0.0598 (0.1216) for all 50915 data (Rint = 0.0887). 
 
A colourless, prism (approximate dimensions 0.125 x 0.08 x 0.025 mm3) gave X-Ray 
diffraction data yielding a four-molecule monoclinic unit cell. The final R1 was 0.0436 and 
wR2 was 0.1152. The maximum electron density on the Fourier map was 0.334 e/Å
3 
(0.76 Å from C13), while the minimum electron density was -0.237 e/Å3 (0.61 Å from C5). 
Atomic coordinates, crystal data and structure refinement tables as well as the IUCR301 
CIF check report are available in Appendix A. Full crystallographic data tables can be 
found in Appendix E. 
 
3.4.3 X-ray structures of the Schiff base ligands 
All the above ligands gave white or colourless crystals suitable for X-ray diffraction 
studies. Some of the single crystals were grown by allowing slow evaporation, 
undisturbed for a few days, from diethyl ether (L1, L4 and L5). Others were formed from 
the reaction mixture on standing (L2h, L6h and L4bh) or were a minor product which 
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precipitated out in a crystalline form along with the powder of the major product (L1bh 
and L2bh). All of the ligands that crystallised were found to be of either the monoclinic or 
orthorhombic systems, with the exception of L4 and L2bh, which crystallised in the 
triclinic crystal system (P 1 ). All nonhydrogen atoms were refined anisotropically. 
Hydrogen atoms were inserted with standard SHELXL291 idealisation parameters in their 
geometrically idealised positions for L4b and constrained to ride on their parent atoms, 
with distances in the range 0.95–1.00 Å. Hydrogen atoms for L1, L5 and L4 were located 











Figure 3.14: Thermal ellipsoid views (with the nitrogen atoms labelled) of the X-ray structures of 
L1, L4 and L5 (50% probability displacement ellipsoids), showing the overall molecular 
conformations. (Hydrogen atoms have been calculated for L1 and L5 and located for L4.) 
 
L1, L4 and L5 are novel examples of structurally characterised N4-donor Schiff base 
ligands; their molecular structures are shown in the thermal ellipsoid plots in Figure 3.14. 
Due to the cis-configuration of the cyclohexane bridge there is no centre of inversion for 
L5 and all the nitrogen atoms are unique. However, L1 has inversion symmetry due to its 
symmetrical ethyl bridge and hence the ligand contains two identical halves. Although 
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that the bridging group has been distorted. Selected bond lengths and angles are shown 
in Table 3.2. The standard uncertainty (estimated standard deviation) is given in 
parenthesis. Note that for bonds to differ by a statistically significant amount, the 
difference must be > 4 x the esd (estimated standard deviation). The lengths of the C=N 
bonds are experimentally equivalent: 1.267(2) (L1), 1.267(2) (L4) and 1.268(2) (L5) Å. 
These lengths fall within the expected range for imine bonds: 1.250 to 1.270 Å.158,302 
 
Table 3.2: Selected average bond lengths (Å) and angles (°) of the free Schiff base ligands. 
 L1 L4 L5 
Ni=Ci 1.267(2) 1.267(2) 1.268(2) 
Np-Cp 1.342(2) 1.347(2) 1.348(2) 
Cf-Cg 1.519(3) 1.539(2) 1.533(2) 
Ci-He 0.981(1) 0.989(2) 0.994(2) 
Ci=Ni-Cf 117.0(1) 116.9(1) 116.5(1) 
Ni-Cf-Cg 111.5(1) 112.2(1) 110.7(1) 
Np-Cp-Ci 115.3(1) 114.9(1) 115.0(1) 
Cp-Ci-Ni 121.9(1) 121.8(1) 122.6(1) 
 
There is no indication of π–π stacking for the pyridine rings in these ligand structures, 
even though such interactions might be expected to occur due to their abundance in 
heteroaromatic systems.303 Complementary short contacts are seen for all three of these 
ligands (as shown in Figure 3.15). Short intermolecular contacts have been observed 
between two neighbouring Schiff base units for the ligand L5 (Ca-Ha···Np and Np···Ha-Ca). 
A similar contact involving the pyridine-nitrogen takes place in L1 between Ci-He···Np and 
Np···He-Ci for adjacent molecules. Because the imine C-H group functions similarly to an 
aromatic C-H group as a known unconventional H-bond donor304, the pair of C-H···N 
interactions between neighbouring molecules is consistent with complemenary H-
bonding. Meanwhile, L4 has a complementary relationship between the bridging 
hydrogens of one molecule with the pyridyl carbon atoms from another molecule. There 
is also a second set of complementary short contacts observed for L5 invloving the 



























Figure 3.15: Complimentary short intermolecular contacts of L5 (2.621(10) and 2.745(10) Å), 













Figure 3.16: Crystal packing diagrams of the unit-cell for L1 (Z = 4), L4 (Z = 2) and L5 (Z = 4), 
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Thus, L1 and L5 represent systems with unconventional complementary (sp2) C-H···N 
hydrogen bonding, while L4 simply has a pair of molecules related by inversion with 
some short non-bonded contacts.  The latter are not in any way stabilising, in contrast to 
the former H-bonded dimers. The unit-cell packing diagrams for each of the ligands are 
depicted in Figures 3.16 and display the patterns in which the molecules are located in 
the solid state. They reveal the infinite two-dimensional network structure for each of the 
compounds. 
 
The ligands with the larger steric bulk on the imine carbon have more difficulty in 
crystallising. None of the methyl-substituted ligands have thus far produced X-ray quality 
crystals and only one structure has been obtained for the phenyl-substituted ligands; 
L4b. The structure of this ligand is shown in Figure 3.17 along with its complementary 
short contacts between Ch-Hh···Ce2 and Ce2···Hh-Ch. This space-filling model clearly 
shows the extra bulk on this ligand.  
 
The other ligands that have formed X-ray quality crystals are mono(imine) ligands (1:1 
ratio of aldehyde to diamine) resulting in an N3 Schiff base ligand. This structure then 
cyclises intramolecularly at the imine carbon atom to produce an imidazole-containing or 
hexahydropyrimidine-containing bidentate ligand. X-ray quality crystals have been 
obtained for: L2h, L6h, L1bh, L2bh and L4bh. Not much success has thus far been had 
in obtaining crystals from their fully reacted ligands (2:1 ratio of aldehyde to diamine). 
Most of these ligands are viscous oils, except for L4b, for which the data has been 
presented here. These bidentate imidazole- or hexahydropyrimidine-containing ligands 
present the possibility of metallation in a 2:1 ligand to metal ratio. This has been 
attempted for L6h with Pt(II) and Pd(II), where metallated adducts in powder form have 
been obtained (see Chapter 2 – Experimental). 
 
The imidazoline derivative, L1bh305, has been reported in the literature with the same 
space group as in this work.  L1bh crystallises in the monoclinic space group C2/c and 
displays an interesting supramolecular structure – a “zip” – that involves corresponding 
hydrogen bonding between neighbouring molecules (Figure 3.18). A similar interlocking 
hydrogen-bonded polymer has been seen by Munro and co-workers for a novel 
crystalline steroidal sapogenin306 and Barboiu et al. have reported metallosupramolecular 
zippers stabilised by strong π–π stacking interactions.307 
 











              
Figure 3.17: Left: The complementary short contacts of 2.842 Å for L4b. Right: The space filling 
model of L4b (top) and a thermal ellipsoid view of the X-ray structure of L4b (50% probability 
displacement ellipsoids), showing the overall molecular conformation where hydrogen atoms are 
rendered with arbitrary radii (bottom). 
Figure 3.18: The packing “zip” of the imidazoline derivative, L1bh, showing short contacts 
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Although L6h has also been synthesised before, it has been reported with space groups 
of Pbca308 and P2/c309. Here our space group setting for L6h is Pbna albeit with a slightly 
higher R-factor (Rint = 0.0972) than those reported for the Pbca and P2/c polymorphs. 
L2h and L2bh are both novel structures, with the only difference between them being 
either a hydrogen atom or a phenyl ring. These structures were synthesised when the 
aldehyde and diamine starting materials reacted in a 1:1 ratio (see page 41). The bulk of 
this group clearly has an effect on the structure as the two molecules show very different 
crystallographic arrangements. L2h has interesting hydrogen bonding which involves the 
water and chloride counter ions.  The π–π stacking seen for this molecule is at a 
distance of 3.355 Å which presumably stabilises the crystal structure (Figure 3.19). L2bh 
does not possess this π–π stacking and the molecules pack in an alternating pattern 
(zig-zag strucrure) using hydrogen bonding to stabilise them (Figure 3.20). Cd-Hd···Np 
complementary hydrogen bonding favours the formation of one-dimensional chains; this 














Figure 3.19: Ball and stick model to show the π–π stacking interactions (left) and a thermal 



































Figure 3.20: The complimentary short contacts of 2.722 Å between neighbouring molecules 




Figure 3.21: The hydrogen-bonded chain of L2bh with two alternating intermolecular 
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The structure of L4bh is rather similar to that of L2bh, differing only by the dimethyl 
substitution of the central carbon of the propyl bridge of the diamine starting material. 
This results in greater bulk on the cyclised hexahydropyrimidine ring and subsequently 
very different packing to that of the triclinic L2bh. There are no complimentary short 
contacts for L4bh; but rather a “circular” arrangement of four molecules (Figure 3.22). 
These four molecules are connected to each other to form a symmetrical pattern, with 
Hf···H3 and C3/C4···Hb short contacts on either side. Chains of these circular four 
molecules are then linked to other chains through Hh···Hh (2.2563 Å) short contacts. 




Figure 3.22: Top: The intermolecular short contacts between neighbouring molecules of L4bh. 
Bottom left: a thermal ellipsoid view (at 50% probability). Bottom right: the packing diagram for 
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C14H14N4F12P2Pt, fw = 723.31 amu, a = 15.0250(19) Å, b = 10.4150(11) Å, c = 
13.0220(10) Å, β = 99.285(9)°, V = 2011.1(4) Å3, monoclinic, C2/c, Z = 4, Dc = 2.389 g 
cm-3, μ = 7.257 mm-1, T = 100(2) K, R1 (wR2) = 0.0483 (0.1017), for 3278 unique data 
with I > 2σ(I), R1 (wR2) = 0.0710 (0.1086) for all 10150 data (Rint = 0.0622). 
 
A yellow-orange needle with the approximate dimensions 0.40 x 0.20 x 0.04 mm3 had X-
ray diffraction data consistent with a four-molecule monoclinic unit cell. The final R1 was 
0.0483 and wR2 was 0.1017. A semi-empirical absorption correction was applied to the 
data using CrysAlis RED 170.288 The maximum and minimum electron densities on the 
Fourier map were 4.000 e/Å3 (0.86 Å from Pt1) and -1.325 e/Å3 (0.77 Å from Pt1). Atomic 
coordinates, crystal data and structure refinement tables as well as the IUCR301 CIF 
check report are available in Appendix B. Full crystallographic data tables can be found 




C14H14N4F12P2Pd, fw = 634.6 amu, a = 14.8209(19) Å, b = 10.3056(10) Å, c = 
13.1386(17) Å, β = 100.091(13)°, V = 1975.7(4) Å3, monoclinic, C2/c, Z = 4, Dc = 2.134 g 
cm-3, μ = 1.224 mm-1, T = 100(2) K, R1 (wR2) = 0.0389 (0.0870), for 2110 unique data 
with I > 2σ(I), R1 (wR2) = 0.0663 (0.0984) for all 3756 data (Rint = 0.0347). 
 
X-ray diffraction data from a small, yellow crystal with the approximate dimensions 0.10 x 
0.15 x 0.20 mm3 gave a four-molecule monoclinic unit cell. The final R1 was 0.0389 and 
wR2 was 0.0870. A semi-empirical absorption correction was applied to the data using 
CrysAlis RED 170.288 The maximum and minimum electron densities on the Fourier map 
were 0.39 e/Å3 (1.04 Å from F1) and -0.51 e/Å3 (0.97 Å from Pd). Atomic coordinates, 
crystal data and structure refinement tables as well as the IUCR301 CIF check report are 
available in Appendix B. Full crystallographic data tables can be found in Appendix E. 
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N,N'-bis[(pyridin-2-yl)methylene]propane-1,3-diamine platinum(II)  
hexafluorophosphate(V) (PtL2) 
C15H16N4F12P2Pt, fw = 737.35 amu, a = 13.134(5) Å, b = 10.611(5) Å, c = 15.103(5) Å, β 
= 101.142(5)°, V = 2065.2(14) Å3, monoclinic, P21/n, Z = 4, Dc = 2.372 g cm
-3, μ = 7.069 
mm-1, T = 100(2) K, R1 (wR2) = 0.0476 (0.1339), for 6656 unique data with I > 2σ(I), R1 
(wR2) = 0.0687 (0.1414) for all 19521 data (Rint = 0.0415). 
 
A four-molecule monoclinic unit cell was obtained for the X-ray diffraction data from a 
yellow crystal with the approximate dimensions 0.50 x 0.40 x 0.20 mm3. The final R1 was 
0.0476 and wR2 was 0.1339. A semi-empirical absorption correction was applied to the 
data using CrysAlis RED 170.288 The maximum and minimum electron densities on the 
Fourier map were 3.113 e/Å3 (0.69 Å from Pt1) and -3.837 e/Å3 (0.71 Å from Pt1). Atomic 
coordinates, crystal data and structure refinement tables as well as the IUCR301 CIF 
check report are available in Appendix B. Full crystallographic data tables can be found 




C15H16N4F12P2Pd, fw = 648.66 amu, a = 13.443(5) Å, b = 10.513(5) Å, c = 14.905(5) Å, β 
= 102.674(5)°, V = 2055.1(14) Å3, monoclinic, P21/n, Z = 4, Dc = 2.096 g cm
-3, μ = 1.179 
mm-1, T = 100(2) K, R1 (wR2) = 0.0282 (0.0797), for 6638 unique data with I > 2σ(I), R1 
(wR2) = 0.0327 (0.0814) for all 19654 data (Rint = 0.0196). 
 
X-ray diffraction data from a yellow crystal with the approximate dimensions 0.60 x 0.50 x 
0.40 mm3 gave a four-molecule monoclinic unit cell. The final R1 was 0.0282 and wR2 
was 0.0797. The maximum and minimum electron densities on the Fourier map were 
0.842 e/Å3 (0.68 Å from F1) and -1.435 e/Å3 (0.68 Å from Pd1). Atomic coordinates, 
crystal data and structure refinement tables as well as the IUCR301 CIF check report are 
available Appendix B. Full crystallographic data tables can be found in Appendix E. 
 
N,N'-bis[(pyridin-2-yl)methylene]2,2-dimethyl-propane-1,3-diamine 
platinum(II) hexafluorophosphate(V) (PtL4) 
C34H40N4F24P4Pt2, fw = 1530.72 amu, a = 10.62600(10) Å, b = 26.9950(3) Å, c = 
16.2420(2) Å, β = 995.1930(10)°, V = 4640(3) Å3, monoclinic, P21/c, Z = 8, Dc = 2.191 g 
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cm-3, μ = 0.630 mm-1, T = 100(2) K, R1 (wR2) = 0.0545 (0.1386), for 17394 unique data 
with I > 2σ(I), R1 (wR2) = 0.0686 (0.1472) for all 2927 data (Rint = 0.0554). 
 
A yellow, plate-shaped crystal with the approximate dimensions 0.60 x 0.40 x 0.20 mm3 
gave X-ray diffraction data consistent with an eight-molecule unit cell comprising two 
independent molecules in the asymmetric unit. The final R1 was 0.0545 and wR2 was 
0.1386. A semi-empirical absorption correction was applied to the data using CrysAlis 
RED 170.288 The maximum and minimum electron densities on the Fourier map were 
1.711 e/Å3 (1.08 Å from Pt1) and -2.687 e/Å3 (1.22 Å from Pt1). Atomic coordinates, 
crystal data and structure refinement tables as well as the IUCR301 CIF check report are 
available in Appendix B. Full crystallographic data tables can be found in Appendix E. 
 
N,N'-bis[(pyridin-2-yl)methylene]2,2-dimethyl-propane-1,3-diamine 
palladium(II) hexafluorophosphate(V) (PdL4) 
C34H40N4F24P4Pd2, fw = 1353.40 amu, a = 10.5160(2) Å, b = 27.1650(5) Å, c = 
16.2810(3) Å, β = 93.884(2)°, V = 4640.26(15) Å3, monoclinic, P21/c, Z = 8, Dc = 1.937 g 
cm-3, μ = 0.105 mm-1, T = 293(2) K, R1 (wR2) = 0.0729 (0.1876), for 17470 unique data 
with I > 2σ(I), R1 (wR2) = 0.1103 (0.2047) for all 74682 data (Rint = 0.0730). 
 
X-ray diffraction data from a yellow crystal with the approximate dimensions 0.30 x 0.30 x 
0.20 mm3 were consistent with an eight-molecule unit cell comprising two independent 
molecules in the asymmetric unit. The final R1 was 0.0729 and wR2 was 0.1876. A semi-
empirical absorption correction was applied to the data using CrysAlis RED 170.288 The 
maximum and minimum electron densities on the Fourier map were 6.609 e/Å3 (0.76 Å 
from Pd2) and -3.924 e/Å3 (0.77 Å from Pd1). Atomic coordinates, crystal data and 
structure refinement tables as well as the IUCR301 CIF check report are available in 
Appendix B. Full crystallographic data tables can be found in Appendix E. 
 
N,N'- bis[(pyridin-2-yl)ethylene] 2,2-dimethyl- propane-1,3- diamine 
palladium(II) hexafluorophosphate(V) (PdL4m) 
C19H24N4F12P2Pd, fw = 704.76 amu, a = 8.262(5) Å, b = 13.068(5) Å, c = 23.981(5) Å, β 
= 98.914(5)°, V = 2557.9(19) Å3, monoclinic, P21/n, Z = 4, Dc = 1.830 g cm
-3, μ = 0.955 
mm-1, T = 296(2) K, R1 (wR2) = 0.0477 (0.1296), for 6099 unique data with I > 2σ(I), R1 
(wR2) = 0.0614 (0.1355) for all 32956 data (Rint = 0.0555). 
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X-ray diffraction data from a yellow-brown crystal with the approximate dimensions 0.55 
x 0.45 x 0.35 mm3 gave a four-molecule monoclinic unit cell. The final R1 was 0.0477 
and wR2 was 0.1296. A semi-empirical absorption correction was applied to the data 
using CrysAlis RED 170.288 The maximum and minimum electron densities on the 
Fourier map were 0.791 e/Å3 (1.32 Å from F11) and -0.747 e/Å3 (0.75 Å from Pd1). 
Atomic coordinates, crystal data and structure refinement tables as well as the IUCR301 
CIF check report are available in Appendix B. Full crystallographic data tables can be 
found in Appendix E. 
 
N,N'-bis[phenyl(pyridin-2-yl)methylene]2,2-dimethyl-propane-1,3-
diamine palladium(II) hexafluorophosphate(V) (PdL4b) 
C29H28N4F12P2Pd, fw = 828.89 amu, a = 18.294(4) Å, b = 10.329(2) Å, c = 17.997(4) Å, β 
= 97.109(3)°, V = 3374.6(12) Å3, monoclinic, P21/c, Z = 4, Dc = 1.631 g cm
-3, μ = 0.738 
mm-1, T = 100(2) K, R1 (wR2) = 0.0415 (0.0997), for 8098 unique data with I > 2σ(I), R1 
(wR2) = 0.0490 (0.1029) for all 21245 data (Rint = 0.1028). 
 
X-ray diffraction data from a yellow crystal of PdL4b (0.1 x 0.1 x 0.1 mm3) were 
consistent with a four-molecule monoclinic unit cell. The final R1 was 0.0415 and wR2 
was 0.1029. The maximum and minimum electron densities on the Fourier map were 
0.851 e/Å3 (0.78 Å from N1) and -0.860 e/Å3 (0.77 Å from Pd1). Atomic coordinates, 
crystal data and structure refinement tables as well as the IUCR301 CIF check report are 
available in Appendix B. Full crystallographic data tables can be found in Appendix E. 
 
3.4.5 X-ray structures of the metal complexes 
Despite the similar coordination geometries offered by this range of ligands with the two 
chosen metals, only eight complexes belonging to this group of compounds were 
structurally characterised in this work, namely PtL1, PdL1, PtL2, PdL2, PtL4, PdL4, 
PdL4m and PdL4b. We encountered problems growing X-ray quality crystals of some of 
the complexes due to the difficulty involved in obtaining bulk material for some of the 
metal complexes. For the first few crystals amenable to X-ray analysis, room 
temperature data collections were employed; however, these structures were 
redetermined at low temperature and better data sets were obtained. Hence, data were 
collected from all other crystals thereafter at 100(2) K. The structures were solved using 
direct methods in WinGX‟s implementation of SHELXS-97289 and refined to R-values all 
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smaller than 8%. All non-H atoms were located in the E-map and refined anisotropically 
with SHELXL-97.291 Hydrogen atoms were located for PdL2, but „added‟ (coordinates of 
the calculated positions were refined using a riding model)291 for the other structures. 
 
         
       
Figure 3.23: Photographs of the different crystal fragments used for data collection for the 
metal complexes. Top: PtL1, PdL1, PtL2, PdL2, and bottom: PtL4, PdL4, PdL4m and PdL4b, 
respectively. 
 
The seven metal complexes presented here were yellow, orange or red in solution and 
the crystals were yellow, brown or orange (Figure 3.23). The crystals for these metal 
complexes were grown either by slow evaporation of acetonitrile (PtL2, PdL2, PdL4m) 
or solvent diffusion in test tubes (PtL1, PdL1, PtL4, PdL4, PdL4b). Different solvent 
systems were used including: acetonitrile/ethanol, 2-methoxy ethanol/ether and distilled 
water/ethanol. 
 
3.4.5.1 Molecular structures 
It is well known that relatively small structural modifications in a multidentate ligand may 
cause significant changes in the reactivity of the complexes. Platinum is a softer centre 
than palladium and subsequently it is more sensitive to electronic communication with 
the chelate ring than palladium. The reactivity of palladium(II) complexes is mostly 
reported to be a factor of 105–106 faster than that of the corresponding platinum(II) 
complexes (dependent on the ligands attached).299 Studies of the favoured 
conformations (in the solid state), as discovered by X-ray analysis, provide useful 
CHAPTER 3 – X-ray Crystallography 
 82 
insights into the differences and similarities in structural conformations and possible 
reactivity. The structures of the seven metal complexes synthesised in this work are 
represented in Figures 3.24 and 3.25. 
 
      
      
Figure 3.24: Thermal ellipsoid views (50% probability displacement ellipsoids) for four of the 
metal cations with the nitrogen atoms labelled. Top: PtL1 and PdL1, and bottom: PtL2 and 
PdL2. Counter ions have been omitted for clarity. 
 
The cation chelates synthesised and structurally characterised in this work exhibit the 
approximately square planar geometry expected for this type of metal and ligand 
combination (as discussed previously). The hydrogen atoms have been calculated for 
most of the complexes and are therefore drawn as fixed-sized spheres in all the 
structures. The structures all display the same general orientation of chemically 
equivalent atoms around the metal centres and differ only by the nature of bridging 
diamine or by the group attached to the imine carbons (Figure 3.25: methyl groups for 
PdL4m and phenyl rings for PdL4b). Distortions from the N4 plane (formed by the two 














CHAPTER 3 – X-ray Crystallography 
 83 
         
 
     
Figure 3.25: Thermal ellipsoid views (50% probability displacement ellipsoids) for four of the 
metal cations with the nitrogen atoms labelled. Top: PtL4, PdL4, and bottom: PdL4m and 
PdL4b. Counter ions have been omitted for clarity. 
 
The Pt(II) and Pd(II) ions exhibit the expected four-coordinate, square planar geometry 
within each of the tetradentate chelates crystallised. These Pt(II) and Pd(II) complexes of 
the same ligands with essentially planar core conformations are isoelectronic, but not 
necessarily isomorphous. From the selected data in Table 3.3 it is noteworthy that the 
distance between the two imine-nitrogen atoms increases substantially from the ethyl-
bridged to the propyl-bridged ligands, ~ 2.6 to ~ 2.9 Å. Due to this additional distance 
between the imine-nitrogen atoms the angle Ni-M-Ni also increases from ~ 85 to ~ 95 °. 
Hence, there is also a noticeable decrease in the angle Np-M-Np from ~ 113 to ~ 105 ° as 
we move from the 2-carbon bridging group to the 3-carbon bridging group. This is due to 
the greater chain length in the central chelate ring of the complex causing the pyridyl 
groups to be pushed further around the metal on each side, closing the gap at the end 
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as the atoms in the vicinity that form the structure of these 5-membered chelates do not 
change, nor does their position. This therefore means that the difference in bite angle 
has to affect the structure by causing a change in the Np-M-Np angles. 
 
Table 3.3: Selected averaged bond lengths (Å) and angles (°) for the metal complexes (esd 
given in parentheses). 
 M-Ni M-Np Ci=Ni Ni to Ni
a Ni-M-Ni Ni-M-Np Np-M-Np 
PtL1 1.953(5) 2.051(5) 1.261(9) 2.652(8) 85.6(3) 80.8(2) 112.9(3) 
PdL1 1.942(4) 2.046(3) 1.261(7) 2.628(5) 85.2(2) 80.7(2) 113.4(2) 
PtL2 1.988(6) 2.060(5) 1.278(8) 2.936(8) 95.2(2) 79.4(2) 106.2(2) 
PdL2 1.998(2) 2.073(2) 1.278(2) 2.922(2) 94.0(7) 80.2 (7) 105.3(3) 
PtL4 1.986(7) 2.038(6) 1.298(10) 2.941(9) 95.6(3) 79.7(3) 106.5(2) 
PdL4 1.992(4) 2.057(4) 1.280(6) 2.927(5) 94.3(2) 80.1(2) 105.5(2) 
PdL4m 1.998(3) 2.056(3) 1.284(5) 2.946(5) 95.0(1) 79.5(1) 105.6(1) 
PdL4b 2.002(5) 2.034(7) 1.291(8) 2.532(8) 96.9(2) 79.9(2) 103.9(2) 
 
a
 Chelate ring "width" measured as the Ni···Ni distance in Mercury 2.4.
310 
 
It may therefore be concluded that as the mean M-Ni distance decreases due to a 
change in metal ion radius or alkyl bridge length in the central chelate ring, the Np-M-Np 
and Ni-M-Ni angles concomitantly become progressively more obtuse and acute, 
respectively. When changing the size of the metal ion and/or the chelate ring the 
combined structural response of the metal ion coordination geometry is presented in 
Figure 3.26. A perturbation of one coordination group parameter (e.g. the M-Ni bond 
length) modulates (increases or decreases) the level of chelate ring strain in the 
complex. Increases in chelate ring strain are evidently alleviated through changes in the 
Np-M-Np and Ni-M-Ni angles with a decrease in one angular variable requiring a 
concomitant increase in the opposite angular variable. This means that the Np-M-Np and 
Ni-M-Ni angles will have opposite and linearly correlated “motion” in this category of 




















Figure 3.26:  Graphs of the variation of Np-M-Np bond angle (left) and Ni-M-Ni bond angle (right) 
with the change in M-Nimine bond distance for eight crystallographically characterised square 
planar Pt(II) and Pd(II) bis(pyridine-imine) chelates. Key: Np, pyridine nitrogen atom; Ni or N
i, 
imine nitrogen atom. The straight lines are linear least-squares fits of the data in each case. 
 
 
Figure 3.27: Linear least-squares fit of the variation of the Np-M-Np angle with the Ni-M-Ni 
angle.  The regression function, correlation coefficient, and 95% confidence interval are shown. 
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Structural changes in the metal ion coordination geometry and central chelate ring are 
also accompanied by structural perturbations of the two imine groups of the complex. 
The relationship between the mean C=N distance of the complex and the mean M-Ni 
bond length is nonlinear (Figure 3.28) and is well fit by a standard quadratic function.  
The minimum in the function is observed at a M-Ni distance of 1.949 Å. The C=Ni 
distance measures 1.261 Å at the turning point and is slightly compressed relative to the 
ideal strain-free distance of 1.266 Å calculated for methanimine in the gas phase. The 
relationship may be interpreted in purely classical terms akin to Hooke‟s Law used to 
describe the deformation of bonds and angles in molecular mechanics force fields.311  
 
 
Figure 3.28:  Plot of the variation in C=Ni bond distance with M-Ni bond distance for eight 
crystallographically characterised square planar Pt(II) and Pd(II) bis(pyridine-imine) chelates.  
The solid line is a nonlinear fit of a quadratic function to the experimental data.  The dashed 
linear line marks the ideal (strain-free) distance for the C=N bond length of methanimine 
(H2C=NH) computed at the B3LYP/6-311G** level of theory in the gas phase. 
 
Compression of the M-Ni bonds from values > 2 Å to values around 1.95 Å requires 
concomitant compression of the C=Ni bonds for optimal C=Ni bonding to be maintained 
in the ligand as it adjusts to fit the changing coordination requirements of the chelated 
metal ion. Compression of the M-Ni bonds to mean distances shorter than 1.949 Å, 
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however, causes undue strain in the two five-membered chelate rings of the complex.  
This perturbation is marked by an increase in the C=Ni bond lengths as the imine 
nitrogen atoms maintain dative covalent bonding to the metal ion and the five-membered 
chelate rings structurally adjust to the increasingly “miss-fitting” metal ion. One caveat 
with the above interpretation is that additional data points for M-Ni distances <1.95 Å 
would be required to fully confirm the quadratic relationship shown in Figure 3.28.  
Despite this limitation, the relationship evident from the graph in Figure 3.28 and its 
interpretation is reasonable particularly since it gauges the perturbation of a key bond in 
the organic ligand and organic bonds are the least likely to depart from Morse- or Hooke-
type deformation functions. 
 
As the size of a chelate ring increases there is an increase in stability to a point after 
which the stability starts to decrease (3-membered < 4-membered, 5-memebered ~ 6-
membered > 7-membered > 8-membered).312 Therefore as the size of the chelate ligand 
increases there must be an effect on the structure of the chelate ring. The angle between 
the metal and two neighbouring donor atoms of a chelate is called the bite angle. It would 
be more energy taxing to alter the organic framework of the chelate than to change the 
bonds and angles around the metal, hence the bite angle and metal bonds are affected. 
This bite angle has been shown to increase with the size of the chelating ring. This may 
be explained by the need to accommodate the longer hydrocarbon chain which then 
forces the two donor atoms further apart. Different metal ions will also affect the size of 
the bite angle due to the different sizes of their preferred bond lengths.312 The smaller 
metal ions will be able to get closer to the 5-membered chelate rings due to the smaller 
bond length; however, the bite angle would also need to be favourable towards smaller 
metals. 
 
A decrease in bite angle with decreasing ring size (6-membered to 5-membered chelate) 
has been observed for a platinum complex with a bidentate (N2 donor) ligand,
313 as well 
as for nickel complexes with a tetradentate (N4 donor) ligand.
314 The greater 
thermodynamic stability of 6-membered rings over 5-membered rings has also been 
shown by Crouch et al. for nitrogen donor ligands with a selection of transition metals.315 
The use of propyl and ethyl bridges and their resulting effects on the complex structure 
have been compared by Shimazaki and co-workers for a salen ligand (N2O2 donor) 
complexed to Ni(II), Pd(II) and Pt(II).316 A greater distortion of the coordination plane was 
observed for the 1,3-diaminopropane backbone causing slightly longer coordination 
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sphere bond lengths. Similar results have been obtained for the palladium(II) complexes 
of bis(pyrrole-imine) ligands; the angle of the 5-membered chelate bite is 83.9(1)º while 
the angle of the 6-membered chelate ring ranges between 94.7(2) and 95.9(2)º. 
 
A chelate ring may not necessarily be the ideal size to “fit” the metal. This is true for both 
5-membered and 6-membered chelate rings and may consequently cause internal 
strain.312 This potential mismatch involves the adjustment of metal-donor distances and 
subsequently the angles around the metal. For multidentate ligands there is more than 
just one chelate ring size to be taken into account. The combination of chelate ring sizes 
may increase or decrease the strain on the structure. For tridentate N3 platinum chelates 
the presence of a 6-membered ring between two 5-membered rings was found to reduce 
the strain.317 It is also possible for the structure of the chelate to pucker causing a tilt out 
of the plane and subsequently a smaller bite angle than if it were flat.312  
 
On careful inspection of the structures presented in Figures 3.24 and 3.25 it may be 
noted that the bridging groups are not completely planar. Distortion from the plane is 
observed for the ethyl bridging group of PtL1 and PdL1. The ethyl bridge is completely 
distorted from planarity resulting in one CH2 below the plane and one above. This 
reduces the strain on the metal and subsequently allows for a smaller bite angle. 
Distortion is also observed for the propyl bridging group of PtL2 and PdL2, but to a 
lesser extent. The three carbon atoms form an envelope shape with the central CH2 
orientated out of the plane and each CH2 on either side in the plane. With the limited 
distortion seen for this bridge it is understandable that it possesses a larger bite angle 
than the ethyl derivatives in order to accommodate the two in-plane CH2 groups. This 
may therefore account for the difference of 10º seen between the bite angles of these 
two chelating groups. There is also a slight inconsistency in the bite angles for metal 
complexes that have the same sized chelating ring. Although the difference is equal 
within the esd of the angle determinations it is noteworthy that the bite angles for the 
platinum complexes are consistently larger than those of the palladium complexes. For 
the complexes of L1 this difference is 0.4º, and 1.2º for the complexes of both L2 and L4. 
This is similar to the increase in the bite angle from the palladium to platinum complexes 
of a salen ligand (with a propyl bridge) which was shown to be ~ 1º.316 
 
Another important factor contributing to the size of the angle is the length of the bonds 
that form this angle. As mentioned, it is not energetically favourable to change the bonds 
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or angles of the organic component of the chelate ring. Consequently, the changes in 
bite angle that occur to accommodate the chelates of different lengths must cause some 
changes to bond lengths. The observed change in the M-Ni bond, when moving from the 
shorter to longer chelate chain, is an increase in length. This increase is 0.035 Å for the 
platinum complexes (PtL1 → PtL2) and 0.056 Å for the palladium complexes (PdL1 → 
PdL2). This somewhat lengthened bond (more than 4 x the esd) therefore helps to 
accommodate the slightly larger bite angle (Figure 3.26). 
 
There is very little difference between PdL4 and PdL4m which differ by the group on the 
imine carbon (–H for PdL4 and –CH3 for PdL4m). Most of the bonds differ by less than 4 
times the esd and these discrepancies are therefore not remarkable. The same is 
generally true for PdL4b, which has a phenyl ring on the imine carbon. The most 
noticeable difference between PdL4, PdL4m and PdL4b is for the distance between the 
two Ni atoms. This distance reduces markedly for PdL4b in comparison to any of the 
other structures. The main reason for this can be attributed to the larger distortions from 
planarity observed for this structure, caused by the greater steric bulk present in this 
complex cation. More data and structures would be required to obtain valid trends and 
draw conclusions about the presence of greater steric bulk on the imine carbon. See 
Chapter 4. 
 
It is important to note the differences or similarities between the central metal atoms. 
Platinum(II) and palladium(II) have already been noted as being isoelectronic and 
isostructural; however, they do have different electron configurations: 5d8 and 4d8 
respectively. If we compare the elements in group 10 we can say that the ionic radius of 
Pd will be larger than Ni due to the valence electrons being in a higher orbital shell. Due 
to the added f electrons between Pd and Pt there is not sufficient shielding for the added 
nuclear charge and hence the outer shell electrons feel a greater attraction to the 
nucleus. This lanthanide contraction therefore plays a role in the size of the ionic radii for 
platinum atoms and ions. The Shannon and Prewit ionic radii  for the Pt(II) and Pd(II) 
square planar atoms are given as 0.60 and 0.64 Å, respectively.318 Platinum and 
palladium have almost the same ionic radii and therefore we expect to see only slight 
differences for the platinum and palladium coordination group geometries.  
 
                                                          
 Effective ionic radii based on r(VIO2
-) = 1.40 Å by Shannon and Prewit. 
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Platinum-nitrogen bonds will normally average around 2.028(10) Å in the range of 
square-planar Pt(II)319 and some similar Pt-Np bonds have been reported as 2.03(1)
320 
and 2.015(4)321. Thus the Pt-Np bonds reported here for the platinum structures of these 
bis(pyridyl-imine) chelates (2.036(7)–2.060(5) Å) are slightly longer than expected; and 
the Pt-Ni bonds are slightly shorter (1.953(5)–1.988(6) Å). The average of all these 
bonds, 2.011 Å, is however close to the expected range. The metal-nitrogen bonds are 
decidedly larger (~ 0.1 Å) for the bond to the pyridine-nitrogen than the bond to the 
imine-nitrogen. This may be attributed to the imine nitrogen being a stronger base when 
compared with the pyridyl nitrogen322 as well as differences in the C=N-C bond angles 
for the two donor atom types. 
 
There are no Schiff base ligands of this type with Pt(II) or Pd(II) in the literature; however, 
some platinum and palladium complexes of structurally similar bis(pyrrole-imine) 
tetradentate N4 chelates do exist (Figure 3.29). These complexes are expected to have 
very similar M-Ni bonds with slightly shorter M-Np bonds than those observed for M-Np in 
this work. Platinum(II) complexes have been synthesised with a trans-cyclohexyl bridging 
group forming three five-membered chelate rings around the square planar platinum 
centre. The Pt-Ni bonds, averaging 1.947(7) Å, are shorter than the Pt-Np bonds, 
averaging 2.021(6) Å. These values are both slightly shorter than those reported in this 




Figure 3.29: The structures of Pt(II) and Pd(II) bis(pyrrole-imine) Schiff base ligands: 
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Palladium complexes of bis(pyrrole-imine) ligands with propyl and trans-cyclohexane 
bridges have been synthesised by Bacchi et al.323 The Pd-Ni bonds for the propyl bridged 
complex, averaged between the four crystallographically independent molecules, 
measure 2.006(7) Å, while for the trans-cyclohexane bridged complex they average 
1.961(3) Å. The Pd-Npyrrole bonds are longer than those for Pd-Ni: 2.046(3) Å (trans-
cyclohexane bridge) and 2.012(2) Å (propyl bridge), as is observed for the complexes in 
this work. The Pd-Ni bonds for the complexes presented here range from 1.942–1.998(4) 
Å and the Pd-Np bonds from 2.046–2.073(4) Å. Once again, with errors accounted for, 
these values are comparable. 
 
The Pd-Ni and Pd-Np bond distances for PAKLOD (palladium complex of a butyl-bridged 
bis(pyridyl-imine) chelate: Figure 3.9)195 average ~ 2.015(7) and ~ 2.033(7) Å, 
respectively. The Pd-Ni bond lengths are shorter for the palladium complexes in this 
work, while the Pd-Np bond lengths are longer. This may be explained by the difference 
in geometry between the square planar complexes in this work and the tetrahedral 
distortion seen for the Pd atom in PAKLOD. This distortion was caused by the large 
deformation in the 2,2‟-dimethyl-substituted biphenyl backbone of the bridging group. 
Another distorted tetrahedral palladium(II) complex is observed when two pyridine-2-
carbaldoxime ligands are coordinated (TIQZEZ).324 These two bidentate ligands allow 
the structure to distort from the expected square planar conformation of the tetradentate 
complexes seen in this work. The donor-acceptor Pd-N distances vary for TIQZEZ 
between 1.9891 Å and 2.074 Å, which agree reasonably well with those recorded here. 
 
The bite angle of Ni-M-Ni for PAKLOD is larger (99.0(3)º) than those observed in this 
work (~ 85–95º).195 This can be easily accounted for by the difference in the size of the 
chelate rings. As discussed, we expect the bite angle to increase with increasing chain 
length of the chelate and hence this 7-membered ring would be expected to have a 
larger bite angle than those for the 5- and 6-membered chelate rings. This same angle in 
TIQZEZ does not form a chelate ring; however, it has a magnitude of 94.68(9)º. This is 
much larger than the bite angles for the palladium complexes with both the 5- and 6-
membered chelate rings. This therefore lends support to our argument that the size and 
type of the chelate ring has an effect on the size of the angle, as does the difference in 
bite angles observed for the palladium(II) bis(pyrrole-imine) derivatives (83.9(1)º for the 
5-membered chelate and between 94.7(2) and 95.9(2)º for the 6-membered chelate).  
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It may be noted from Table 3.3 that the Pt(II) and Pd(II) coordination group distances are 
equal within the esd values of the distance determinations. This is expected due to the 
lanthanide contraction, as mentioned above. Equivalent bonds are therefore quite similar 
for the different ligands as well as for both the platinum and palladium derivatives. The 
imine bonds are relatively consistent throughout and rather similar for both the Pt and Pd 
derivatives of the same ligand, but do offer an interesting trend (Figure 3.28). The 
chelate ring strain and its alleviation through structural adjustments leads to measurable 
changes in the C=N bonds. The Ci=Ni bond lengths range from 1.261(9)–1.291(5) Å for 
these metal complexes and this is within the range of previously reported values 
observed for imine bonds.323,325  
 
We have investigated the structures, conformations, and electronic properties of several 
new bis(pyridine-imine) chelates of Pt(II) and Pd(II) in an effort to understand the 
coordination chemistry displayed by them. Single-crystal XRD data at low temperature 
reveal the complexes to be mainly planar around the four nitrogen atoms, with barely any 
or very little distortion. The distortion of these square planar complexes out of the plane 
has been measured for the metal, Ca of the pyridine rings and the central CH2 of the 
bridging group (Table 3.4). The four nitrogen donor atoms are taken to lie exactly on the 
mean plane of the molecule and measurements are made from there. 
 
The metal lies in the N4 plane for the complexes of L1, but is slightly displaced 
(perpendicular to the plane) for the complexes of L2, L4 L4m and L4b. There is no 
obvious trend in the distortion of the metal for the complexes of these ligands. There is, 
however, a notable change in the distortion of the metal from the plane from the ligand 
with the 2-carbon bridge to the 3-carbon bridge. The metal is in the N4 plane for the ethyl 
bridge and then moves out of the plane for the longer propyl bridge. This is supported by 
the lengthening of the M-N bonds moving from complexes of L1 to L2. The ethyl bridging 
groups show slight distortion from the plane, which increases for the central carbon of 
the propyl bridges. The palladium complex is distorted slightly more than its platinum 
counterpart in each case. This is also true for the distortion of the pyridine rings from the 
N4 plane, except for the complexes of L1. The structure of PdL4b shows the greatest 
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Table 3.4: The conformations around the metal centre for each complex and their distortions 




Pyridine rings tilted 







PtL1 planar -0.012 0.012 0.251
b 
0 
PdL1 planar -0.004 0.004 0.230
b 
0 


















0.427 / 0.519c 











0.460 / 0.552c 













-0.521 +0.414 0.646 0.038 
 
a Distance measured from the plane to Ca in Mercury.
310 
b Cf for L1 complexes. 
c Cg for L2, L4, L4m and L4b complexes. 
 
3.4.5.2 Crystal Packing 
Complexes of L1 and L2: 
Both the complexes of L1 crystallise in the same space group: monoclinic, C2/c; and the 
complexes of L2 also crystallise in the equivalent space group: monoclinic, P21/n. The 
only short contacts seen for PtL1, PdL1 and PtL2 are those to the PF6
-
 counter ions 
which pack in-between the cations as seen in Figures 3.30 and 3.31. The F···H 
intermolecular contacts observed here allow for the formation of relatively stable crystal 
lattices. The strange behaviour of fluorine in non-bonded interactions has been 
recognised in the literature.326 Mostly, fluorine will rarely form hydrogen bonds, which is 
explained by many electrostatic and steric factors (e.g. its low polarisability and tightly 
contracted lone pairs).327 Despite these interactions involving fluorine being much 
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weaker than conventional hydrogen bonds the role which they play in molecular packing 
cannot be ignored.327 A search of the CSD reveals the common occurrence of C–H···F 
interactions in organic crystals. Althoff et al. have shown that even a single C–H···F–C 
contact may be strong enough to pair two molecules.328  
 
 
Figure 3.30: Crystal packing viewed down the b-axis for PtL1 (Z = 4) and PdL1 (Z = 4). 
 
 
Figure 3.31: Crystal packing viewed down the b-axis for PtL2 (Z = 4) and PdL2 (Z = 4). 
 
The metal cations and hexafluorophosphate ions of PtL1, PdL1 and PtL2 are connected 
via C–H···F hydrogen bonding with H···F distances ranging from 2.200 to 2.628 Å. These 
short C–H···F contacts are presented in Table 3.5 and are consistent with relatively 
strong hydrogen bonds between the hydrogen atoms of the cationic metal chelates and 
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the fluorine atoms of the anions. A three-dimensional hydrogen-bonded network is 
created between the interacting cations and anions. Crystal structures were not obtained 




). This fact 
alone clearly suggests the importance of these particular counter ions and their 
intermolecular interactions that evidently allow the formation of these crystals.  
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For PdL2 there are complementary short contacts of 2.848 Å between Cf-Hf···Cc. Once 
more, as seen for the respective ligands, there is no experimentally significant π–π 
stacking involving the pyridine rings of adjacent molecules. One important reason for 
this, despite the aromatic nature of the pyridyl groups and the fact that they are well 
known to π-stack,303 is that the cationic chelates in the present salts are divalent. Hunter 
and Sanders have shown that π-π interactions occur when attractive contacts that take 
place between π-electrons and the σ-framework prevail over unfavourable contributions, 
e.g. π-electron repulsion.329 Thus the complexes in this work possess significant 
Coulombic repulsion which is likely between cations in the lattice320 and these forces of 
repulsion presumably outweigh any attractive London/dispersion forces that contribute to 
π-π stacking. 
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The observed short contacts may be explained for the L1 complexes by the size of the 
bridging group. Due to the bridging group being rather small the cation is mostly flat and 
hence there is barely any out-of-plane tilting of the pyridyl groups. Thus there is not much 
contact between the cations themselves, but somewhat more between the cations and 
their PF6
-
 counter ions. These anions are positioned between the metal complexes in the 
horisontal plane as well as in the vertical plane between the cations. The conformation of 
the propyl bridge linking the two pyridyl groups is not the regular staggered arrangement 
for an aliphatic chain. It is clear that the bridging group adopts a more curved 
conformation, which allows the two imine nitrogen atoms to point towards the metal 
centre. The structure of PtL2 is nonetheless predominantly flat with only minor distortions 
from the N4 plane.  
 
For PdL2 the distortion out of the N4 plane is slightly greater (visible in the packing in 
Figure 3.31). This is due to the difference in size between the metal centres as the ligand 
has to slightly ruffle in order to fit around the smaller palladium atom. This therefore 
allows the complimentary short contact observed between two cations for Cf-Hf···Cc.  
 
Due to the similarities between platinum(II) and palladium(II) it is obvious that these two 
metals are likely to have similar preferences with respect to their ligand selectivity and the 
symmetry of their coordination compounds.
330 Each divalent metal centre is encircled by a 
distorted square planar array of four nitrogen atoms with the metal ion located in the 
mean square plane formed by these four ligating atoms (PtL1 and PdL1) or only slightly 
distorted from it (PtL2 and PdL2). The two complexes of each ligand are therefore 
isomorphous; they have the same space group, and remarkably similar bond distances 
and angles as well as similar unit cell parameters. This can be easily observed from their 
packing arrangements which are almost identical for each group of complexes. The only 
difference between them is the position of the cations of the Pd(II) chelates. For the 
Pd(II) chelates, the alkyl bridges of the cations point along a negative b-axis direction, 
while those of the Pt(II) chelates point along the positive b-axis direction. In effect, the 
cation orientations differ about an axis that lies in the ac plane and bisects the a-O-c 
angle (where O is the cell origin) for the Pt(II) and Pd(II) salts, by a 180º rotation.  
 
Complexes of L4, L4m and L4b: 
PtL4 and PdL4 each have two molecules with different conformations, one saddled and 
the other „twisted‟. This out-of-plane tilt of the pyridine rings (relative to the N4 plane) may 
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be accredited to alleviation of unfavourable steric interactions between the adjacent 
pyridine rings. These molecules crystallise in alternating layers of the two types of 
cations (saddled and twisted) with the anions forming a barrier between them. Both PtL4 
and PdL4 crystallise in the monoclinic space group P21/c. Their short contacts (not 
including those to the counter ions, PF6
-
) are shown in Figure 3.32. For PtL4 there is 
again no π–π stacking; however, the structure of PdL4 is loosely stabilised by π–π 
interactions between pyridine rings of adjacent molecules along the stack. Since the 
complexes PtL4 and PdL4 do not have isomorphous structures, the packing is distinct in 







Figure 3.32: Illustration of the short intermolecular contacts for PtL4 (top left) and PdL4 (right). 
 
The π–π stacking observed for PdL4 will be rather weak due to the lack of significant 
ring-ring overlap. This is, however, consistent with the 2+ charge on each cation and the 
significant Coulombic repulsion between these cations. An offset overlap of two pyridine 
rings (Figure 3.33) is more common than complete overlap; complete overlap is indeed 
considered to be a rather rare phenomenon.303 The distances for the Cp-Cc short 
contacts are 3.384(7) and 3.392(7) Å due to the tilted orientation of the two PdL4 cations 
towards each other. For the complexes with the 2,-2-dimethylpropane bridge the greater 
steric bulk causes a much greater distortion from a planar chelate geometry. This allows 
the molecules to be tilted enough for the short C-C contacts observed. Finally, due to this 
more distorted conformation and less-ordered packing some π–π interactions are 




3.392(7) Å 3.384(7) Å 
CHAPTER 3 – X-ray Crystallography 
 98 
 
Figure 3.33: The overlap of the observed π–π stack in PdL4 as viewed down the c-axis.  
 
PdL4m only has a saddled structure (unlike PtL4 and PdL4) which crystallises in the 
monoclinic, P21/n space group. The cations form an interesting alternating conformation 
as shown in Figure 3.34, which demonstrates an inversion pair. The centre of inversion 
exists halfway between the two Pd(II) ions in the dimer. The complementary π–π 
stacking of the pyridine rings of neighbouring cations is also slightly offset, as observed 
for PdL4.  Short contacts are present between the pyridine carbon atoms of 
neighbouring molecules with a Cc···Cc distance of 3.353(8) Å. The perpendicular distance 
between the mean planes calculated for the four nitrogen atoms of adjacent molecules is 
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Figure 3.34: Illustration of the alternating packing for PdL4m (left) with a view of the π-π 
stacking and the overall interplanar distance (right). 
 
The larger, more bulky structure of PdL4b shown in Figure 3.35 exhibits no π–π 
stacking. The alkyl C-H groups are not good H-bond donors so C-H···π interactions 
between cations, which are weakly stabilising, are unlikely. Here, the only short contacts 
observed between the metal cations are: C3···Hh-Ch (2.826 Å) and C4···Hh-Ch (2.714 Å). 
These short, nonbonded contacts between cations form a crystallographcally-generated 
chain of cations along a 2-fold screw axis in the unit cell. These chains are in turn held in 
position by short contacts to the PF6
-
 anions present in the crystal. This is a very different 
packing to either that of PdL4 or PdL4m, which have the same bridging groups. It 
therefore seems that the change in bulk of the group on the imine carbon and the 
subsequent distortion from planarity cause great changes in the way these cations stack 
in the crystal lattice. 
 
3.938(10) Å 
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Figure 3.35: Illustration of the one-dimensional chains formed for PdL4b, as viewed down the 
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CHAPTER 4 – Density Functional Theory 
 
4.1 Introduction 
Computational chemistry uses the fundamental laws of physics (either wholly or only 
partially) as its basis to predict chemical structures and reactions numerically. This then 
allows the study of chemical phenomena of these compounds and reactions by 
performing calculations instead of merely using experimental examinations. Thus 
computational chemistry can be used, not only as an independent study method, but also 
in conjunction with experimental investigations to further broaden experimental 
knowledge.331 Molecular simulations are also useful because they do not merely help 
calculate the properties of synthesised compounds, but they can also predict the 
structures, energies and other features of unknown molecules.332 These chemical 
calculation techniques are therefore significant applications that have often been used in 
chemical research.  
 
There is an elementary distinction between experimental techniques and the calculations 
performed (quantum-mechanical or force field), because calculations can also be carried 
out on molecules that have no real existence; molecules that can either not exist under 
normal conditions or compounds that have yet to be synthesised.332 Quantum chemical 
techniques are therefore especially useful when studying unstable species as these are 
not easily examined by conventional structure determination procedures; examples 
include reactive intermediates, excited states, transition states, etc.333 
 
These types of calculations can provide extraordinary amounts of information compared 
with what chemists obtain from experimental techniques. For example, modern DFT 
calculations can give the molecular structure, heat of formation, dipole moment, 
ionisation potentials, charge densities, bond orders and spin densities in one experiment. 
There is still, unfortunately, the possibility that these results obtained from calculations 
may be unreliable. However, for the most common methods, the advantages and 
disadvantages have already been established and thus the probable accuracies can be 
sensibly predicted.332  
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There are two broad methodologies within computational chemistry; molecular 
mechanics and electronic structure theory, and both are primarily dedicated to the 
structure and reactivity of compounds. They both perform the same basic types of 
calculations: geometry optimisations, and computing the energy and vibrational 
frequencies. Molecular mechanics uses the laws of classical physics, while electronic 
structure methods use the laws of quantum mechanics. There are two major classes of 
electronic structure methods:331 
  
Semi-empirical methods: e.g. AM1, PM3,331 used in programmes like HyperChem and 
Gaussian, which use parameters already obtained from experimental data in order to 
simplify the calculation. They solve an approximate form of the Schrödinger equation 
according to their possession of suitable parameters for that specific system. They are 
largely characterised by their differing parameter sets.331 
 
Ab initio methods: these use no experimental parameters in computations; rather, 
computations are founded exclusively on the laws of quantum mechanics—the name ab 
initio means ―first principles‖—and on a few physical constants (Planck’s constant, speed 
of light, masses and charges of electrons and nuclei).331 There are a few simplifying 
assumptions involved in ab initio theory, but the calculations are more comprehensive 
(and therefore computationally more expensive) than those of semi-empirical 
methods.332 
 
The ab initio procedure generally searches for exact solutions; all quantities in the 
calculation are computed as precisely as is numerically possible. The semi-empirical 
procedure seeks, from the beginning, only approximate solutions. Often the 
simplifications used may be quite radical, but they are nonetheless required to always be 
physically justified.334 The basic steps for the execution of a typical ab initio or semi-
empirical calculation are very similar.335 Lately, a third class of electronic structure 
methods has been used in computations: Density Functional Theory (DFT). Density 
Functional Theory is not much different from the ab initio methods and the calculations 
need about the same total of computation resources as the Hartree-Fock theory (the 
least expensive ab initio method).331 DFT methods are more appealing due to their 
inclusion of the effects of electron correlation, whereas Hartree-Fock (HF) calculations 
regard this effect only in an average sense, which causes less accuracy for some 
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systems. Therefore using DFT has the advantage and benefits of more expensive 
methods, but at the performance cost of Hartree-Fock theory.331 
 
DFT based techniques draw from the quantum mechanics research of the 1920s 
(especially the Thomas-Fermi-Dirac model), and also from fundamental work in quantum 
chemistry done by Slater in the 1950s.335 The approach of these DFT methods is 
founded on a strategy of modelling electron correlation using functionals of the density of 
the electrons.331 In the last decade, methods based on DFT have gained steadily in 
popularity. In recent years, DFT has proved to be extremely useful and has been applied 
to a variety of problems that occur in Schiff base chemistry. DFT can take electron 
correlation into account in a computationally efficient manner and hence provides 
practical results.333 The best DFT methods achieve considerably better accuracy than 
Hartree-Fock methods with only a small increase in computational cost. DFT methods 
aim at providing, in one batch of self-consistent field (SCF) iterations, the real density 
distribution of correlated electrons in the ground state and the associated energy.336  
 
Another role played by these theoretical studies is their usefulness in helping to 
understand structural details in the crystalline solid state. This has been seen for 
geometrical and structural optimisations of free Schiff base ligands in the recent 
past.337,338,339 There is also an interest in whether the observed structural packing is 
indeed a fundamental property of the molecule or merely a result of crystal packing 
forces. This is important particularly in the case of nonplanarity in the structures. It is 
possible for quantum chemistry to readily distinguish between such intramolecular and 
intermolecular effects. It has been shown that crystal packing effects are partially 
responsible for the planarity seen for an important class of diorganotin (IV) complexes 
derived from Schiff bases, as shown by DFT calculations.340 As a final point, quantum 
chemical computations supply us with the information to be able to understand molecular 
energetics or thermochemistry in terms of structural properties and molecular structure in 
terms of electronic structure.333 
 
The foundation for DFT (as it is known today) was created in 1964 when a landmark 
paper appeared in the journal Physical Review.341 All modern day density functional 
theories are based on the main theoretical support of the theorems that Hohenberg and 
Kohn proved in this publication.335 This publication demonstrated the existence of a 
unique functional which can determine the ground state energy and density exactly.331,342 
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It also showed that the ground state electronic energy is determined by the electron 
density, ρ,342 implying then that there exists a one-to-one correspondence between the 
electron density of a system and any property of the system in its ground state, including 
energy.336 This is different to using the wave function approach, where the number of 
coordinates is 3N in an N-electron system (3 for each electron and 4 including spin).342 
Squaring the wave function and integrating over the N–1 electron coordinates gives the 
electron density; it depends on three coordinates and is independent of the number of 
electrons.342 Thus, while the complexity of a wave function increases according to the 
number of electrons, the electron density, independent of the system size, has the same 
number of variables.342 There is, however, a problem. Although each different density 
produces a different ground state energy, which has been proven, the connecting 
functional of these two is not known.342 The objective of DFT methods is to devise 
functionals connecting the electron density with the energy.343 
 
There is a difference between a function and a functional; a function is a prescription for 
generating a number from a set of variables (coordinates) and a functional produces a 
number from a function (which in turn depends on variables).342 In mathematics, 
functionals are defined as a function of a function. An energy that depends on an 
electron density or a wave function is a functional; and the electron density or wave 
function is a function.342 DFT methods use general functionals of the electron density to 
compute electron correlation.331 
 
In DFT, functionals are functions of the electron density which is itself a function of 
coordinates in real space. These functionals divide the electronic energy into several 
components which are each computed separately. In comparison with the wave 
mechanics method, it is evident that the energy functional may be divided into three 
parts. These three parts are kinetic energy, T[ρ]; attraction between the nuclei and 
electrons, Ene[ρ]; repulsion between electrons, Eee[ρ] (in the Born-Oppenheimer 
approximation the nuclear-nuclear repulsion is a constant);342 and then there is also an 
exchange-correlation term to account for the remainder electron-electron interactions, 
Exc[ρ], (in most actual DFT formulations it is divided into separate exchange and 
correlation components).331 A general equation for the energy functional is shown below: 
 
        EDFT = T[ρ] + Ene[ρ] + Eee[ρ] + Exc[ρ]                                                       (1) 
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The second major paper of modern DFT, written by Kohn and Sham,344 appeared about 
a year after that of Hohenberg and Kohn. This report proposed how the universal 
functional, which was unheard of up until then, could easily be handled. Their basic idea 
was to split the kinetic energy functional into two parts. One would be calculated exactly, 
while the other would be a small correction term. Their proposal was based on the 
acknowledgement of a common problem with direct density functionals (e.g. the 
Thomas-Fermi method) being associated with the way the kinetic energy is 
established.335 Kohn and Sham therefore launched the idea of a non-interacting 
reference system made from a collection of orbitals; one electron functions. It had also 
been noted that orbital-based approaches such as the Hartree-Fock method performed a 
lot better in this respect. It permits the exact treatment of the majority of the contributions 
to the electronic energy of an atomic or molecular system, thus allowing the major part of 
the kinetic energy to be computed more accurately.335 
 
In reality, however, the electrons are interacting and therefore the total kinetic energy is 
not provided, but the difference between the exact kinetic energy and that which is 
calculated, assuming non-interacting orbitals, is small.342 The remainder is absorbed into 
an exchange-correlation term; it is merged with the non-classical contributions to the 
electron-electron repulsion. These are typically also small and include the non-classical 
fraction of the electron-electron interaction accompanied by the correction for the self-
interaction and the component of the kinetic energy that is not included in the non-
interacting reference system.335 This method allows the maximum amount of information 
to be computed exactly so that only a small part need be calculated from an approximate 
functional.335 
 
A few procedures have been promoted to deal with the Kohn-Sham equations: (1) the 
―scattered wave‖ (SW) or ―multiple scattering‖ (MS) technique (founded on the so-called 
―muffin-tin‖ approximate potential); (2) the discrete variational method (DVM) (relying on 
the numerical sampling of Slater orbitals; and (3) as standard molecular orbitals, the 
expansion as linear combinations of Gaussian atomic functions.336 After the work done 
by Kohn and Sham, the approximate functionals used by present DFT methods divide 
the electronic energy into several terms, shown in the general expression:331,342 
 
                  EDFT = Ts[ρ] + Ene[ρ] + J[ρ] + Exc[ρ]                                                          (2) 
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where Ts[ρ] is the term for kinetic energy (from the motions of the electrons), Ene[ρ] 
includes terms for the repulsion between pairs of nuclei and the potential energy for the 
nuclear-electron attraction, J[ρ] represents the electron-electron repulsion (also known 
as the Coulomb electron density self-interaction). The term Exc[ρ] represents exchange-
correlation and also comprises the leftover components of the electron-electron 
interactions. These include exchange energy evolving from the anti-symmetry of the 
quantum mechanical wavefunction, and dynamic correlation in the movement of 
individual electrons.331,342 
 
If EDFT is equated to the exact energy then it may be seen as the definition of Exc; the 
portion which is left over after taking away the non-interacting kinetic energy, and the Ene 
and J potential energy terms:342 
 
                  Exc[ρ] = (T[ρ] - Ts[ρ]) + (Eee[ρ] - J[ρ])                                                        (3) 
 
The kinetic correlation energy is shown in the first parenthesis and the second contains 
both the exchange and potential correlation energy.342 This equation may be rewritten 
as:331  
 
                  Exc[ρ] = E
X[ρ] + EC[ρ]                                                                                (4) 
 
Exc is determined entirely by the electron density and is usually divided into two parts. 
These are the exchange and correlation parts, which actually respectively correspond to 
the same-spin and mixed-spin interactions.331 All three of the equation components are 
functionals of the electron density; the two terms on the right hand side are the exchange 
and correlation functionals, respectively. Both of these can be of two distinct types (1) 
local functionals (which depend only on ρ); and (2) gradient-corrected functionals which 
depend on ρ as well as its gradient.331 
 
The advantage of DFT is that only the total density needs to be taken into account. 
However, to accurately calculate the kinetic energy, it is necessary that orbitals be 
reintroduced. Nonetheless, as previously mentioned, DFT has a computational cost 
which is similar to that of the least expensive ab initio method, Hartree-Fock theory, but it 
also has the advantage of possibly yielding more accurate results.331,342 Despite the 
similarities, there is one important difference between ab initio methods, wave mechanics 
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Hartree-Fock theory and DFT. DFT methods could give the exact total energy (including 
electron correlation) if the exact Exc[ρ] was known.
331,342 DFT methods are popular due to 
their inclusion of the effects of electron correlation in their model. These effects refer to 
the reality that electrons in a molecular system react to each other’s motion and will try to 
stay out of the other’s way. Therefore DFT methods have the ability to offer the benefits 
usually associated with more expensive ab initio methods at a Hartree-Fock cost.331 
Hartree-Fock theory considers this method as an average only (causing less accurate 
results for some types of systems) while methods that include electron correlation 
account for the instantaneous interactions of electron pairs with opposite spin.331 
 
The reliable prediction and simulation of molecular structures is one of the most 
important applications of computational chemistry. A great deal of experience and 
knowledge has been gathered regarding the functioning and performance of each of the 
methods that have been employed. Therefore, as opposed to the early days of 
computational chemistry, it is now rather simple and easy to perform geometry 
optimisations on systems of more than 50 atoms. Most of these techniques generally 
have an accuracy performance of about 0.02 Å; this often improves bond lengths where 
molecules that contain main group elements are involved.331 It is now acknowledged 
(and has been for a long time) that bond lengths are predicted shorter than they actually 
are by Hartree-Fock theory. Owing to the neglect of electron correlation, simulating 
multiple bonds is inclined to be complicated.331 The precision of the bond energies 
acquired from the use of DFT calculations has been significantly enhanced by taking into 
account the nonuniformity of the electron density in the exchange and correlation 
functionals.336 
 
Rather than restricted Hartree–Fock (RHF), Car–Parinello molecular dynamics and 
quantum chemical simulations have shown the DFT approach to be more suitable to 
describe rotational strength (RS) spectral dependences.345 Conversely, the regularly 
cited main shortfall of DFT is the official incapability to methodically progress the 
accuracy of quantitative predictions. There are a few key difficulties with DFT, which are 
clearly documented (weak interactions, excited states and highly degenerate systems). 
However, to forecast any other possible errors in DFT a priori is not possible without a 
thorough understanding of the fundamental aspects of the theory. Additionally, it has 
repeatedly been stated that when density functional methods do not succeed in a 
particular situation, then there is no exact course of action that may be followed to 
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correct the imperfections, in view of the fact that the underlying reasons for the limitations 
in the theory are a long way from being understood. This is true when the reason for 
failure is not the selection of the functional, integration grid, or basis set.335 
 
DFT methods account reasonably well for hydrogen bonding, which is mainly 
electrostatic. There are, however, indications that DFT methods less accurately predict 
relative energies and inadequately portray transition structures. Nevertheless, it must be 
remembered that for DFT methods the number of systems for which it has been 
calibrated is still somewhat undersized.342 DFT methods differ according to the choice of 
the functional form of the exchange-correlation energy. The most preferable DFT method 
was found to be the gradient functional method of Becke.346 Theory gives rather little 
guidance about how such functionals should be chosen and therefore many different 
potentials have been put forward. A variety of functionals has been defined in 
computational chemistry history and they are characterised by the means by which they 
deal with the exchange and correlation components.331 
 
4.2 Functionals 
4.2.1 Local Density Methods 
Local exchange and correlation functionals engage only the values of the electron spin 
densities.331 The Local Density Approximation (LDA) assumes the electron density is a 
slowly varying function, i.e. that the electron density locally can be treated as a 
hypothetical uniform electron gas.335,342 The number of electrons and the gas volume are 
thought to move toward infinity at the same time as the electron density remains finite 
and reaches a stable value.335 LDA has been extended to the Local Spin Density 
Approximation (LSDA),335 which is the unrestricted case where the spin densities, α and 
β, are not equal. It is also possible to write LSDA in terms of the total density and spin 
polarisation. This LSDA will be equal to LDA for closed shell systems.342 
 
For a number of different densities, by using Monte Carlo methods, the correlation 
energy of a uniform electron gas has been established.335,342 It is necessary to have an 
appropriate analytic interpolation formula to use these results in DFT computations; 
similarly to that constructed by Vosko, Wilk and Nusair in 1980 (VWN),347 which is a 
widely-used functional.342 Often, instead of LDA defining the model of local density 
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approximation, the acronym SVWN is used. The LSDA method does, unfortunately, have 
limitations. Although its results are mostly superior to that of the Hartree-Fock method, it 
has a tendency to overestimate outcomes.335 This LSDA approximation, unfortunately, 
has a tendency to underestimate the exchange energy by about 10%, which in turn 
causes errors larger than the whole correlation energy, which is itself overestimated 
(regularly by a factor close to 2). Consequently, the bond strengths will also be 
overestimated.342 LSDA techniques may offer outcomes with comparable accuracy to 
those acquired from Hartree-Fock methods, in spite of the simplicity of their fundamental 
assumptions.331,342  
 
4.2.2 Gradient Methods 
In the early eighties, the first successful expansions to the purely local approximations 
were developed.335 To improve on the LSDA approach, a non-uniform electron gas 
needs to be considered. One way to do this is to make the correlation and exchange 
energies dependent on electron density and derivatives of the density; thus gradient-
corrected functionals will entail electron spin densities as well as their gradients.331,342 
The name given to these processes is Gradient Corrected or Generalised Gradient 
Approximation (GGA) methods (also sometimes called non-local functionals in the 
literature, which is somewhat misleading). 342 
 
In 1986, Perdew and Wang (PW86)348 suggested altering the existing LSDA exchange 
expression. And in 1988 Becke349 proposed a gradient-corrected correlation functional (B 
or B88) which became rather popular, followed by another widely-used functional (not a 
correction) by Lee, Yang and Parr (LYP) in the same year.350 (These two forms were 
also combined to make the B-LYP method.) There is one empirical parameter in the LYP 
functional and it differs from other GGA functionals because it includes a few local 
components.335 Another functional, with a correction to the LSDA energy, was proposed 
by Perdew and Wang in 1991,331,342 PW91.351 It should, however, be noted that quite a 
few of these proposed functionals defied fundamental restrictions. P86 and PW91, for 
example, predict correlation energies for one-electron systems and for others, the 
exchange energy may be unsuccessful in cancelling the Coulomb self-repulsion.342 
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4.2.3 Hybrid Functionals 
Generally, the exchange contributions are considerably larger in absolute numbers than 
the analogous correlation effects. Therefore, a prerequisite for acquiring useful outcomes 
from DFT is a precise expression for the exchange functional specifically.335 A precise 
link can be made between the exchange-correlation energy and the corresponding 
potential connecting the non-interacting reference and actual system using the 
Hamiltonian and the definition of the exchange-correlation energy.342 The resulting 
equation involves integration over a parameter that allows for the electron-electron 
interaction. This equation is known as the Adiabatic Connection Formula (ACF).342 
 
The Half-and-Half method may be described by writing the exchange energy as a blend 
of LSDA, a gradient correction term and exact exchange. Hybrid methods frequently 
refer to models that include exact exchange. The Adiabatic Connection Model (ACM) 
and Becke 3 parameter functional (B3)352 are therefore examples of hybrid models. 
These functionals operate well and thus the Half-and-Half model is hardly ever used.344 
Several hybrid functionals define the exchange functionals as a linear combination of 
Hartree-Fock, local, and gradient-corrected exchange terms. This exchange functional is 
then joined with a local and/or gradient-corrected correlation functional.331 Becke’s three-
parameter formulation, B3 (B3LYP),352 is the best known of these hybrid functionals and 
these Becke-style hybrid functionals have been found to be superior to the conventional 
functionals defined thus far.331  
 
From the time of their manifestation in the early nineties these hybrid functionals have 
experienced unparalleled success.335 In particular, the B3LYP functional has become a 
well known and extremely useful functional, due to its surprisingly good performance in 
many chemical applications.335 It was suggested by Stevens et al. in 1994353 and has an 
unsigned error of only slightly above 2 kcal/mol (with respect to the G2 data base). It is 
related to that originally suggested by Becke (using B88 and PW91); however, the PW91 
correlation functional has been exchanged for the LYP functional.335 
 
In 1996 Becke made further progress by dropping the number of parameters to one 
where the amount of exact exchange was empirically ascertained. This resulted in the 
B1B95 functional.354 Becke presented a new type of exchange-correlation functional, 
founded on an intricate fitting procedure, in the closing stages of his string of papers on 
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density functional thermochemistry. It was aptly labelled B97.355 Together, Schmider and 
Becke, then reparameterised this functional (with respect to the extended G2 set)356 and 
the ensuing B98 functional preserves the good absolute average and low maximum 
errors (11.9 kcal/mol and 9.1 kcal/mol, respectively). Additional development was also 
carried out in the same year on the original B97 functional by Hamprecht et al.; they 
called their result B97-1.335 The year 1998 also saw van Voorhis and Scuseria357 offer a 
new exchange-correlation functional known as VSXC; it was dependent on the non-
interacting kinetic energy density, as well as on ρ and its gradient, Δρ.335 
 
Development and research into the discovery of new and improved functionals 
continues. Some of the current functionals do have the ability to yield energy related 
results approaching alleged ―chemical accuracy‖. This means that the results are within 
less than 2 kcal/mol of experimentally determined energies, which is very high accuracy. 
There are many literature records showing high accuracy obtained by means of modern 
functionals, and more are being published each year.335 Theory does not provide much 
assistance in choosing functionals, thus numerous different potentials have been 
suggested. To determine the best performing functional involves a comparison with 
experiments of high-level wave mechanics calculations or with functionals known to have 
been successful for similar compounds in the past.  
 
4.3 Performing a calculation 
In order to meet the requirements of accuracy as well as computing economy, both the 
theoretical method and the type of basis set need to be taken into account. Over the 
years it has been found that density functional theory (DFT) is extremely useful in 
predicting and discussing electronic structures of molecules. The important requirement 
of a DFT method is the selection of an appropriate structure for the exchange and 
correlation energies.342 It is possible to use a combination for the exchange and 
correlation energies; a LSDA form for one and a gradient form for the other. However, 
this is not actually uniform. The Dirac-Slater expression gives the exchange within the 
LSDA approximation, thus the only distinction is the interpolation function which is used 
in the reproduction of (very good) Monte Carlo results for the correlation.342 The term 
LSDA is generally connected to the acronym SVWN, because the VWN formula is 
considered to be such a good interpolation function. Gradient corrected methods will 
typically use the B88 exchange functional or the B3/ACM hybrid, and this will be coupled 
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with the LYP, P86 or PW91 correlation functional. Other related acronyms are BLYP, 
BP86, BPW91, B3LYP, B3P86, and B3PW91.342 
 
Current functionals inadequately describe weak interactions due to dispersion (van der 
Waals type interactions).358 LDA predicts for example (though not very precisely) an 
attraction between rare gas atoms, whereas all gradient methods foretell a purely 
repulsive interaction (at least in the case of correction for basis set superposition 
error).342 LSDA methods do not usually perform as well as gradient corrected methods. 
There is a notable improvement attained by the addition of gradient terms and hybrid 
methods operate almost as well as the complex G2 model for some test situations.342 
Using the GGA methods for stable molecules usually presents geometries and 
vibrational frequencies of better or similar quality to those from perturbation methods like 
MP2 and the computational cost is analogous to that of Hartree-Fock.342 
 
Lastly, DFT methods at the moment are poorly matched for excited states that possess 
the same symmetry as the ground state. It is not easy to guarantee orthogonality 
between excited and ground states due to the deficiency of a wave function.342 Results of 
DFT procedures have, however, been shown to produce outcomes that are as good as 
those of coupled cluster methods in multi-reference character systems, where MP2 
generally does not succeed. DFT methods founded on unrestricted determinants for 
open shell systems have another advantage in that they are not as sensitive to ―spin 
contamination‖. 342 
 
4.4 DFT and Schiff Base Ligands 
High-quality geometry optimisations of large polycyclic molecules are a somewhat more 
recent advance in computational chemistry. These calculations were originally thought to 
be a technical feat; however, in this day and age they are routinely possible with the use 
of DFT methods.359 Density functional theory is nowadays the accepted method (the 
post-HF approach) for the computation of molecular structure, vibrational frequencies 
and energies of molecules, resulting in a detailed quantum chemical study. There are 
methods, especially nonlocal DFT (NLDFT) methods that yield structural information that 
is of such high quality that it is able to rival experimental data, like that acquired from 
high-quality crystallographic measurements.  
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In the literature there are more than a hundred cases of DFT being used to analyse free 
Schiff base compounds, with around a hundred more examining various metal 
complexes of Schiff base ligands. Although no DFT studies for this particular range of 
ligands can be found (due to their limited literature), it is possible to find DFT work that 
has been performed on the pyrrole analogues of our ligands. Much of the literature is 
focused on Salen-type ligands (ONNO donor ligands synthesised from diamines and 
aromatic o-hydroxyaldehydes). 
 
Many of the papers apply restricted Hartree–Fock (RHF) and several DFT quantum 
chemical approaches in order to clarify the experimental data available for the studied 
molecules. However, to our knowledge, complete vibrational studies of the Schiff base 
ligands discussed herein and their metallated counterparts have not been reported. In 
most cases in the literature, where DFT computations have been used to compute data 
about Schiff base ligands, Beke’s 3 parameter hybrid functional (B3LYP) is commonly 
used. The choice of basis sets does however differ according to the type of compound 
and desired results. Although the basis sets are mostly those from the Pople split 
valence basis set group, they vary according to the extent of the polarisation function    
(*, **, (d) or (d,p)) and the diffuse function (+ or ++). 
 
DFT computations (B3LYP/6-31+G* level of theory) were performed in 2003 by Salva 
and co-workers to study a Schiff base formation of vitamin B6 analogues and to study 
the topology of the charge density function of the optimised structures. These 
calculations gave the description for the geometries of all intermediates and transition 
structures in the reaction pathway.360 DFT has also been used in conjunction with X-ray 
studies to compare the molecular conformation of some Schiff bases between optimised 
quantum mechanical calculations and crystal structures. Structures from both methods, 
theoretical and experimental, were shown to be very similar and compared well.361,362  
 
There has been much discussion about the tautomeric forms of some Schiff base ligands 
involving different configurations of enol-, keto- and zwitterionic 
structures.339,361,362,363,364,365,366,367 DFT has played a large role in elucidating the 
structures of many of these ligands. Recently Dziembowska et al. considered solvent 
effects on the tautomeric equilibrium of a Schiff base derived from 2-hydroxy-1-
naphthaldehyde and methylamine. Gaussian 03 was used with the functional B3LYP and 
basis set 6-31G(d,p) to determine the structure in five different solvents.363 
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In the last decade, researchers have used DFT to determine, assign and compare 
vibrational frequencies in Schiff base ligands.367,368 Thube and co-workers used Hartree-
Fock to calculate vibrational frequencies and obtained results that compared favourably 
to their experimental work.368 Nowadays, DFT is accepted as a popular post-HF 
approach in order to compute molecular structure, energies of molecules and vibrational 
frequencies. In 2007 Pajak et al. optimised structures and determined IR and Raman 
frequencies and intensities using the DFT method with the hybrid B3LYP functional and 
the 6-31++G(d,p) basis set. After scaling the frequencies, these density functional 
calculations made interpretation of the experimental spectra far simpler.367 Theoretical 
harmonic frequencies derived using DFT were also found to be in good agreement with 
their observed spectral values by Sun et al.369 
 
There has also been a great deal of computational work dedicated to metallated Schiff 
bases. DFT work with metallated Schiff base ligands has involved, amongst other things, 
the theoretical calculations for the interaction with an anion, e.g. BF4
-
,370 crystal packing 
effects340 and absorption spectra371.  
 
DFT calculations have been reported for a pyrrole analogue of the ligands presented in 
this work; this particular analogue is complexed to nickel.372 The results obtained from 
the B3LYP/6-31G(d) level of theory agree well with the experimental X-ray values and 
provide insight about the frontier molecular orbitals. In 2004 Rogachev and co-workers 
reported on the combination of theoretical methods (ROHF for geometry optimisation 
and DFT/B3LYP for energy calculation) used to obtain geometry parameters for 
heterobimetallic complexes. The data showed remarkable agreement with the 
experimental X-ray results and the bonding energy corresponded precisely with the 
experimental mass-spectroscopy data.373 
 
Using DFT B3LYP/6-311G(d,p) level calculations the equilibrium geometries, vibrational 
frequencies and related intensities were determined and analysed for metal complexes 
of Schiff base ligands.15 In these complexes the metal is coordinated to salicylic oxygen 
and azomethine nitrogen atoms for Fe(III), Co(II) and Ni(II), and to salicylic and carbonyl 
oxygen and azomethine nitrogen atoms for Cu(II) and Zn(II). From this work and the 
comparison between theoretical and experimental data, Serbest et al. concluded that this 
level of theory is reliable for the prediction of data for these complexes.  
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Chen et al.372 have spectroscopically and theoretically studied the effects of axial 
coordination for metal-salen complexes in order to try and link axial coordination with 
catalytic properties of the complexes. This, in turn, will then help with the design and 
development of new, improved catalysts. Barone et al. showed that the DFT-B3LYP 
method is able to correctly compute (in agreement with the experimental data) the 
stability predictions of the different spin states of Fe-Salen derivatives. The DFT 
computations also gave dependable results for the complexes’ structure, energetic and 
magnetic properties.374 Kwit and co-workers used CD spectroscopy combined with DFT 
calculations (B3LYP/6-31G*) to study structural changes of macrocyclic salen 
molecules.375 
 
Overall we see good correlation between computational DFT work and experimental 
values obtained in numerous studies performed for Schiff base ligands and their 
complexes. The chosen levels of theory presented here gave results that compared well 
to the experimentally obtained figures. It is therefore clear that DFT is an extremely 
useful tool for amongst other things: the elucidation of structures, spectral data 
assignment and determination of energies of molecules. 
 
4.4.1 Choosing the Functionals and Basis Sets 
The two variable parameters in DFT methods are the basis set and the variety of 
exchange-correlation potentials.342 In chemistry a commonly used functional is BLYP, 
made up of Becke’s 1988 functional (incorporates the Slater exchange and corrections 
involving the gradient of the density)349 and the correlation functional of Lee, Yang, and 
Parr (includes both local and non-local terms).350 Even more widely used is B3LYP; a 
hybrid functional in which the exchange energy (from Becke's exchange functional) is 
combined with the exact energy from Hartree-Fock theory. There are three parameters 
that define the hybrid functional and specify how much of the exact exchange is mixed in. 
The B3LYP scheme is often considered to be the most suitable method for structure 
calculations. Density functional theory has shown good results for the treatment of 
electronic structures of molecules containing transition metals. 
 
Efficient quantum chemical calculations require the foundation of modern electronic 
structure theory; basis sets. Throughout the years, many basis sets have been 
generated in the context of wave function-based approaches to quantum chemistry.335 A 
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basis set is defined as the mathematical description of the orbitals in a molecule (which 
in turn combine to approximate the total electronic wavefunction) used to carry out the 
theoretical calculation. The basis set thus restricts each electron to an exacting area of 
space; therefore the more accurate approximations are made by larger basis sets 
because they impose fewer restrictions on the locations in space.331,342 The larger the 
basis set, however, the more computational resources required.331 Therefore it is 
necessary to find the largest basis set possible, that will accomplish the job with the best 
results, without calling for unmanageably large computational resources. Minimal basis 
sets are the fastest – but the least accurate – in common use. A simple basis set with 
added flexibility and polarisation functions on atoms heavier than Ne gives reasonable 
results.  
 
Density functional theory is an extremely popular choice for the study of many systems 
using first-principles approaches at a similar computational cost to calculations at the 
Hartree-Fock level. The reliability of this method has now been established for small 
organic molecules; however, results for compounds that contain transition metals are 
less developed. For meeting the needs of both computing economy and accuracy, the 
choice of theoretical methods, as well as basis sets, should be taken into account. The 
basis set to be used must therefore be a balance between the required accuracy and a 
realistic amount of computing time. There are no set rules regarding which methods give 
the best results for which systems. The best starting place is to ascertain whether any 
successful (or unsuccessful, in the case of elimination) calculations have been performed 
previously on similar systems. Once it has been established that there have been 
successful DFT methods on related systems then the pros and cons of the different 
accessible basis sets have to be inspected. Therefore it is easy to use experimental data 
to guide the choices of the computational type. 
 
For free Schiff base ligands with similar structure to those in this work, there are a 
number of DFT computations. Chatziefthimiou and co-workers have used DFT in order to 
differentiate between the consequences of intermolecular interactions and the position of 
a methoxy group in stabilising the keto form in a range of planar 
salicylalideneimine(amine) moieties in the crystalline state.361 To accomplish this the 
B3LYP21 and B3P8621 functionals were used in conjunction with the cc-pVDZ, aug-cc-
pVDZ, and aug-cc-pVTZ correlation consistent basis sets of Dunning376 (which 
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accurately describe core-core and core-valence correlation effects for second row atoms 
and molecules). 
 
The 6-31G(d,p) basis set was used to study solvent effects on tautomeric equilibrium by 
Dziembowska et al. in 2009.363 While in 2004, Krygowski and co-workers carried out 
calculations in order to connect structures to common tautomeric forms. Using 6-3G(d,p), 
the C=N bond length was in good agreement 5 B3LYP has also been used to examine 
tautormeric forms of an ortho-hydroxy Schiff base (in conjunction with 6-311+G**),366 for 
pyridoxal-50-phosphate methylamine Schiff bases (in conjunction with 6-31G*)364 and for 
sterically hindered Schiff bases (in conjunction with 6-31++G(d,p)).367 
 
Ab initio calculations at the level of B3LYP/6-31G** were performed for three ortho-
hydroxy Schiff bases with methyl and ethyl substituents in order to compare with 
experimental data.377 Bond lengths were mostly overestimated, but valence angles were 
relatively well predicted. DFT computations (6-31+G(d,p) and 6-11+G(d,p) basis sets) 
were used to favourably compare the structure, proton transfer, and vibrational dynamics 
of a selected ortho-hydroxy Schiff base type compound containing a low-barrier 
hydrogen bond.337 
 
Munro et al. showed that DFT calculations at the B3LYP/6-31G** level of theory 
appropriately predict the chief geometrical attributes of a dimer structure; while the 
differences show the function that crystal packing plays in the geometry of the 
structure.378 Comparison with crystallographic data showed that B3LYP in combination 
with the 6-31G* or 6-311G* split valence basis set accurately predicts the conformations 
of some N-benzylideneanilines.379 
 
Hydrogen bond geometries have been calculated for a series of Schiff bases, N-(R1-
salicylidene)-alkyl(R2)amines, using B3LYP functional, combined with the standard basis 
set 6-31++G(d). An estimated margin of error was found to be 5% between the 
crystallographic data and that computed by DFT.380 Accurately predicted results for the 
geometry and vibrational frequencies were obtained for some antipyrine derivates when 
using B3LYP in conjunction with 6-31G(d).369 
 
In each of the papers that was examined the functional used was always B3LYP and the 
basis sets were mostly split-valence basis sets. B3LYP is a thoroughly tested method 
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and therefore it stands to reason why it is so often chosen. It is particularly good for so-
called "short range" correlation effects and offers good reliability and electron correlation 
treatment. The split-valence 6- 31G basis set and versions thereof are used for 
compounds containing: C, H, N and O. Polarisation functions are added when there are 
heavy atoms (first row and up) and diffuse functions are used when there are non-
bonding interactions or anions. For the study of fairly large organic molecules the basis 
set 6-31G(d) has shown promise due to its acceptable accuracy and economical 
computational cost.369 The difference between the basis set 6-31G(d) and the basis set 
6-31G(d,p) is that the former adds polarisation functions to heavy atoms and the latter to 
hydrogen atoms as well. Both basis sets have 15 basis functions for first row atoms, but 
6-31G(d,p) has 5 for hydrogen atoms whereas 6-31G(d) has only 2.331 
 
These methods presented above, based on the hybrid density functionals (especially 
B3LYP), predict structures and vibrational spectra of organic molecules very accurately. 
We are therefore justified in choosing B3LYP as the basic functional for analysis of our 
free base ligands. For our ligands we do not require any diffuse functions and therefore 
6-31+G(d) or 6-31++G(d) would not be essential options. Thus the most obvious choice, 
and one that has shown accurate and well predicted information for other Schiff base 
ligands as shown above, is that of 6-31G(d,p). 
 
An excess of basis sets are therefore on hand when working with light elements; 
however, a much smaller choice is available when incorporating the heavier elements or 
all the elements. Basis sets like TZVP72 and 6-31G(d) are only parametrised to Kr and 
therefore effective core potential basis sets need to be used for heavier elements like Pd 
and Pt. The Effective Core Potential (ECP) basis sets that are defined for all the 
elements include: LANL2DZ, CEP-121G and SDD.381 Although the results from all three 
are relatively equal, SDD (stands for Stuttgart-Dresden, the cities of the inventors) is 
somewhat better and has – in some cases – now replaced the LANL2DZ and CEP-121 
basis sets. These particular basis sets are valuable because they are quicker (core-
electrons replaced by a potential function representing the effective nuclear charge), are 
available for all elements and can be ―quasirelativistic" (specified in parameters). They 
are, however, not appropriate for the computations of NMR shifts but this is not within the 
scope of this work. 
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In the case of DFT calculations, there is evidence of its success for many different 
relevant metal Schiff base complexes. A problem sometimes experienced with DFT is its 
failure to predict the asymmetric Metal-O bonds observed experimentally due to the 
affinity of DFT to prefer delocalised, higher symmetry structures.382 This should, 
however, not be a factor in our work as there are only metal-N bonds.  
 
In order to correctly compute data for some elements e.g. Hg, Au and Pt, it is important 
to take relativistic effects into account. When using the SDD basis set for gold it will 
reproduce relativistic effects without using an explicit relativistic calculation.381 When 
heavy metals like Zn, Cd and Hg are metallated with Schiff ligands then SBKJC 
pseudopotentials have been used as they include relativistic correction for heavy 
elements.383 Qualitative agreement has been found for data computed for lead Schiff 
complexes using the LanL2DZ valence set.384 Other researchers obtained results from 
optimisations done at the PBE0 level with SDD and LANL2DZ basis sets for Schiff 
complexes containing Ir and Hg. It was noted that the larger basis set, SDD, gave 
structural parameters that were closer to the crystal data than those computed by the 
LANL2DZ basis set for these particular complexes.385 However, those of particular 
interest in order to choose the level of theory for this work are Schiff base complexes that 
involve platinum(II) and palladium(II). There are relatively fewer DFT studies reported 
concerning platinum group metals (PGM). 
 
In 2006 Liu and co-workers successfully used the B3LYP method with the LanL2DZ 
basis set (containing effective core potential (ECP) representations of electrons near the 
nuclei) for palladium and platinum Schiff base complexes.386 Shimazaki et al. also 
performed computations on Schiff complexes containing platinum and palladium; 
however, they used the PBE0 functional and the SDDAll basis set.387 (They chose the 
PBE0 functional due to work done by Poverenov and co-workers388 on a series of Pt 
pincer complexes that showed the ability of this functional in accurately simulating 
coordination sphere geometries.) The computed results at this level of theory compared 
reasonably well with those obtained from the X-ray data. Perez and co-workers used the 
B3LYP functional with the LANL2DZ basis set for novel five-membered pallada- and 
platinacycles (with terdentate ligands)389 and for new palladium(II)-allyl complexes390. In 
both cases reasonably good agreement was found between the optimised data and the 
experimental information, even allowing the assignment of main UV-Vis bands for the 
pallada- and platinacycles.389 B3LYP/LANL2DZ was used to rationalise observed results 
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obtained by Arnais and co-workers in 2007 for terdentate Schiff base NNO-coordinated 
ligands bonded to palladium with nitromethane. This level was used to optimise the 
structures and transition states were reinforced by a vibrational analysis (including one 
imaginary frequency) and IRC calculations.391 
 
The work discussed above on metallated Schiff Base ligands used the B3LYP or the 
PBE0 functional in the computations performed. The basis sets varied according to the 
type of metals in the complexes: SBKJC, LanL2DZ and SDD. In particular, the work for 
platinum and palladium complexes used either the B3LYP or PBE0 functional with either 
the LanL2DZ or SDD basis set. The results in all cases were noted to be reliable and 
correlated well with the experimental data obtained. Thus, there seems to be reasonable 
competition between these functionals and basis sets for the best results, depending on 
the actual complexes for which information is being computed. It is therefore necessary 
to decide which of these functionals and basis sets will be the best method for obtaining 
the most correct and accurate predictions for the complexes presented in this work. Due 
to the superiority of the SDD basis set in computing geometrical parameters closer to 
experimental values for various metal complexes (including carboplatin),392 it was 
decided that the B3LYP functional would be used in conjunction with this basis set. 
 
4.4.2 Computational Methods 
DFT calculations (B3LYP functional,352 6-31G**331  or SDD basis set, coarse/medium  
grid) were performed with Gaussian 03W393 V 6.1, Rev. C.02 running on an Intel dual 
core or AMD Athlon 64-bit machine under Windows XP-64. We have chosen the 
functional and basis set to be used to perform all geometry optimisations and data 
computations due to the literature reviewed above. The 6-31G** basis set is a split 
valence basis set; it has two (or more) sizes of basis function for each valence orbital. It 
also adds polarisation functions to the hydrogen atoms as well as all non-H atoms.331 
The SDD basis set has been chosen as it employs a double-zeta treatment to the 
valence shell, so it is not overly expensive in terms of computational cost and it includes 
relativistic effects to the heavier atoms. 
 
The input files for the free ligands were generated in Gaussian and optimised by PM3 
where no X-ray structure has been determined. Otherwise the CIF file created from the 
X-ray crystallography data was used as the starting point for these ligands. Seven of the 
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metal complexes used input files that contained coordinates from the X-ray structures of 
the synthesised compound, again using the CIF file created from the X-ray 
crystallography data. In the case where a crystal structure was not obtained, the complex 
was either generated in Gaussian or modified from another similar crystal structure. 
 
All input files contained the full structure of each compound so that any effect that the 
varying bridge substituents may have on the structure was factored into all the 
computations performed. Each of the structures was symmetrised in order to make use 
of molecular point group symmetry and to reduce the number of basis functions in the 
calculation. Once the geometries had been optimised, frequency jobs were run on each 
structure to obtain the theoretical IR frequencies for each type of vibrational stretch or 
bend in the free ligand or metal complex.  
 
4.5 Objectives 
The goal of this work was to carry out modern level quantum mechanical calculations on 
all the free Schiff base ligands and their respective metal complexes. The aim was to 
determine the stable configurations, relative energies, and structural and spectral 
features of different variations of bis(pyridine-imine) chelates of PGMs. The results of this 
spectroscopic and theoretical study will then be used to derive trends and for the 
prediction of geometries of the investigated compounds. 
 
The main objectives of this chapter were to: 
1) optimise the geometries of the Schiff base ligands and their metal complexes; 
2) compare the results for the metal complexes with those observed in the solid 
state; 
3) study the predicted geometrical parameters for the complexes that have not been 
synthesised and compare to those that have; 
4) characterise the molecular orbitals of this series of metallated Schiff compounds; 
5) compute the frequencies for each ligand and complex to enable comparison of the 
theoretical and experimental IR spectra for the imine bond as well as determining 
the lowest energy vibrations; and 
6) determine the difference between the free ligands and their respective metal 
complexes. 
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4.6 Results and Discussion  
4.6.1 Introductory remarks 
1970 saw the introduction of the first programme in the GAUSSIAN series; and in 1971 it 
was made available via QCPE.394 It was called GAUSSIAN70 and was capable of 
performing single-point calculations or optimisations (using Gaussian basis sets 
containing s- and p-orbitals) by cyclic variation of all parameters. This was the first ab 
initio program that found extensive approval. The basis sets, STO-3G and 4-31G, were 
the two most well-known to be built into the programme. This programme was 
subsequently used expansively externally to the laboratory in which it was produced, due 
to the simplicity of the input structure and GAUSSIAN70’s swiftness.332 
 
The Gaussian 03W version was used for this work.393 This is a very user-friendly version 
compared to earlier versions; all of the standard input is free-format and mnemonic with 
reasonable default settings. The output files are simply laid out and are self-explanatory. 
This version of Gaussian (and others) have found application by chemists, chemical 
engineers, biochemists, physicists and others where research is being carried out in 
other chemical interest areas.395 
 
Gaussian 03W393 is capable of predicting the energies, molecular structures, absorption 
bands and vibrational frequencies of molecular systems. It is then also viable for 
numerous molecular properties to be derived from these basic computation types. These 
computations can help in the analysis of compounds that may be difficult or impractical to 
examine experimentally and it is possible for the conditions of the studies to be altered, 
e.g. properties can be computed in the presence of particular solvents.395 
 
In this work, DFT calculations that were performed393 were executed in order to acquire a 
correlation between the theory and the practically collected data. DFT simulations were 
performed for the fifteen synthesised ligands, three putative ligands, and a total of thirty 
six putative and synthesised metal complexes. The metallated structures of these 
complexes are shown in Chart 4.1. All the values ascertained from these computations 
can be compared to experimental values; any possible discrepancies can then be 
investigated and their causes examined. These calculations can help in the 
understanding of many different concepts related to the properties observed for the 
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Schiff base in question, due to the vast quantity of information that is obtainable from 
these types of computations. This included IR frequency bands, NBO energies, 
molecular orbitals and possible conformations for each of our synthesised ligands and 
metal complexes. Not only do such simulations help in the understanding of the specific 
data of the particular compound for which the calculations were carried out, but 
simulations at this level of theory facilitate the discovery of trends that may well occur in 
similar compounds.  
 
For the notation used to denote the different atoms in the structures please refer to 
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4.6.2 Geometry Optimisations 
The DFT-optimised coordination geometries and those obtained from X-ray 
crystallography in the solid state may be compared. There may be some notable 
differences between the final structures determined by these two techniques; both small 
and large conformational deviations may often be attributed to structural deformations 
brought about by crystal packing interactions in the solid state. The structures 
determined by X-ray diffraction will include lattice-induced molecular distortions; 
however, the computations are for the free structure in the gas phase (where possible 
packing effects are absent). Crystal packing can result in either the flattening of the 
structure (planarity) or a distortion that pushes the structure out of its planar position 
(nonplanarity). Thus the observed difference between the two structures (DFT and X-ray) 
is likely to be merely the level of this distortion from planarity. A simple, yet effective way 
to explore these differences is by superimposing the DFT-calculated and X-ray 























 a)              b)           c) 
Figure 4.1: Least-squares fit of the DFT-calculated (from the X-ray CIF files) (green) and 
experimental (blue) structures of a) L1 (RMSD = 0.357 Å), b) L4 (RMSD = 0.293 Å) and c) L5 
(RMSD = 0.488 Å) for all non-H atoms.  
 
Optimisations at the B3LYP/6-31G** level of theory were performed for all eighteen 
ligands. The CIF files created from the X-ray crystallography data were used as input 
files for the three ligands, L1, L4 and L5. The DFT optimises the conformation for the 
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structure with the lowest energy in the gas phase. Subsequently the optimised forms of 
these gas-phase X-ray structures differ from the solid-phase structures. This difference is 
mainly for the position of the pyridyl-imine "arms" of the ligands as there is good 
correlation between the two structures for each ligand for the bridging groups (Figure 
4.1). These differences between the two sets of data can be explained by the different 
states in which the data has been obtained. For the gas phase structure (DFT-computed) 
there is freedom of rotation around the bonds, allowing for different forms and 
subsequently an ideal conformation representing a lowest-energy geometry of all these 
possibilities is acquired. There are also no counter ions or other molecules and therefore 
intermolecular interactions are not taken into account by the DFT computations. In the 
solid state, however, there are forces experienced by the molecules due to crystal 
packing.  
 
There are short contacts between the molecules in the solid state crystal structures 
(Figure 3.15) that cause these deviations of the peripheral groups from the predicted 
idealised geometries by DFT. For L1 nonbonded short contacts between the imine 
hydrogen to a neighbouring Np (2.656(10) Å) will cause the pyridyl-imine ―arms‖ to start 
to bend away from their predicted ideal gas phase orientations (for which these gas 
phase interactions are absent). In addition, there are also short contacts between some 
of the pyridine carbon atoms which will subsequently draw the pyridine rings towards 
neighbouring molecules. This will tilt the pyridine rings away from their expected 
orientation due to the forces brought about by the other molecules in the crystal lattice 
which are not accounted for in the gas-phase computation. 
 
L5 has a short contact between the Ni and a neighbouring molecule (2.745(10) Å), as 
well as between Ci and a neighbouring molecule (2.392(10) Å). This causes the same 
type of bending of the pyridyl-imine ―arms‖ for this structure. The pyridine rings are also 
tilted away from their expected positions due to short contacts between pyridine carbons 
of one molecule and Np of another. For L4 there are short contacts between pyridine 
carbon atoms and neighbouring molecules which will then result in the same tilting of the 
pyridine rings. The fit for L4 is slightly better than for L1 and L5 as it shows no short 
contacts between the imine bond and neighbouring molecules. This results in greater 
correlation between the position of the imine bonds for this ligand between the DFT-
computed and experimentally determined X-ray structures. The resulting deviations 
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between these structures will therefore be predominantly for the tilting of the pyridine 
rings. This can be clearly seen in Figure 4.1.  
 
Lui et al. have shown that a similar ligand demonstrates a crystal structure with similarly 
tilted pyridine rings.153 The enantiomer of this ligand was shown to also have these 
slightly twisted pyridine rings in the solid state.158 We can therefore conclude that the 
absence of intramolecular interactions in the gas phase clearly accounts for the 
conformational differences between the two structures. 
 
Data have also been obtained for L4b which differs by the much bulkier group on the 
imine. The presence of this phenyl group causes considerable alteration to the structure 
compared to L4, although now the bridging group agrees almost perfectly with that of the 
X-ray structure (RMSD = 0.00652 Å for the four carbon bridge). The differences between 
the computed and experimental structures are again seen for the orientation of the 
pyridyl-imine "arms" of the bridge (Figure 4.2). Again the CIF file for the X-ray data was 
optimised and good agreement between the experimental and DFT-computed structures 
is observed (RMSD = 0.252 Å for all non-H atoms in the structure).  
 
 
Figure 4.2: Least-squares fit of the DFT-optimised (green) and X-ray (blue) structures of L4b.  
The DFT structure was generated with Gaussian393 as an optimisation of the CIF file from the X-
ray data. 
 
In particular, the deviations between the two structures are for the pyridine and phenyl 
rings. This may again be explained by the nonbonded short contacts observed for the X-
ray structure (Figure 4.3). There are short contacts between a carbon atom of the 
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pyridine ring of one molecule with its associate carbon atom in a neighbouring molecule 
(3.339 Å). An H···H short contact (2.349 Å) exists between the pyridine and phenyl rings 
of adjacent molecules, as well as an H··C (2.796 Å) short contact. There are no 
intramolecular interactions and therefore these intermolecular contacts that involve the 
aromatic rings are likely to justify their changes in orientation. 
 
 
Figure 4.3: Illustration of significantly short H···C and H···H contacts observed in the X-ray 
structure of L4b between neighbouring molecules. Such interactions are absent for DFT-
calulated structures in the gas phase. 
 
Overall, when the differences between the two states for which the structures are 
obtained are taken into account, there is very good correlation between the theoretical 
and experimental data. This can further be shown by the molecular geometry 
measurements for the structures, as given in Table 4.1. Not only do the angles of the 
conformations agree to within 0.2 to 2.0º, but the bond lengths deviate by less than 1% 
(except for the Cf-Cf’ bonds for L1 and L5 which deviate by 1.1 and 1.5%, respectively). 
This shows an excellent relationship between the predicted and determined structures 
for these four ligands. Given the above degree of similitude between the calculated and 
experimental data, structural and conformational parameters computed at this level of 
theory (B3LYP 631G**) are likely to be of acceptable accuracy, particularly for similar 
structures. Hence the data obtained for the other ligands, putative and synthesised, may 
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Table 4.1: Average selected bond lengths (Å) and angles (°) for the free ligands calculated by 
DFT simulations (top) and determined from the X-ray structures (bottom). 
 L1 L4 L5 L4b 
Ni=Ci 
1.274 1.273 1.273 1.280 
1.267(2) 1.267(2) 1.268(2) 1.278(2) 
Ci–Cp 
1.479 1.4879 1.479 1.493 
1.474(2) 1.481(2) 1.474(2) 1.496(2) 
Ni–Cf 
1.451 1.451 1.453 1.455 
1.457(2) 1.463(2) 1.464(2) 1.465(2) 
Cf–Cg 
1.537* 1.55 1.556* 1.548 
1.519(3)* 1.539(2) 1.533(2)* 1.540(2) 
Cf-Cg-Cf 
– 108.1 – 109.8 
– 108.3(9) – 110.2(1) 
Ci-Ni-Cf 
118.0 118.4 118.2 121.4 
117.0(1) 116.9(1) 116.5(1) 120.0(1) 
Cp-Ci-Ni 
122.3 122.4 122.4 123.4 




123.6 123.5 123.6 118.8 
122.3(9) 122.2(9) 122.7(8) 118.4(1) 
                      *For these ligands the distance Cf-Cf ' is given (where ' designates a symmetry related atom). 
 
Similarly, the theoretically and experimentally determined conformations for each of the 
metal complexes of these ligands are almost identical. The calculated geometries for the 
metal complexes are therefore also acceptable, given the degree of similitude between 
the X-ray and DFT-calculated structures. Small differences seen between the calculated 
and observed geometrical parameters may be attributed to experimental values 
corresponding to structures in the crystalline state while theoretical calculations have 
been performed on single molecules in the gaseous phase. However, there is also the 
possibility that these differences may be due to under- or overestimated parameters 
arising from inherent shortfalls in the DFT method used.   
 
Metallation of the ligands forces the four N-donor atoms from their various positions into 
a plane around the metal centre which becomes the basic outline for each of the 
conformations. Each of the metal complexes has these four N-donor atoms and therefore 
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the only differences in the metallated structures are expected to be distortions from this 
plane. The extent of these deviations will therefore reflect the geometric constraints now 
imposed by the presence of the metal.  
 
In each conformation the deviation may be seen by the slight tilting (out of the N4 plane) 
of the pyridine rings. Usually one pyridine ring is tilted slightly above the plane and the 
other slightly below. The distance between the central carbon atom of the pyridine ring 
(Ca) and the plane formed by the four nitrogen atoms (N4 plane) is measured; this may 




Figure 4.4: The structure of PdL2 to illustrate the distance measured to determine distortion of 
the molecule from the N4 plane. 
 
These distances are mostly calculated to be larger than those observed for the X-ray 
structures as displayed in Chart 4.2. (For PtL4 and PdL4 only the twisted X-ray 
structures were compared to the DFT-computed structures.) The flatter geometries for 
the X-ray structures may therefore reflect the intermolecular interactions present in the 
crystal lattice making the structure less twisted than in the DFT-calculated conformation 
(gas phase). As the counter ions (PF6
-
) are not taken into account in the DFT 
computations, the prominent short interactions involving them in the crystallographically 
observed structures do not play a role in the computed structures. These crystal packing 
interactions may modulate the observed solid state conformation by flattening the chelate 
structure beyond that predicted in the absence of such lattice interactions. 
Distance of Ca from the N4 plane 



























Chart 4.2: Distance (Å) that the central pyridine hydrogen atoms (Ca) are distorted from the N4 
plane for each structure. DFT-computed values in green and X-ray measured distances in blue. 
 
The least-squares fits of the N4 plane for the platinum complexes of L1, L2 and L4 are 
shown in Figure 4.5. The RMSD for each complex is given in Table 4.2. The most 
noticeable differences (if any) from the overlaying of the X-ray structures and the DFT-
calculated structures are for the bridges of the chelating ligand structure. As the length of 
the bridging group increases from a 2-carbon to a 3-carbon bridge, so there is a slight 
deterioration of the fit between the computed and experimental data (Table 4.2). 
However, the increase in bulk on the 3-carbon bridge causes a reduction in the RMSD 
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central carbon of the propyl bridge is distorted from the N4 mean plane; however, when 










Figure 4.5: Least-squares fit of the DFT-calculated (green) and experimental (blue) structures 
of the platinum complexes of L1, L2 and L4 (RMSD = 0.0537, 0.0820 and 0.0546 Å, 








Figure 4.6: The different conformations of the X-ray structure (left) and computed DFT structure 
(right) for PdL4m.  
 
The fit has also been performed for all the non-H atoms in the structure (excluding the 
metal) as shown in Table 4.2. In each case there is an increase of the RMSD when 
including all the non-H atoms in the least-square fit rather than just the N4 plane. This 
shows relatively good agreement between the calculated and experimental nitrogen 
atom planes for each of the complexes; however, larger deviations are present for the 
bridging groups (as discussed above) and pyridine rings. In particular, the RMSD for the 
fit of PdL4m increases 3-fold from the N4 plane when including all non-H atoms. This can 
be explained by the very different structures for the theoretical and experimental 
orientations of the pyridine rings. In the crystal structure the pyridine rings are both tilted 
out of the plane in the same direction causing a saddling type of structure (Figure 4.6), 
while the DFT method used computes a structure similar to the others with one pyridine 
tilted on either side of the N4 plane. The differences for the other structures can be 
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explained by the larger deviations calculated by the DFT method as it does not take 
crystal packing interactions into account.  
 
A relatively high RMSD is observed for the least-square fit for all the non-H atoms of 
PdL4b, although lower than that of PdL4m. In this case both structures have the same 
conformation so the better fit is expected. There is a more than 5-fold increase from the 
least-square fit for the N4 plane of PdL4b which shows that most of the deviations 
between the structures are not from the plane around the metal, but rather for the bulky 
substituents. This sort of deviation between the two conformations has been noted for 
the other structures that have been compared. These discrepancies may therefore also 
be explained by crystal packing interactions which cause tilting of the aromatic rings.  
 
Table 4.2: The RMSD values (Å) for each of the least-squares fits for the metal complexes. 
 
 PtL1 PdL1 PtL2 PdL2 PtL4 PdL4 PdL4m PdL4b 
RMSD – fit 
based on the 
N4 plane 
0.0537 0.0651 0.0820 0.0835 0.0546 0.0386 0.121 0.0419 
RMSD – fit 
based on all 
non-H 
atoms* 
0.0876 0.104 0.208 0.180 0.0814 0.0672 0.367 0.222 
*Least-squares fit on all non-H atoms excludes the metal atom. 
 
 
Although the ligands L1–L4b are slightly different in each case, the basic structures are 
comparable and therefore some similarities between the bond lengths and bond angles 
of the structures will be expected. Structural parameters have been obtained for the X-
ray structures (Chapter 3 – X-ray Crystallography) and these values, along with those 
calculated by DFT, are given in Tables 4.3 and 4.5. Chemically equivalent bond lengths 
are, as expected, very similar to one another; there are no significant outliers and most 
differ only in the third decimal place.  
 
In order to compare and obtain trends from these measurements DFT computations 
were performed for theoretical platinum(II) and palladium(II) complexes of bis(pyridyl-
imine) Schiff base ligands with methylene and butyl bridges. This allows us to compare 
the differences in bond lengths and angles caused by the size of the bridging group and 
analyse whether the deviations are a definite trend. The data for these computed values 
are presented in Table 4.4 and 4.6.  
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Table 4.3: Average bond lengths (Å) calculated by the DFT simulations and observed in the X-
ray structures (in italics), where possible, for selected bonds. 
 M–Ni M–Np Ci=Ni Ci–Cp Ni–Cf 
PtL1 
1.984(0) 2.099(0) 1.303(0) 1.468(0) 1.498(0) 
1.953(5) 2.051(5) 1.261(9) 1.464(10) 1.475(8) 
PdL1 
1.980(0) 2.101(0) 1.301(0) 1.468(0) 1.495(0) 
1.942(4) 2.046(3) 1.261(7) 1.467(6) 1.494(6) 
PtL2 
2.034(4) 2.093(1) 1.305(1) 1.458(0) 1.491(1) 
1.988(6) 2.060(5) 1.278(8) 1.444(9) 1.479(10) 
PdL2 
2.035(4) 2.094(2) 1.303(1) 1.460 (0) 1.488(2) 
1.998(2) 2.073(2) 1.278(2) 1.451(3) 1.475(2) 
PtL3 2.033(4) 2.090(1) 1.304(1) 1.458(1) 1.484(3) 
PdL3 2.033(8) 2.092(1) 1.302(1) 1.459(1) 1.481(3) 
PtL4 
2.033(1) 2.095(2) 1.305(1) 1.457(1) 1.490(2) 
1.986(7) 2.038(6) 1.298(10) 1.441(11) 1.478(11) 
PdL4 
2.032(3) 2.096(3) 1.303(1) 1.460(0) 1.487(2) 
1.992(4) 2.057(4) 1.280(6) 1.457(6) 1.472(6) 
PtL5 1.986(2) 2.099(2) 1.302(0) 1.469(0) 1.510(9) 
PdL5 1.981(2) 2.101(3) 1.299 1.469 1.506(9) 
PtL6 1.993(0) 2.088(0) 1.311(0) 1.461(0) 1.433(0) 
PdL6 1.988(0) 2.090(0) 1.309(0) 1.461(0) 1.429(0) 
PtL1m 1.987(0) 2.089(0) 1.312(0) 1.488(0) 1.497(0) 
PdL1m 1.981(0) 2.090(0) 1.310(0) 1.489(0) 1.494(0) 
PtL2m 2.041(1) 2.076(1) 1.318(1) 1.480(0) 1.490(0) 
PdL2m 2.038(1) 2.075(1) 1.316(2) 1.482(0) 1.487(2) 
PtL3m 2.039(1) 2.076(1) 1.318(1) 1.479(0) 1.484(1) 
PdL3m 2.036(0) 2.075(1) 1.316(2) 1.481(0) 1.481(1) 
PtL4m 2.026(0) 2.080(0) 1.315(2) 1.483(0) 1.490(0) 
PdL4m 
2.035(0) 2.074(2) 1.313(0) 1.483(0) 1.486(2) 
1.998(3) 2.056(3) 1.284(5) 1.457(6) 1.461(5) 
PtL5m 1.994(15) 2.082(8) 1.313(3) 1.490(4) 1.512(19) 
PdL5m 1.987(17) 2.082(10) 1.311(3) 1.492(4) 1.508(17) 
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PtL6m 1.999(0) 2.073(0) 1.324(0) 1.485(0) 1.440(0) 
PdL6m 1.992(0) 2.073(0) 1.322(0) 1.486(0) 1.436(0) 
PtL1b 1.985(0) 2.088(0) 1.318(0) 1.493(0) 1.494(0) 
PdL1b 1.978(0) 2.089(0) 1.316(0) 1.493(0) 1.491(0) 
PtL2b 2.041(6) 2.076(2) 1.322(1) 1.481(1) 1.488(2) 
PdL2b 2.039(8) 2.075(2) 1.320(1) 1.483(1) 1.486(3) 
PtL3b 2.040(6) 2.075(2) 1.323(1) 1.481(1) 1.482(1) 
PdL3b 2.037(8) 2.074(4) 1.322(1) 1.483(1) 1.480(2) 
PtL4b 2.024(0) 2.076(0) 1.322(0) 1.484(0) 1.490(0) 
PdL4b 
2.018(0) 2.074(0) 1.320(0) 1.487(0) 1.487(0) 
2.002(5) 2.034(7) 1.291(8) 1.477(7) 1.465(7) 
PtL5b 1.992(14) 2.085(6) 1.316(0) 1.491(2) 1.514(17) 
PdL5b 1.985(16) 2.085(9) 1.314(0) 1.491(0) 1.510(17) 
PtL6b 1.999(0) 2.075(0) 1.326(0) 1.484(0) 1.441(0) 
PdL6b 1.992(0) 2.075(0) 1.324(0) 1.485(0) 1.437(0) 
 
 
Table 4.4: Average bond lengths (Å) calculated by DFT simulations for selected bonds of 
platinum and palladium complexes with methylene (Mbridge) or butyl bridges (Bbridge). 
 M–Ni M–Np Ci=Ni Ci–Cp Ni–Cf 
Pt_Mbridge 1.957(0) 2.123(0) 1.315(2) 1.483(0) 1.486(2) 
Pd_Mbridge 1.957(0) 2.123(0) 1.297(0) 1.481(0) 1.513(0) 
Pt_Bbridge 2.059(7) 2.082(0) 1.307(1) 1.456(0) 1.495(7) 










CHAPTER 4 – Density Functional Theory  
135 
 
Table 4.5: Average bond angles (°) calculated by the DFT simulations and observed in the X-
ray structures (in italics), where possible, for selected angles. 
 Ni-M-Np Ni-M-Ni Np-M-Np Cp-Ci-Ni 
PtL1 
80.0(0) 85.1(0) 115.2(0) 115.7(0) 
80.8(2) 85.6(3) 112.9(3) 115.9(6) 
PdL1 
80.5(0) 84.1(0) 115.1(0) 116.4(0) 
80.7(2) 85.2(2) 113.4(2) 115.8(4) 
PtL2 
79.2(0) 96.4 105.8 117.5(1) 
79.4(2) 95.2(2) 106.2(2) 116.8(6) 
PdL2 
79.9(0) 95.4 105.2 118.2(1) 
80.2 (7) 94.0(7) 105.6(1) 117.8(2) 
PtL3 79.3(0) 96.1(0) 105.8(0) 117.5(1) 
PdL3 80.0(0) 95.3(0) 105.3(0) 118.2(2) 
PtL4 79.5(3) 95.4(0) 106.3(0) 117.7(1) 
 80.1(2) 94.3(2) 105.5(2) 116.8(9) 
PdL4 
80.1(0) 94.7(0) 105.5(0) 118.4(1) 
80.1(2) 94.3(2) 105.5(2) 117.1(4) 
PtL5 80.1(1) 85.0(0) 115.1(0) 115.9(1) 
PdL5 80.6(2) 84.1(0) 114.9(0) 116.6(1) 
PtL6 80.5(0) 84.2(0) 114.8(0) 115.9(0) 
PdL6 81.0(0) 83.5(0) 114.4(0) 116.5(0) 
PtL1m 79.7(0) 86.1(0) 114.6(0) 113.5(0) 
PdL1m 80.2(0) 85.4(0) 114.4(0) 114.0(0) 
PtL2m 78.6(1) 98.5(0) 105.2(0) 114.8(1) 
PdL2m 79.3(1) 97.8(0) 104.6(0) 115.3(3) 
PtL3m 79.2(6) 98.1(0) 105.4(0) 114.8(1) 
PdL3m 79.4(1) 97.5(0) 104.8(0) 115.3(3) 
PtL4m 76.2(0) 94.6(0) 109.8(0) 114.3(0) 
PdL4m 
79.5(1) 97.3(0) 104.7(0) 115.4(2) 
79.5(1) 95.0(1) 105.6(1) 115.8(4) 
PtL5m 80.0(5) 86.6(0) 113.8(0) 113.5(3) 
PdL5m 80.5(5) 85.8(0) 113.4(0) 114.1(3) 
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PtL6m 80.4(0) 85.3(0) 113.5(0) 113.6(0) 
PdL6m 80.9(0) 84.8(0) 113.1(0) 114.0(0) 
PtL1b 79.6(0) 86.0(0) 114.9(0) 113.0(0) 
PdL1b 80.1(0) 85.3(0) 114.9(0) 113.5(0) 
PtL2b 78.8(2) 98.4(0) 104.9(0) 114.6(1) 
PdL2b 79.4(2) 97.9(0) 104.3(0) 115.1(2) 
PtL3b 78.8(2) 98.2(0) 105.0(0) 114.6(1) 
PdL3b 79.5(2) 99.6(0) 104.4(0) 115.1(2) 
PtL4b 79.3(0) 94.7(0) 109.1(0) 114.0(0) 
PdL4b 
80.0(0) 94.1(0) 108.7(0) 114.4(0) 
79.9(2) 96.9(2) 103.9(2) 115.5(5) 
PtL5b 80.0(5) 86.4(0) 113.9(0) 113.6(5) 
PdL5b 80.5(6) 85.7(0) 113.6(0) 114.0(6) 
PtL6b 80.7(0) 85.4(0) 113.1(0) 113.8(0) 
PdL6b 81.2(0) 84.9(0) 112.6(0) 114.2(0) 
 
 
Table 4.6: Average bond angles (°) calculated by DFT simulations for selected angles of 
platinum and palladium complexes with methylene (Mbridge) or butyl bridges (Bbridge). 
 Ni-M-Np Ni-M-Ni Np-M-Np Cp-Ci-Ni 
Pt_Mbridge 80.4(0) 69.8(0) 129.5(0) 114.1(0) 
Pd_Mbridge 80.5(0) 69.3(0) 129.8(0) 114.8(0) 
Pt_Bbridge 79.0(1) 101.0(0) 103.1(0) 118.0(3) 
Pd_Bbridge 79.8(1) 100.3(0) 102.6(0) 118.6(3) 
 
 
The differences and similarities between the platinum(II) and palladium(II) centres have 
been noted in Chapter 3 – X-ray Crystallography. These 5d8 and 4d8 metals have similar 
ionic radii and therefore similar geometrical properties. The metal-Np bond is always 
slightly longer than that of the M-Ni bond (as was observed for the X-ray data – see 
Chapter 3) due to the stronger basicity of the imine nitrogen. This DFT-computed bond 
length (metal-Np) stays relatively constant throughout the range of metallated structures 
for both platinum and palladium complexes.287 The environment of the pyridyl-nitrogen 
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does not change and therefore this is expected due to the similar ionic radii of the 
metals. The metal-Ni bond shows more variation; however, for platinum and palladium 
complexes of the same ligand it is mostly quite similar (within experimental error). These 
differences between ligand structures may be explained by the effect of the change in 
bridging groups. Little change in bond lengths is noted when varying the group on the 
imine carbon. Most often, only a very slight increase when moving from the hydrogen to 
the methyl-group, and barely any change on further increase in bulk to the phenyl-group. 
 
The imine bond distances range from about 1.29 to 1.32 Å and compare favourably with 
one another; however, they are decidedly longer than those measured for the X-ray 
structures (~ 1.27Å). In general, there seems to be slightly better correlation between the 
X-ray and DFT-calculated data for the Ci-Cp and Ni-Cf bond lengths for the palladium 
complexes in comparison to the platinum complexes. This difference is, however, very 
small and therefore the prediction of these geometrical parameters is of acceptable 
accuracy at this level of theory. 
 
With increasing chain length there is an increase in stability up to a point after which the 
stability will decrease.312 This change is usually seen around the 5-membered and 6-
membered rings created by this chelation, as these are the most stable forms. The 
difference in size between these two bite angles for these different chelate rings has 
been shown in the literature.313,314,315,316 The larger chelate ring has the greater bite 
angle (as discussed in Chapter 3, pp 85–87). For the X-ray structures in this work an 
increase in Ni-M-Ni was noted as the length of the bridging group increased; this is also 
true for the DFT-computed structures (for the methyl-substituted and phenyl-substituted 
ligands as well).  
 
This trend was also followed by the theoretical structures computed for complexes 
similar to those in this work, but with methylene and butyl bridges. These different sized 
bridges illustrate smaller and larger bite angles, relative to the ethyl and propyl bridges, 
respectively. This trend for the size of these bite angles has been represented pictorially 
in Figure 4.6: methylene < ethyl < propyl < butyl. The distance between each Np (pyridyl 
nitrogen) and its adjoining Ni (imine nitrogen) stays constant therefore there is very little 
change in these angles. Subsequently the change due to the chain length of the bridge 
must cause alteration of the bite angle. The planar coordination sphere must always 
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equal 360º and therefore this in turn causes a change in the Np-M-Np angle – as the bite 
angle increases so this angle must decrease.  
 
The increase in size of the bite angles can be observed in Figure 4.7. The increase from 
the methyl to ethyl to propyl chelates is around 15º and 11º, respectively for both metal 
complexes. The increase from the propyl to butyl bridging chains is however less than 4º. 
The general trend of increasing angle with increasing length of the chelate is, however, 
shown to be accurate for this range of metal complexes. There is also a slight 
discrepancy in the bite angle for metal complexes of the same size chelate ring.  With 
increasing chelate length these discrepancies for the platinum and palladium complexes 
are 0.5º, 1º, 1º and 0.7º, respectively. This is similar to the increase in the bite angle from 
the palladium to platinum complexes of a salen ligand (with a propyl bridge) which was 
shown to be ~ 1º.316 
 
























Figure 4.7: Portions of the platinum complexes (top) and palladium complexes (bottom) 
showing the increasing size of the DFT-computed bite angles for the increasing length of the 
chelate ring's bridging group. 
 
Distortion from the plane is observed for the ethyl bridging group of PtL1 and PdL1. The 
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and one above. This reduces the strain on the metal and subsequently allows for a 
smaller bite angle. Distortion is also observed for the propyl bridging group of PtL2 and 
PdL2, but to a lesser extent. The three carbon atoms form an envelope shape with the 
central CH2 orientated out of the plane and each CH2 on either side in the plane. With 
the limited distortion seen for this bridge it is understandable that it possesses a larger 
bite angle than the ethyl derivatives, in order to accommodate the two in-plane CH2 
groups. 
 
It has been noted that it would be more energetically favourable for the bonds and angles 
of the metal centre to change, rather than those of the carbon-chain chelate rings (page 
88). We subsequently expect to see some changes in the bond lengths to the metal 
caused by these changes in bite angles. There is an increase in the length of the M-Ni 
bond when moving from the ethyl to the propyl bridging groups. This is true for both the 
DFT-computed and the X-ray data for both the platinum and palladium complexes. The 
same trend has been observed for the methylene and butyl bridging groups. The 
methylene bridge has shorter M-Ni bond lengths than for the ethyl bridge, while for the 
butyl derivative they are marginally longer than for all the others.  This increase therefore 
helps to assist the increase in the bite angle with increasing chelate length.  
 
A moderate change in bite angle has also been noted for the different groups of ligands. 
When moving from the original set of ligands to the methyl-substituted ligands, there is 
now an increased bite angle; e.g. the bite angle is 85.1º for PtL1 and 86.1º for PtL1m. 
This is true for both platinum and palladium complexes and the difference ranges from 1 
to 3º. Bayat et al. also observed this change when moving from H to the electron 
donating methyl group.287 A similar trend is seen for the phenyl-substituted ligands with 
very little difference in bite angles between them and the methyl-substituted ligands. 
These small differences may therefore be attributed to the presence of the methyl or 
phenyl groups attached to the imine carbon. 
 
4.6.3 Molecular Orbitals 
Also determined from the computations were the four frontier molecular orbitals (FMOs) 
for each of the metal complexes. Although these orbitals may be useful in the qualitative 
understanding of some molecules, they are merely mathematical functions that represent 
solutions to the Hartree-Fock equations for that molecule. It is possible for other orbitals 
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to exist, which look quite different, yet produce the same energy and properties. There is 
no physical reality that can be connected with these images; individual orbitals are 
mathematical not physical constructs.331  
 
Here, we are mainly interested in determining to what degree the different bridging 
groups and metals may or may not perturb the frontier MOs of the complex. GaussView 
3.09396 was used to compute the surfaces for the four frontier molecular orbitals of the 
thirty-six metal complexes. These four frontier molecular orbitals include the highest and 
second-highest occupied molecular orbitals and the lowest and second-lowest 
unoccupied molecular orbitals. These are denoted HOMO, HOMO-1, LUMO, LUMO+1, 
respectively. Given that the frontier molecular orbitals for each range of metal complexes 
are all rather similar, for brevity we shall present the discussion for the metal complexes 
of one ligand from each group. The wavefunctions for the molecular orbitals of platinum 
and palladium complexes of L2, L2m and L2b are shown pictorially in Figures 4.8, 4.9 
and 4.10, respectively. 
 
Molecular orbitals can be useful in identifying the orbitals involved in electronic 
excitations. The frontier molecular orbitals play an important role in electric, optical and 
spectroscopic properties, as well as chemical reactivity. These orbitals have been 
generated using an isovalue for the surfaces of 0.02 (smaller isosurface values produce 
larger orbitals). The red and green colours of the orbitals represent different phases of 
the wavefunction. Sometimes molecular orbitals are consistent with our ideas of bonding 
and anti-bonding, sometimes they are delocalised. 
 
There is impressive similarity observed for the corresponding molecular orbitals for the 
platinum and palladium complexes of L2, as seen in Figure 4.8. This is also the case for 
the equivalent MOs of the platinum and palladium complexes of L2m and L2b. Each of 
the two HOMO and each of the two LUMO orbitals for all three sets of ligands look 
almost identical. The HOMO and LUMO levels have π symmetry, with opposite phases 











































Figure 4.8: LUMOs (top) and HOMOs (bottom) calculated for PtL2 (left images) and PdL2 
(right images) with GaussView.396 
Pt Pd 






































Figure 4.9: LUMOs (top) and HOMOs (bottom) calculated for PtL2m (left images) and PdL2m 
(right images) with GaussView.396 
Pt Pd 




































Figure 4.10: LUMOs (top) and HOMOs calculated for PtL2b (left images) and PdL2b (right 
images) with GaussView.396 
Pt Pd 
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For all six of the complexes they are localised mainly on the central metal and imine/ 
pridine ligand structure, with little or no contribution from the bridging groups, depending 
on the particular complex and orbital. The HOMO-1 orbitals generated for the metal 
complexes of L2 and L2m seem to be localised metallic orbitals (Pt(II) or Pd(II) dz2 
orbitals); while the HOMOs are π molecular orbitals of mainly pyridine and imine 
character mixed with a dyz metal-based orbital. The HOMO-1 is therefore mainly the dz2 
orbital that has only partial mixing with the ligand causing them to be close to pure metal 
atomic orbitals. The HOMO is metal dyz orbital mixed with ligand π-orbital with its main 
components on the pyridine rings and imine double bonds. 
 
The LUMO and LUMO+1 are mainly composed of the metal centre, pyridine rings and 
imine, with almost negligible contribution from the bridging fragments. The LUMO is near 
degenerate with the LUMO+1; this trend is evident for these frontier orbitals for the other 
complexes as well. There is an interesting inverse symmetry observed for the LUMO+1 
and delocalised orbitals across the metal for the LUMOs. The LUMO is essentially a pure 
ligand π* molecular orbital, while the LUMO+1 is the metal dxz orbital mixed with the 
ligand π* MO. 
 
The LUMOs and LUMO+1 molecular orbitals for the platinum and palladium complexes 
of L2b are quite similar to those of L2 and L2m. They also show negligible contribution 
from the bridging fragments, as well as from the phenyl groups. Inverse symmetry is also 
present for the delocalised orbitals across the metal for the LUMOs. The HOMO and 
HOMO-1 orbitals are very different to those of the L2 and L2m complexes. They are 
based predominantly on the phenyl substituents with little or no contribution from the rest 
of the structure. These molecular orbitals are near-degenerate. 
 
The energies of the four frontier molecular orbitals of all thirty-six complexes are given in 
Table C2.2 in Appendix C. Orbital energy level diagrams with structures showing the 
calculated energy levels of the HOMO-1, HOMO, LUMO, and LUMO+1 orbitals of the 
complexes are shown in Figures 4.11, 4.12 and 4.13.  From the figures, it is clear that 
the bridge structure affects the HOMO-LUMO gap and energies and that similar trends 
exist for the Pt(II) and Pd(II) chelates. The HOMO and LUMO energies systematically 
increase in a similar manner as we move to the bulkier ligands; however, the magnitudes 
are clearly metal dependent. 
 
 






Figure 4.11: The frontier molecular orbitals for the metal complexes of the original ligands: L1 – L6. 
 
 





Figure 4.12: The frontier molecular orbitals for the metal complexes of the methyl-substituted ligands: L1m – L6m. 
 
 





Figure 4.13: The frontier molecular orbitals for the metal complexes of the phenyl-substituted ligands: L1b – L6b. 




For the complexes of the original ligands (Figure 4.11) there is a general increase in MO 
energy with increasing bridge length and/or complexity for both metals. The difference in 
energy between HOMO-1 and HOMO, as well as the difference between LUMO and 
LUMO+1, for each metal complex is relatively similar. However, the energies for the 
LUMOs for the complexes of L6 are almost identical. This is also seen for the metal 
complexes of L6m (Figure 4.12). The other methyl-substituted ligand complexes (L1m–
L5m) show a slightly less defined increase with steric bulk; however, there is a definite 
increase in energies in comparison to Figure 4.11. This may be accounted for by the 
addition of the electron-donating methyl group. The energies for the metal complexes of 
the phenyl-substituted ligands increase even further (Figure 4.13). These frontier 
molecular orbitals are all very similar to each other; the exception once again is for the 
complexes with the aromatic ring bridging group (L6b). The HOMO and HOMO-1 
energies are almost identical for each of these metal complexes. 
 
The energy gaps between the HOMO and the LUMO orbitals for each complex are 
depicted in Table 4.7. The energy of the LUMO is directly related to the electron affinity 
and the energy of the HOMO is directly related to the ionisation potential. Thus the 
energy difference between HOMO and LUMO orbitals, the so-called HOMO-LUMO gap, 
is important with regards to the stability of structures.397 The magnitude of this HOMO–
LUMO energy gap could then indicate the reactivity pattern of the molecule. According to 
molecular orbital theory, HOMOs and LUMOs have an important influence on 
bioactivity.397 The interaction between the receptor of the cancer cell and the complex 
may be dominated by π–π or hydrophobic interaction amid these frontier molecular 
orbitals. The positive charges located on the atoms will most likely interact with the 
negative part of the receptor. In contrast, the most negatively charged parts will interact 
quite easily with the positively charged part of the receptor. These interactions will 
subsequently be part of the molecular mechanism of action that may inhibit the growth of 
cancer cells. 
 
The larger the HOMO-LUMO gap, the higher the kinetic stability as it is energetically 
unfavourable to extract electrons from a low-lying HOMO or to add them to a high-lying 
LUMO.398 There is an obvious increase in the HOMO–LUMO gap from the platinum 
complexes to the palladium complexes. The Pd(II) complexes are harder in Pearson's 
classification of hard and soft metal ions;399 they are less polarisable than the Pt(II) 
complexes. The largest HOMO–LUMO energy gap is calculated for PdL1m and the 




smallest for PtL3b. An increase in the metal-ligand interaction energy is noted when the 
electron donating methyl group is present on the imine carbon and a decrease when this 
is exchanged for a conjugating phenyl ring.287 This is expected as the energy levels of 
the occupied orbitals will clearly change due to electrostatic effects caused by these 
groups. 
 




gap / eV 
Complex 
Energy 
gap / eV 
Complex 
Energy gap / 
eV 
PtL1 3.918 PtL1m 4.000 PtL1b 3.265 
PdL1 4.245 PdL1m 4.381 PdL1b 3.374 
PtL2 3.918 PtL2m 3.973 PtL2b 3.211 
PdL2 4.245 PdL2m 4.354 PdL2b 3.320 
PtL3 3.864 PtL3m 3.946 PtL3b 3.156 
PdL3 4.218 PdL3m 4.163 PdL3b 3.265 
PtL4 3.973 PtL4m 4.082 PtL4b 3.292 
PdL4 4.299 PdL4m 4.381 PdL4b 3.429 
PtL5 3.918 PtL5m 4.000 PtL5b 3.265 
PdL5 4.218 PdL5m 4.327 PdL5b 3.374 
PtL6 3.401 PtL6m 3.483 PtL6b 3.311 
PdL6 3.374 PdL6m 3.456 PdL6b 3.238 
 
The NBO (natural bond orbital) analysis provides accurate representations of the 
electron density as the orbital details are mathematically chosen. It provides information 
about interactions in both filled and virtual orbital spaces.397 The metal orbital energies 
and electron populations are given for each of the metal complexes in Table 4.8. The 
electron population on each of the metals is more than expected which may be due to σ-
donation from the ligand. The partial atomic charges are all very similar for each of the 
metal atoms; with the platinum derivative of the same ligand having slightly less positive 
charge than the palladium complex. This is consistent with the Pt(II) ion having a 
marginally softer character than the Pd(II) ion399 for the same ligand, as evidenced by the 
smaller HOMO-LUMO gaps for the Pt(II) complexes relative to the Pd(II) complexes. 
 




Table 4.8: Key NBO charge and electron populations for the platinum and palladium atoms 
calculated at the B3LYP/SDD level of theory. 
Complex Atom Charge Core Valence Rydberg Total 
PtL1 Pt 0.785 67.989 9.193 0.033 77.215 
PdL1 Pd 0.799 35.990 9.178 0.034 45.201 
PtL2 Pt 0.727 67.990 9.197 0.036 77.223 
PdL2 Pd 0.784 35.990 9.191 0.035 45.216 
PtL3 Pt 0.789 67.990 9.186 0.035 77.212 
PdL3 Pd 0.811 35.990 9.162 0.037 45.189 
PtL4 Pt 0.775 67.989 9.201 0.035 77.225 
PdL4 Pd 0.779 35.990 9.195 0.036 45.221 
PtL5 Pt 0.781 67.989 9.197 0.033 77.219 
PdL5 Pd 0.794 35.990 9.182 0.034 45.206 
PtL6 Pt 0.790 67.990 9.188 0.032 77.210 
PdL6 Pd 0.806 35.990 9.171 0.033 45.194 
PtL1m Pt 0.775 67.990 9.204 0.032 77.225 
PdL1m Pd 0.791 35.990 9.186 0.033 45.209 
PtL2m Pt 0.767 67.990 9.211 0.032 77.233 
PdL2m Pd 0.790 35.990 9.186 0.034 45.210 
PtL3m Pt 0.766 67.990 9.211 0.033 77.234 
PdL3m Pd 0.789 35.990 9.186 0.034 45.211 
PtL4m Pt 0.770 67.989 9.209 0.032 77.230 
PdL4m Pd 0.790 35.990 9.184 0.035 45.210 
PtL5m Pt 0.771 67.989 9.208 0.033 77.229 
PdL5m Pd 0.786 35.990 9.190 0.034 45.214 
PtL6m Pt 0.778 67990 9.200 0.032 77.222 
PdL6m Pd 0.797 35.990 9.180 0.033 45.203 
PtL1b Pt 0.772 67.989 9.207 0.032 77.228 
PdL1b Pd 0.787 35.990 9.191 0.033 45.213 
PtL2b Pt 0.766 67.990 9.213 0.032 77.234 
PdL2b Pd 0.787 35.990 9.189 0.033 45.213 
PtL3b Pt 0.765 67.990 9.213 0.032 77.235 
PdL3b Pd 0.786 35.990 9.190 0.034 45.214 
PtL4b Pt 0.768 67.989 9.211 0.032 77.232 
PdL4b Pd 0.787 35.990 9.190 0.033 45.213 
PtL5b Pt 0.768 67.989 9.210 0.032 77.232 
PdL5b Pd 0.782 35.990 9.195 0.033 45.218 
PtL6b Pt 0.774 67.990 9.205 0.032 77.226 
PdL6b Pd 0.791 35.990 9.186 0.032 45.209 





Geometry optimisations and energy calculations ignore vibrations in the molecular 
system; thus calculations are performed using an idealised view of the nuclear positions. 
In reality the nuclei in molecules are constantly in motion; these vibrations are regular 
and predictable in equilibrium states and thus can be used to identify molecules from 
their characteristic spectra. Gaussian 03 computes vibrational spectra for both the 
excited and ground states. Besides predicting the frequency and intensity of spectral 
lines, the programme can also depict the displacements undergone by a system in its 
normal modes. This means it can predict the direction and magnitude of the nuclear 
displacements that occur when a system absorbs a quantum of energy.331 
 
A significant application for modern quantum chemical methods is the computational 
prediction of vibrational spectra, since it permits the elucidation and understanding of 
experimental spectra. This may then be used to assist with identification of unknown 
compounds or help to clarify the structures of already known compounds. There are two 
characteristics of vibrational spectra that need to be considered; the frequency of the 
absorbed incident light and how much is absorbed. To determine the frequency and 
intensity the harmonic vibrational frequencies of the particular molecule are calculated 
and accurate intensities must be supplied. For IR spectra, ―the intensity is related to the 
square of the infinitesimal change of the electric dipole moment µ with respect to the 
normal coordinates‖.331These intensities will be calculated as sharp peaks, not broad 
bands as for the experimental data.  
 
The crude frequency values calculated using the Hartree-Fock level have systematic 
errors because electron correlation is ignored and this results in overestimates of around 
10-20%. Therefore it is normal for values that have been computed at the Hartree-Fock 
level to be scaled by an empirical factor of 0.8929.331 It has been found that the use of 
this factor results in good agreement with experimental values for a broad series of 
systems. Different factors are required for different method and basis set 
combinations.400 For the particular level of theory used in this work for the ligands, 
B3LYP/6-31G(d,p), the scale factor to be used is 0.9613 (RMS error = 34 cm-1).331 The 
scale factor for the metal complexes was taken to be the same despite the different basis 
set that was used (basis set for the metal complexes: SDD). 
 




The individual values are usually more useful in the qualitative sense, as it is the trends 
they display that are generally more important than the actual values. The most 
significant and useful stretching vibration in the compounds investigated in this work is 
for the imine bonds. Not only does this prominent vibrational mode prove synthesis of 
these Schiff bases, but it also gives a specific means to characterise and compare these 
compounds. The corrected DFT data gave relatively good results that matched up to the 
experimental spectra for all the ligands and complexes, where possible.  
 
Some of the calculated modes show a zero intensity which is due to the fact that there is 
no change in the dipole moment. Therefore even though the mode has been calculated it 
will instead be seen in the resonance Raman spectra of the compound.  On further 
inspection, it was clear that when the intensity was zero it was always only the 
symmetrical stretch; in particular for the ligands with an ethyl bridging group. In the 
experimental data there is only one peak, which either represents both the symmetrical 
and asymmetrical stretches, or is an average of the two. 
 
The theoretical and calculated values for the imine vibrational modes for the free ligands 
are given in Table 4.9. The DFT-calculated frequencies for the C=N bonds of the original 
free ligands are all around 1660 cm-1, except for L6 which is about 15 cm-1 less. This 
same trend is observed for the experimental values except at about 10 cm-1 less, in the 
region of 1650 cm-1. The calculated frequency for L6 is slightly lower by a further 25    
cm-1. This may be explained by conjugation effects introduced by the aromatic ring which 
is the bridging group for this ligand. The aryl bridge will cause the shift to lower 
frequencies around 1631-1613 cm-1 for compounds of the type ArCH=NAr'.162 The DFT 
computations therefore seem to slightly underestimate the effect of the aromatic group; 
however, they interpret the nature of effect it will have (reduced frequency) correctly. 
 
All the experimental vibrational modes for the imine bond for the methyl-substituted 
ligands are just less than 1700 cm-1. This is a substantial increase of about 50 cm-1 in 
comparison to the original ligands. The difference between these two structures is the 
presence of the electron-donating –CH3 on the carbon atom of the imine bond. The shift 
to higher wavenumber for the C=N band suggests an increased bond order, as might be 
expected if π-overlap was enhanced by an electron-releasing methyl substituent. The 
phenyl-substituted ligands only show a slightly more than 10 cm-1 increase from the 
original ligands. The phenyl group withdraws electron density from the imine group and 




this weakens π-overlap for the C=N bond; the band thus shifts to lower frequency. The 
effect of the conjugation of the phenyl ring bridging group is not prominent for the methyl-
ligands and is unknown for the phenyl-substituted ligands as L6b could not be 
synthesised. The DFT computations consistently calculate the conjugation effects for L6, 
L6m and L6b (decrease in C=N stetching frequency) in comparison to the other ligands 
in each group.  
 
Table 4.9: Experimental peaks (where possible) and theoretical peaks (calculated at B3LYP/6-















DFTcorr Int. DFTcorr Int. 
L1 1648 1651
139 1663 0 1662 137.98 -14.5 
L2 1647 1590
146 1661 46.39 1659 46.16 -13 
L3 1649 * 1667 48.51 1663 59.00 -16 
L4 1645 * 1662 34.09 1662 79.25 -17 
L5 1649 1645
152 1664 53.53 1658 72.40 -12 
L6 1625 1618
162 1643 109.64 1646 37.05 30.5 
L1m 1697 1680
167 1665 0 1663 170.92 33 
L2m 1698 1592
146 1667 44.56 1665 96.32 32 
L3m 1697 * 1671 86.11 1663 85.84 30 
L4m 1699 * 1664 68.54 1662 109.45 36 
L5m 1698 1638
182 1669 93.73 1660 73.52 33.5 




1640 0 1638 226.96 26 
L2b 1662 1595
127 1638 33.07 1636 114.18 25 
L3b 1662 * 1640 112.79 1631 93.11 26.5 
L4b 1626 * 1639 53.79 1637 124.22 -12 
L5b –# * 1638 93.12 1632 93.38  
L6b –# * 1625 141.67 1623 116.41  
DFTcorr = corrected value for the DFT calculation using the factor 0.9613.  
Int. = the intensity of the DFT calculated values in arbitrary units. 
#
 = no experimental value as these ligands could not be synthesised.  
* = no literature data available.
 
$
 = the experimental value – average of the DFT values. 




Overall the DFT frequencies are calculated to be higher than the experimental values for 
the original ligands; however, lower for the ligands with substituted groups on the imine 
(methyl-substituted and phenyl-substituted ligands). There is little difference between the 
DFT-computed values for the original and methyl-substituted ligands; however, there is  
~ 20 cm-1 decrease for the phenyl-substititued ligands. The literature values for the C=N 
stetching modes cited for L1, L5, L6, L1m and L1b compare well (within 1% error) to the 
experimental values obtained in this work. The values for L2, L2m and L2b all show 
consistently larger (~ 4–7% higher) vibrational modes than have been recorded in the 
literature by Rahaman and co-workers.127,146 The frequency for L5m also differs (60    
cm-1) from the value given by Yoshida et al.; however, this band has not been definitively 
assigned by them. Nonetheless, there is good correlation of the experimental values, 
within each type of ligand. The effect of the type of imine group is consistent for each 
collection of ligands with little effect from the change in bridging group (except for L6). 
 
The C=N stretching frequencies of the platinum and palladium complexes are given in 
Tables 4.10 and 4.11, respectively. There is a marked difference in frequency between 
the free ligand and the metal complex. For both the platinum and palladium complexes 
the experimental values of the frequencies decrease by about 15–40 cm-1 for ligands L1, 
L2, L4 and L5. The DFT-computed values also show this decrease; however, to a much 
greater extent. The difference in these imine stretching frequencies may confirm the 
greater electron-withdrawing effect of the chelating Schiff base ligands.167 When the 
Schiff base is coordinated to the metal through the Ni atoms then the metal back-donates 
electron-density into the π* MO that involves the imine groups (e.g., the LUMO of Figure 
4.9). It is likely that some of the π-bond character for the C=N groups will therefore be 
affected. (Note that the π* MO or LUMO has nodes at the C=N bonds.) This lower bond 
order would result in a higher electron density in the antibonding MO which causes the 
lower stretching value for the metal complexes. For most of the other metal complexes, 
for which there are no experimental values, the DFT computed frequencies are in the 
high 1500s. There are a few complexes that have frequencies in the low 1500s which are 
mostly those with phenyl substituents. These stretching values are this low due to the 
added effect of the phenyl group as the imine-substituent. It behaves as an electron 
donating group which would result in a higher electron density for the ligand and in turn 
for the imine bond which causes the further reduction in the wavenumber.   
 




Table 4.10: Experimental peaks (where possible) and theoretical peaks (calculated at the 











DFTcorr Int. DFTcorr Int. 
L1 1632 1595 62.39 1571 70.71 49 
L2 1632 1595 32.18 1567 62.96 51 
L3  1600 33.00 1568 49.02  
L4 1604 1591 31.95 1569 66.08 24 
L5 1634 1591 42.45 1572 78.24 52.5 
L6  1551 9.50 1569 87.97  
L1m  1593 9.97 1587 86.75  
L2m  1562 42.03 1551 45.34  
L3m  1561 40.60 1551 47.08  
L4m  1571 6.66 1570 122.20  
L5m  1588 37.90 1561 63.49  
L6m  1522 3.36 1565 129.43  
L1b 1667 1559 14.27 1555 131.25 110 
L2b 1660 1522 105.45 1517 183.44 140.5 
L3b  1519 109.83 1514 214.05  
L4b 1670 1547 1.50 1525 246.30 134 
L5b  1534 75.10 1545 117.54  
L6b  1508 3.51 1505 86.33  
DFTcorr = corrected value for the DFT calculation using the factor 0.9613.  
Int. = the intensity of the DFT calculated values in arbitrary units. 
$














Table 4.11: Experimental peaks (where possible) and theoretical peaks (calculated at the 











DFTcorr Int. DFTcorr Int. 
L1 1644 1603 70.94 1597 90.28 64 
L2 1642 1527 27.45 1505 53.75 126 
L3  1608 49.40 1568 50.41  
L4 1629 1595 42.83 1593 26.20 35 
L5 1642 1599 51.58 1593 60.76 76 
L6  1572 7.60 1566 70.39  
L1m  1597 13.44 1591 157.36  
L2m  1565 68.31 1553 66.66  
L3m  1564 68.07 1553 66.24  
L4m 1623 1580 11.17 1570 108.01 48 
L5m  1590 66.96 1565 109.30  
L6m  1556 11.44 1564 162.19  
L1b  1574 38.29 1555 212.32  
L2b  1526 123.34 1521 265.77  
L3b  1523 130.99 1517 291.74  
L4b 1664 1547 1.34 1529 336.98 126 
L5b  1538 36.02 1537 141.35  
L6b  1508 5.90 1505 114.32  
DFTcorr = corrected value for the DFT calculation using the factor 0.9613.  
Int. = the intensity of the DFT calculated values in arbitrary units. 
$
 = the experimental value – average of the DFT values. 
 
One important frequency in the calculated output of the DFT calculations is the value for 
the lowest energy vibration determined for each ligand and complex. If this value is 
negative, then the geometry optimisation has located a transition state instead of a local 
minimum. For each of our computations, the lowest energy vibrations were above zero 
(the smallest being around 4 cm1) and thus stable minimum energy conformations were 
computed in all cases. These values and their respective assignments are shown in 
Table 4.12.  
 




Table 4.12: The lowest energy DFT-computed vibration for each of the Schiff base ligands and 
their metal complexes. 
 
These lowest vibrations have rather small intensities for the free ligands (all below 4 
units) and metal complexes (except for PtL1: 10.11 and PdL1: 7.09). The vibration 
associated with each of these values according to the DFT computation is caused by the 
distorted motion of the bridge and its pyridine ring substituents. The trend seen for the 
free ligands is an eclipsed conformation with each pyridyl-imine ―arm‖ hanging down on 
either side of the bridging group. As more steric bulk is added to the group on the imine 
carbon and to the alkyl bridge this conformation changes to having one ―arm’ up and one 
―arm‖ down. For all the phenyl-substitiuted free ligands this staggered conformation is 





Free ligands Platinum complexes Palladium complexes 


















L1 6.7 3.47 eclipsed 48.3 10.11 saddled 48.4 7.09 saddled 
L2 11.5 1.48 eclipsed 45.9 5.70 saddled 51.1 1.36 saddled 






L4 9.2 1.33 eclipsed 36.5 0.22 saddled 35.1 1.36 saddled 
L5 12.7 1.04 eclipsed 44.5 0.41 twisting 44.7 0.04 saddled 
L6 23.4 0.25 eclipsed 46.0 0.00 twisting 46.9 0.00 twisting 
L1m 9.1 3.11 eclipsed 37.0 0.00 twisting 37.3 0.00 twisting 
L2m 6.0 1.32 eclipsed 34.8 2.55 saddled 28.8 0.21 saddled 
L3m 10.3 1.44 eclipsed 34.9 2.76 saddled 27.9 0.43 saddled 
L4m 10.5 1.57 eclipsed 32.6 1.35 saddled 31.6 0.84 saddled 
L5m 9.1 0.35 staggered 28.5 2.82 saddled 29.6 2.45 saddled 
L6m 21.9 0.44 
eclipsed  
staggered 
27.7 0.01 twisting 28.4 0.01 twisting 
L1b 3.9 1.72 twisting 18.0 0.01 twisting 16.7 0.01 twisting 
L2b 6.8 0.39 twisting 17.7 0.69 saddled 17.4 0.32 saddled 
L3b 8.3 0.07 twisting 16.9 0.92 saddled 16.6 0.53 saddled 
L4b 8.3 0.87 twisting 17.9 0.43 saddled 18.8 0.21 saddled 
L5b 4.6 0.35 twisting 17.7 0.56 saddled 17.5 0.32 saddled 
L6b 16.0 0.04 
eclipsed  
staggered 
11.7 0.05 twisting 13.5 0.09 twisting 

















Figure 4.12: Schematic diagrams and examples of the eclipsed (left) and staggered (right) 
geometries observed for the lowest vibrational modes for the free ligands. The terms "eclipsed" 














Figure 4.15: The general distortions associated with saddling (left) and twisting (right) of the 
metal complexes observed for the lowest vibrational modes for the free ligands. The N4 atoms 
form the plane from which distortion is observed. 
 
The platinum(II) and palladium(II) complexes mostly maintain the general conformation 




















L5m, L2b, L3b, L4b and L5b. The frequency of these lowest-energy vibrations 
computed for each metal complex is on average 2–4 times larger than that of the free 
ligands. This presumably reflects a stiffer chelate conformation that is less amenable to 
distortion as a result of coordination of the metal ion. The largest frequencies are 
generally observed for the twisting distortion rather than for the saddling motion. In 
general, a twisting distortion is observed for the complexes of the ligands with ethyl and 
phenyl bridging groups (except for L1).  
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CHAPTER 5 – DNA Binding Studies 
 
5.1 Introduction 
DNA is the intracellular target of anticancer metallodrugs, making metal complexes that 
can bind to specific nucleotides of DNA immensely significant.401 The interaction of small 
molecules with DNA is vital in the design of new pharmaceutical molecules, which makes 
it one of the major challenges in the field of molecular recognition. An understanding of 
how DNA sites can be targeted with specificity will make it possible to design and 
synthesise new chemotherapeutics. This will also allow DNA to be probed for the 
subsequent development of highly receptive diagnostic agents.402 The binding affinities 
of small molecules to DNA is thus useful and important for understanding the individual 
molecule’s behaviour; as well as for the further design and development of DNA 
molecular probes and novel therapeutic reagents.403 
 
After the discovery of the chemical nuclease activity of transition metal complexes in the 
1980s, interest in the interaction and mechanism of these complexes with DNA grew 
markedly. Their applications in antineoplastic medication, molecular biology and 
bioengineering were also of significance.404 Complexes containing metal centres may be 
useful as investigative tools in biological systems if they are spectroscopically active, 
water-soluble, stable and inert.402 Metal centres in complexes also have different redox 
and spectral properties, as well as versatile coordination environments. All of this 
provides the capacity to design new species that are able to bind and cleave DNA.405 
 
Some of the first compounds discovered to be active against deoxyribonucleic acid 
(DNA) were sulfur mustards; however, their high toxicity resulted in the search for other, 
possibly more efficient compounds, but with less toxicity.406 Reports on the occurrence of 
a non-covalent interaction between acridine and DNA gave grounds to the idea that 
anticancer agents worked by interacting with DNA.407 The prerequisites for an anticancer 
drug are inhibition of DNA replication and transcription. This is achieved by the drugs 
either distorting the double-helix structure, alkylating or even cleaving a DNA strand.208 
The antitumour drugs and many antiviral and antibacterial therapies developed and 
discovered that target DNA can be grouped according to their mode of action.  




The different ways in which metal complexes can interact non-covalently with DNA 
include external binding, groove binding and intercalation408 (as illustrated in Figure 5.1). 
External binding refers to binding that takes place on the surface of the DNA, often 
occurring by means of the ionic atmosphere of the biopolymer capturing the complex. A 
stronger interaction takes place if the molecule is a suitable size and shape to fit into a 
groove of DNA. If the molecule is predominantly planar and aromatic then it may be able 
to intercalate between two adjacent bases at the core of the macromolecule. This means 
that square planar molecules are usually capable of this insertion and will, in principle at 
least, almost certainly be intercalators.409 Complexes with tetrahedral or octahedral 
coordination, however, are therefore unlikely to be able to insert themselves between the 
two adjacent base pairs of DNA and hence normally bind externally. 
 
Intercalation is a useful mode by which many molecules interact with the base pairs of 
double-stranded DNA. The drug forces the sequential base pairs apart; this increases 
the helix’s length and stiffness, which subsequently prevents the transcription and 
replication of DNA.410 These intercalators often have antitumour properties associated 
with them (e.g. doxorubicin411 and daunomycin411,412) or may find application as 
structural and functional probes for nucleic acids (ethidium and a variety of metal 
complexes).413 Intercalation does not necessarily imply the whole molecule. The original 
design of an intercalator414 was that the entire molecule would fit in between the base 
pairs; however, since then partial intercalation has also been reported.408 The expected 
intercalation mode of a flat molecule may be disrupted by distortions from planarity or 
also by bulky substituents attached to this predominantly planar molecule. This may then 
allow for partial intercalation or be able to change the mode completely to external 
binding. 
 
For an aromatic complex it has been found that perfect coplanarity of the rings present is 
unnecessary. Either the twist of DNA base pairs is complemented or enhanced by some 
distortion in the bonds joining the aromatic rings or it may open up to lodge the skewed 
group.408 Thus, deviation from planarity does not necessarily destroy the intercalating 
ability of a complex, but may in fact play a role in improving it. Cusumano et al. have 
shown an out of plane phenyl group to largely increase the complex’s binding affinity for 
DNA.408 
 





Figure 5.1: The structure of the DNA double helix; colour-coded by nucleotides: adenine (A), 
thymine (T), cytosine (C) and guanine (G).415 The positions of the black blocks represent the 
three types of non-covalent binding modes possible between metal complexes and DNA. 
 
A driving force may be provided by the different hydrophilic and hydrophobic interactions 
between an intercalator and the nucleobases and phosphate groups. If the intercalator 
has a positive charge then the interaction with the negatively charged DNA phosphate 
backbone also contributes electrostatically. The presence of aromatic ring stacking 
between nucleobases and intercalators is also thought to be a chief structural and 
mechanistic requirement leading to binding.416 All substances that incorporate aromatic 
coplanar rings may be possible DNA intercalators; however, noncoplanar-aromatic and 
planar-nonaromatic complexes are not.417,418 
 
The quality of the toxicity of a possible drug (its cytotoxicity) does not depend entirely on 
its interaction with DNA. In order for a drug to be biologically active it is necessary for it to 
target DNA; however, this is not the only criterion. There are some intercalators that do 
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obstacles in order to be completely effective. This may include metabolic pathways, and 
nuclear and cytoplasmic membranes.419 The drug needs to be capable of achieving entry 
into the nucleus and of forming a stable complex with the DNA (with a relatively long half-
life). Cytotoxicity is a consequence when important enzymes such as DNA 
topoisomerases420 are poisoned. These enzymes are involved in the fundamental steps 
of cellular growth (DNA replication), DNA recognition, and the S- and M-phases of the 
cell cycle. Once poisoning has taken place the ternary DNA-drug-topoisomerase 
cleavage complex will be detected as damaged, which starts a sequence of events; 
almost certainly the most important being cell apoptosis (programmed cell death).420 
 
In clinical trials, cytotoxicity is used to measure a drug’s ability to function as an 
antitumour agent. The assessment of a new compound as a cytotoxic agent may be 
done either in vitro or in vivo. In vitro studies are the more common choice and the most 
accepted method is the one used by the National Cancer Institute (NCI).421 A group of 
cells is incubated with the potential drugs in different concentrations (< 100 μM) and with 
reference compounds.422 If the IC50 is less than 100 μM then other probes and 
concentrations will be evaluated. The activity of a compound is determined by the goal of 
the study and is therefore dependent on design and synthesis.423 
 
Once the ability of the drug to function as an antitumour agent has been established it is 
important to try and determine the mode of action associated with it. Due to the 
interaction taking place between the drug and DNA, it is expected that there will be some 
sort of relationship between the drug's cytotoxicity and its DNA affinity constant. Other 
studies have suggested that the efficiency of the drug seems to be dependent on the 
binding character and mode of the drug, as well as nucleobase selectivity and the kinetic 
mechanism when it reacts with DNA.424,425 Studies on DNA binding therefore help in 
determining the applications of these complexes as gene regulators or as 
chemotherapeutic agents. 
 
It is not always the case that direct structural analogues of known DNA intercalator drugs 
will show comparable or improved clinical efficacy in relation to the parent drug. A 
possible explanation is that if the test drug does bind DNA, then it will be with an identical 
mode and thus produce the same biological mode of action.426 Therefore, although it is 
necessary to take inspiration from known drugs, it is equally important to look beyond 
those structure-activity relationships and attempt to identify novel materials as potential 
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anticancer agents. This may also provide an answer to drug-resistance if their DNA 
binding modes or molecular mechanisms of action are different.  
 
Positively charged metallointercalators are of particular interest, with how they interact 
with the base-pair stack of DNA being highly desirable for delineating their molecular 
mechanism of action.427 Metal complexes with square planar coordinating multidentate 
aromatic ligands (N4 or N2O2) have, in particular, been significant in these studies due to 
their DNA-binding affinity and cytostatic properties.428  
 
Numerous reviews have shown that the activity of the anticancer drug cisplatin is due to 
it binding directly to DNA.429 Cisplatin's cytotoxicity stems from its role in interstrand 
cross-linking430 and this mode of binding deactivates the DNA as a template for 
replication and probably transcription as well. Research in the area of inorganic 
antitumour agents has largely been inspired by the considerable success of cisplatin in 
the clinical treatment of human malignancies.431 Intercalating drugs containing platinum 
have subsequently been extensively investigated in binding studies.432,433,434 It has been 
determined that N7 atoms of guanine and adenine are the primary binding sites of 
platinum complexes, found in the major groove of DNA.435 Non-covalent intercalation is 
dependent on numerous factors, including aromaticity, planarity and surface size and 
expansion. Platinum(II) complexes have been studied as intercalators due to their 
appropriate geometry, high electron density and inertness toward possible competitive 
covalent processes.436 
 
The literature shows that square-planar complexes of Pt(II) containing aromatic ligands 
in particular, are good intercalators.437 Such complexes possess the correct geometry 
and are inert towards possible competitive covalent processes. Several investigators 
have shown that the role of platinum may consist largely of imposing this appropriate 
geometry and positive charge to the complexes.413 There is also the wide choice of 
ligands that may be used which can modify the electronic and steric properties of the 
complexes. The efficacy of the intercalation event may be fundamentally influenced by 
the electronic and steric properties of non-interacting ligands. The remarkable similarity 
between Pt(II) and Pd(II) coordination stereochemistry has encouraged studies of 
palladium(II) compounds as anticancer drugs.431 The intercalation of Pd(II) and Pt(II) 
complexes between DNA base pairs causing detrimental changes to the DNA has been 
acknowledged in the literature.426 It has been reported that some palladium complexes 
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bind DNA through π-π interactions, as well as covalent binding and may promote DNA 
cleavage.438,439,440 
 
In 1974, Jennette and co-workers identified a square planar platinum(II) complex that 
would bind to DNA by intercalation; the complex had an aromatic heterocyclic ligand.419 
Four years later a square planar platinum complex, bound within a dinucleotide duplex, 
reported by Wang and co-workers, also showed intercalation.441 Interest in DNA-
intercalators that bind tightly but reversibly to DNA between the base pairs has since 
grown,442 which includes work on platinum(II) and palladium(II) complexes which can 
have potential antitumour activity.443,444 It has been shown that the binding of platinum 
complexes to DNA can start the apoptotic processes in tumour cells.445,446 Palladium 
complexes have been chosen in this work due to the remarkable analogy between the 
coordination stereochemistry of Pt(II) and Pd(II). It is also an advantage that palladium(II) 
chelates have a high solubility in water and are cheaper than platinum.447,448  
 
The most common way to investigate the interactions of complexes with DNA is to use 
electronic absorption spectroscopy.449,450,451,452 A compound binding to DNA through 
intercalation usually results in hypochromism due to the intercalation mode involving a 
strong a strong π-π stacking interaction between the aromatic chromophore and the 
DNA base pairs.453 It seems to be generally accepted that the extent of the 
hypochromism in the UV-vis band is consistent with the strength of intercalative 
interaction.449 Van der Waals forces, as well as hydrogen bonding and/or charger 
transfer forces stabilise the complexes of DNA intercalators. These processes are all 
reversible and subsequently there must be an equilibrium constant related to them.  
 
A range of platinum(II) and palladium(II) cytotoxic agents with nitrogen donor ligands are 
shown in Table 5.1. Their structures and binding constants as well as their binding 
modes are given. Platinum complexes with a rigid aromatic bidentate ligand and either a 
non-aromatic bidentate ligand or a monodentate ligand may be potent DNA intercalators. 
These additional ligands can determine the efficacy of the interaction according to their 
electronic and steric properties.413 Higher binding affinities may be attributed to larger 
stacking surfaces, e.g. the presence of additional phenyl rings.408 Enhanced cytotoxicity 
of an intercalator may indirectly reflect the extent to which the compound may intercalate 
DNA in a chromatin setting (i.e., within a cell's nucleus). It has been revealed that there 
is a direct relationship between binding affinity and electron density of the intercalating 
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moiety. (Kb values increase with increasing σ- donor power of pyridine nitrogens). This 
may imply that van der Waals interactions are more important than CT interactions.408 
 
The palladium structure [Pd(L)2Cl2]•DMF has no chelating ligands and has a mixed 
binding mode between covalent interaction and intercalation.426 Platinum- and palladium-
intercalators containing bipyridyl or other bidentate aromatic ligands have binding 
constant values of the order 103–107 M-1. In particular, those with two bidentate ligands 
seem to have the higher binding constants413,427,434,454,455 relative to those that have only 
one bidentate chelate.451,456,457 There are, however, exceptions to this, e.g. [Pd(phen)(L-
asp)]•3H2O
442 and 56MEEN455(2 bidentate chelates) have binding constants ~ 104 while 
[Pt(bipy)(py)2]
2+ (only one bidentate chelate) has a binding constant ~ 105 (or higher, 107, 
for the extended structure of [Pt(4,4’-Ph2bipy)(py)2]
2+). 
 
Moderate binding to CT-DNA (calf thymus DNA) through an intercalative mode has been 
observed for platinum complexes with two bidentate (N2) ligands (Figure 5.1).  
Hypochromicity of up to more than 40% accompanied by large shifts in the π→π* bands 
have been observed.434 Unusual spectral changes have been observed for platinum(II) 
complexes with thioureas on addition of CT-DNA. After the addition of a small amount 
there is an increase in the absorption peak at 300–500 nm; however, upon further 
additions the expected hypochromic shifts are observed. This implies intercalation of the 
complex into the DNA.458  
 
The binding constant for Pt(II) complexes may sometimes be much greater than that of 
Pd(II) complexes; however, a palladium complex with a N3 tridentate ligand showed 
hyperchromism with blue shift in the absorption band at ~ 400 nm and was found to have 
an intercalating binding mode (Kb = 1.47 x 10
5 M-1).453 The two tridentate platinum 
complexes represented here have comparable binding constants and intercalation. The 
only complex shown in the table with a tetradentate chelate is a platinum complex that 
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Table 5.1: Binding constants, sites per nucleotide (where given) and mode of binding for some 
platinum(II) and palladium(II) cytotoxic complexes. 
Complex 
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[Pt(en)(phen)]2+ 2.2(5) x 10
6
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56MERR 4.1 x 104 – 





















[Pt(S,R-tmcp)(phen)]Cl2 8.6(2) x 10
5 
8.6(2) 

























# CG = cholylglycinate 
 




The principal aims of this chapter were to: 
1) test several new Pt(II) and Pd(II) complexes for cytotoxicity against cancer cell 
lines; 
2) obtain equilibrium constants for DNA binding using electronic absorption 
spectroscopy; and 
3) characterise the mode of interaction observed for these complexes with CT-DNA. 
 
Here we report the experimental findings of the biological testing and the results of an 
investigation of the interaction of six metal complexes with CT-DNA. These binding 
constants are expected to provide a basis for understanding how these N4 square planar 
platinum group metal complexes interact with DNA. Comparisons to literature binding 
constants have been used when warranted to help to characterise the mode of action of 
these complexes. This data may also help in clarifying the results obtained for the 
cytotoxicity screening of these platinum group metal complexes.  
 
5.3 Experimental 
5.3.1 Materials and Chemicals 
5.3.1.1 Biological screening 
Cell Line: A549/ATCC (Non-small lung cancerous cell line), Control: Au(dppe)2Cl.  
Cell Line: U251 (Central Nervous System (CNS) cancerous cell line) Control: 
Au(dppe)2Cl. 
MTS (Celltiter One Solution, Promega, USA). 
 
5.3.1.2 DNA Binding 
Ultra pure water was used in all experiments. Calf thymus DNA (CT-DNA) was 
purchased from Sigma-Aldrich and stored in the fridge until use. The phosphate buffer 
solution (0.0580 M Na2HPO4, 0.0420 M NaH2PO4, pH ~ 7.0) was prepared using de-
ionised water.401,463 
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A solution of CT-DNA in the buffer gave a ratio of UV-visible absorbance at 260 and 280 
nm of 1.7:1, indicating that the DNA was sufficiently free of protein.401 The concentration 
of the CT-DNA base pairs was determined by using absorption spectroscopy and the 
molar absorptivity per base pair (6600 M-1 cm-1) at 260 nm.401 
 
All reagents and solvents were purchased commercially and used without purification. 
 
5.3.1.3 Topoisomerase II kinetoplast DNA (kDNA) decatenation assay 
Purified topoisomerase II (8 U Topo II) was used for these studies. Kinetoplast DNA  
(200 ng) was used as the substrate in these experiments, and the control was VP-16 
(etoposide). 
 
5.3.2 Physical Measurements 
5.3.2.1 Biological screening 
In vitro cytotoxicity studies were carried out at Mintek, Johannesburg, SA by a standard 
method. 
 
Cells were trypsinised on day one, distributed in a flat bottomed 96 well plate to have a 
final concentration of 2 x 105 cells/mL, and left to adhere overnight. On day two the 
compounds were administrated at a final starting concentration of 100 μM per well with 
subsequent serial dilutions (eight in total). Au(dppe)2Cl was started at a final 
concentration of 12 μM per well. On day four (72 hours after compound administration), 
MTS was added and a reading taken after a good colour change was observed. 
Concentrations were duplicated per plate and experiments were repeated three times. 
Sigmoidal curves were fitted to the results using Origin 6.1 to calculate the IC50 value. 
 
5.3.2.2 DNA Binding 
UV-visible spectra were recorded on a Perkin Elmer Lambda 45 double beam scanning 
spectrophotometer using 1.0 cm path length quartz cuvettes at room temperature. The 
absorption titrations of the complexes were carried out in the pH 7 phosphate buffer 
using a fixed complex concentration to which aliquots of the DNA stock solution were 
added. A concentration of 50 to 150 µM was used for the complexes.  
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Initially, 3000 µL of the buffer only was placed in the reference cuvette and 3000 µL of 
the complex in the buffer solution was placed in the second cuvette. The spectra were 
recorded between the 250 and 650 nm range. Gradually aliquots (10–100 µL) of the 
DNA stock solution were added to the complex and to the blank, so as to eliminate the 
absorbance of DNA itself. The solutions were mixed by repeated inversion and then 
allowed to incubate for 5 minutes before recording the electronic absorption spectra.  
 
The titration was repeated until binding saturation was achieved. This was indicated 
when there was no further change in the spectra for at least four DNA aliquot additions. 
Absorbance values were corrected for dilution. 
 
5.3.2.3 Topoisomerase II kinetoplast DNA (kDNA) decatenation assay 
The titration of PdL2 was performed by Alex Fageson (Prof. Mark T. Muller's group, 
College of Medicine, University of Central Florida, USA). 
 
For a typical in vitro decatenation assay, 107 fibroblasts were fractionated. Nuclear 
extracts were assayed for decatenatory activity using the TopoGEN Eukaryotic TopoII 
Assay kit (TopoGEN, Inc., Port Orange, FL). The standard assay was perfomed following 
the method published by TopoGen.464 
 
5.4 Results and Discussion 
The results of the growth inhibition assays of the platinum and palladium complexes 
against the L1210 mouse Leukaemia cell lines are presented in Table 5.2. None of the 
tested complexes, nor their free ligands, inhibited the growth of the selected cancer cell 
lines. This suggests that the compounds do not reach nuclear DNA in living cells or that 
such compounds are possibly substrates for efflux transporters. This was an unfortunate 
result; however, it does not rule out interaction of the complexes with DNA. Only two cell 
lines have been used in the testing of cytotoxicity for our metal complexes which means 
activity for other cell lines may still be possible. Subsequently these complexes may also 
have some kind of interaction with DNA even if their cytotoxicity is not particularly high. 
The type and extent of this interaction therefore needs to be assessed. Thus we have 
studied the interactions of the complexes with calf thymus (CT) DNA, using an 
absorption technique to obtain the binding constants. This may allow us to characterise 
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the drug binding mode as the observed changes in the absorption spectrum of the 
complex caused by the presence of DNA are commonly used to assist in the 
determination of its binding mode and binding affinity.434 
 
Table 5.2: Results of the growth inhibition assays of our new Pt(II) and Pd(II) complexes against 
the L1210 mouse Leukaemia cell lines. 
Compound A549 IC50 (μM) U251 IC50 (μM) 
L2 > 100 > 100 
L4m > 100 > 100 
PdL2 > 100 > 100 
PtL2 > 100 > 100 
PdL4 > 100 > 100 
PtL4 > 100 > 100 
PdL4m > 100 > 100 
 
The different ways in which drugs may bind are dependent on the site in the DNA duplex 
where they bind: between two base pairs, major or minor grooves, on the outside of the 
helix or electrostatically.465 The binding of these drugs to double-stranded DNA may be 
characterised through absorption spectral titrations and the binding constants (with 
binding sites) may be determined. Generally, DNA intercalators demonstrate 
hypochromism and broadening of the absorption maximum and a shift in wavelength (red 
shift) when they bind to DNA.442,465,466,467 This red shift has been associated with the 
decrease in the energy gap between the HOMO and LUMO after binding of the complex 
to DNA.468 The magnitude of the intercalative interaction determines the degree of 
hypochromism in the UV–vis band. Groove binders will also show spectral changes, but 
these are likely to be less pronounced than for intercalators. They have been found to 
cause hyperchromism and small red shifts.469,470 Substantial increases in intensity 
(absorbance) may be attributed to electrostatic interaction between the complex and the 
phosphate backbone of the DNA.471 This may decrease the repulsion between the 
negatively charged phosphate moieties and subsequently cause the stabilisation of the 
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The binding constant, Kb, was calculated using the following equations:452,463  
                  ... equation 1 
 
 
                     ... equation 2 
 
 
Where [DNA] is the concentration of DNA in base pairs, εa is the extinction coefficient 
(Aobs/[complex]), εf and εb are the free extinction coefficients for the free metal complex 
and the extinction coefficient for the metal complex in the fully bound form, respectively. 
Kb is the equilibrium binding constant, Ct is the total metal complex concentration and s is 
the binding site size. 
 
Owing to their design, which includes coplanar aromatic rings and planarity, all of these 
complexes have the ability to behave as intercalators.416 They also have an acceptable 
size, shape and charge to allow these complexes to slip easily between adjacent base 
pairs of the biopolymer, giving rise to potentially efficient intercalative interaction. The 
differences between these complexes are the metal centres and the substituents on the 
imine nitrogen. These variations may be used to observe if, and to what extent, these 
differences are reflected in the DNA binding ability of the complexes.  
 
For brevity, examples of the data obtained for the metal complexes during the CT-DNA 
titrations will be discussed. Spectra for the other metal complexes may be found in 
Appendix D and full listings of DNA titration data are included in Appendix E. The 
platinum and palladium complexes of the ligand 2 will be presented. Treatment of PtL2 
with calf thymus DNA resulted in spectral changes characterised by hypochromicity. 
Although no obvious bathochromic or hypsochromic effects have been noted for the 
bands seen in Figure 5.2, there is the characteristic hypochromism for each of the five 
bands. The bands at 282 and 307 nm may be those of intraligand π-π* transitions, while 
the bands at 325, 346 and 376 nm are tentatively assigned to MLCT. These MLCT 
bands arise due to the transfer of charge from a d-orbital of the Pt(II) ion to the π* orbital 
of the ligand. The intensity of the peak at 307 nm was reduced by 14.1% upon addition of 
DNA. No other peaks are prominent in this spectrum, nor were any obvious isosbestic 
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points observed. The spectral data does however suggest binding to the biopolymer by 
this metal complex through a noncovalent intercalative mode.432 
 




















Figure 5.2: The absorption spectra for PtL2 (where      denotes the starting spectrum) in a 
phosphate buffer (pH = 7.1) at 298 K with subsequent CT-DNA additions; from 270 to 390 nm. All 
the spectra have been corrected for dilution. 
 
The absorption spectrum for PdL2 is shown for the ultraviolet region in Figure 5.3. In this 
part of the spectrum there are two clearly visible peaks at 289 nm and 306 nm; both 
show decreasing absorption intensity on addition of the CT-DNA. The spectral variation 
for the band at 286 nm, however, takes place as a three-step function. First, there is a 
slight decrease in absorbance, then a slightly bigger increase and finally hypochroism for 
the last additions of DNA. These absorption bands appear to correspond to intraligand π- 
π* transitions, but may also have some charge-transfer character (Pd(II) dπ–π* metal-to-
ligand, MLCT). Fewer and further blue shifted MLCT bands, in comparison to the 
platinum complex, are in agreement with other spectral data observed for palladium 
complexes.452,465 Palladium(II) is a weaker electron donor than platinum(II) and thus the 
MLCT transition should occur at higher energies (shorter wavelengths) when compared 
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Although the exact assignment of this band is uncertain, the spectral perturbation may 
show an interaction taking place between the metal complex and DNA bases.460  As this 
band at 306 nm is the absorption maximum this characteristic hypochroism may 
demonstrate intercalation of the complex with DNA;452,465,466 however, the lack of 





















Figure 5.3: Absorption spectra for PdL2 (where      denotes the starting spectrum) in a 
phosphate buffer (pH = 7.1) at 298 K with subsequent CT-DNA additions; 270 to 330 nm region. 
All the spectra have been corrected for dilution. 
 
Slight bathochromic and then hypsochromic effects (red and blue shifts, respectively) are 
seen for the band at 289 nm. The occurrence of isosbestic points for the duration of the 
titration of the metal complexes with DNA may assist in proving the existence of only the 
free and intercalated complex. Furthermore, it also denotes equilibrium between the free 
and bound metal complex. There are no isosbestic points visible for either PtL2 or PdL2, 
and this lack of isosbestic points suggests that the chromophore environment was not 
altered after the interaction, which in turn implies multiple equilibria more consistent with 
306 
289 
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ion associations than intercalation.468 The intensity of the peak at 306 nm decreased by 
around 6.5% when the concentration of the DNA reached ~ 3.0 x 10-4 M.  
 
The binding constant for the binding taking place between the metal complexes and DNA 
is determined from the fits for the variation of ( a– f)/( b– f) with increasing [DNA]. These 
plots are shown for PtL2 and PdL2 in Figures 5.4 and 5.5, respectively. It was noted that 
the data obtained for the series of palladium complexes were rather similar to each other, 
as were the data for the platinum complexes (Appendix D2). It was also noted that the 
non-linear equation fitted the data for the palladium complexes slightly better than for 
those of the platinum complexes. This may show a difference in their mode of interaction 
with the DNA dependent on the metal centre. 
 


















Figure 5.4: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for the 
titration of PtL2 with CT-DNA.   
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Figure 5.5: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for the 
titration of PdL2 with CT-DNA. 
 
The binding constants (Kb) for the platinum(II) and palladium(II) complexes in this work 
towards CT-DNA are of the order of 105 dm3 mol-1 as estimated by using UV/vis 
absorption spectroscopy. Comparatively, these experimentally determined binding 
abilities are in the average scope of many reported platinum and palladium complexes 
(as presented in Table 5.1). The results for the binding constants, binding sites and % 
hypochromicity for each of the metal complexes tested are shown in Table 5.3. The 
palladium and platinum complexes in this work have a similar DNA binding affinity to 
known intercalators such as ethidium bromide (EB-DNA, 3.3 × 105 M-1 in 50 mmol L-1 
Tris-HCl/1.0 mol L-1 NaCl buffer, pH 7.5).475 This may be accredited to the 2+ charge that 
each metal cation possesses which would favour strong electrostatic binding. This could 
even be strong enough to compete with an intercalator that has only a single positive 

















binding sites per 
DNA base pair) 
Wavelength  
(nm) 
% Change in 
absorption# 
PtL2 1.6(5) x 105 1.30(8) 307 14.1% 
PdL2 4.5(8) x 105 1.72(6) 306 6.5% 
PtL4 2.1(8) x 105 0.79(7) 326 7.7% 
PdL4 1.1(6) x 105 0.47(4) 323 6.3% 
PdL4m 0.9(2) x 105 1.05(5) 312 4.4% 
PdL4b 2.2(3) x 105 0.138(3) 315 29.8% 
#  The % change in the absorption at the given wavelength upon binding of the complex with [DNA] = ~ 3.0 x 10-4 M. 
 
Binding constants for N4 chelates with platinum and palladium could not be found in the 
literature; however, the binding constants found for N-donor Pt(II) and Pd(II) complexes 
compare well to the literature values of these complexes with bidentate ligands (see 
Table 5.1). Many of these complexes have shown an intercalating mode of action with a 
few acting as groove binders. The spectral changes on addition of CT-DNA are all rather 
similar for the complexes in this work; except for PdL4b. 
 
If the mode of action of the complexes in this work were to be considered as intercalation 
then there are certain factors to consider. From X-ray data (Chapter 3) and DFT 
computations (Chapter 4) it is obvious that these complexes show only minor distortions 
from being perfectly planar. Thus all the complexes have the correct charge, size and 
geometry to allow for intercalation. It must, however, be noted that these characteristics 
are also appropriate for groove-binders. The binding constant of an intercalator is 
dependent on the planar aromatic surface of the complex to accommodate it between 
the nucleobases and to allow for stacking.436 As no steric limitations seem to exist for the 
intercalation of PtL2, PdL2, PtL4 and PdL4, it seems the whole surface is potentially 
available for intercalation. The slightly lower binding constant for PdL4m may then be 
attributed to the minmal steric interference by the methyl groups on the imine carbon. 
The similarity in the data may, however, reflect similar interactions for the metal 
complexes.  
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The only predicament with the assignment of a purely intercalated mode of action is the 
spectral changes observed for the absorbance spectra on addition of CT-DNA. All the 
complexes have the same skeletal design with isoelectronic metal centres. This explains 
the analogous results for each complex as it is expected that they will all bind in a similar 
manner. Similar effects and changes are observed in the UV-Vis spectra for both the 
Pt(II) and Pd(II) cations of L2 when CT-DNA is added. Hypochromism and bathochroism 
are associated with intercalation, therefore the lack of shift in the wavelength and small 
changes in intensity for the metal complexes in this work are more indicative of weak 
electrostatic interactions. This would be consistent with non-intercalative binding; either 
simple electrostatic adduct formation or major/minor groove binding.  
 
Norden et al. have described some platinum complexes that seem to initially intercalate 
but then coordinate to vertically-positioned nitrogens on adjacent bases on one of the 
DNA strands.476 This is unlikely for our complexes as a tetradentate chelate should resist 
base dissociation for a kinetically inert d8 metal chelate. In order for the complexes in this 
work to show either groove binding or electrostatic association we would expect 
hyperchroism of the spectrum of the drug on the addition of CT-DNA.469 However, 
groove binders may also show slight changes in the spectrum (either increasing or 
decreasing absorption) depending on the type and strength of the groove binding that is 
taking place which is dependent on the structure of the drug being tested. Some platinum 
complexes have however been identified as nonintercalating when hypochromicity and 
no obvious red shift were observed.457  Our complexes show exactly these results which 
therefore raises the question – if the mode of action for the complexes in this work is not 
intercalation, then what is causing the spectral changes on addition of DNA? When the 
ionic atmosphere around the chromophore is changed, even for only weak interactions 
with DNA, the transition dipoles responsible for the MLCT bands are likely to be affected.  
Thus if the chromophore is bound electrostatically to the negatively charged DNA poly-
anion a loss of intensity is consistent with a weaker oscillation of the electric dipole 
involved in the transition. 
 
Although these changes are not as intense as expected nor are these variations typical 
of intercalating drugs, they can most likely not be attributed to covalent interactions.475 
Small changes are often more likely to reflect groove binding; however, the decrease in 
the absorption intensity of our group of metal chelates is definitely true, and hence 
intercalation cannot yet be ruled out. There are also no observed bathochromic shifts; 
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however, there are some drugs that have been diagnosed as intercalators even without 
significant bathochromic spectral shift in the UV-Vis spectra.477 The absorption for the 
complexes in this work do show the expected hypochroism for intercalators; but very 
weakly in comparison to some well known intercalators. The best way to confirm the 
mode of interaction would therefore be to compare the data to a known intercalator. 
Ethidium bromide (EB) was chosen for its known intercalative mechanism. The 
absorption spectra for EB and the changes in these absorptions on addition of CT-DNA 





















Figure 5.6: Absorption spectra for ethidium bromide (where  denotes the starting spectrum) 
in a phosphate buffer (pH = 7.1) at 298 K with subsequent CT-DNA additions; 270 to 650 nm 
region. All the spectra have been corrected for dilution.  
 
The addition of CT-DNA to EB, at pH ~ 7, causes immediate spectral changes 
characterised by strong hypochromicity and a significant red shift of the absorption 
maxima. These changes adequately indicate the intercalative binding of EB as does the 
presence of the isosbestic points at 302, 321, 394 and 519 nm. These points are 
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consistent and conserved throughout the titration and show the presence of only two 
absorbing species; free EB and bound EB. The absorption maximum is shifted by 1 nm 
on the first addition of CT-DNA and finally ends up red shifted by 14 nm, while the band 
at 487 nm shifts to 522 nm. The intensity is decreased by 13.2% and 16.4% after the first 
addition of CT-DNA for the bands at 287 and 487 nm, respectively. These absorbance 
changes are very different to those observed for the metal complexes in this work and it 
is now possible to exclude intercalation as a possible mode of interaction for these Pt(II) 
and Pd(II) chelates. 
 
The binding constant for EB acquired from the plot of of ( a– f)/( b– f) versus [DNA] is 7.1 
x 105 (Figure 5.7) and the number of binding sites per DNA base pair is s = 0.0046(1). 
These values compare well to those in this work; however, there is a considerable 
difference in the shape of the plots. When comparing the plot for EB with those of PtL2 
and PdL 2 (Figures 5.4 and 5.5, respectively) it is evident that there is a much “flatter” 
curve observed for the complexes in this work in comparison to EB. This may also 
establish the difference in the modes of action and hence substantiate the idea that 
PtL2, PdL2, PtL4, PdL4 and PdL4m do not behave as DNA intercalators. 
 



















Figure 5.7: The non-linear fit for ethidium bromide for the titration with CT-DNA. 
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The data for PdL4b (Figure 5.8) are quite different from that observed for the other 
complexes, despite having a similar binding constant. The absorption spectra show 
hyperchroism (band at 277 nm) and hypochroism (band at 213 nm) as well as isosbestic 
points at 248 and 289 nm. There are also shifts observed for the two main bands; the 
band at 213 nm shows a bathochromic shift to 220 nm and the band at 277 is blue 
shifted by 3 nm. Hyperchromism and hypochromism are spectral features concerning the 
double-helix structure of DNA and are indicative of the interaction occurring between the 
metal complex and DNA. Enhanced absorption intensity can be caused by a distortion in 
























Figure 5.8: Absorption spectra for PdL4b (where          denotes the starting spectrum) in a 
phosphate buffer (pH = 7.1) at 298 K with subsequent CT-DNA additions; 205 to 400 nm region. 
All the spectra have been corrected for dilution. 
 
It has therefore been suggested that enhancement in absorption intensity and 
hyperchroism in absorption spectra may be due to a mixed mode of intercalation and 
surface binding.479 Pure intercalation is unlikely for this metal complex due to the large 
steric bulk; however, if a planar ring was to insert into the helix then the other rings would 
213 
277 
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extend away from the plane due to stereochemical constraints on binding. Subsequently, 
some of the planar aromatic rings may be available for electrostatic binding. It is 
expected that this complex will interact with DNA in a similar manner to the other 
complexes in this work, therefore, the observed spectral changes for PdL4b may be 
rationalised in terms of electrostatic binding and partial intercalation. 
 
More evidence of a non-intercalative mode is obtained from the decatenation assay by 
Topo II (Topoisomerase II) for PdL2 (Figure 5.9). The control used, VP-16 (etoposide), is 
a Topo II poison and blocks re-ligation of cleaved double-stranded DNA.  Linear DNA is 
thus detected on the gel. A catalytic inhibitor of Topo II should bind DNA if it does not 
target the ATPase domain of the enzyme.  Non-specific inhibition is normal for most salts 
at a high enough concentration as seen in the gel. PdL2 was not a Topoisomerase II 






Figure 5.9: Decatenation assay by Topo II employing kinetoplast DNA as the substrate and 
different concentrations of PdL2. 
 
If these complexes are not intercalators then it accounts for their lack of cyctotoxicity.  A 
complex cation that binds electrostatically to the outside of the sugar-phosphate 
backbone would only show a weak spectral change as it enters the ion cloud of the DNA 
duplex. It would not disrupt DNA topoisomerases and is thus likely not to be cytotoxic 
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(assuming efflux pumps are inoperative). This lends support to the idea that our 
complexes may, in fact, not be DNA intercalators despite showing high binding constants 
to DNA. It is more likely that there is electrostatic non-intercalative binding to DNA. 
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CHAPTER 6 – Conclusion 
 
The primary objective of this work was to synthesise and characterise a range of 
tetradentate bis(pyridyl-imine) ligands for the chelation of selected Platinum Group 
Metals (PGMs) and to explore the chemotherapeutic potential of the metal complexes 
which, by design, have the potential to bind to DNA. A total of eight metal complexes 
(tetradentate bis(pyridyl-imine) chelates of Pd(II) or Pt(II)) have been characterised by X-
ray diffraction, as well as four metal-free tetradentate bis(pyridyl-imine) ligands and five 
cyclised hexahydropyrimidine- or imidazole-containing bidentate ligands. A further eleven 
metal-free ligands and five metal complexes have been synthesised and characterised 
making a total of fifteen ligands (three novel) and thirteen metal complexes (all novel) 
that are presented and established in this work. 
 
Due to their configurations the X-ray structures obtained for the free ligands generally did 
not possess inversion symmetry, except for L1. This resulted in all four nitrogen atoms 
being unique for these structures. No π–π stacking for the pyridine rings was observed in 
the ligand structures, except for the cyclised structure of L2h. Short intermolecular 
contacts have been examined between neighbouring Schiff base units for all the free 
ligands; however, no hydrogen bonding has been observed. 
 
All metal chelates had the expected nominal square planar coordination geometry for 
Pd(II) and Pt(II) and approximate or exact C2 molecular symmetry. Distortions were 
observed for the metal complexes from the N4 plane formed by the two imine (Ni) and 
two pyridine (Np) nitrogen atoms around the metal centre. These distortions were mostly 
observed for the pyridine rings and the bridging groups of the metal chelates. Pt(II) 
complexes with propyl bridging groups exhibited the most significant nonplanar 
conformations. The length of the bridging group was observed to have an effect on the 
bite angle of the chelate as well as the mean M-Ni distance, while the Np-M-Np and Ni-M-
Ni angles had opposite and linearly correlated “motion”. It was discovered that structural 
changes in the metal ion coordination geometry and central chelate ring were also 
accompanied by structural perturbations of the two imine groups of the complex. The 
relationship between the mean C=N distance of the complex and the mean M-Ni bond 
length was found to be nonlinear. The metal-nitrogen bonds observed for the metal 
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complexes were all consistent with the normal ranges for Pt-N and Pd-N bonds reported 
in the literature. 
 
Short intermolecular nonbonded contacts were observed for the metal complexes PtL1, 
PdL1 and PtL2; these occurred primarily between the PGM cations and the adjacent 
layers of PF6
-
 ions in the crystal lattice. The observed F···H intermolecular contacts allow 
for the formation of relatively stable crystal lattices. PtL4 also shows no π–π stacking; 
however, the structure of PdL4 is loosely stabilised by π–π interactions between pyridine 
rings of adjacent molecules along the stack. This is also true for PdL4m, which has π–π 
stacking; however, similar interactions were not observed for PdL4b. 
 
DFT geometry optimisations at the B3LYP/6-31G** level of theory were performed for all 
eighteen ligands and at the B3LYP/SDD level of theory for the thirty-six metal 
complexes. More specifically, the simulations (a) delineated key differences between 
gas-phase and solid state (X-ray) structures, (b) probed the effect of the structural 
variations of the bridging and imine substituent groups and (c) offered insights as to the 
preferred conformational isomers as well as their electronic structures (including FMO 
symmetries). 
 
Structures were determined for the lowest energy in the gas phase during DFT 
computations which differed from the solid-phase structures. The main difference for the 
structures of the free ligands was the position of the pyridyl-imine "arms" as there was 
good correlation for the bridging groups. No intermolecular interactions nor forces 
experienced by the molecules due to crystal packing deviations were taken into account 
by the DFT computations; this may explain the deviations of the peripheral groups from 
the predicted idealised geometries by DFT. Thus structures computed at this level of 
theory (B3LYP 631G**), putative and synthesised, were likely to be of acceptable 
accuracy, particularly for similar structures.  
 
The structures of the metal complexes determined by X-ray diffraction included lattice-
induced molecular distortions; however, the computations were for the free structure (gas 
phase) with no counter ions, absent of possible packing effects. As the counter ions  
(PF6
-
) were not taken into account in the DFT computations the prominent short 
interactions involving them in the crystallographically observed structures did not play a 
role in the computed structures. The most noticeable differences between the X-ray 
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structures and the DFT-calculated structures were for the bridges of the chelating ligand 
structure. Bond distances were mostly calculated to be slightly larger than those 
observed for the X-ray structures. Generally, there seems to be slightly better agreement 
between the calculated and observed bond distances of Ci-Cp and Ni-Cf for the palladium 
complexes in comparison to the platinum complexes. The DFT-computed structures also 
predicted an increase in Ni-M-Ni angle and the length of the M-Ni bond as the length of 
the bridging group increased. The calculated geometries for the metal complexes were 
therefore of acceptable accuracy at this level of theory. 
 
The four frontier molecular orbitals for all the metal complexes were calculated using 
DFT. Metal complexes of the original (H-atom appended to the imine carbon atom) and 
methyl-substituted ligands (methyl group appended to the imine carbon atom) were 
found to have very similar molecular orbitals. The HOMO and HOMO-1 orbitals of the 
phenyl-substituted ligands (phenyl group appended to the imine carbon atom) were very 
different and based predominantly on the phenyl substituents with little or no contribution 
from the rest of the structure. The DFT-calculations predicted a significant increase in the 
HOMO–LUMO gap for the Pd(II) chelates relative to the Pt(II) chelates, consistent with 
the softer character of the latter metal ion.  
 
The DFT-computed frequencies were calculated to be higher than the experimental 
values for the ligands with H-atom substituents on their imine units; however, lower for 
the ligands with substituted groups on the imine carbon atoms (methyl-substituted and 
phenyl-substituted ligands). The DFT-computed values for the C=N modes showed the 
expected frequency decrease from the free ligands to the metal complexes observed for 
the experimental data. The frequency of the lowest-energy vibrations were computed for 
each ligand and metal complex. The distortional mode characteristic of these vibrations 
was related to the energy; larger frequencies were generally observed for a twisting 
distortion mode rather than a saddle-like distortion mode of the metal chelate.  
 
Finally, the resulting metal complexes were evaluated for their cytotoxicity against a 
range of cancer cell lines. None of the tested complexes showed inhibition of growth of 
the selected cancer cell lines. Association constants for the binding of the metal 
complexes to calf thymus DNA (CT-DNA) were determined spectroscopically. The Pt(II) 
and Pd(II) complexes tested in this work have not shown spectral evidence that they bind 
by intercalation to DNA; the data were consistent with the proposal that the complexes 
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interact electrostatically with DNA and may possibly be groove-binders. Additional 
research, for example molecular simulations, to obtain the exact binding mode of these 
complexes is necessary. Selective interaction may occur with particular DNA sequences 
and therefore a better understanding of the binding mode is necessary. Proposed 
methods to further elucidate the mode of action may include viscosity measurements, 
circular dichroism (CD) spectral studies or even thermal denaturation; which are currently 
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A1 – Crystallographic data tables for L1 
 
Table A1-1: Crystal data and structure refinement for L1. 
______________________________________________________________________ 
Identification code  rs_l1 
Empirical formula  C14 H14 N4 
Formula weight  238.29 amu 
Temperature  102(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 18.9472(19) Å α = 90°. 
 b = 5.8207(4) Å β = 121.851(15)°. 
 c = 13.0548(15) Å γ = 90°. 
Volume 1223.0(2) Å3 
Z 4 
Density (calculated) 1.294 Mg/m3 
Absorption coefficient 0.081 mm-1 
F(000) 504 
Crystal sise 0.50 x 0.40 x 0.20 mm3 
Theta range for data collection 3.18 to 28.66°. 
Index ranges –25 ≤ h ≤ 4  
 –6 ≤ k ≤ 7 
 –17 ≤ l ≤17 
Reflections collected 2163 
Independent reflections 1374 [Rint = 0.0187] 
Completeness to theta = 25.00° 99.9 %  
Max. and min. transmission 0.9840 and 0.9605 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1374 / 0 / 110 
Goodness-of-fit on F2 1.064 
Final R indices [I > 2σ(I)] R1 = 0.0461, wR2 = 0.1188 
R indices (all data) R1 = 0.0570, wR2 = 0.1253 
Largest diff. peak and hole 0.184 and –0.260 e Å-3 










Table A1-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for L1. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(1) 7089(1) -1876(2) 1028(1) 32(1) 
C(2) 6712(1) -2180(2) 1686(1) 35(1) 
C(3) 6134(1) -580(2) 1567(1) 35(1) 
C(4) 5948(1) 1264(2) 797(1) 30(1) 
C(5) 6350(1) 1425(2) 159(1) 27(1) 
C(6) 6169(1) 3299(2) -706(1) 28(1) 
C(7) 5429(1) 6397(2) -1929(1) 31(1) 
N(1) 6921(1) -109(2) 278(1) 30(1) 


























Table A1-3: IUCR CIF check report for L1. 
 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_l1  
 
Bond precision: C-C = 0.0019 A Wavelength=0.71073 
Cell: a=18.9472(19) b=5.8207(4) c=13.0548(15) 
 alpha=90 beta=121.851(15) gamma=90 
Temperature:  102 K   
 Calculated Reported 
Volume 1223.0(3)  1223.0(2) 
Space group C 2/c  C 2/c  
Hall group -C 2yc  -C 2yc  
Moiety formula C14 H14 N4  C14 H14 N4  
Sum formula C14 H14 N4  C14 H14 N4  
Mr 238.29 238.29  
Dx,g cm-3 1.294 1.294  
Z 4 4  
Mu (mm-1) 0.081 0.081  
F000 504.0 504.0 
F000' 504.15   
h,k,lmax 25,7,17 25,7,17 
Nref 1577  1374  
Tmin,Tmax 0.962,0.984 0.961,0.984 
Tmin' 0.960  
Correction method= MULTI-SCAN  
Data completeness= 0.871 Theta(max)= 28.660 
R(reflections)= 0.0461( 1095) wR2(reflections)= 0.1253( 1374) 
S = 1.064 Npar= 110 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
Click on the hyperlinks for more details of the test. 
 
Alert level C 
PLAT790_ALERT_4_C Centre of Gravity not Within Unit  Cell: Resd.                                                        
 
Alert level G 





PLAT005_ALERT_5_G No _iucr_refine_instructions_details in CIF .... ?
 
 
PLATON version of 11/07/2011; check.def file version of 04/07/2011  


















A2 – Crystallographic data tables for L4 
 
Table A2-1: Crystal data and structure refinement for L4. 
______________________________________________________________________ 
Identification code  rs_l4 
Empirical formula  C17H20N4 
Formula weight  280.37 amu 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P 1  
Unit cell dimensions a = 5.8140(14) Å α = 101.812(2)°. 
 b = 11.526(3) Å β = 97.454(3)°. 
 c = 12.033(3) Å γ = 93.603(3)°. 
Volume 779.3(3) Å3 
Z 2 
Density (calculated) 1.195 Mg/m3 
Absorption coefficient 0.073 mm-1 
F(000) 300 
Crystal sise 0.40 x 0.25 x 0.14 mm3 
Theta range for data collection 2.23 to 28.63°. 
Index ranges –7 ≤ h ≤ 7 
 –15 ≤ k ≤ 14 
 –15 ≤ l ≤ 16 
Reflections collected 8755 
Independent reflections 3641 [Rint = 0.0220] 
Completeness to theta = 25.00° 99.0 %  
Max. and min. transmission 0.9898 and 0.9712 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3641 / 0 / 270 
Goodness-of-fit on F2 1.060 
Final R indices [I > 2σ(I)] R1 = 0.0414, wR2 = 0.1054 
R indices (all data) R1 = 0.0476, wR2 = 0.1103 
Largest diff. peak and hole 0.368 and –0.215 e Å-3 
______________________________________________________________________ 





Table A2-2: Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 x 
103) for L4. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
N(4) 1088(2) 4666(1) 7476(1) 21(1) 
N(3) -2450(2) 3504(1) 4804(1) 19(1) 
N(2) -3688(2) 1228(1) 1443(1) 19(1) 
C(10) -655(2) 3854(1) 5548(1) 18(1) 
C(11) -786(2) 4627(1) 6681(1) 18(1) 
C(5) -3027(2) 1605(1) -383(1) 19(1) 
C(6) -2407(2) 1136(1) 662(1) 21(1) 
C(15) 1024(2) 5320(1) 8529(1) 23(1) 
C(16) -2383(2) 873(1) 4525(1) 21(1) 
C(9) -2115(2) 2722(1) 3725(1) 18(1) 
C(4) -5079(2) 2144(1) -572(1) 22(1) 
C(8) -3386(2) 1474(1) 3568(1) 16(1) 
N(1) -1465(2) 1479(1) -1125(1) 26(1) 
C(7) -2920(2) 711(1) 2426(1) 19(1) 
C(13) -2742(2) 5918(1) 7992(1) 23(1) 
C(12) -2726(2) 5244(1) 6896(1) 20(1) 
C(3) -5508(3) 2604(1) -1549(1) 27(1) 
C(1) -1946(3) 1905(1) -2075(1) 31(1) 
C(2) -3913(3) 2479(1) -2320(1) 29(1) 
C(17) -6005(2) 1537(1) 3564(1) 22(1) 


















Table A2-3: IUCR CIF check report for L4. 
 
IUCR CheckCIF/PLATON (standard)  
No syntax errors found.                                
Datablock: rs_l4  
 
Bond precision: C-C = 0.0018 A Wavelength=0.71073 
Cell: a=5.8140(14) b=11.526(3) c=12.033(3) 
 alpha=101.812(2) beta=97.454(3) gamma=93.603(3) 
Temperature:  100 K   
 Calculated Reported 
Volume 779.3(3)  779.3(3) 
Space group P -1  P -1  
Hall group -P 1  -P 1  
Moiety formula C17 H20 N4  C17 H20 N4  
Sum formula C17 H20 N4  C17 H20 N4  
Mr 280.37 280.37  
Dx,g cm-3 1.195 1.195  
Z 2 2  
Mu (mm-1) 0.073 0.073  
F000 300.0 300.0 
F000' 300.09   
h,k,lmax 7,15,16 7,15,16 
Nref 3991  3641  
Tmin,Tmax 0.978,0.990 0.971,0.990 
Tmin' 0.971  
Correction method= MULTI-SCAN  
Data completeness= 0.912 Theta(max)= 28.630 
R(reflections)= 0.0414( 3157) wR2(reflections)= 0.1103( 3641) 
S = 1.060 Npar= 270 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
PLAT790_ALERT_4_C Centre of Gravity not Within Unit Cell: Resd  
 
Alert level G 
PLAT005_ALERT_5_G No _iucr_refine_instructions_details in CIF ....          ? 
 






PLATON version of 11/07/2011; check.def file version of 04/07/2011  



















A3 – Crystallographic data tables for L5 
 
Table A3-1: Crystal data and structure refinement for L5. 
______________________________________________________________________ 
Identification code  rs_l5 
Empirical formula  C18H20N4 
Formula weight  292.38 amu 
Temperature  102(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 10.8006(6) Å α = 90°. 
 b = 9.7411(5) Å β = 96.412(5)°. 
 c = 15.4012(8) Å γ = 90°. 
Volume 1610.22(15) Å3 
Z 4 
Density (calculated) 1.206 Mg/m3 
Absorption coefficient 0.074 mm-1 
F(000) 624 
Crystal sise 0.55 x 0.40 x 0.40 mm3 
Theta range for data collection 3.03 to 28.67°. 
Index ranges –14 ≤ h ≤ 11  
 –13 ≤ k ≤ 10 
 –12 ≤ l ≤ 20 
Reflections collected 6230 
Independent reflections 3607 [Rint = 0.0299] 
Completeness to theta = 25.00° 99.8 %  
Max. and min. transmission 0.9710 and 0.9604 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3607 / 0 / 279 
Goodness-of-fit on F2 0.949 
Final R indices [I > 2σ(I)] R1 = 0.0430, wR2 = 0.1034 
R indices (all data) R1 = 0.0593, wR2 = 0.1086 











Table A3-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for L5. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(1) 3654(1) 2685(1) 1829(1) 33(1) 
C(2) 3438(1) 2620(1) 929(1) 32(1) 
C(3) 3688(1) 1406(2) 525(1) 35(1) 
C(4) 4134(1) 303(2) 1027(1) 32(1) 
C(5) 4307(1) 449(1) 1931(1) 25(1) 
C(6) 4755(1) -674(1) 2527(1) 25(1) 
C(7) 5481(1) -2828(1) 2968(1) 26(1) 
C(8) 4436(1) -3877(1) 3008(1) 29(1) 
C(9) 4768(1) -4897(2) 3749(1) 34(1) 
C(10) 6009(1) -5611(1) 3663(1) 32(1) 
C(11) 7041(1) -4559(1) 3586(1) 30(1) 
C(12) 6706(1) -3547(1) 2829(1) 26(1) 
C(13) 7474(1) -4347(1) 1565(1) 23(1) 
C(14) 7436(1) -5165(1) 758(1) 22(1) 
C(15) 6354(1) -5830(1) 403(1) 24(1) 
C(16) 6356(1) -6520(1) -379(1) 27(1) 
C(17) 7455(1) -6572(1) -768(1) 29(1) 
C(18) 8501(1) -5921(1) -358(1) 28(1) 
N(1) 4080(1) 1636(1) 2332(1) 29(1) 
N(2) 5125(1) -1828(1) 2272(1) 28(1) 
N(3) 6562(1) -4321(1) 2014(1) 24(1) 
















Table A3-3: IUCR CIF check report for L5. 
 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_l5  
 
Bond precision: C-C = 0.0019 A Wavelength=0.71073 
Cell: a=10.8006(6) b=9.7411(5) c=15.4012(8) 
 alpha=90 beta=96.412(5) gamma=90 
Temperature:  102 K   
 Calculated Reported 
Volume 1610.22(15)  1610.22(15) 
Space group P 21/n  P 21/n  
Hall group -P 2yn  -P 2yn  
Moiety formula C18 H20 N4  C18 H20 N4  
Sum formula C18 H20 N4  C18 H20 N4 
Mr 292.38 292.38 
Dx,g cm-3 1.206 1.206  
Z 4 4  
Mu (mm-1) 0.074 0.074  
F000 624.0 624.0 
F000' 624.19   
h,k,lmax 14,13,20 14,13,20 
Nref 4149  3607  
Tmin,Tmax 0.965,0.971 0.960,0.971 
Tmin' 0.960  
Correction method= MULTI-SCAN  
Data completeness= 0.869 Theta(max)= 28.670 
R(reflections)= 0.0430( 2637) wR2(reflections)= 0.1086( 3607) 
S = 0.949 Npar= 279 
 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
PLAT045_ALERT_1_C Calculated and Reported Z Differ by ............       0.80 Ratio 
PLAT790_ALERT_4_C Centre of Gravity not Within Unit Cell: Resd.  #1                                                        
 
Alert level G 





FORMU01_ALERT_1_G  There is a discrepancy between the atom counts in the 
 _chemical_formula_sum and _chemical_formula_moiety.  
PLAT005_ALERT_5_G No _iucr_refine_instructions_details in CIF ....          ? 
PLAT128_ALERT_4_G Alternate Setting of Space-group P21/c   .......      P21/n       
PLAT793_ALERT_4_G The Model has Chirality at C7      (Verify) ....          S       
PLAT793_ALERT_4_G The Model has Chirality at C12     (Verify) ....          R       
 
 
PLATON version of 11/07/2011; check.def file version of 04/07/2011  














A4 – Crystallographic data tables for L2h 
 
Table A4-1: Crystal data and structure refinement for L2h. 
______________________________________________________________________ 
Identification code  rs_l2 
Empirical formula  C18 H26 Cl2 N6 O1 
Formula weight  413.35 amu 
Temperature  100(2) K 
Wavelength  1.54184 Å 
Crystal system  Orthorhombic 
Space group  Pbcn 
Unit cell dimensions a = 14.8632(4) Å α = 90°. 
 b = 7.6289(2) Å β = 90°. 
 c = 17.8066(5) Å γ = 90°. 
Volume 2019.09(9) Å3 
Z 8 
Density (calculated) 1.360 Mg/m3 
Absorption coefficient 3.062 mm-1 
F(000) 872 
Crystal sise 0.30 x 0.20 x 0.10 mm3 
Theta range for data collection 4.97 to 67.21°. 
Index ranges –17 ≤ h ≤ 16 
 –8 ≤ k ≤ 9 
 –19 ≤ l ≤ 21 
Reflections collected 5131 
Independent reflections 1788 [Rint = 0.0271] 
Completeness to theta = 67.21° 99.0 %  
Absorption correction Analytical 
Max. and min. transmission 0.926 and 0.805 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1788 / 0 / 135 
Goodness-of-fit on F2 1.064 
Final R indices [I > 2σ(I)] R1 = 0.0350, wR2 = 0.0948 
R indices (all data) R1 = 0.0380, wR2 = 0.0970 










Table A4-2: Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 
103) for L2h. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(1) 1528(1) 6922(2) -83(1) 20(1) 
C(2) 1921(1) 6169(2) -784(1) 20(1) 
C(3) 1391(1) 5759(2) -1397(1) 27(1) 
C(4) 1806(1) 5110(2) -2037(1) 31(1) 
C(5) 2722(1) 4871(2) -2039(1) 26(1) 
C(6) 3200(1) 5318(2) -1401(1) 24(1) 
C(7) 1757(1) 7988(2) 1192(1) 26(1) 
C(8) 787(1) 7478(2) 1319(1) 26(1) 
C(9) 240(1) 7977(2) 630(1) 26(1) 
N(1) 663(1) 7239(2) -43(1) 23(1) 
N(2) 2069(1) 7260(2) 480(1) 22(1) 
N(3) 2818(1) 5962(2) -776(1) 24(1) 
O(1) 5000 5644(2) 2500 35(1) 























Table A4-3: IUCR CIF check report for L2h. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_l2h  
 
Bond precision: C-C = 0.0020 A Wavelength=1.54184 
Cell: a=14.8632(4) b=7.6289(2) c=17.8066(5) 
 alpha=90 beta=90 gamma=90 
Temperature:  100 K   
 Calculated Reported 
Volume 2019.09(9)  2019.09(9) 
Space group P b c n  P b c n  
Hall group -P 2n 2ab  -P 2n 2ab  
Moiety formula 2(C9 H12 N3), H2 O, 2(Cl)  C72 H104 N24 O4 Cl8  
Sum formula C18 H26 Cl2 N6 O  C18 H26 Cl2 N6 O 
Mr 413.35 413.35 
Dx,g cm-3 1.360 1.360  
Z 4 8  
Mu (mm-1) 3.062 3.062  
F000 872.0 872.0 
F000' 876.99   
h,k,lmax 17,9,21 17,9,21 
Nref 1805  1788  
Tmin,Tmax 0.504,0.736 0.805,0.926 
Tmin' 0.380  
Correction method= ANALYTICAL  
Data completeness= 0.991 Theta(max)= 67.210 
R(reflections)= 0.0350( 1604) wR2(reflections)= 0.0970( 1788) 
S = 1.064 Npar= 135 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
ABSTY02_ALERT_1_C  An _exptl_absorpt_correction_type has been given without 
            a literature citation.  
PLAT042_ALERT_1_C Calc. and Reported MoietyFormula Strings  Differ          ? 
PLAT045_ALERT_1_C Calculated and Reported Z Differ by ............       0.50 Ratio 
 





Alert level G 
FORMU01_ALERT_1_G  There is a discrepancy between the atom counts in the 
            _chemical_formula_sum and _chemical_formula_moiety.  




PLATON version of 11/07/2011; check.def file version of 04/07/2011  















A5 – Crystallographic data tables for L1bh 
 
Table A5-1: Crystal data and structure refinement for L1bh. 
______________________________________________________________________ 
Identification code  rs_l1b 
Empirical formula  C14H15N3 
Formula weight  225.29 amu 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 16.727(2) Å α = 90°. 
 b = 5.8039(5) Å β = 95.320(7)°. 
 c = 24.4882(17) Å γ = 90°. 
Volume 2367.1(4) Å3 
Z 8 
Density (calculated) 1.264 Mg/m3 
Absorption coefficient 0.077 mm-1 
F(000) 960 
Crystal sise 0.55 x 0.45 x 0.35 mm3 
Theta range for data collection 3.09 to 28.74°. 
Index ranges –21 ≤ h ≤ 22 
 –7 ≤ k ≤ 7 
 –32 ≤ l ≤ 32 
Reflections collected 19111 
Independent reflections 2872 [Rint = 0.0426] 
Completeness to theta = 25.00° 99.9 %  
Max. and min. transmission 0.9734 and 0.9586 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2872 / 0 / 162 
Goodness-of-fit on F2 1.071 
Final R indices [I > 2σ(I)]] R1 = 0.0467, wR2 = 0.1158 
R indices (all data) R1 = 0.0555, wR2 = 0.1192 











Table A5-2: Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103) for L1bh. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(1) 8321(1) 4077(3) 304(1) 46(1) 
C(2) 8760(1) 2470(3) 46(1) 51(1) 
C(3) 8913(1) 382(3) 304(1) 50(1) 
C(4) 8613(1) -28(3) 804(1) 39(1) 
C(5) 8183(1) 1702(2) 1036(1) 29(1) 
C(6) 7812(1) 1364(2) 1584(1) 29(1) 
C(7) 8953(1) 687(3) 2163(1) 49(1) 
C(8) 8695(1) 3127(4) 2265(1) 62(1) 
C(9) 6930(1) 734(2) 1450(1) 28(1) 
C(10) 6724(1) -1372(2) 1201(1) 37(1) 
C(11) 5921(1) -1951(3) 1078(1) 45(1) 
C(12) 5321(1) -447(3) 1196(1) 49(1) 
C(13) 5525(1) 1648(3) 1432(1) 49(1) 
C(14) 6325(1) 2248(2) 1558(1) 37(1) 
N(1) 8039(1) 3750(2) 793(1) 37(1) 
N(2) 8239(1) -487(2) 1898(1) 39(1) 





















Table A5-3: IUCR CIF check report for Llbh. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_l1bh  
 
Bond precision: C-C = 0.0020 A Wavelength=0.71073 
Cell: a=16.727(2) b=5.8039(5) c=24.4882(17) 
 alpha=90 beta=95.320(7) gamma=90 
Temperature:  296 K   
 Calculated Reported 
Volume 2367.1(4)  2367.1(4) 
Space group C 2/c  C 2/c  
Hall group -C 2yc  -C 2yc  
Moiety formula C14 H15 N3  C112H120N24  
Sum formula C14 H15 N3  C14 H15 N3 
Mr 225.29 225.29 
Dx,g cm-3 1.264 1.264  
Z 8 8 
Mu (mm-1) 0.077 0.077  
F000 960.0 960.0 
F000' 960.29   
h,k,lmax 22,7,33 22,7,32 
Nref 3063  2872  
Tmin,Tmax 0.959,0.973 0.959,0.973 
Tmin' 0.959  
Correction method= MULTI-SCAN  
Data completeness= 0.938 Theta(max)= 28.740 
R(reflections)= 0.0467( 2389) wR2(reflections)= 0.1192( 2872) 
S = 1.071 Npar= 162 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
PLAT042_ALERT_1_C Calc. and Reported MoietyFormula Strings  Differ          ? 
PLAT045_ALERT_1_C Calculated and Reported Z Differ by ............       1.60 Ratio 
PLAT241_ALERT_2_C Check High      Ueq as Compared to Neighbors for         C8      
PLAT420_ALERT_2_C D-H Without Acceptor       N2     -   H2A    ...          ?       
 





Alert level G 
FORMU01_ALERT_1_G  There is a discrepancy between the atom counts in the 
            _chemical_formula_sum and _chemical_formula_moiety.  
 
PLAT005_ALERT_5_G No _iucr_refine_instructions_details in CIF ....          ? 
 
 
PLATON version of 11/07/2011; check.def file version of 04/07/2011  














A6 – Crystallographic data tables for L2bh 
 
Table A6-1: Crystal data and structure refinement for L2bh. 
______________________________________________________________________ 
Identification code  rs_l2bh 
Empirical formula  C15 H17 N3 
Formula weight  239.32 amu 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P 1  
Unit cell dimensions a = 8.2380(9) Å α = 97.310(7)°. 
 b = 9.0960(8) Å β = 94.450(8)°. 
 c = 9.2759(8) Å γ = 111.855(9)°. 
Volume 633.95(10) Å3 
Z 2 
Density (calculated) 1.254 Mg/m3 
Absorption coefficient 0.076 mm-1 
F(000) 256 
Crystal sise 0.45 x 0.35 x 0.20 mm3 
Theta range for data collection 2.85 to 26.05°. 
Index ranges –10 ≤ h ≤ 10 
 –11 ≤ k ≤ 11 
 –11 ≤ l ≤ 11 
Reflections collected 7440 
Independent reflections 2495 [Rint = 0.0624] 
Completeness to theta = 25.00° 99.9 %  
Max. and min. transmission 0.9849 and 0.9665 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2495 / 0 / 171 
Goodness-of-fit on F2 0.948 
Final R indices [I > 2σ(I)] R1 = 0.0484, wR2 = 0.1200 
R indices (all data) R1 = 0.0766, wR2 = 0.1329 











Table A6-2:  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for L2bh. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(1) 8561(2) 2849(2) -166(2) 52(1) 
C(2) 10193(2) 2966(2) 422(2) 52(1) 
C(3) 10719(2) 3540(2) 1894(2) 47(1) 
C(4) 9595(2) 3970(2) 2714(2) 39(1) 
C(5) 7970(2) 3814(2) 2035(2) 34(1) 
C(6) 6680(2) 4360(2) 2857(2) 34(1) 
C(7) 6341(2) 2659(2) 4754(2) 52(1) 
C(8) 4451(2) 1662(2) 4081(2) 57(1) 
C(9) 4261(2) 1723(2) 2464(2) 48(1) 
C(10) 7113(2) 6117(2) 2711(2) 34(1) 
C(11) 8739(2) 7287(2) 3346(2) 44(1) 
C(12) 9184(2) 8873(2) 3202(2) 52(1) 
C(13) 8004(3) 9330(2) 2422(2) 56(1) 
C(14) 6397(2) 8194(2) 1797(2) 52(1) 
C(15) 5942(2) 6599(2) 1933(2) 42(1) 
N(1) 7449(2) 3261(2) 605(1) 44(1) 
N(2) 6996(2) 4293(2) 4417(1) 41(1) 




















Table A6-3: IUCR CIF check report for L2bh. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_l2bh  
 
Bond precision: C-C = 0.0024 A Wavelength=0.71073 
Cell: a=8.2380(9) b=9.0960(8) c=9.2759(8) 
 alpha=97.310(7) beta=94.450(8) gamma=111.855(9) 
Temperature:  296 K   
 Calculated Reported 
Volume 633.95(11)  633.95(10) 
Space group P -1  P -1  
Hall group -P 1  -P 1  
Moiety formula C15 H17 N3  C15 H17 N3  
Sum formula C15 H17 N3  C15 H17 N3  
Mr 239.32 239.32  
Dx,g cm-3 1.254 1.254  
Z 2 2  
Mu (mm-1) 0.076 0.076  
F000 256.0 256.0 
F000' 256.08   
h,k,lmax 10,11,11 10,11,11 
Nref 2498  2495  
Tmin,Tmax 0.969,0.985 0.966,0.985 
Tmin' 0.966  
Correction method= MULTI-SCAN  
Data completeness= 0.999 Theta(max)= 26.050 
R(reflections)= 0.0484( 1676) wR2(reflections)= 0.1329( 2495) 
S = 0.948 Npar= 171 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
PLAT420_ALERT_2_C D-H Without Acceptor       N2     -   H2A    ...          ?       
 
Alert level G 
PLAT005_ALERT_5_G No _iucr_refine_instructions_details in CIF ....          ? 
PLAT180_ALERT_4_G Check Cell Rounding: # of Values Ending with 0 =          4       






PLATON version of 11/07/2011; check.def file version of 04/07/2011  




















A7 – Crystallographic data tables for L4b 
 
Table A7-1: Crystal data and structure refinement for L4b. 
______________________________________________________________________ 
Identification code  rs_l4b 
Empirical formula  C29 H28 N4 
Formula weight  432.55 amu 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 10.0325(15) Å α = 90°. 
 b = 24.790(4) Å β = 112.559(2)°. 
 c = 10.0691(15) Å γ = 90°. 
Volume 2312.7(6) Å3 
Z 4 
Density (calculated) 1.242 Mg/m3 
Absorption coefficient 0.074 mm-1 
F(000) 920 
Crystal sise 0.43 x 0.30 x 0.25 mm3 
Theta range for data collection 1.64 to 28.68°. 
Index ranges –13 ≤ h ≤ 7 
 –31 ≤ k ≤ 32 
 –13 ≤ l ≤ 13 
Reflections collected 13631 
Independent reflections 5397 [Rint = 0.0299] 
Completeness to theta = 25.00° 98.7 %  
Max. and min. transmission 0.9817 and 0.9688 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5397 / 0 / 300 
Goodness-of-fit on F2 1.031 
Final R indices [I > 2σ(I)]] R1 = 0.0539, wR2 = 0.1419 
R indices (all data) R1 = 0.0663, wR2 = 0.1509 











Table A7-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for L4b. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
N(1) 6497(2) 3517(1) 3167(2) 20(1) 
N(2) 9311(1) 4384(1) 5144(1) 19(1) 
C(1) 6541(2) 3146(1) 4065(2) 19(1) 
C(13) 7756(2) 3609(1) 2796(2) 20(1) 
C(23) 10616(2) 4279(1) 9012(2) 20(1) 
C(16) 9202(2) 4342(1) 6363(2) 18(1) 
C(8) 7807(2) 2774(1) 4763(2) 19(1) 
C(14) 7941(2) 4213(1) 2535(2) 18(1) 
N(4) 7306(2) 3999(1) 7065(2) 28(1) 
C(2) 5262(2) 3071(1) 4461(2) 20(1) 
C(28) 9305(2) 4270(1) 2210(2) 22(1) 
C(15) 8064(2) 4545(1) 3866(2) 19(1) 
C(9) 8803(2) 2898(1) 6098(2) 22(1) 
C(22) 10507(2) 4168(1) 7629(2) 19(1) 
C(27) 11628(2) 3896(1) 7416(2) 24(1) 
C(24) 11835(2) 4124(1) 10178(2) 26(1) 
C(29) 6640(2) 4426(1) 1258(2) 23(1) 
C(17) 7848(2) 4435(1) 6646(2) 19(1) 
C(11) 10140(2) 2109(1) 5997(2) 28(1) 
C(7) 5212(2) 2646(1) 5335(2) 29(1) 
C(26) 12834(2) 3734(1) 8589(2) 29(1) 
C(20) 5385(2) 4552(1) 7182(2) 29(1) 
C(19) 5969(2) 4993(1) 6768(2) 31(1) 
C(18) 7210(2) 4937(1) 6487(2) 26(1) 
C(25) 12941(2) 3848(1) 9979(2) 28(1) 
C(3) 4131(2) 3435(1) 3979(2) 26(1) 
C(12) 9100(2) 1990(1) 4666(2) 37(1) 
C(4) 2966(2) 3373(1) 4376(2) 33(1) 
C(6) 4033(2) 2587(1) 5720(2) 35(1) 
N(3) 7924(2) 2323(1) 4030(2) 41(1) 
C(21) 6068(2) 4058(1) 7306(2) 30(1) 
C(10) 9974(2) 2565(1) 6711(2) 29(1) 
C(5) 2908(2) 2951(1) 5247(2) 31(1) 
______________________________________________________________________ 





Table A7-3: IUCR CIF check report for L4b. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_l4b  
 
Bond precision: C-C = 0.0027 A Wavelength=0.71073 
Cell: a=10.0325(15) b=24.790(4) c=10.0691(15) 
 alpha=90 beta=112.559(2) gamma=90 
Temperature:  100 K   
 Calculated Reported 
Volume 2312.6(6)  2312.7(6) 
Space group P 21/c  P 21/c  
Hall group -P 2ybc  -P 2ybc  
Moiety formula C29 H28 N4  C29 H28 N4  
Sum formula C29 H28 N4  C29 H28 N4  
Mr 432.55 432.55  
Dx,g cm-3 1.242 1.242  
Z 4 4  
Mu (mm-1) 0.074 0.074  
F000 920.0 920.0 
F000' 920.30   
h,k,lmax 13,33,13 13,32,13 
Nref 5968  5397  
Tmin,Tmax 0.974,0.982 0.969,0.982 
Tmin' 0.969  
Correction method= MULTI-SCAN  
Data completeness= 0.904 Theta(max)= 28.680 
R(reflections)= 0.0539( 4387) wR2(reflections)= 0.1509( 5397) 
S = 1.031 Npar= 300 
 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
DIFMX01_ALERT_2_C  The maximum difference density is > 0.1*ZMAX*0.75 
DIFMX02_ALERT_1_C  The maximum difference density is > 0.1*ZMAX*0.75 
PLAT097_ALERT_2_C Large Reported Max.  (Positive) Residual Density       0.57 eA-3  
PLAT230_ALERT_2_C Hirshfeld Test Diff for    N3     --  C8      ..        6.5 su    





PLAT230_ALERT_2_C Hirshfeld Test Diff for    C9     --  C10     ..        5.1 su    
 
Alert level G 
PLAT005_ALERT_5_G No _iucr_refine_instructions_details in CIF ....          ? 
 
 
PLATON version of 11/07/2011; check.def file version of 04/07/2011  
















A8 – Crystallographic data tables for L4bh 
 
Table A8-1: Crystal data and structure refinement for L4bh. 
______________________________________________________________________ 
Identification code  rs_l4bh 
Empirical formula  C17 H21 N3 
Formula weight  267.37 amu 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 14.7533(6) Å α = 90°. 
 b = 6.0380(2) Å β = 90.923(2)°. 
 c = 16.4381(6) Å γ = 90°. 
Volume 1464.12(9) Å3 
Z 4 
Density (calculated) 1.213 Mg/m3 
Absorption coefficient 0.073 mm-1 
F(000) 576 
Crystal sise 0.125 x 0.08 x 0.025 mm3 
Theta range for data collection 1.38 to 29.89°. 
Index ranges –20 ≤ h ≤ 20 
 –8 ≤ k ≤ 8 
 –22 ≤ l ≤ 22 
Reflections collected 50915 
Independent reflections 4118 [Rint = 0.0887] 
Completeness to theta = 29.89° 99.5 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4118 / 0 / 191 
Goodness-of-fit on F2 1.040 
Final R indices [I > 2σ(I)]] R1 = 0.0436, wR2 = 0.1152 
R indices (all data) R1 = 0.0589, wR2 = 0.1216 












Table A8-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for L4bh. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(12)            2610(1)      7583(3)         4424(1)        19(1) 
C(13)            3314(1)           4071(3)          4700(1)        20(1) 
C(9)             4561(1)          4803(3)          1321(1)           19(1) 
C(14)            3055(1)          6172(3)          4964(1)           19(1) 
C(10)           4601(1)          1044(3)         1758(1)             19(1) 
C(11)            5006(1)          2777(3)         1349(1)             20(1) 
N(3)            3762(1)          5187(3)         1676(1)             16(1) 
C(17)            3766(1)          1392(3)         2118(1)             16(1) 
C(15)            2423(1)          6933(3)         3626(1)             16(1) 
C(16)            3129(1)          3416(3)         3903(1)             17(1) 
N(2)             1962(1)          5782(3)         2047(1)             14(1) 
N(1)             1924(1)          2014(2)         2558(1)             14(1) 
C(3)             1009(1)          3074(3)         1296(1)             16(1) 
C(6)             2466(1)          4044(3)         2487(1)             12(1) 
C(7)             2679(1)          4841(3)         3357(1)             13(1) 
C(8)             3369(1)          3490(3)         2068(1)             13(1) 
C(5)             1523(1)          1277(3)         1777(1)             15(1) 
C(4)             1656(1)          5042(3)         1233(1)             15(1) 
C(1)                137(1)          3748(4)         1721(1)             23(1) 



















Table A8-3: IUCR CIF check report for L4bh. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_l4bh 
 
Bond precision: C-C = 0.0015 A Wavelength=0.71073 
Cell: a=14.7533(6) b=6.0380(2) c=16.4381(6) 
 alpha=90 beta=90.923(2) gamma=90 
Temperature: 100 K   
 Calculated Reported 
Volume 1464.12(9) 1464.12(9) 
Space group P 21/c P 21/c 
Hall group -P 2ybc -P 2ybc 
Moiety formula C17 H21 N3 C17 H21 N3 
Sum formula C17 H21 N3 C17 H21 N3 
Mr 267.37 267.37 
Dx,g cm-3 1.213 1.213 
Z 4 4 
Mu (mm-1) 0.073 0.073 
F000 576.0 576.0 
F000' 576.17  
h,k,lmax 20,8,23 20,8,22 
Nref 4240 4118 
Tmin,Tmax 0.993,0.998  
Tmin' 0.991  
Correction method= Not given  
Data completeness= 0.971 Theta(max)= 29.890 
R(reflections)= 0.0436( 3130) 
wR2(reflections)= 0.1216( 
4118) 
S = 1.040 Npar= 191 
 
The following ALERTS were generated. Each ALERT has the format 
 test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
PLAT420_ALERT_2_C D-H Without Acceptor       N1     -  H1     ...          ?       
 
    
 






PLATON version of 18/07/2011; check.def file version of 04/07/2011 
Datablock rs_l4bh - ellipsoid plot 
 
 





B1 – Crystallographic data tables for PtL1 
Table B1-1: Crystal data and structure refinement for PtL1. 
Table B1-2:  Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for PtL1. U(eq) is defined as one third of the trace of the 
orthogonalised Uij tensor. 
Table B1-3: IUCR CIF check report for PtL1. 
 
B2 – Crystallographic data tables for PdL1 
Table B2-1: Crystal data and structure refinement for PdL1. 
Table B2-2: Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for PdL1. U(eq) is defined as one third of the trace of the 
orthogonalised Uij tensor. 
Table B2-3: IUCR CIF check report for PdL1. 
 
B3 – Crystallographic data tables for PtL2 
Table B3-1:  Crystal data and structure refinement for PtL2. 
Table B3-2:  Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for PtL2. U(eq) is defined as one third of the trace of the 
orthogonalised Uij tensor. 
Table B3-3: IUCR CIF check report for PtL2. 
 
B4 – Crystallographic data tables for PdL2 
Table B4-1: Crystal data and structure refinement for PdL2. 
Table B4-2:  Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for PdL2. U(eq) is defined as one third of the trace of the 
orthogonalised Uij tensor. 
Table B4-3: IUCR CIF check report for PdL2. 
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B5 – Crystallographic data tables for PtL4 
Table B5-1: Crystal data and structure refinement for PtL4. 
Table B5-2: Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for PtL4. U(eq) is defined as one third of the trace of the 
orthogonalised Uij tensor. 
Table B5-3: IUCR CIF check report for PtL4. 
 
B6 – Crystallographic data tables for PdL4 
Table B6-1:  Crystal data and structure refinement for PdL4. 
Table B6-2:  Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for PdL4. U(eq) is defined as one third of the trace of the 
orthogonalised Uij tensor. 
Table B6-3: IUCR CIF check report for PdL4. 
 
B7 – Crystallographic data tables for PdL4m 
Table B7-1: Crystal data and structure refinement for PdL4m. 
Table B7-2: Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for PdL4m. U(eq) is defined as one third of the trace of the 
orthogonalised Uij tensor. 
Table B7-3: IUCR CIF check report for PdL4m. 
 
B8 – Crystallographic data tables for PdL4b 
Table B8-1: Crystal data and structure refinement for PdL4b. 
Table B8-2: Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2 x 103) for PdL4m. U(eq) is defined as one third of the trace of the 
orthogonalised Uij tensor. 
Table B8-3: IUCR CIF check report for PdL4m. 
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B1 – Crystallographic data tables for PtL1 
 
Table B1-1: Crystal data and structure refinement for PtL1. 
________________________________________________________________ 
Identification code  rs_pt_l1 
Empirical formula  C14 H14 F12 N4 P2 Pt 
Formula weight  723.31 amu 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 15.0250(19) Å α = 90°. 
 b = 10.4150(11) Å β = 99.285(9)°. 
 c = 13.0220(10) Å γ = 90°. 
Volume 2011.1(4) Å3 
Z 4 
Density (calculated) 2.389 Mg/m3 
Absorption coefficient 7.257 mm-1 
F(000) 1368 
Crystal sise 0.40 x 0.20 x 0.04 mm3 
Theta range for data collection 2.74 to 32.10°. 
Index ranges –15 ≤ h ≤ 22 
 –15 ≤ k ≤ 15 
 –18 ≤ l ≤ 19 
Reflections collected 10150 
Independent reflections 3278 [Rint = 0.0622] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9716 and 0.7601 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3278 / 0 / 150 
Goodness-of-fit on F2 0.957 
Final R indices [I > 2σ(I)] R1 = 0.0483, wR2 = 0.1017 
R indices (all data) R1 = 0.0710, wR2 = 0.1086 
Largest diff. peak and hole 4.000 and –1.325 e Å-3 
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Table B1-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for PtL1. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(3) 3968(4) 5047(7) 5475(5) 40(1) 
C(4) 3499(5) 4537(7) 4567(5) 46(2) 
C(5) 3434(4) 3207(7) 4461(5) 46(2) 
C(6) 3837(4) 2433(7) 5257(5) 42(1) 
C(7) 4299(4) 3013(6) 6164(5) 35(1) 
C(8) 4055(5) 6425(7) 5690(6) 46(2) 
C(10) 4590(5) 8006(6) 7061(6) 53(2) 
N(2) 4380(3) 4266(5) 6278(4) 34(1) 
N(9) 4498(4) 6730(5) 6564(5) 42(1) 
F(12) 1339(3) 7344(4) 6623(3) 57(1) 
F(13) 1926(3) 6089(5) 5463(3) 60(1) 
F(14) 1501(3) 5705(4) 7781(3) 60(1) 
F(15) 2684(3) 6394(6) 7078(4) 76(2) 
F(16) 2065(5) 4478(4) 6614(4) 76(2) 
F(17) 725(4) 5425(5) 6157(5) 83(2) 
P(11) 1704(1) 5899(2) 6619(1) 35(1) 
Pt(1) 5000 5354(1) 7500 33(1) 
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Table B1-3: IUCR CIF check report for PtL1. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_pt_l1  
 
Bond precision: C-C = 0.0097 A Wavelength=0.71073 
Cell: a=15.0250(19) b=10.4150(11) c=13.022(1) 
 alpha=90 beta=99.285(9) gamma=90 
Temperature:  100 K   
 Calculated Reported 
Volume 2011.1(4)  2011.1(4) 
Space group C 2/c  C 2/c  
Hall group -C 2yc  -C 2yc  
Moiety formula C14 H14 N4 Pt, 2(F6 P)  C14 H14 N4 Pt, 2(F6 P)  
Sum formula C14 H14 F12 N4 P2 Pt  C14 H14 F12 N4 P2 Pt  
Mr 723.31 723.31  
Dx,g cm-3 2.389 2.389  
Z 4 4  
Mu (mm-1) 7.257 7.257  
F000 1368.0 1368.0 
F000' 1363.20   
h,k,lmax 22,15,19 22,15,19 
Nref 3528  3278  
Tmin,Tmax 0.191,0.748 0.760,0.972 
Tmin' 0.050  
Correction method= MULTI-SCAN  
Data completeness= 0.929 Theta(max)= 32.100 
R(reflections)= 0.0483( 2506) wR2(reflections)= 0.1086( 3278) 
S = 0.957 Npar= 150 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
PLAT094_ALERT_2_C Ratio of Maximum / Minimum Residual Density ....       3.02       
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of         P11      
PLAT342_ALERT_3_C Low Bond Precision on  C-C Bonds ...............     0.0097 Ang   
 
 




Alert level G 
PLAT005_ALERT_5_G No _iucr_refine_instructions_details in CIF ....          ? 
PLAT432_ALERT_2_G Short Inter X...Y Contact  F15    ..  C8      ..       2.95 Ang.  
PLAT710_ALERT_4_G Delete 1-2-3 or 2-3-4 Linear Torsion Angle ... #         45      
PLAT764_ALERT_4_G Overcomplete CIF Bond List Detected (Rep/Expd) 1.20 Ratio 
PLAT779_ALERT_4_G Suspect or Irrelevant (Bond) Angle in CIF .... #          5      
PLAT779_ALERT_4_G Suspect or Irrelevant (Bond) Angle in CIF .... #         20      
 
 
PLATON version of 11/07/2011; check.def file version of 04/07/2011  
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B2 – Crystallographic data tables for PdL1 
 
Table B2-1: Crystal data and structure refinement for PdL1. 
   
Identification code  rs_pd_l1 
Empirical formula  C14 H14 F12 N4 P2 Pd 
Formula weight  634.63 amu 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 14.8209(19) Å α = 90°. 
 b = 10.3056(10) Å β = 100.091(13)°. 
 c = 13.1386(17) Å γ = 90°. 
Volume 1975.7(4) Å3 
Z 4 
Density (calculated) 2.134 Mg/m3 
Absorption coefficient 1.224 mm-1 
F(000) 1240 
Crystal sise 0.20 x 0.15 x 0.10 mm3 
Theta range for data collection 3.15 to 29.34°. 
Index ranges –18 ≤ h ≤ 19 
 –9 ≤ k ≤ 13 
 –18 ≤ l ≤ 12 
Reflections collected 3756 
Independent reflections 2110 [Rint = 0.0347] 
Completeness to theta = 25.00° 92.1 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2110 / 0 / 173 
Goodness-of-fit on F2 0.762 
Final R indices [I > 2σ(I)] R1 = 0.0389, wR2 = 0.0870 
R indices (all data) R1 = 0.0663, wR2 = 0.0984 
Largest diff. peak and hole 0.627 and –0.650 e.Å-3 
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Table B2-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for PdL1. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
Pd(1) 0 369(1) 2500 32(1) 
P(2) -1713(1) 4107(1) -1642(1) 33(1) 
F(2) -1496(2) 4285(3) -2774(2) 50(1) 
F(3) -1391(2) 2628(2) -1644(2) 50(1) 
F(6) -1934(2) 3914(3) -505(2) 51(1) 
F(5) -699(2) 4514(3) -1162(3) 69(1) 
F(4) -2722(2) 3679(3) -2110(2) 62(1) 
F(1) -2029(3) 5565(3) -1628(2) 66(1) 
N(1) -624(2) -721(3) 1274(3) 29(1) 
C(2) -1162(3) -2555(5) 247(3) 37(1) 
N(2) -494(3) 1756(3) 1566(3) 41(1) 
C(5) -1023(3) 58(4) 470(3) 34(1) 
C(3) -1561(3) -1772(5) -536(4) 41(1) 
C(4) -1498(3) -446(5) -420(4) 40(1) 
C(1) -697(3) -1998(4) 1145(3) 32(1) 
C(6) -945(3) 1452(4) 693(4) 42(1) 
C(9) -388(4) 3057(5) 2074(5) 53(1) 
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Table B2-3: IUCR CIF check report for PdL1. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.  
Datablock: rs-pd-l1 
 
Bond precision: C-C = 0.0053 A Wavelength=0.71070 
Cell: a=14.8209(19) b=10.3056(10) c=13.1386(17) 
 
alpha=90 beta=100.091(13) gamma=90 




Volume 1975.7(4) 1975.7(4) 
Space group C 2/c C2/c 
Hall group -C 2yc -C 2yc 
Moiety formula C14 H14 N4 Pd, 2(F6 P) C14 H14 N4 Pd, 2(F6 P) 
Sum formula C14 H14 F12 N4 P2 Pd C14 H14 F12 N4 P2 Pd 
Mr 634.63 634.63 
Dx,g cm-3 2.134 2.134 
Z 4 4 
Mu (mm-1) 1.224 1.224 
F000 1240.0 1240.0 
F000' 1237.77 
 
h,k,lmax 20,14,18 19,13,18 
Nref 2720 2095 
Tmin,Tmax 0.791,0.874 0.981,1.000 
Tmin' 0.773 
 
Correction method= MULTI-SCAN 
 
Data completeness= 0.770 Theta(max)= 29.340 
R(reflections)= 0.0373( 1460) 
wR2(reflections)= 0.0659( 
2095) 
S = 0.885 Npar= 150 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P1      
PLAT431_ALERT_2_C Short Inter HL..A Contact  F3     ..  N2      ..       2.89 Ang.  
 
Alert level G 
PLAT003_ALERT_2_G Number of Uiso or Uij Restrained Atom Sites ....          2       
PLAT005_ALERT_5_G No _iucr_refine_instructions_details in CIF ....          ? 
PLAT432_ALERT_2_G Short Inter X...Y Contact  F3     ..  6 2.95 Ang.  
PLAT860_ALERT_3_G Note: Number of Least-Squares Restraints .......         12       
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PLATON version of 18/07/2011; check.def file version of 04/07/2011 
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B3 – Crystallographic data tables for PtL2 
 
Table B3-1: Crystal data and structure refinement for PtL2. 
   
Identification code  rs_pt_l2 
Empirical formula  C15 H16 F12 N4 P2 Pt 
Formula weight  737.35 amu 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 13.134(5) Å α = 90.000(5)°. 
 b = 10.611(5) Å β = 101.142(5)°. 
 c = 15.103(5) Å γ = 90.000(5)°. 
Volume 2065.2(14) Å3 
Z 4 
Density (calculated) 2.372 Mg/m3 
Absorption coefficient 7.069 mm-1 
F(000) 1400 
Crystal sise 0.50 x 0.40 x 0.20 mm3 
Theta range for data collection 2.69 to 32.23°. 
Index ranges –18 ≤ h ≤ 18 
 –14 ≤ k ≤ 15 
 –22 ≤ l ≤ 22 
Reflections collected 19521 
Independent reflections 6656 [Rint = 0.0415] 
Completeness to theta = 25.00° 99.9 %  
Max. and min. transmission 0.3321 and 0.1261 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6656 / 0 / 307 
Goodness-of-fit on F2 1.213 
Final R indices [I > 2σ(I)] R1 = 0.0476, wR2 = 0.1339 
R indices (all data) R1 = 0.0687, wR2 = 0.1414 
Largest diff. peak and hole 3.113 and –3.837 e Å-3 
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Table B3-2: Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 x 
103) for PtL2. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(1) 1262(5) -1983(6) 9325(5) 30(2) 
C(2) 394(5) -2607(7) 8846(5) 30(2) 
C(3) -445(5) -1936(6) 8416(4) 27(1) 
C(4) -416(5) -622(7) 8479(4) 27(1) 
C(5) 464(5) -53(6) 8964(4) 22(1) 
C(6) 565(5) 1291(6) 9049(4) 25(1) 
C(7) 1543(7) 3087(8) 9648(8) 61(3) 
C(8) 2555(7) 3533(7) 9914(7) 69(4) 
C(9) 3385(7) 3064(7) 10529(9) 66(3) 
C(10) 4410(5) 1263(7) 10996(5) 29(1) 
C(11) 4529(5) -97(6) 11043(4) 21(1) 
C(12) 5419(5) -661(6) 11497(4) 24(1) 
C(13) 5454(5) -1975(6) 11524(4) 26(1) 
C(14) 4614(5) -2631(7) 11084(5) 34(2) 
C(15) 3749(5) -1997(7) 10628(5) 30(2) 
N(1) 3685(4) -740(5) 10596(3) 18(1) 
N(2) 1416(4) 1706(5) 9515(4) 28(1) 
N(3) 1308(4) -722(5) 9393(3) 21(1) 
N(4) 3547(5) 1690(6) 10561(4) 31(1) 
F(1) 1697(4) 2485(4) 6534(3) 42(1) 
F(2) 2722(3) 768(4) 6544(3) 37(1) 
F(3) 2209(3) 1379(5) 7817(3) 47(1) 
F(4) 1549(4) -398(4) 7105(4) 51(1) 
F(5) 530(3) 1327(4) 7106(3) 35(1) 
F(6) 1034(4) 715(5) 5821(3) 47(1) 
F(7) 4450(3) 1268(4) 12954(3) 39(1) 
F(8) 3277(3) 2464(4) 13499(3) 41(1) 
F(9) 2774(4) 1297(6) 12237(3) 51(1) 
F(10) 2255(3) 743(4) 13521(3) 38(1) 
F(11) 3430(4) -445(5) 12991(5) 60(2) 
F(12) 3941(4) 721(5) 14253(3) 50(1) 
P(1) 1623(1) 1036(2) 6828(1) 26(1) 
P(2) 3351(1) 994(2) 13244(1) 28(1) 
Pt(1) 2490(1) 435(1) 10021(1) 20(1) 
_________________________________________________________________________________________________________ 
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Table B3-3: IUCR CIF check report for PtL2. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_ptl2 
 
Bond precision: C-C = 0.0052 A Wavelength=0.71073 
Cell: a=15.103(5) b=10.611(5) c=13.134(5) 
 
alpha=90 beta=101.142(5) gamma=90 




Volume 2065.2(14) 2065.2(14) 
Space group C 2/c C2/c 
Hall group -C 2yc -C 2yc 
Moiety formula C15 H16 N4 Pt, 2(F6 P) C15 H16 N4 Pt, 2(F6 P) 
Sum formula C15 H16 F12 N4 P2 Pt C15 H16 F12 N4 P2 Pt 
Mr 737.34 737.35 
Dx,g cm-3 2.372 2.372 
Z 4 4 
Mu (mm-1) 7.069 7.069 
F000 1400.0 1400.0 
F000' 1395.20 
 
h,k,lmax 22,15,19 22,15,18 
Nref 3659 3331 
Tmin,Tmax 0.097,0.120 0.171,1.000 
Tmin' 0.073 
 
Correction method= MULTI-SCAN 
 
Data completeness= 0.910 Theta(max)= 32.230 
R(reflections)= 0.0321( 3088) 
wR2(reflections)= 0.0830( 
3331) 
S = 1.097 Npar= 190 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
Click on the hyperlinks for more details of the test. 
 
Alert level B 
PLAT410_ALERT_2_B Short Intra H...H Contact  H1     ..  H1      ..       1.87 Ang.  
 
Alert level C 
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P1      
PLAT250_ALERT_2_C Large U3/U1 Ratio for Average U(i,j) Tensor ....        2.3       
PLAT303_ALERT_2_C Full Occupancy H-Atom  H7A    with # Connections          2       
PLAT303_ALERT_2_C Full Occupancy H-Atom  H8A    with # Connections          2       
PLAT431_ALERT_2_C Short Inter HL..A Contact  F4     ..  N2A     ..       2.78 Ang.  
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Alert level G 
PLAT002_ALERT_2_G Number of Distance or Angle Restraints on AtSite          7       
PLAT003_ALERT_2_G Number of Uiso or Uij Restrained Atom Sites ....          5       
PLAT153_ALERT_1_G The su's on the Cell Axes   are Equal ..........    0.00500 Ang.  
PLAT164_ALERT_4_G Nr. of Refined C-H H-Atoms in Heavy-Atom Struct.          1       
PLAT301_ALERT_3_G Note: Main Residue  Disorder ...................         25 Perc. 
PLAT432_ALERT_2_G Short Inter X...Y Contact  F3     ..  C6      ..       2.94 Ang.  
PLAT720_ALERT_4_G Number of Unusual/Non-Standard Labels ..........          1       
PLAT860_ALERT_3_G Note: Number of Least-Squares Restraints .......         34       
 
 
PLATON version of 18/07/2011; check.def file version of 04/07/2011 










Appendix B – X-ray Crystallography 
 
 260 
B4 – Crystallographic data tables for PdL2 
 
Table B4-1: Crystal data and structure refinement for PdL2. 
   
Identification code  rs_pd_l2 
Empirical formula  C15 H16 F12 N4 P2 Pd 
Formula weight  648.66 amu 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 13.443(5) Å α = 90.000(5)°. 
 b = 10.513(5) Å β = 102.674(5)°. 
 c = 14.905(5) Å γ = 90.000(5)°. 
Volume 2055.1(14) Å3 
Z 4 
Density (calculated) 2.096 Mg/m3 
Absorption coefficient 1.179 mm-1 
F(000) 1272 
Crystal sise 0.60 x 0.50 x 0.40 mm3 
Theta range for data collection 2.68 to 32.18°. 
Index ranges –19 ≤ h ≤ 17 
 –15 ≤ k ≤ 15 
 –19 ≤ l ≤ 21 
Reflections collected 19654 
Independent reflections 6638 [Rint = 0.0196] 
Completeness to theta = 25.00° 99.9 %  
Max. and min. transmission 0.6498 and 0.5380 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6638 / 0 / 307 
Goodness-of-fit on F2 1.070 
Final R indices [I > 2σ(I)] R1 = 0.0282, wR2 = 0.0797 
R indices (all data) R1 = 0.0327, wR2 = 0.0814 
Largest diff. peak and hole 0.842 and –1.435 e Å-3 
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Table B4-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for PdL2. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
Pd(1) 7523(1) 429(1) 4938(1) 15(1) 
P(2) 8319(1) -3997(1) 3259(1) 19(1) 
P(1) 8375(1) 1068(1) 8097(1) 18(1) 
F(1) 9454(1) 1359(1) 7838(1) 27(1) 
F(2) 8958(1) 706(1) 9123(1) 33(1) 
F(5) 7298(1) 799(1) 8357(1) 26(1) 
F(8) 7252(1) -4243(1) 3549(1) 29(1) 
F(6) 8438(1) -375(1) 7791(1) 34(1) 
F(10) 9386(1) -3742(1) 2970(1) 31(1) 
F(11) 8916(1) -4243(1) 4299(1) 36(1) 
F(7) 8247(1) -2510(1) 3492(1) 34(1) 
F(3) 8320(1) 2526(1) 8411(1) 33(1) 
F(12) 7722(1) -3744(1) 2227(1) 33(1) 
F(9) 8392(1) -5476(1) 3043(1) 37(1) 
C(12) 4566(1) -675(2) 3550(1) 22(1) 
F(4) 7801(1) 1438(1) 7074(1) 33(1) 
C(5) 9532(1) -55(2) 6016(1) 18(1) 
C(11) 5468(1) -102(2) 3984(1) 18(1) 
N(2) 6471(1) 1715(1) 4388(1) 19(1) 
C(10) 6232(1) -2034(2) 4415(1) 24(1) 
C(6) 10402(1) -605(2) 6544(1) 21(1) 
N(3) 6309(1) -772(1) 4420(1) 17(1) 
N(1) 8605(1) 1729(1) 5373(1) 18(1) 
C(3) 8492(1) 3106(2) 5193(1) 25(1) 
C(9) 8738(1) -1999(2) 5721(1) 23(1) 
C(1) 6644(1) 3099(2) 4359(1) 25(1) 
C(4) 9441(1) 1308(2) 5864(1) 21(1) 
N(4) 8695(1) -744(1) 5601(1) 17(1) 
C(7) 10427(1) -1917(2) 6660(1) 21(1) 
C(8) 9588(1) -2619(2) 6239(1) 24(1) 
C(13) 4506(1) -1999(2) 3545(1) 22(1) 
C(2) 7426(1) 3563(2) 5184(1) 23(1) 
C(15) 5599(1) 1267(2) 3997(1) 22(1) 
C(14) 5348(1) -2681(2) 3988(1) 24(1) 
_________________________________________________________________________________________________________ 
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Table B4-3: IUCR CIF check report for PdL2. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_pd_l2 
 
Bond precision: C-C = 0.0025 A Wavelength=0.71073 
Cell: a=13.443(5) b=10.513(5) c=14.905(5) 
 
alpha=90 beta=102.674(5) gamma=90 




Volume 2055.1(14) 2055.1(14) 
Space group P 21/n P21/n 
Hall group -P 2yn -P 2yn 
Moiety formula C15 H16 N4 Pd, 2(F6 P) C15 H16 N4 Pd, 2(F6 P) 
Sum formula C15 H16 F12 N4 P2 Pd C15 H16 F12 N4 P2 Pd 
Mr 648.66 648.66 
Dx,g cm-3 2.096 2.096 
Z 4 4 
Mu (mm-1) 1.179 1.179 
F000 1272.0 1272.0 
F000' 1269.78 
 
h,k,lmax 20,15,22 19,15,21 
Nref 7257 6625 
Tmin,Tmax 0.498,0.624 0.595,1.000 
Tmin' 0.488 
 
Correction method= MULTI-SCAN 
 
Data completeness= 0.913 Theta(max)= 32.180 
R(reflections)= 0.0279( 5725) 
wR2(reflections)= 0.0792( 
6625) 
S = 1.053 Npar= 307 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
Click on the hyperlinks for more details of the test. 
 
Alert level B 
PLAT112_ALERT_2_B ADDSYM Detects Additional (Pseudo) Symm. Elem...          A      
 
Alert level C 
PLAT410_ALERT_2_C Short Intra H...H Contact  H9     ..  H10     ..       1.91 Ang.  
PLAT431_ALERT_2_C Short Inter HL..A Contact  F12    ..  N2      ..       2.89 Ang.  
 
Alert level G 
PLAT128_ALERT_4_G Alternate Setting of Space-group P21/c   .......      P21/n       
PLAT153_ALERT_1_G The su's on the Cell Axes   are Equal ..........    0.00500 Ang.  
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PLAT432_ALERT_2_G Short Inter X...Y Contact  F1     ..  C4      ..       2.94 Ang.  
PLAT432_ALERT_2_G Short Inter X...Y Contact  F10    ..  C15     ..       2.94 Ang.  
PLAT790_ALERT_4_G Centre of Gravity not Within Unit Cell: Resd.  #    3        F6 P                                                              
 
 
PLATON version of 18/07/2011; check.def file version of 04/07/2011 
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B5 – Crystallographic data tables for PtL4 
 
Table B5-1: Crystal data and structure refinement for PtL4. 
   
Identification code  rs_pt_l4 
Empirical formula  C17.50 H17 F12 N4 P2 Pt 
Formula weight  768.37 amu 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/m 
Unit cell dimensions a = 16.563(5) Å α = 90.000(5)°. 
 b = 27.167(5) Å β = 96.312(5)°. 
 c = 10.778(5) Å γ = 90.000(5)°. 
Volume 4820(3) Å3 
Z 8 
Density (calculated) 2.118 Mg/m3 
Absorption coefficient 0.606 mm-1 
F(000) 2927 
Crystal sise 0.60 x 0.40 x 0.20 mm3 
Theta range for data collection 2.57 to 26.14°. 
Index ranges –20 ≤ h ≤ 20 
 –33 ≤ k ≤ 33 
 –13 ≤ l ≤ 13 
Reflections collected 25206 
Independent reflections 4891 [Rint = 0.0858] 
Completeness to theta = 25.00° 99.8 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4891 / 0 / 346 
Goodness-of-fit on F2 1.039 
Final R indices [I > 2σ(I)] R1 = 0.0545, wR2 = 0.1386 
R indices (all data) R1 = 0.0686, wR2 = 0.1472 
Largest diff. peak and hole 1.711 and –2.687 e Å-3 
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Table B5-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for PtL4. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
Pt(1) 2604(1) 0 1187(1) 38(1) 
N(1A) 2657(4) -600(2) 2326(7) 41(2) 
C(5A) 2469(5) -1030(3) 1698(8) 45(2) 
C(4A) 2429(6) -1478(3) 2287(10) 57(2) 
C(3A) 2612(7) -1502(4) 3554(11) 63(3) 
C(2A) 2827(8) -1084(4) 4187(10) 71(3) 
C(1A) 2833(7) -638(4) 3559(9) 60(3) 
C(6A) 2382(6) -969(3) 358(9) 52(2) 
N(2A) 2477(4) -538(2) -50(7) 43(2) 
Pt(10) 5000 7590(1) 5000 55(1) 
N(11) 4743(4) 8046(3) 3497(6) 40(2) 
C(5B) 4462(5) 7792(3) 2451(7) 41(2) 
C(4B) 4278(6) 8024(4) 1319(8) 53(2) 
C(1B) 4868(6) 8525(4) 3386(8) 50(2) 
C(2B) 4684(7) 8773(4) 2294(9) 57(2) 
N(16) 5310(8) 7096(3) 6327(9) 87(4) 
P(17) 5000 0 0 44(1) 
F(18) 5262(18) 0 1382(12) 217(11) 
F(19) 4358(6) -412(3) 61(15) 173(6) 
P(20) 5000 0 5000 54(1) 
F(21) 5549(7) 0 6301(9) 94(3) 
F(22) 5567(6) 404(3) 4512(9) 120(3) 
P(23) 7087(2) 8012(1) 2427(2) 53(1) 
F(24) 6422(6) 7606(3) 2202(12) 136(4) 
F(25) 6682(7) 8194(5) 3554(9) 150(4) 
F(26) 7744(5) 8426(3) 2659(9) 117(3) 
F(27) 7654(6) 7671(4) 3269(13) 154(5) 
F(28) 7480(8) 7831(7) 1301(12) 206(7) 
F(29) 6544(6) 8364(4) 1561(9) 137(4) 
P(1) 5000 6236(2) 0 68(1) 
F(1) 4545(7) 6615(6) -834(16) 222(8) 
F(2) 5702(5) 6230(4) -869(8) 112(3) 
C(8A) 2067(8) 0 -1933(12) 51(3) 
C(9A) 2170(11) 0 -3353(14) 74(5) 
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Table B5-2: Continued. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(3B) 4385(6) 8523(4) 1240(9) 57(2) 
C(7A) 2513(8) -462(4) -1399(9) 63(3) 
C(10A) 1198(11) 0 -1725(15) 75(5) 
F(3) 5463(7) 5826(5) 786(11) 167(5) 
C(6B) 5573(6) 7273(4) 7410(9) 53(2) 
C(8B) 5000 6356(5) 5000 49(3) 
C(9B) 5000 5801(6) 5000 107(8) 
C(7B) 5280(20) 6566(5) 6145(17) 239(19) 
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Table B5-3: IUCR CIF check report for PtL4. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_pt_l4 
 
Bond precision: C-C = 0.0066 A Wavelength=0.71073 
Cell: a=10.6260(1) b=26.9950(3) c=16.2420(2) 
 
alpha=90 beta=95.193(1) gamma=90 




Volume 4639.88(9) 4639.88(9) 
Space group P 21/c P 1 21/c 1 
Hall group -P 2ybc -P 2ybc 
Moiety formula C17 H20 N4 Pt, 2(F6 P) C17 H20 N4 Pt, 2(F6 P) 
Sum formula C17 H20 F12 N4 P2 Pt C17 H20 F12 N4 P2 Pt 
Mr 765.39 765.40 
Dx,g cm-3 2.191 2.191 
Z 8 8 
Mu (mm-1) 6.297 6.297 
F000 2928.0 2928.0 
F000' 2918.41 
 
h,k,lmax 16,42,25 16,42,24 
Nref 19305 17350 
Tmin,Tmax 0.240,0.284 0.413,1.000 
Tmin' 0.139 
 
Correction method= MULTI-SCAN 
 
Data completeness= 0.899 Theta(max)= 34.260 
R(reflections)= 0.0484( 12951) wR2(reflections)= 0.1262( 17350) 
S = 0.994 Npar= 666 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level B 
            Crystal system given = monoclinic 
PLAT112_ALERT_2_B ADDSYM Detects Additional (Pseudo) Symm. Elem...          A      
 
NOTE: this was investigated.  The FALSE alert arises because two PF6- 
counterions in the asymmetric unit are located on centers of inversion in the 
structure.  They exhibit half-occupancy. The remaining three counterions are 
located at general positions and are fully occupied.  Both cations are found at 
general positions and are fully occupied.  Use of PLATON’s ADDSYM algorithm 
clearly reveals that the correct space group choice has been used for the model. 
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Alert level C 
PLAT143_ALERT_4_C su on c - Axis Small or Missing ................    0.00010 Ang.  
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P1      
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P2      
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P3      
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P4      
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P5      
PLAT250_ALERT_2_C Large U3/U1 Ratio for Average U(i,j) Tensor ....        2.1       
PLAT410_ALERT_2_C Short Intra H...H Contact  H1B    ..  H15B    ..       1.97 Ang.  
PLAT410_ALERT_2_C Short Intra H...H Contact  H1A    ..  H15A    ..       1.91 Ang.  
 
Alert level G 
PLAT003_ALERT_2_G Number of Uiso or Uij Restrained Atom Sites ....          2       
PLAT301_ALERT_3_G Note: Main Residue  Disorder ...................          2 Perc. 
PLAT432_ALERT_2_G Short Inter X...Y Contact  F5     ..  C10A    ..       2.94 Ang.  
PLAT432_ALERT_2_G Short Inter X...Y Contact  F7     ..  C7B     ..       2.96 Ang.  
PLAT432_ALERT_2_G Short Inter X...Y Contact  F10    ..  C6B     ..       2.92 Ang.  
PLAT432_ALERT_2_G Short Inter X...Y Contact  F12    ..  C1B     ..       2.90 Ang.  
PLAT605_ALERT_4_G Structure Contains Solvent Accessible VOIDS of .         28 A**3  
PLAT720_ALERT_4_G Number of Unusual/Non-Standard Labels ..........          8       
PLAT860_ALERT_3_G Note: Number of Least-Squares Restraints .......         18       
PLAT869_ALERT_4_G ALERTS Related to the use of SQUEEZE Suppressed           ! 
 
PLATON version of 18/07/2011; check.def file version of 04/07/2011 
Datablock rs_pt_l4 - ellipsoid plot 
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B6 – Crystallographic data tables for PdL4 
 
Table B6-1: Crystal data and structure refinement for PdL4. 
   
Identification code  rs_pd_l4 
Empirical formula  C17 H20 F12 N4 P2 Pd 
Formula weight  676.71 amu 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 10.506(5) Å α = 90°. 
 b = 27.297(5) Å β = 94.032(5)°. 
 c = 16.327(5) Å γ = 90°. 
Volume 4671(3) Å3 
Z 8 
Density (calculated) 1.925 Mg/m3 
Absorption coefficient 1.042 mm-1 
F(000) 2672 
Crystal sise 0.40 x 0.40 x 0.40 mm3 
Theta range for data collection 2.69 to 26.07°. 
Index ranges –12 ≤ h ≤ 7 
 –33 ≤ k ≤ 33 
 –20 ≤ l ≤ 20 
Reflections collected 32251 
Independent reflections 9184 [Rint = 0.0730] 
Completeness to theta = 25.00° 99.6 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9184 / 0 / 656 
Goodness-of-fit on F2 1.054 
Final R indices [I > 2σ(I)] R1 = 0.0585, wR2 = 0.1565 
R indices (all data) R1 = 0.0666, wR2 = 0.1606 
Largest diff. peak and hole 2.457 and –1.929 e Å-3 
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Table B6-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for PdL4. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
C(3) 1412(4) 5609(2) 7181(3) 24(1) 
C(4) 757(5) 6050(2) 7216(3) 27(1) 
C(5) 1413(5) 6474(2) 7438(3) 24(1) 
C(6) 2726(5) 6447(2) 7612(3) 22(1) 
C(7) 3326(4) 5992(2) 7557(3) 18(1) 
C(8) 4689(4) 5934(2) 7648(3) 21(1) 
C(10) 6534(4) 5434(2) 7517(3) 23(1) 
C(11) 7037(4) 4960(2) 7929(3) 22(1) 
C(12) 8479(5) 4959(2) 7853(4) 34(1) 
C(13) 6532(4) 4508(2) 7445(3) 24(1) 
C(14) 4716(4) 4000(2) 7610(3) 19(1) 
C(16) 3338(4) 3938(2) 7534(3) 17(1) 
C(18) 1442(4) 4313(2) 7108(3) 21(1) 
C(19) 796(5) 3870(2) 7143(3) 22(1) 
C(20) 1452(4) 3453(2) 7399(3) 22(1) 
C(21) 2755(5) 3485(2) 7598(3) 21(1) 
C(22) 6730(5) 4934(2) 8831(3) 27(1) 
C(26) -2580(4) 2829(2) 4547(3) 18(1) 
C(27) -3679(4) 3082(2) 4288(3) 22(1) 
C(28) -3714(4) 3590(2) 4368(3) 23(1) 
C(29) -2652(4) 3829(2) 4712(3) 22(1) 
C(30) -1567(4) 3558(2) 4952(3) 19(1) 
C(31) -2517(4) 2291(2) 4582(3) 20(1) 
C(33) -1452(5) 1572(2) 5078(3) 24(1) 
C(34) -122(4) 1343(2) 5044(3) 19(1) 
C(35) -268(5) 795(2) 5214(4) 32(1) 
C(36) 814(4) 1548(2) 5709(3) 21(1) 
C(38) 2297(4) 2217(2) 5765(3) 21(1) 
C(39) 2558(4) 2737(2) 5669(2) 17(1) 
C(41) 1708(4) 3488(2) 5239(3) 20(1) 
C(42) 2892(4) 3718(2) 5385(3) 22(1) 
C(43) 3908(4) 3442(2) 5683(3) 22(1) 
C(44) 3754(4) 2941(2) 5827(3) 20(1) 
C(45) 371(5) 1411(2) 4185(3) 29(1) 
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Table B6-2: Continued. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
N(2) 2670(4) 5569(1) 7349(2) 19(1) 
N(9) 5149(4) 5501(1) 7534(2) 18(1) 
N(15) 5151(4) 4429(1) 7485(2) 19(1) 
N(17) 2688(4) 4357(1) 7311(2) 18(1) 
N(24) -1513(3) 3067(1) 4858(2) 16(1) 
N(32) -1499(3) 2108(1) 4932(2) 19(1) 
N(37) 1164(4) 2064(1) 5580(2) 19(1) 
N(40) 1522(3) 3007(1) 5392(2) 16(1) 
F(47) 5070(3) 4511(1) 5555(2) 33(1) 
F(48) 4337(4) 5284(1) 5713(2) 48(1) 
F(49) 6362(4) 5157(2) 5408(2) 47(1) 
F(51) 6105(4) 2883(2) 7595(2) 54(1) 
F(52) 7751(3) 3388(1) 7859(2) 35(1) 
F(53) 8080(4) 2570(1) 7818(2) 46(1) 
F(54) 6774(3) 3362(1) 6578(2) 41(1) 
F(55) 7103(4) 2536(1) 6537(2) 41(1) 
F(56) 8742(3) 3055(2) 6791(2) 41(1) 
F(58) 9385(3) 4652(1) 5666(2) 34(1) 
F(59) 11326(3) 4997(1) 5546(2) 33(1) 
F(60) 9555(3) 5474(1) 5491(2) 39(1) 
F(62) 6222(4) 7094(2) 7455(3) 80(2) 
F(63) 7754(3) 6535(1) 7637(2) 33(1) 
F(64) 6590(4) 6560(2) 6429(2) 58(1) 
F(65) 8260(5) 7326(1) 7512(2) 64(1) 
F(66) 8636(3) 6796(1) 6489(2) 37(1) 
F(67) 7085(6) 7358(2) 6292(3) 82(2) 
F(69) 4317(3) 6306(1) 10710(2) 36(1) 
F(70) 6173(3) 6132(1) 9256(2) 34(1) 
F(71) 4601(4) 6663(2) 9477(2) 53(1) 
F(72) 6281(4) 6579(2) 10423(2) 49(1) 
F(73) 4233(4) 5852(2) 9548(2) 50(1) 
F(74) 5890(4) 5772(1) 10493(2) 47(1) 
P(46) 5000 5000 5000 17(1) 
P(50) 7436(1) 2961(1) 7196(1) 20(1) 
P(57) 10000 5000 5000 21(1) 
P(61) 7432(1) 6952(1) 6962(1) 26(1) 
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Table B6-2: Continued. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
P(68) 5249(1) 6219(1) 9987(1) 24(1) 
Pd(1) 3864(1) 4965(1) 7367(1) 16(1) 
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Table B6-3: IUCR CIF check report for PdL4. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs_pd_l4
 
Bond precision: C-C = 0.0071 A Wavelength=0.71073 
Cell: a=10.506(5) b=27.297(5) c=16.327(5) 
 alpha=90 beta=94.032(5) gamma=90 
Temperature: 100 K   
 Calculated Reported 
Volume 4671(3) 4671(3) 
Space group P 21/c P21/c 
Hall group -P 2ybc -P 2ybc 
Moiety formula C17 H20 N4 Pd, 2(F6 P) C17 H20 N4 Pd, 2(F6 P) 
Sum formula C17 H20 F12 N4 P2 Pd C17 H20 F12 N4 P2 Pd 
Mr 676.71 676.71 
Dx,g cm-3 1.925 1.925 
Z 8 8 
Mu (mm-1) 1.042 1.042 
F000 2672.0 2672.0 
F000' 2667.59  
h,k,lmax 12,33,20 12,33,20 
Nref 9233 9184 
Tmin,Tmax 0.666,0.659 0.322,1.000 
Tmin' 0.653  
Correction method= MULTI-SCAN  
Data completeness= 0.995 Theta(max)= 26.070 
R(reflections)= 0.0585( 7731) wR2(reflections)= 0.1606( 9184) 
S = 1.054 Npar= 656 
 
The following ALERTS were generated. Each ALERT has the format 
test-name_ALERT_alert-type_alert-level. 
 
Alert level B 
PLAT112_ALERT_2_B ADDSYM Detects Additional (Pseudo) Symm. Elem...          A      
 
NOTE: this has been inspected.  The model is NOT in error; there are two PF6- 
anions located on special positions with half occupancy that lead to this flag. 
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Alert level C 
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P1      
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P2      
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P3      
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P4      
PLAT250_ALERT_2_C Large U3/U1 Ratio for Average U(i,j) Tensor ....        2.5       
PLAT250_ALERT_2_C Large U3/U1 Ratio for Average U(i,j) Tensor ....        2.7       
PLAT410_ALERT_2_C Short Intra H...H Contact  H1A    ..  H15A    ..       1.98 Ang.  
PLAT410_ALERT_2_C Short Intra H...H Contact  H1B    ..  H15B    ..       1.96 Ang.  
 
Alert level G 
PLAT072_ALERT_2_G SHELXL First  Parameter in WGHT Unusually Large.       0.11       
PLAT083_ALERT_2_G SHELXL Second Parameter in WGHT Unusually Large.       8.94       
PLAT153_ALERT_1_GThesu's on the Cell Axes   are Equal ..........    0.00500 Ang.  
PLAT432_ALERT_2_G Short Inter X...Y Contact  F14    ..  C6A     ..       2.97 Ang.  
PLAT432_ALERT_2_G Short Inter X...Y Contact  F19    ..  C6B     ..       2.93 Ang.  
PLAT432_ALERT_2_G Short Inter X...Y Contact  F21    ..  C1B     ..       2.92 Ang.  
PLAT605_ALERT_4_G Structure Contains Solvent Accessible VOIDS of .         30 A**3  
PLAT720_ALERT_4_G Number of Unusual/Non-Standard Labels ..........          8       
PLAT790_ALERT_4_G Centre of Gravity not Within Unit Cell: Resd.  #          4      F6 P                                                              
PLAT790_ALERT_4_G Centre of Gravity not Within Unit Cell: Resd.  #    6              F6 P                                                              
PLAT869_ALERT_4_G ALERTS Related to the use of SQUEEZE Suppressed      ! 
 
PLATON version of 18/07/2011; check.def file version of 04/07/2011 
Datablock rs_pd_l4 - ellipsoid plot 
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B7 – Crystallographic data tables for PdL4m 
 
Table B7-1: Crystal data and structure refinement for PdL4m. 
   
Identification code  rs_pd_l4m 
Empirical formula  C19 H24 F12 N4 P2 Pd 
Formula weight  704.76 amu 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 8.262(5) Å α = 90.000(5)°. 
 b = 13.068(5) Å β = 98.914(5)°. 
 c = 23.981(5) Å γ = 90.000(5)°. 
Volume 2557.9(19) Å3 
Z 4 
Density (calculated) 1.830 Mg/m3 
Absorption coefficient 0.955 mm-1 
F(000) 1400 
Crystal sise 0.55 x 0.45 x 0.35 mm3 
Theta range for data collection 3.01 to 28.75°. 
Index ranges –11 ≤ h ≤ 11 
 –17 ≤ k ≤ 16 
 –31 ≤ l ≤ 32 
Reflections collected 32956 
Independent reflections 6099 [Rint = 0.0555] 
Completeness to theta = 25.00° 99.8 %  
Max. and min. transmission 0.7309 and 0.6216 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6099 / 0 / 347 
Goodness-of-fit on F2 1.023 
Final R indices [I > 2σ(I)] R1 = 0.0477, wR2 = 0.1296 
R indices (all data) R1 = 0.0614, wR2 = 0.1355 
Largest diff. peak and hole 0.791 and –0.747 e Å-3 
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Table B7-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for PdL4m. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________
C(1) 2894(7) 382(3) -246(2) 60(1) 
C(2) 3154(8) 161(4) -783(2) 68(1) 
C(3) 3223(7) 942(4) -1156(2) 61(1) 
C(4) 3020(6) 1912(3) -985(2) 52(1) 
C(5) 2783(5) 2115(3) -439(2) 37(1) 
C(6) 2689(5) 3146(3) -206(2) 40(1) 
C(7) 2654(6) 4044(4) -579(2) 59(1) 
C(8) 2686(6) 4182(3) 602(2) 47(1) 
C(9) 3181(6) 4154(3) 1244(2) 46(1) 
C(10) 3209(7) 5279(3) 1440(2) 63(1) 
C(11) 2061(7) -376(3) 1076(2) 65(1) 
C(12) 1520(8) -1163(4) 1386(2) 73(2) 
C(13) 665(7) -898(4) 1814(2) 64(1) 
C(14) 417(6) 114(4) 1923(2) 57(1) 
C(15) 1017(5) 855(3) 1598(2) 44(1) 
C(16) 985(5) 1941(3) 1718(2) 46(1) 
C(17) 206(8) 2325(5) 2201(2) 77(2) 
C(18) 1888(6) 3622(3) 1528(2) 55(1) 
C(19) 4867(6) 3681(4) 1412(2) 61(1) 
N(1) 2726(4) 1335(2) -61(1) 39(1) 
N(2) 1799(4) 600(2) 1157(1) 43(1) 
N(3) 1727(4) 2522(2) 1409(1) 41(1) 
N(4) 2655(4) 3188(2) 328(1) 36(1) 
F(1) 6332(5) 2048(3) 277(3) 161(3) 
F(2) 6353(4) 3654(2) 64(2) 84(1) 
F(3) 6784(6) 2452(6) -526(2) 186(3) 
F(4) 8840(6) 3445(4) -167(3) 171(3) 
F(5) 8867(4) 1829(2) 65(2) 119(2) 
F(6) 8462(7) 3031(5) 652(2) 179(3) 
F(7) 4565(7) 36(4) 2364(2) 143(2) 
F(8) 4184(7) 1623(5) 2500(3) 166(2) 
F(9) 6018(8) 1148(4) 1959(2) 150(2) 
F(10) 6852(8) 1868(6) 2767(3) 212(4) 
F(11) 7243(8) 222(7) 2588(4) 221(4) 
 
Appendix B – X-ray Crystallography 
 
 277 
Table B7-2: Continued. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________
F(12) 5544(6) 670(7) 3181(2) 201(4) 
P(1) 7619(1) 2747(1) 72(1) 55(1) 
P(2) 5759(2) 934(1) 2575(1) 63(1) 
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Table B7-3: IUCR CIF check report for PdL4m. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs-pdl4m  
 
Bond precision: C-C = 0.0066 A Wavelength=0.71073 
Cell: a=8.262(5) b=13.068(5) c=23.981(5) 
 alpha=90 beta=98.914(5) gamma=90 
Temperature:  296 K   
 Calculated Reported 
Volume 2557.9(19)  2557.9(19) 
Space group P 21/n  P 21/n  
Hall group -P 2yn  ?  
Moiety formula C19 H24 N4 Pd, 2(F6 P)  C19 H24 N4 Pd, 2(F6 P)  
Sum formula C19 H24 F12 N4 P2 Pd  C19 H24 F12 N4 P2 Pd  
Mr 704.76 704.76  
Dx,g cm-3 1.830 1.830  
Z 4 4  
Mu (mm-1) 0.955 0.955  
F000 1400.0 1400.0 
F000' 1397.81   
h,k,lmax 11,17,32 11,17,32 
Nref 6622  6099  
Tmin,Tmax 0.603,0.716 0.622,0.731 
Tmin' 0.586  
Correction method= MULTI-SCAN  
Data completeness= 0.921 Theta(max)= 28.750 
R(reflections)= 0.0477( 4845) wR2(reflections)= 0.1355( 6099) 
S = 1.023 Npar= 347 
 
The following ALERTS were generated. Each ALERT has the format 
       test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P1      
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of          P2      
PLAT250_ALERT_2_C Large U3/U1 Ratio for Average U(i,j) Tensor ....        3.0       
PLAT410_ALERT_2_C Short Intra H...H Contact  H1     ..  H11     ..       1.98 Ang.  
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Alert level G 
PLAT005_ALERT_5_G No _iucr_refine_instructions_details in CIF ....          ? 
PLAT128_ALERT_4_G Alternate Setting of Space-group P21/c   .......      P21/n       
PLAT153_ALERT_1_G The su's on the Cell Axes   are Equal ..........    0.00500 Ang.  
PLAT710_ALERT_4_G Delete 1-2-3 or 2-3-4 Linear Torsion Angle ... #         51      
PLAT710_ALERT_4_G Delete 1-2-3 or 2-3-4 Linear Torsion Angle ... #         52      
PLAT710_ALERT_4_G Delete 1-2-3 or 2-3-4 Linear Torsion Angle ... #         59      
PLAT710_ALERT_4_G Delete 1-2-3 or 2-3-4 Linear Torsion Angle ... #         60      
PLAT710_ALERT_4_G Delete 1-2-3 or 2-3-4 Linear Torsion Angle ... #         61      
PLAT710_ALERT_4_G Delete 1-2-3 or 2-3-4 Linear Torsion Angle ... #         62      
PLAT710_ALERT_4_G Delete 1-2-3 or 2-3-4 Linear Torsion Angle ... #         69      
PLAT710_ALERT_4_G Delete 1-2-3 or 2-3-4 Linear Torsion Angle ... #         70      
 
 
PLATON version of 11/07/2011; check.def file version of 04/07/2011  
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B8 – Crystallographic data tables for PdL4b 
 
Table B8-1: Crystal data and structure refinement for PdL4b. 
   
Identification code  rs_pdl4b 
Empirical formula  C29 H36 F12 N4 P2 Pd 
Formula weight  828.89 amu 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 18.294(4) Å α = 90.000(5)°. 
 b = 10.329(2) Å β = 97.109(3)°. 
 c = 17.997(4) Å γ = 90.000(5)°. 
Volume 3374.6(12) Å3 
Z 4 
Density (calculated) 1.631 Mg/m3 
Absorption coefficient 0.739 mm-1 
F(000) 1656 
Crystal sise 0.1 x 0.1 x 0.1mm3 
Theta range for data collection 2.24 to 28.91°. 
Index ranges –24 ≤ h ≤ 20 
 –13 ≤ k ≤ 13 
 –24 ≤ l ≤ 22 
Reflections collected 21245 
Independent reflections 8098 [Rint = 0.1028] 
Completeness to theta = 25.00° 99.5 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8098 / 0 / 434 
Goodness-of-fit on F2 0.994 
Final R indices [I > 2σ(I)] R1 = 0.0415, wR2 = 0.0997 
R indices (all data) R1 = 0.0490, wR2 = 0.1029 
Largest diff. peak and hole 0.851 and –0.860 e Å-3 
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Table B8-2:  Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 
x 103) for PdL4b. U(eq) is defined as one third of the trace of the orthogonalised Uij tensor. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________
F(3) -413(2) 2318(3) 1093(2) 25(1) 
F(1) 429(2) 1210(4) 1880(2) 32(1) 
F(6) 509(2) 3227(4) 534(2) 30(1) 
F(2) 424(2) 1045(3) 623(2) 31(1) 
F(4) 1351(2) 2123(4) 1321(2) 34(1) 
F(5) 504(2) 3396(4) 1791(2) 33(1) 
F(10) 3875(2) -2000(5) 1828(3) 45(1) 
F(8) 2782(2) -2455(4) 2203(2) 40(1) 
F(7) 3214(3) -423(4) 2317(3) 52(1) 
F(11) 3345(3) -414(4) 1069(3) 54(1) 
F(12) 2904(3) -2452(4) 972(3) 49(1) 
F(9) 2249(3) -902(5) 1462(3) 58(1) 
C(20) 1763(3) 5219(5) 2304(3) 19(1) 
C(19) 1750(3) 5108(6) 3127(3) 21(1) 
C(16) 3788(3) 4789(6) 1864(4) 31(1) 
C(13) 3275(3) 2779(5) 1172(3) 23(1) 
C(17) 2706(3) 3596(5) 2295(3) 22(1) 
C(14) 3419(3) 3472(5) 1933(3) 23(1) 
C(18) 1462(3) 4002(6) 3425(3) 23(1) 
C(15) 3934(3) 2585(6) 2437(3) 29(1) 
C(25) 1288(3) 6168(5) 1867(3) 19(1) 
C(29) 983(3) 7045(5) 673(3) 21(1) 
C(22) 2026(3) 5996(6) 4370(3) 26(1) 
C(23) 1728(3) 4886(7) 4664(3) 28(1) 
C(21) 2024(3) 6105(6) 3599(3) 24(1) 
C(28) 550(3) 7981(6) 958(3) 23(1) 
C(26) 856(3) 7049(6) 2171(3) 22(1) 
C(24) 1439(3) 3901(6) 4190(3) 26(1) 
C(27) 473(3) 7976(6) 1711(3) 24(1) 
Pd(1) 2015(1) 4716(1) 817(1) 16(1) 
P(2) 472(1) 2210(1) 1206(1) 19(1) 
P(3) 3067(1) -1433(2) 1643(1) 28(1) 
N(2) 2187(3) 4541(4) 1934(2) 19(1) 
N(4) 1831(2) 4701(4) -322(2) 17(1) 
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Table B8-2: Continued. 
______________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________________ 
N(3) 2818(2) 3519(4) 591(3) 20(1) 
N(1) 1336(2) 6130(4) 1115(2) 18(1) 
C(6) 2960(3) 3530(5) -95(3) 18(1) 
C(7) 3604(3) 2870(5) -352(3) 21(1) 
C(2) 1193(3) 5012(6) -1544(3) 24(1) 
C(5) 2399(3) 4176(5) -635(3) 17(1) 
C(4) 2404(3) 4135(5) -1399(3) 23(1) 
C(3) 1793(3) 4576(6) -1867(3) 25(1) 
C(1) 1230(3) 5081(5) -767(3) 21(1) 
C(12) 3639(3) 1525(6) -358(4) 32(1) 
C(9) 4814(4) 2985(9) -729(4) 41(2) 
C(8) 4201(4) 3607(7) -538(4) 33(1) 
C(10) 4857(3) 1643(8) -731(4) 40(2) 
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Table B8-3: IUCR CIF check report for PdL4b. 
 
IUCR CcheckCIF/PLATON (standard)  
No syntax errors found.                             
Datablock: rs-pdl4b  
 
Bond precision: C-C = 0.0041 A Wavelength=0.71073 
Cell: a=18.294(4) b=10.329(2) c=17.997(4) 
 alpha=90 beta=97.109(3) gamma=90 
Temperature: 100 K   
 Calculated Reported 
Volume 3374.6(12) 3374.6(12) 
Space group P 21/c P 21/c 
Hall group -P 2ybc -P 2ybc 
Moiety formula C29 H28 N4 Pd, 2(F6 P) C29 H28 N4 Pd, 2(F6 P) 
Sum formula C29 H28 F12 N4 P2 Pd C29 H28 F12 N4 P2 Pd 
Mr 828.89 828.89 
Dx,g cm-3 1.632 1.631 
Z 4 4 
Mu (mm-1) 0.738 0.738 
F000 1656.0 1656.0 
F000' 1653.91  
h,k,lmax 24,14,24 24,13,24 
Nref 8892 8098 
Tmin,Tmax 0.929,0.929  
Tmin' 0.929  
Correction method= Not given  
Data completeness= 0.911 Theta(max)= 28.910 
R(reflections)= 0.0415( 6725) 
wR2(reflections)= 0.1029( 
8098) 
S = 0.994 Npar= 434 
 
The following ALERTS were generated. Each ALERT has the format 
 test-name_ALERT_alert-type_alert-level. 
 
Alert level C 
PLAT244_ALERT_4_C Low   'Solvent' Ueq as Compared to Neighbors of P3      
 
Alert level G 
PLAT605_ALERT_4_G Structure Contains Solvent Accessible VOIDS of 90 A**3  
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PLAT790_ALERT_4_G Centre of Gravity not Within Unit Cell: Resd.  # 3 F6 P                                                              
PLAT869_ALERT_4_G ALERTS Related to the use of SQUEEZE Suppressed ! 
 
 
PLATON version of 18/07/2011; check.def file version of 04/07/2011 


















C1 – Conversions 
Energy conversions: 
All DFT-calculated energies are given in Hartrees in the computational output data files. 
They are then converted to electron volts (eV) by convention.  
 
1 Hartree = 27.211 eV 
 
C2 – Data for the metal complexes computed by DFT 
Table C2-1: Distance (Å) that the central pyridine hydrogen atoms (Ca) are distorted 
from the N4 plane. 
Table C2-2: The MO energies (eV) for each of the orbitals for each complex: LUMO+1, 
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Table C2-1: Distance (Å) that the central pyridine hydrogen atoms (Ca) are distorted from the N4 
plane. 
 DFT predictions X-ray computed 
PtL1 -0.093, +0.093 -0.012, +0.012 
PdL1 -0.109, +0.109 -0.004, +0.004 
PtL2 -0.370, +0.379 -0.049, +0.037 
PdL2 -0.387, +0.346 -0.086, +0.061 
PtL4 +0.285, -0.348 +0.231, -0.374 
PdL4 +0.306, -0.362 +0.236, -0.366 
PdL4m +0.515, -0.457 +0.239, +0.067 
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Table C2-2: The MO energies (eV) for each of the orbitals for each complex: LUMO+1, LUMO, 
HOMO and HOMO-1. 
 PtL1 PtL2 PtL3 PtL4 PtL5 PtL6 
LUMO+1 -9.306 -9.224 -9.116 -9.143 -9.061 -9.660 
LUMO -9.959 -9.823 -9.714 -9.714 -9.687 -9.714 
HOMO -13.877 -13.741 -13.578 -13.687 -13.605 -13.116 
HOMO-1 -14.014 -13.877 -13.660 -13.741 -13.741 -13.469 
 PdL1 PdL2 PdL3 PdL4 PdL5 PdL6 
LUMO+1 -9.333 -9.252 -9.143 -9.170 -9.061 -9.578 
LUMO -9.877 -9.741 -9.578 -9.605 -9.605 -9.741 
HOMO -14.122 -13.986 -13.796 -13.905 -13.823 -13.116 
HOMO-1 -14.177 -14.068 -13.877 -13.932 -13.877 -13.469 
 PtL1m PtL2m PtL3m PtL4m PtL5m PtL6m 
LUMO+1 -8.871 -8.816 -8.871 -8.735 -8.680 -9.279 
LUMO -9.497 -9.415 -9.497 -9.279 -9.279 -9.306 
HOMO -13.497 -13.388 -13.442 -13.360 -13.279 -12.789 
HOMO-1 -13.633 -13.497 -13.524 -13.388 -13.388 -13.224 
 PdL1m PdL2m PdL3m PdL4m PdL5m PdL6m 
LUMO+1 -8.871 -8.843 -8.898 -8.735 -8.680 -9.279 
LUMO -9.497 -9.306 -9.388 -9.279 -9.279 -9.306 
HOMO -13.497 -13.660 -13.551 -13.360 -13.279 -12.789 
HOMO-1 -13.633 -13.687 -13.714 -13.388 -13.388 -13.224 
 PtL1b PtL2b PtL3b PtL4b PtL5b PtL6b 
LUMO+1 -8.435 -8.435 -8.463 -8.381 -8.326 -8.952 
LUMO -9.088 -9.034 -9.088 -8.925 -8.952 -8.952 
HOMO -12.354 -12.245 -12.245 -12.218 -12.218 -12.163 
HOMO-1 -12.381 -12.272 -12.272 -12.245 -12.245 -12.218 
 PdL1b PdL2b PdL3b PdL4b PdL5b PdL6b 
LUMO+1 -8.463 -8.463 -8.490 -8.408 -8.354 -8.843 
LUMO -9.007 -8.925 -8.980 -8.816 -8.871 -8.980 
HOMO -12.381 -12.245 -12.245 -12.245 -12.245 -12.218 
HOMO-1 -12.381 -12.272 -12.272 -12.245 -12.272 -12.218 
       
 






D1 – Absorption spectra of metal complexes with subsequent 
CT-DNA additions 
Figure D1-1: The absorption spectra for PtL4 (         ) in a phosphate buffer (pH = 7.1) at 
298 K with subsequent CT-DNA additions; from 270 to 400 nm. 
Figure D1-2: The absorption spectra for PdL4 (         ) in a phosphate buffer (pH = 7.1) 
at 298 K with subsequent CT-DNA additions; from 270 to 340 nm. 
Figure D1-3: The absorption spectra for PdL4m (          ) in a phosphate buffer (pH = 7.1) 
at 298 K with subsequent CT-DNA additions; from 280 to 325 nm. 
 
D2 – Plots of (εa–εf)/(εb–εf) against [DNA base pairs] for the 
metal complexes 
Figure D2-1: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for 
the titration of PtL4 with CT-DNA.   
Figure D2-2: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for 
the titration of PdL4 with CT-DNA. 
Figure D2-3: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for 
the titration of PdL4m with CT-DNA. 
Figure D2-4: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for 































Figure D1-1: The absorption spectra for PtL4 (         ) in a phosphate buffer (pH = 7.1) at 298 K 
with subsequent CT-DNA additions; from 270 to 400 nm. 
 




















Figure D1-2: The absorption spectra for PdL4 (         ) in a phosphate buffer (pH = 7.1) at 298 K 
with subsequent CT-DNA additions; from 270 to 340 nm. 

























Figure D1-3: The absorption spectra for PdL4m (         ) in a phosphate buffer (pH = 7.1) at 298 







































Figure D2-1: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for the 
titration of PtL4 with CT-DNA.   
 



















Figure D2-2: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for the 
titration of PdL4 with CT-DNA. 
























Figure D2-3: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for the 
titration of PdL4m with CT-DNA. 
 





















Figure D2-4: The non-linear fit for the plot of ( a– f)/( b– f) against [DNA base pairs] for the 
titration of PdL4b with CT-DNA.
